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ABSTRACT 
 
Alzheimer’s disease is a progressive neurodegenerative disorder that affects 
approximately twenty eight million people worldwide. Collectively DNA 
mutations only explain approximately 33% of Alzheimer’s disease incidence. 
Therefore, Alzheimer’s disease has been hypothesised to have both an 
environmental and epigenetic contribution to disease aetiology. Epigenetics 
refers to the heritable changes in gene expression that do not involve changes 
to the underlying DNA sequence. Epigenetic changes can be transient, varying 
in levels according to a person’s age, sex, environmental exposure, genetics 
and disease status. The identification of robust epigenetic changes in 
Alzheimer’s disease would give the potential to open up a variety of new 
treatment options for the disease.  
 
Previous epigenome-wide association studies in Alzheimer’s disease have 
highlighted neuropathology-associated DNA hypermethylation in the ANK1 
gene. To date, however, no studies have examined whether other epigenetic 
mechanisms are altered in this gene in Alzheimer’s disease pathology, or 
whether these ANK1 epigenetic changes are seen in other neurodegenerative 
diseases.  
 
The aim of this thesis was to characterise the epigenetic profile (DNA 
methylation, DNA hydroxymethylation and histone modifications) of ANK1 in 
Alzheimer’s disease.  In addition, it sought to determine whether the previously 
identified ANK1 DNA methylation changes in Alzheimer’s disease are specific to 
this dementia, or are observed in a number of other neurodegenerative 
diseases. The results provide further support for a role for epigenetic 
dysfunction of ANK1 in Alzheimer’s disease as well as some other 
neurodegenerative diseases.  
 
In summary, the work presented in this thesis represents the first epigenome-
wide association study of DNA methylation and DNA hydroxymethylation 
simultaneously in Alzheimer’s disease across two brain regions, highlighting 
changes in DNA modifications in ANK1. The thesis then highlights ANK1 DNA 
methylation changes in other neurodegenerative diseases and explores the 
histone modification profile of the ANK1 locus in Alzheimer’s disease.   
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ABBREVIATIONS 
Abbreviation  Term 
∆  Corrected DNA methylation difference 
450K array   Illumina Infinium 450K Methylation BeadChip Array 
5caC  5-carboxylcytosine 
5fC  5- formylcytosine 
5hmC  5-hydroxymethylcytosine 
5hmU  5-hydroxymethyluracil 
5mC  5-methylcytosine 
AD  Alzheimer’s disease  
ALS  Amyotrophic lateral sclerosis  
BER  Base excision repair 
BP  Biological process  
BS  Bisulfite  
CAA  cerebral amyloid angiopathy 
CC  Cellular component  
CER   Cerebellum  
CETS  Cell epigenotype specific  
CGIs  CpG Islands  
ChIP  Chromatin Immunoprecipitation  
ChIP-qPCR  Chromatin Immunoprecipitation quantitative PCR  
chr   Chromosome 
CME  Clathrin-mediated endocytosis  
CSF   Cerebrospinal fluid 
DHP(s)  Differentially hydroxymethylated position(s) 
DHR(s)  Differentially hydroxymethylated region(s) 
DLB   Dementia with Lewy bodies  
DMoP(s)  Differentially modified position(s) 
DMP(s)  Differentially methylated position(s) 
DMR(s)  Differentially methylated region(s)  
DNA   Deoxyribose nucleic acid 
DNMT  DNA methyltransferase  
dNTP(s)  Deoxynucleotide(s)  
DP  Distal promoter 
DS  Downstream  
EC  Entorhinal cortex  
EOAD  Early onset Alzheimer’s disease  
EPIC array   Illumina Infinium EPIC Methylation BeadChip Array 
ESC  Embryonic stem cells  
EWAS  Epigenome-wide association study  
FAD  Familial Alzheimer’s disease  
GB  Gene body  
GO  Gene ontology 
GWAS  Genome-wide association study  
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H3K27me3  Tri-methylation of lysine at position 27 of histone 3 
H3K4me3  Tri-methylation of lysine at position 4 of histone 3  
HBSS  Hanks’ balanced salt solution  
HCP(s)  High CpG content promoter(s)  
HD  Huntington's disease  
hMeDIP  Hydroxymethylated DNA immunoprecipitation 
HS  Hereditary Spherocytosis  
IG  Intergenic 
LCP(s)  Low CpG content promoters(s) 
LD  Linkage disequilibrium 
LNDBB   London Neurodegenerative Diseases Brain Bank  
LOAD  Late onset Alzheimer’s disease  
MAF  Minor allele frequency  
MAP   Microtubule-associated protein  
MCI  Mild cognitive impairment  
MeDIP  Methylated DNA immunoprecipitation 
MF  Molecular function 
miRNA(s)  Micro-RNA(s)  
NC  Outside CpG island 
NFT(s)  Neurofibrillary Tau tangle(s)  
NTC  No template control 
OxBS  Oxidative Bisulfite  
PBS  Phosphate buffered saline  
PCI  Phenol / Chloroform / Isoamyl Alcohol  
PCR  Polymerase chain reaction  
PD  Parkinson's disease  
PET  positron-emission tomography  
PGS  Polygenic risk scores 
PHFs  Paired helical filaments  
PIC  Protease inhibitor cocktail  
PP  Proximal promoter 
QC  Quality control 
qPCR  Quantitative polymerase chain reaction  
RNA   Ribose nucleic acid  
RRHP  Reduced representation hydroxymethylation profiling 
SHE  CpG island shelf  
SHO  CpG island shore  
SN   Substantia nigra  
SNP  Single nucleotide polymorphism  
STG  Superior temporal gyrus  
STR  Striatum  
SWDBB  South West Dementia Brain Bank  
TBE  Tris-borate EDTA  
TdT  Terminal deoxynucleotidyl transferase 
TET  Ten-eleven translocation dioxygenase 
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TPM  Transcripts per million  
TSS  Transcription start sites  
UA  Unannotated 
VaD  Vascular dementia 
vLDL  Very low density lipoproteins  
β-amyloid  Amyloid-beta  
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This chapter introduces research that has been performed in the field of 
Alzheimer’s disease (AD) and epigenetics to date. The work presented in this 
chapter comparing genetic and epigenetic studies in AD is based on a 
published review (Smith et al. 2016), which can be found in Appendix 1. 
 
1.1. Alzheimer’s disease  
 
Dementia is an umbrella term that encompasses a large number of neurological 
diseases, including AD, Dementia with Lewy bodies (DLB), Vascular dementia 
(VaD), Huntington’s disease (HD) and Parkinson’s disease (PD) dementia. 
Each disease has phenotypic symptoms or pathological hallmarks that are 
specific to that disease; however they all result in the deterioration of the mental 
ability of patients leading to a demented state. AD is a progressive 
neurodegenerative disorder characterised by the accumulation of amyloid-beta 
(β-amyloid) plaques and neurofibrillary Tau tangles (NFTs) within the brain 
(Querfurth et al. 2010) and accounts for approximately 60% of the dementia 
prevalence around the world (Fratiglioni et al. 1999). 
 
1.1.1. Types of AD   
 
AD is sub-categorised into early onset (EOAD), which occurs before the age of 
65 and late onset (LOAD), which occurs after 65 years of age. EOAD accounts 
for a very small percentage (1-5%) of total AD cases and is usually caused by 
autosomal dominant mutations in one of three genes (Amyloid precursor protein 
(APP), Presenilin1 (PSEN1) and Presenilin2 (PSEN2)) (Bekris et al. 2010). As a 
result this form of AD is directly heritable and is termed familial AD (FAD). 
Although AD is typically thought to be a disease of old age, EOAD can present 
considerably earlier, in patients as young as 40.   
 
LOAD is far more common, accounting for ~95% of AD incidence. Apart from 
the difference in age of onset, the characteristic pathological hallmarks of these 
two classes of AD are very similar. However, one study has shown significant 
differences in the Praxis, which tests the ability to correctly imitate hand 
gestures and voluntarily mime tool use and Temporal Orientation performance, 
which is related to a tendency for impairment in visual memory of EOAD 
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compared to LOAD patients.  This suggests a localised disease sub-type 
specific development, with EOAD patients having a greater left posterior 
hemisphere susceptibility and LOAD having a more localized disease to the 
limbic structures (Sá et al. 2012).  
 
1.1.2. Prevalence and economic burden 
 
An estimated 28 million people around the world are currently living with AD, 
with this figure predicted to continue rising (Prince et al. 2015); the number of 
people living with AD in Western Europe alone is projected to increase from 5 
million in 2015 to over 9.5 million by 2050 (Prince et al. 2015). In the UK 
specifically, over 560,000 people are currently living with AD (Prince et al. 
2014). In 2015, the leading cause of death for women and the second leading 
cause for men in the UK was AD and other dementias, accounting for 15% and 
8% of deaths, respectively (McLaren 2015). This has put a growing strain on the 
health care systems in the UK and around the world, with 42% of unplanned UK 
hospital admissions, being from people over the age of 70 suffering from 
dementia (Sampson et al. 2009).  
 
Coupled to this high demand for care comes a substantial cost; an estimated 
£13.8 billion is spent on AD care each year in the UK. This is comprised of 
health care costs of £800 million, social care costs of £5.5 billion and the 
greatest cost being the £7.5 billion value for the time given by unpaid carers of 
AD patients. Due to an increasingly ageing population this is predicted to rise to 
£39.3 billion by 2050 (Lewis et al. 2014). This pattern is reflected globally, with 
the cost of AD projected to reach $0.6 trillion dollars by 2018 and will double to 
$1.2 trillion by 2030 (Wimo et al. 2017). 
 
1.1.3. Disease progression  
 
The progression of AD is typically slow and is comprised of three general 
stages — mild (early-stage), moderate (middle-stage) and severe (late-stage). 
Specific AD symptoms vary between patients and occur at different times in the 
disease progression. Despite this, the most common earliest symptoms are a 
worsening ability to retain new information leading to disruptions in daily routine. 
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This is followed by a difficulty in planning/solving problems, confusion related to 
time and/or place, speech trouble and mood/personality changes (Burns et al. 
2009). Although the progression of disease is patient-specific the late stages 
tend to result in a lack of patient movement (Brunnström et al. 2009). At that 
point there is an increased risk of infections such as aspiration pneumonia, 
which is the leading cause of death in AD patients (Leonard 2011). As a result 
of the differing symptom severity between patients, being able to distinguish 
different stages in a clinical setting is challenging, this is made even more 
complex by inaccessibility of the brain for diagnostic testing and the delay 
between pathological and symptomatic onset. By the time individuals become 
symptomatic, there is already considerable neuronal cell loss, plaque 
deposition, and tangle burden within the brain, which can appear up to 10 years 
before a clinical diagnosis is made (Jack et al., 2010). As such, the only reliable 
method of AD diagnosis is a post-mortem measure of NFT pathology spread 
throughout the brain, called Braak staging (Braak et al. 1991). Braak stages I/II 
are used when neurofibrillary tangle pathology is confined mainly to the 
transentorhinal region of the brain, stages III/IV when there is also involvement 
of limbic regions, and V/VI when there is extensive neocortical involvement 
(Braak et al. 1991). As such, the earliest site of AD pathology is the entorhinal 
cortex (EC) which exhibits increased pathology as Braak staging progresses. 
The cerebellum has the lowest levels of NFT pathology even at the very last 
stages of disease (Braak et al. 1989). Both EC and CER were assessed in this 
thesis, as they represent high and low levels of pathology respectively.  
 
1.1.4. Causes of AD 
 
Although the neuropathology in AD has now been well characterised, the exact 
mechanisms driving disease onset and progression are still poorly understood. 
The focus of research is slowly shifting to drug targets and treatment strategies; 
however the vast majority of current AD research is still primarily focussed on 
aetiology, investigating molecular causes of disease.  Research to date has 
nominated three main hypotheses as to the cause of disease pathology: the 
amyloid cascade hypothesis, the tau tangle hypothesis and the inflammatory 
hypothesis. 
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1.1.4.1. Amyloid cascade hypothesis 
 
The amyloid cascade hypothesis is built around the presence of extracellular Aβ 
plaques in the brain of AD patients. Intermembrane bound APP is cleaved by 
Beta (β) secretase and Gamma (γ) secretase leaving a long amino-acid strand 
(sAPP-β) and a short amino acid strand (β-amyloid). These soluble β-amyloid 
protein monomers aggregate to form dense insoluble plaques. These plaques in 
turn cause neuritic injury, neuronal dysfunction and cell death, leading to AD 
(Hardy et al. 1992) (Figure 1.1). There are however numerous reports that the 
soluble β-amyloid precursors of these plaques are the cause of pathology, as 
they show greater correlation with AD symptoms than plaque burden (Lue et al. 
1999, Naslund et al. 2000). It is hypothesised that that the APOE protein binds 
β-amyloid directly, with the protein encoded by the ε4 allele having a greater 
affinity for β-amyloid than the corresponding ε3 or ε2 alleles (Strittmatter et al. 
1993, Strittmatter et al. 1993, Sanan et al. 1994). However, this was disputed in 
1994 when the reverse was shown to be true (LaDu et al. 1994). More recent 
work has shown that the level of APOE affinity for β-amyloid is dependent on 
the lipidation status of APOE (Carter 2005), Further details on APOE and 
hypotheses involving its role in AD can be found in Section 1.1.4.3.   
 
 
1.1.1.1. Tau tangle hypothesis  
 
The presence of NFTs of hyperphosphorylated tau in the brain correlates more 
closely with neurodegeneration and disease symptoms than β-amyloid plaques 
(Figure 1.2). β-amyloid plaque levels plateau at their highest amount before the 
earliest cognitive symptoms appear in patients (Jack et al. 2010). Tau 
pathology, on the other hand, is still rising as patients experience mild cognitive 
decline and plateaus when patients reach full dementia status (Jack et al. 
2010). Tau is a microtubule-associated protein (MAP), which is involved in the 
polymerisation of tubules and maintenance of neuronal structure. 
Hyperphosphorylation of the tau protein causes the removal of tau from the 
microtubule structure leading to destabilisation and degradation. 
Phosphorylated tau aggregates and form paired helical filaments (PHFs) and 
further disrupts normal microtubule function, mainly in the organisation of 
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cytoplasm (Kosik et al. 1986). PHF deposition leads to NFTs, a primary 
pathological hallmark of AD (Figure 1.3).  The tau protein is actively 
phosphorylated in pathology-free individuals and is a mechanism of regulating 
neuronal axon length. It is therefore thought that this phosphorylation must be 
tightly regulated by phosphatases such as tau protein phosphatase (Gotz et al. 
2001). Decreased function of this class of enzyme may be one possible 
explanation for the accumulation of NFTs in AD. β-amyloid has been found to 
have an effect on the deposition of NFTs increasing levels five-fold in transgenic 
mouse models, further highlighting the multifactorial nature of AD pathology 
(Gotz et al. 2001).  
2
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    Figure 1.2; Graphical representation of the onset of pathological hallmarks of 
AD in relation to symptomatic onset. (Taken from (Imagilys 2015)) 
Figure 1.3; Schematic highlighting pathological changes in tau in AD. Tau 
protein hyperphosphorylation leads to the formation of Paired Helical Filaments 
(PHFs) and ultimately Neurofibrillary Tangles (NFTs), one of the major hallmarks of 
AD. 
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1.1.1.2. Inflammatory hypothesis 
 
Both tau tangles and β-amyloid plaques are detrimental aggregates that occur 
in AD brain. These protein oligomers are usually cleared by microglial-regulated 
processes, before they have an impact on neuronal health and function (Daniel 
Lee et al. 2010). An impaired immune response could lead to errors in the 
clearance of these proteins in the brains of affected patients. Several studies 
have shown that the normal process of physiological ageing causes the 
pathological conformational changes of microglia (Norden et al. 2013), the 
immune regulators of the brain (Sheng et al. 1997), into a pre-activated state, 
termed priming. Increased expression of inflammatory markers including MHC 
class II and complement receptor 3 (CR3 - Cd11b/CD18) have been observed 
in the aged human and mouse brain (Streit et al. 2004, Godbout et al. 2005).  In 
addition, evidence of activated microglial morphology has been identified in 
aged models of the brain; staining microglia for the cell surface protein Iba1 
indicates that microglia from non-diseased healthy aged brains have shorter 
and less branched dendrites than those in younger animals (Choi et al. 2007, 
Hwang et al. 2008), morphology typical of primed microglia. Under standard 
homeostatic conditions, the function and abundance of microglia within the CNS 
is tightly regulated. However, in response to the aforementioned tau tangles and 
β-amyloid aggregates, primed microglia, which are hypersensitive to 
inflammatory stimuli, cause an exaggerated inflammatory response (Perry et al. 
2014). The increased response resulting from this could, in turn, lead to further 
neuronal damage. This theory has been termed the inflammatory hypothesis 
(Figure 1.4).      
 
 
 
3
0
 
 F
ig
u
re
 1
.4
; S
c
h
e
m
a
tic
 s
h
o
w
in
g
 th
e
 p
o
te
n
tia
l ro
le
 o
f m
ic
ro
g
lia
 in
 A
D
. R
e
s
tin
g
 m
ic
ro
g
lia
 b
e
c
o
m
e
 p
rim
e
d
 b
y
 th
e
 n
o
rm
a
l p
ro
c
e
s
s
 o
f a
g
e
in
g
. W
ith
 
s
e
c
o
n
d
a
ry
 in
s
u
lt (i.e
. N
F
T
s
 a
n
d
 β
-a
m
y
lo
id
 p
la
q
u
e
s
) th
e
s
e
 m
ic
ro
g
lia
 g
o
 th
ro
u
g
h
 a
 c
o
n
fo
rm
a
tio
n
a
l c
h
a
n
g
e
 in
to
 a
 fu
lly
 a
c
tiv
a
te
d
 fo
rm
, w
h
ic
h
 h
a
v
e
 a
 
n
e
u
ro
to
x
ic
 p
h
e
n
o
ty
p
e
. T
h
e
s
e
 m
ic
ro
g
lia
 p
ro
d
u
c
e
 p
ro
-in
fla
m
m
a
to
ry
 fa
c
to
rs
 th
a
t c
a
u
s
e
 d
a
m
a
g
e
 to
 th
e
 n
e
u
ro
n
e
s
 o
f a
n
 A
D
 p
a
tie
n
t’s
 b
ra
in
.  
 
 
31 
 
1.1.1.3. Genetic mechanisms 
 
Quantitative genetic analyses have demonstrated high heritability estimates (58%-
79%) for AD (Gatz et al. 2006), and thus initial approaches to understanding 
aetiology have focused on uncovering a genetic contribution to disease 
susceptibility. In recent years, the recruitment of large cohorts and the now relatively 
inexpensive cost of assessing genetic variation through genome-wide association 
studies (GWAS) has allowed the identification of multiple variants associated with an 
elevated risk of developing AD. Many of these genes have also been robustly 
associated with AD via subsequent meta-analyses (Harold et al. 2009, Sleegers et 
al. 2010, Hollingworth et al. 2011, Naj et al. 2011, Lambert et al. 2013); in addition to 
the well documented APOE ε4 allele, 19 GWAS loci were identified by Lambert et al. 
(2013) in the largest AD meta-analysis of GWAS to date (Table 1.1). Since then, 
polygenic risk scores (PRS) for AD have also been developed (Escott-Price et al. 
2015). Collectively, common single nucleotide polymorphisms (SNPs) are believed 
to only account for 33% of the attributed risk of disease (Ridge et al. 2013) and the 
mechanisms behind their action remains largely unknown. Exome-sequencing 
projects have also identified other variants e.g. TREM2 (Guerreiro et al. 2012), which 
have a larger effect size, yet are relatively rare in the standard population.  
 
By far the most robust genetic loci associated with LOAD development risk is the 
APOE ε4 allele. The rate of β-amyloid monomer aggregation is thought to be 
affected by APOE genotype status. Inheritance of two APOE ε4 alleles infers a 
considerably higher risk of inheriting AD at some point in a person’s lifetime (Corder 
et al. 1993). However the inheritance of the APOE ε2 allele actually infers a 
protective effect from neurodegenerative disease (Corder et al. 1994) and APOE ε3 
has no effect on disease risk. Hypotheses as to the role the APOE protein plays in 
the process of β-amyloid congregation are varied and contradictory. The first theory 
revolves around APOE’s role as the major protein component of very low density 
lipoproteins (vLDL), the major apolipoprotein within the brain. Research has shown 
that high levels of LDL cholesterol in the brain correlate with AD pathology post-
mortem (Kuo et al. 1998). Specifically, the quantity of cholesterol in the neuronal 
plasma membrane has been shown to make neurones more susceptible to the 
damage caused by β-amyloid in AD (Arispe et al. 2002). Other studies suggest that 
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cholesterol acts directly on the amyloid cascade by promoting pathogenic processing 
of APP (Mattson 2004); work in APP mutant transgenic mice has shown that 
cholesterol metabolism can increase the production of β-amyloid (Puglielli et al. 
2003). Another hypothesis regarding the role APOE plays in AD pathology revolves 
around its ability to clear amyloid deposits in certain conditions based on APOE’s 
concentration within the brain/cerebrospinal fluid (CSF) (Cruchaga et al. 2012). The 
concentration of proteins is thought to vary as a function of the APOE allele(s) 
inherited. However, studies have shown that the presence of the APOE ε4 allele 
leads to lower concentrations of the resulting protein in the plasma, but no significant 
change in CSF levels (Rezeli et al. 2015), with further work showing that plasma 
APOE levels have no effect on disease susceptibility (Simon et al. 2012). Recent 
work by Chung et al. (2016) supports an alternative theory, by showing that APOE 
isoforms have profound effects on the accumulation of complement protein C1q in 
ageing brain. C1q is an important factor in the rate of astrocytic turnover of 
synapses. More specifically it has been found that the APOE ε2 allele increased 
synaptic phagocytosis by astrocytes, whereas APOE ε4 caused a decrease, 
potentially leading to the build-up of senescent synapses, leading to 
neurodegenerative diseases such as AD (Chung et al. 2016).  
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SNP Chr.  Position  Gene Name Alleles Meta P  
rs6733839 2 127892810 BIN1 C/T 6.9 × 10−44 
rs10792832 11 85867875 PICALM G/A 9.3 × 10−26 
rs9331896 8 27467686 CLU T/C 2.8 × 10−25 
rs6656401 1 207692049 CR1 G/A 5.7 × 10−24 
rs983392 11 59923508 MS4A6A A/G 6.1 × 10−16 
rs4147929 19 1063443 ABCA7 G/A 1.1 × 10−15 
rs11218343 11 121435587 SORL1 T/C 9.7 × 10−15 
rs28834970 8 27195121 PTK2B T/C 7.4 × 10−14 
rs11771145 7 143110762 EPHA1 G/A 1.1 × 10−13 
rs9271192 6 32578530 
HLA-DRB5– HLA-
DRB1 
A/C 2.9 × 10−12 
rs10948363 6 47487762 CD2AP A/G 5.2 × 10−11 
rs1476679 7 100004446 ZCWPW1 T/C 5.6 × 10−10 
rs2718058 7 37841534 NME8 A/G 4.8 × 10−9 
rs10498633 14 92926952 SLC24A4 / RIN3 G/T 5.5 × 10−9 
rs17125944 14 53400629 FERMT2 T/C 7.9 × 10−9 
rs10838725 11 47557871 CELF1 T/C 1.1 × 10−8 
rs7274581 20 55018260 CASS4 T/C 2.5 × 10−8 
rs35349669 2 234068476 INPP5D C/T 3.2 × 10−8 
rs190982 5 88223420 MEF2C A/G 3.2 × 10−8 
 
Table 1.1; Genome wide significant genetic variants associated with AD. The largest 
GWAS meta-analysis of LOAD identified 19 loci that reached genome wide significance (P < 
5x10-8) (Lambert et al. 2013).   
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1.1.1.4. Non-genetic mechanisms 
 
Back in 2001 the “Challenging Views of Alzheimer's Disease” meeting discussed the 
proposition that environmental agents, such as diet, aluminium, and viruses, are as 
important as genetic factors in the aetiology of AD. Dietary levels of fat were found to 
be a significant risk factor for the development of AD in a dozen countries (Grant et 
al. 2002). This could be linked to the amyloid cascade hypothesis where it is 
suggested that high levels of CSF cholesterol can cause neurones to be more 
susceptible to β-amyloid derived damage. Diet, aluminium, and viral infections may 
increase the prevalence of AD through action of the inflammatory hypothesis, 
eliciting inflammation, which may cause the neurological damage that result in AD. A 
prospective analysis of risk factors for AD was performed in 2002, and not 
surprisingly found increasing age and fewer years of education to be the main risk 
factors for AD (Lindsay et al. 2002). Interestingly, no statistically significant 
association was found for family history of dementia, sex, history of depression, 
oestrogen replacement therapy, head trauma, antiperspirant or antacid use, 
smoking, high blood pressure, heart disease, or stroke. 
 
In recent years researchers have used epigenome-wide association studies (EWAS) 
to identify epigenetic changes in disease with the aim of elucidating additional novel 
mechanisms involved in aetiology, which may also provide a link between genetic 
and environmental factors. Epigenetic processes mediate the reversible regulation of 
gene expression, occurring independently of DNA sequence variation, acting 
principally through chemical modifications to DNA and nucleosomal histone proteins 
(Lunnon et al. 2013). Dynamic changes to the epigenome orchestrate a diverse 
range of important neurobiological and cognitive processes in the brain (Lunnon et 
al. 2013). Recent advances in genomic technology have allowed the first genome-
scale studies assessing methylomic variation in AD. These studies have identified 
AD-associated DNA methylomic variation at numerous loci in the cortex, with 
consistent findings across multiple independent study cohorts, in addition to brain-
region specific changes and blood DNA methylation signatures (De Jager et al. 
2014, Lunnon et al. 2014), which are discussed in more detail in Section 1.2.5. 
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1.2.  Epigenetics  
 
“Epi” literally means above, therefore, “epigenetics” is essentially information that is 
coded above the level of the standard genetic code. As such, epigenetics refers to 
alterations in gene expression, which are brought about by heritable, but potentially 
reversible, changes in chromatin structure and/or DNA modifications (Steven 
Henikoff et al. 1997). Although every nucleated cell in the human body contains the 
same genetic information, no two cell types are physiologically the same. This is due 
to a complex interplay of epigenetic mechanisms that regulate the expression of 
genes on a cellular basis. This regulation can be altered by a number of different 
stimuli. As such, epigenetic mechanisms are dynamic, allowing the cell to adapt to its 
environment without changing its underlying genetic code (Jaenisch et al. 2003) . 
However, this change can also be the cause of disease with many studies showing 
that changes in the epigenetic landscape can lead to various forms of cancer (Jones 
et al. 1999, Feinberg et al. 2004, Laird 2005, Esteller 2008, Rauch et al. 2012), and 
such changes have been hypothesised to play a role in various neurological 
diseases, such as AD (Mill 2011). As epigenetic modifications are transient, it gives 
credence to the idea that if an epigenetic cause for disease can be identified, 
reversing this change could be a feasible treatment method. 
 
1.2.1. Cytosine modifications  
 
DNA methylation, which modulates the transcription of mammalian genomes, is the 
best characterised and most stable epigenetic modification. This is due to its ability 
to be interrogated using archived genomic DNA resources, which are the focus of 
most human epidemiological epigenetic research to date (Lunnon et al. 2013). The 
methylation of a cytosine in a CpG dinucleotide, forming 5-methylcytosine (5mC), 
can disrupt the cell’s transcriptional machinery by blocking the binding of 
transcription factors and attracting methyl-binding proteins that initiate chromatin 
compaction and bring about gene silencing (Klose et al. 2006). The predominant 
focus to date is methylation within CpG Islands (CGIs), dense regions of CpG sites, 
located within the 5’ promoters of many constitutively expressed housekeeping 
control genes. However, recent data suggests that the relationship between 5mC 
and transcription may be more complex, with gene body methylation and non-CpG 
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methylation often being associated with active gene expression (Hellman et al. 2007, 
Ball et al. 2009, Lister et al. 2009, Rauch et al. 2009, Aran et al. 2011) and 
alternative splicing (Lyko et al. 2010, Flores et al. 2012). 
 
Further research has now demonstrated that other cytosine modifications not only 
exist, but may also have functional roles in gene regulation (Inoue et al. 2011, Ito et 
al. 2011).   These modifications include 5-hydroxymethylcytosine (5hmC), 5-
formylcytosine (5fC) and 5-carboxylcytosine (5caC), which occur as stages in the de-
methylation of cytosine (Breiling et al. 2015) (Figure 1.5). DNA Methyl transferase 
(DNMT) catalyses the addition of a methyl group to the fifth carbon of cytosine to 
generate 5mC. During demethylation 5mC is oxidised to 5hmC by the Ten-eleven 
translocation (TET) family of enzymes (Tahiliani et al. 2009, Ito et al. 2010). TET 
enzymes continue to oxidise 5hmC to 5fC and on to 5caC (Ito et al. 2011). 5fC and 
5caC can then be converted to unmodified cytosine following base-pair excision / 
Terminal deoxynucleotidyl transferase (TdT) (Guo et al. 2011). As such, these 
modifications were previously considered to only be transient changes, having no 
effect on gene transcription/regulation.  It has been suggested that DNA replication 
leads to a passive removal of 5hmC from the genome (Inoue et al. 2011), however 
work by Hashimoto et al. (2012) has shown that the DNA methyl transferase 3B 
(DNMT3B) shows an equal affinity for un-methylated, hemi-methylated or hemi-
hydroxymethylated DNA post replication, leading to the theory that 5hmC is also 
maintained during cellular replication (Hashimoto et al. 2012). Although considerably 
less abundant in the genome (Breiling et al. 2015), these modifications, especially 
5hmC, have recently been shown to be more stable than previously thought 
(Bachman et al. 2014). Recent research has found that 5hmC in particular has a 
significantly higher abundance in the brain compared to other tissues (Lister et al. 
2013). 5hmC was also found to be elevated and highly dynamic during foetal 
development (Wang et al. 2012, Spiers et al. 2017). These studies, coupled with 
advances in research methodologies, mean that 5hmC, and other modifications, are 
starting to be researched in the context of complex diseases, with recent studies 
demonstrating that 5hmC and 5mC have opposing effects on gene expression 
(Sherwani et al. 2015). 
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Figure 1.5; Cytosine modifications as stages of the de-methylation process. 
Cytosine can be methylated to 5mC by DNA methyltransferase (DNMT). 5mC can 
then be oxidised to 5hmC, 5fC and 5caC by ten-eleven translocation (TET) 
dioxygenases and through a process of base excision repair (BER) is returned to 
cytosine.  
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1.2.2. Histone modifications  
 
Cytosine modifications are by no means the full extent of the epigenetic mechanisms 
that regulate gene expression.  A complex interplay of DNA wound around octamers 
of core histone proteins to form nucleosomes, the basic component of chromatin 
(Figure 1.6), also plays a key role. This complex three-dimensional structure is found 
in the nuclei of all eukaryotic cells. The wrapping of the double stranded DNA helix 
around histone proteins enables the 10,000-20,000 fold level of compaction 
necessary to fit a genome into the small volume of the nucleus (Zentner et al. 2013). 
The level of chromatin compaction and therefore transcriptional ability is regulated by 
conformational changes to histone proteins including modifications such as 
methylation, phosphorylation, acetylation, ubiquitination, sumoylation, citrullination 
and adenosine diphosphate-ribosylation as well as other post-translational 
modifications of the amino acids that make up histone protein structure 
(Sadakierska-Chudy et al. 2015). These histone “tail” modifications regulate the level 
of accessibility of transcription start sites (TSS) and promotor regions within the DNA 
to transcription factors and other necessary cellular machinery required for 
transcription. This is done by shifting the chromatin from a condensed state 
(heterochromatin) to a more relaxed form (euchromatin). Acetylation and methylation 
are the most widely studied histone modifications (Table 1.2). Histone acetylation 
appears to be a ubiquitous marker of gene expression (Kim 2014).  The second most 
studied histone modification is methylation. The methylation of histones has differing 
effects on gene transcription based on which amino acid within the histone is 
methylated and the number of methylation groups per amino acid. Further details on 
histone methylation can be found in Section 5.1.  
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Figure 1.6; Nucleosome, the core component of chromatin. DNA is wrapped 
around the octameric nucleosome core of histone proteins which exist as dimers 
(H2A & H2B, H3 & H4) and then bound in position by a fifth linker histone protein 
monomer (H1/H5). Image taken from (Popa 2017) 
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Table 1.2; Major modifications of histone proteins and their impact on genetic 
function. Taken from (Kim 2014) 
 
 
 
 
 
 
 
 
 
Modification 
Position Mono-Methylation Di-Methylation Tri-Methylation Acetylation 
H2AK5 - - - Activation 
H2AK7 - - - Activation 
H2AK9 - - - Activation 
H2AK13 - - - Activation 
H2BK5 - - - Activation 
H2BK15 - - - Activation 
H2BK20 - - - Activation 
H2BK120 - - - Activation 
H3R2 Activation - - - 
H3K4 Activation Activation Activation - 
H3K9 
Activation/ 
repression 
Repression 
Activation/ 
repression 
- 
H3K14 - - - Activation 
H3R17 Activation - - - 
H3K18 - - - Activation 
H3K23 - - - Activation 
H3R26 Activation - - - 
H3K27 Activation Repression Repression Activation 
H3K36 - Activation Activation - 
H3K56 - - - Activation 
H3K79 Activation Repression Repression 
 
H3K115 - - - Activation 
H4R3 - Activation - - 
H4K5 - - - Activation 
H4K8 - - - Activation 
H4K12 - - - Activation 
H4K16 - - - Activation 
H4K20 
Activation/ 
repression 
Repression Repression Activation 
H4K59 Repression - - - 
H4K91 - - - Activation 
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Histone modifications have been shown to be largely restricted to transcribed 
regions of the genome, suggesting that their function is tightly linked to polymerase 
activity (Schübeler et al. 2004). Histone modifications occur in a highly cell-type-
specific manner at enhancers; interestingly however, there appears to be similar 
patterns of histone modifications at promotors between cell types.  This therefore 
suggests that enhancers are the most variable class of transcriptional regulatory 
element and probably drives the cell-type-specific gene expression patterns 
(Heintzman et al. 2009).  In heterochromatin, low levels of acetylation, methylation 
and phosphorylation can be detected on genes, however these levels are not 
sufficient to cause transcription. Typically euchromatin has higher levels of 
acetylation and is tri-methylated at H3K4, H3K36 and H3K79. The methylation of 
histone sites is typically associated with changes in gene transcription and DNA 
repair (Kouzarides 2007).  
 
1.2.3. Micro-RNAs  
 
Another interesting field of epigenetic regulation is the study of micro-RNAs 
(miRNAs), which also play a critical role in gene regulation.  Currently 2588 mature 
miRNAs are listed in release 21 of miRBase in the human genome across multiple 
human tissues, including the brain (Kozomara et al. 2014). The small 19-26 
nucleotide RNAs often originate from their own genes with their own promoter and 
regulatory regions (Bartel 2004). miRNAs regulate gene expression post-
transcriptionally by binding to their target mRNAs and inhibiting translation or, less 
often, inducing cleavage of the mRNAs (Bartel 2004). 
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1.3.  Epigenetic studies in AD 
 
Although many of the genomic studies to date have identified robust and 
reproducible findings of genetic variation linked to AD pathology, these do not 
account for all of disease incidence.  This, coupled with a number of disease 
attributes, are suggestive of an epigenetic contribution to pathology. For example, 
differential vulnerability of specific brain regions to pathology, the age of disease 
onset, environmental influences on disease and the absence of a statistically 
significant association of family history of dementia (Lindsay et al. 2002, Profenno et 
al. 2010). There have been numerous studies into the epigenetics of AD, for a 
detailed review see Smith et al. (2017). To date, three EWAS of DNA methylomic 
variation, in AD transgenic mice, have been published (Sanchez-Mut et al. 2013, 
Agbemenyah et al. 2014, Cong et al. 2014). Sanchez-Mut et al. (2013) identified a 
number of genes that were differentially methylated in diseased mouse brain, 
including Tbxa2r, F2rl2, Sorbs3 and Spnb. They were also able to translate these 
findings to patients with AD, identifying 5mC-associated silencing of TBXA2R, 
SORBS3 and SPTBN. Using methylated DNA immunoprecipitation (MeDIP)-chip 
Cong et al. (2014) and Agbemenyah et al. (2014) identified over 2000 
hypermethylated CpG sites. However, there are limitations to the utility of rodents for 
modelling human AD, for example mice do not naturally get AD symptoms or 
produce amyloid plaques; therefore transgenic mouse models of amyloid pathology 
are due to them producing human amyloid.  Currently no mouse model has all the 
features of human LOAD and these models are currently based on genetic mutations 
associated with familial AD. Therefore these mice simply model the effects of the 
accumulation of β-amyloid plaques and/or NFTs, rather than being a model of 
sporadic AD, which accounts for ~95% of cases.  However, the majority of epigenetic 
studies of AD have focussed on studying the human disease in post-mortem brain 
samples. As this is a new research field, to date epigenetic studies in AD post-
mortem brain have been generated by only a handful of researchers in a small 
number of research teams, this source of potential bias will resolve as research 
interest grows.  
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1.3.1. DNA Methylation in AD 
 
Attempts to characterise the global DNA methylome in AD brain using antibodies has 
shown reductions in 5mC across numerous brain regions (Mastroeni et al. 2009, 
Mastroeni et al. 2010, Chouliaras et al. 2013). However, other studies have not 
supported these findings (Bradley-Whitman et al. 2013, Condliffe et al. 2014, 
Coppieters et al. 2014, Lashley et al. 2015). Candidate gene studies aiming to 
identify AD-associated 5mC changes have been carried out in human blood (Bollati 
et al. 2011, Arosio et al. 2012, Furuya et al. 2012, Furuya et al. 2012, Di Francesco 
et al. 2013, Hernandez et al. 2014) and brain tissue (Sun-Chong Wang 2008, 
Barrachina et al. 2009, Brohede et al. 2010, Iwata et al. 2014, Silva et al. 2014). 
These studies targeted many of the genes nominated from genetic studies of familial 
AD, in addition to enzymes involved in DNA methylation, for example DNMT1.  
 
More recently, advances in epigenomic technology have allowed the quantification of 
DNA methylomic variation across the genome in AD. The first EWAS of AD (Bakulski 
et al. 2012) used the Illumina Infinium 27K Beadarray to quantify 5mC at ~27,000 
CpG sites in the frontal cortex of 12 late-onset AD donors and 12 cognitively normal 
matched control subjects. Despite low sample numbers their most significant loci 
was found in the TMEM59 gene, which is thought to be involved in APP processing. 
Sanchez-Mut et al. (2014) also used the 27K Beadarray to examine hippocampal 
samples from five control donors to those with early-stage AD (Braak I-II), mid-stage 
AD (Braak III-IV) and late-stage AD (Braak V-VI), demonstrating a >25% methylation 
difference between controls and Braak stage V–VI at single CpG sites within three 
genes: CLDN15, QSCN6 and DUSP22, however these results have not been 
replicated since.  Since then, the development of the Illumina Infinium 450K 
Beadarray (450K array), has allowed researchers to profile ~485,000 CpG sites. De 
Jager et al. (2014) used this technology in a large cohort of 708 prefrontal cortex 
samples to examine DNA methylomic differences associated with neuritic plaque 
burden. They identified 71 differentially methylated probes, 11 of which were 
replicated by Lunnon et al. (2014). Furthermore, altered gene expression with AD 
pathology was found in seven of the replicated differentially methylated genes in 
separate temporal cortical samples, including the ANK1 gene. Simultaneously, 
Lunnon et al. (2014) performed a cross-tissue analysis of 5mC changes associated 
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with Braak Stage using the 450K Beadarray in a discovery cohort of 117 individuals. 
Combining EWAS data from different cortical brain regions from the same donors, 
they were able to identify a number of consistently differentially methylated loci, 
which included CpG sites in the ANK1 gene.  They confirmed this region of Braak-
associated DNA hypermethylation in ANK1 in an independent 450K EWAS dataset 
of 146 cortical brain samples, and in a separate replication cohort of 62 samples, 
where they used pyrosequencing to look at an extended region of eight CpG sites in 
the ANK1 gene. This showed that the differentially methylated region (DMR) in ANK1 
in AD cortex spanned at least six CpG sites. Watson et al. (2016) also used the 
450K Beadarray platform to identify AD-related 5mC changes in the superior 
temporal gyrus in 34 AD cases and 34 non-demented controls matched by age at 
death, race, and sex. They also showed overlap between their most significant 
DMRs and those loci nominated by the Lunnon et al. and De Jager et al. studies. 
Since, a number of further studies have built on these now publically available 
EWAS datasets, looking for associations in genetic risk variants for AD from GWAS 
(Chibnik et al. 2015), or exome sequencing studies (Smith et al. 2016).  
 
1.3.2. Other epigenetic modifications in AD  
 
To date studies of 5hmC in AD brain have been largely limited to global profiling 
methods, with conflicting results. Two studies have shown global decreases in 5hmC 
in the hippocampus (Chouliaras et al. 2013), EC and CER (Condliffe et al. 2014), 
with another study showing increased 5hmC in the middle frontal gyrus and middle 
temporal gyrus (Coppieters et al. 2014), whilst a fourth study revealed no difference 
in the EC (Lashley et al. 2015). Previous publications, described in Section 1.3.1, 
that used bisulfite treatment to assess DNA methylation have in fact, profiled the 
combination of both 5mC and 5hmC as a combined measure. This is due to 5hmC 
reacting with bisulfite to form 5-methylenesulfonate which, similarly to 5mC, does not 
undergo C-to-T transition following PCR (Huang et al. 2010). This means previous 
5mC results are confounded by 5hmC suggesting that genes of interest have been 
missed. One recent study claimed to have undertaken the first EWAS of 5hmC in AD 
used a selective chemical labelling technique to enrich for 5hmC, and then 
sequenced captured libraries from a small cohort of 30 individuals with either AD, 
mild cognitive impairment (MCI) or no dementia (Zhao et al. 2017). However, due to 
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low sequencing resolution, this study’s analysis was unable to discriminate between 
5hmC and 5mC and as such; an EWAS of 5hmC in AD is still required. 
 
Histone modifications have also been studied in respect to AD pathology. Two 
studies, looking at APP/PS1 transgenic mice and human post-mortem temporal lobe 
respectively, have identified a significantly lower amount of histone acetylation at a 
global level (Francis et al. 2009, Zhang et al. 2012).  However, work by Walker et al. 
(2013) has found higher H3 and H4 acetylation levels in neurones from a 3x 
transgenic AD mouse model (PS1, APP and MAPT) compared to controls. Finally, 
Rao et al. (2012) found global histone phosphorylation in post-mortem frontal cortex, 
although they only analysed a small (N = 20) number of individuals. In summary, 
although there has been a rapid increase in the amount of epigenetic research in 
AD, further research is required to establish the role of 5hmC and histone 
modifications in the disease. 
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1.4.  Integration of genetic and epigenetic studies to identify dysfunctional AD 
pathways  
 
Although GWAS and EWAS analyses have identified multiple genes associated with 
AD, with the exception of BIN1 the genetic location of loci identified do not overlap. 
However, a number of overlapping pathways have been identified between 
published GWAS and EWAS studies, highlighting dysfunctional synaptic, lipid 
metabolism, plasma membrane/cytoskeleton, mitochondrial and immune cell 
activation pathways (Smith et al. 2016). The identification of common pathways 
altered in genetic and epigenetic studies will aid our understanding of disease 
mechanisms and identify potential novel targets for pharmacological intervention.  
 
1.4.1. Plasma membrane/cytoskeleton 
 
We have previously reported that the plasma membrane/cytoskeletal pathway 
contains the largest number of loci nominated from published GWAS and EWAS 
studies (Smith et al. 2016). The plasma membrane insulates the intracellular 
components from the extracellular environment, as well as catalysing the transport of 
specific compounds, including nutrients and ions. Phospholipids that make up the 
membrane provide suitable fluidity and permeability. Alterations in the receptor 
function, membrane integrity, and membrane-dependent processes seen in AD have 
been previously reviewed (Farooqui et al. 1995). The cytoskeleton provides 
contractility and couples biochemical responses with mechanical stresses in cells. It 
is vital in the movement of cellular machinery around the cell and to the membrane, 
as well as orchestrating the procedures needed for cellular movement and re-
shaping, a function important in the microglial cells of the brain in the response to 
inflammatory stimuli (Sheng et al. 1997). For an overview of cell mechanics and the 
cytoskeleton see the review by Fletcher et al. (2010). The inability of neurones to 
regulate calcium homeostasis through cell surface ion channels is an aspect of AD 
pathogenesis that appears to be intimately involved in the dysfunction and death of 
neurones (Mattson 2004). Familial AD mutations in APP and PSEN1 support a role 
for perturbed calcium regulation in AD (Mattson 2004). In addition, all of the 
enzymatic machinery responsible for the generation of the pathogenic β-amyloid 
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species are plasma membrane based (Lukiw 2013); suggesting that damage to the 
plasma membrane may be the cause of β-amyloid pathology typical of AD.   
 
BIN1 has been nominated by both GWAS and EWAS, and in addition to its role in 
synaptic signalling, it also has a role in plasma membrane/cytoskeletal processes as 
it acts as an amphiphysin, which are known to promote caspase-independent 
apoptosis as well as play an important role in neuronal membrane organisation 
(Wigge et al. 1997). Major learning defects and seizures have been linked to 
decreased expression of amphiphysins in murine brain (Di Paolo et al. 2002). In 
addition, altered expression of BIN1 has been shown in ageing mouse models of AD 
(Yang et al. 2008), providing further evidence for its role in AD pathology. Despite 
having no previous link to AD, ANK1 is now one of the strongest reported candidate 
genes in AD EWAS as described in Section 1.3.1, with strong links to cell structure. 
ANK1 is found in multiple different isoforms and is expressed at different levels 
throughout the brain (Gallagher et al. 1997), with some evidence for differential 
splicing in AD (Lunnon et al. 2014). As with BIN1, one of the main functions of ANK1 
is compartmentalisation and maintenance of the plasma membrane and it is possible 
that the altered expression of this gene could lead to neuronal membrane 
dysfunction in AD (Lunnon et al. 2014).  
 
The PVRL2 gene identified by GWAS encodes a single-pass type I membrane 
glycoprotein, which is one of the plasma membrane components of adherens 
junctions. Cell to cell connections brought about by adherens junctions are vital for 
effective neuronal signalling (Marambaud et al. 2002). Interestingly, Marambaud et 
al. (2002) used various immunological based methods to investigate the PSEN1/γ-
secretase system, where mutations are associated with familial AD, and showed it 
disrupted adherens junctions in AD. Expression of PVRL2 has been detected in 
many organs including the brain, and it was later suggested it was associated with 
human longevity along with the AD GWAS nominated loci TOMM40 and APOE (Lu 
et al. 2014). In addition, Elias-Sonnenschein et al., showed a significant correlation 
between the GWAS nominated locus MS4A4A and β-amyloid pathology, but not with 
tau pathology in AD (Elias-Sonnenschein et al. 2013). Despite this, there is little-to-
no research on the specific function of MS4A4A, although the gene product is 
associated with GO pathways that indicate it is an integral component of the plasma 
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membrane. However, GO pathways have limited value as they are based on 
incomplete gene annotations, with a large number of genes that are not linked to any 
pathway (Khatri et al. 2012).  
 
1.4.2. Lipid homeostasis  
 
Recent epidemiological, molecular and biochemical evidence has strengthened the 
hypothesis that cholesterol is a risk factor for AD, and although cholesterol 
homeostasis in the brain is largely unexplored, new findings strongly support the 
involvement of cholesterol in both the generation and deposition of β-amyloid 
(Puglielli et al. 2003). Specifically, the quantity of cholesterol in the neuronal plasma 
membrane has been shown to make neurones more susceptible to the damage 
caused by β-amyloid in AD (Arispe et al. 2002). Other studies suggest that 
cholesterol acts directly on the amyloid cascade by promoting amyloidogenic 
processing of APP (Mattson 2004). Interestingly, statins, which are a class of 
cholesterol-lowering drugs, decrease β-amyloid levels as well as plaque deposition 
in APP transgenic mouse models (Fassbender et al. 2001). In addition, high 
cholesterol levels and changes to cholesterol metabolism can increase the 
production of β-amyloid in cell culture and mouse models (Puglielli et al. 2003). 
Three of the most significant genes identified in AD GWAS are associated with lipid 
metabolism (APOE, APOC1, CLU). APOE was first identified as a genetic risk factor 
for AD in 1993 (Strittmatter et al. 1993), using immuno-staining and genotyping 
analysis of 30 AD cases and 91 controls. Since 2006, and the wide application of 
GWAS to AD research (Grupe et al. 2007), the APOE polymorphism has been 
successfully replicated in several other studies (Coon.; et al. 2007, Abraham et al. 
2008, Kramer et al. 2011, Logue et al. 2011, Meda et al. 2012, Ramanan et al. 
2014), making APOE the most robust gene linked to LOAD risk to date. The 
proportion of genetic variance for LOAD risk attributed to APOE genotype is 
estimated to be 10–20% (Slooter et al. 1998). APOE is a 299 amino acid 
glycoprotein and the major protein component of vLDL, the major apolipoprotein in 
the brain (Puglielli et al. 2003), as well as having a functional role in cholesterol and 
triglyceride metabolism (Breslow et al. 1982). There are three APOE alleles that 
affect one’s risk of developing AD (2, 3 and 4), in addition to age of onset (Roses 
1996). Of the three alleles; APOE 2 demonstrates a protective effect, with an OR of 
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0.3 for possessing one 2 allele, whilst APOE 4 is associated with a higher LOAD 
risk, with an OR of 4.4 and 19.3 respectively for having one or two alleles (Corder et 
al. 1994), as well as a younger median age of dementia onset (Corder et al. 1994, 
Reiman et al. 2007). It has been suggested that the mutated APOE hinders 
clearance of soluble β-amyloid protein from the brain, leading to the hallmark β-
amyloid aggregation into fibrils. Furthermore, APOE has been shown to promote 
neurodegeneration by directing the toxic β-amyloid oligomers to synapses (Ramanan 
et al. 2014). However, a recent positron-emission tomography (PET) study to 
measure β-amyloid in 602 individuals found that the ε4 allele is neither necessary, 
nor sufficient, for the development of AD pathology (Ramanan et al. 2014).  
 
SORL1 has been identified in several genomic studies of AD, using GWAS and 
exome sequencing methods (Rogaeva et al. 2007, Miyashita et al. 2013). In addition, 
Yu et al. found epigenetic changes in this gene when they investigated 5mC 
changes in candidate genes in AD EWAS data (Yu et al. 2014). It has many 
functional domains with different functions, including cargo transport, chaperone-like 
activity, signalling, and intracellular sorting (Jacobsen et al. 2001). When acting as a 
sorting receptor, the SORL1 gene product protects APP from being directed to the 
endosome where it would be cleaved by β-secretase, producing β-amyloid 
(Louwersheimer et al. 2015). Further, SORL1 can bind APOE, making SORL1 an 
important component in the pathophysiology of AD (Elias-Sonnenschein et al. 2013). 
 
1.4.3. Synaptic signalling  
 
Synaptic dysfunction is possibly the best-established of all the proposed pathological 
mechanisms for AD to date as it shows clear progression throughout the entire 
disease, including pre-symptomatic changes (Masliah et al. 2001). Early stages of 
AD are characterised by a 25-35% decrease in numerical density of synapses per 
cortical region (Davies et al. 1987). There has also been evidence that the loss of 
synapses correlates with the soluble pool of cortical β-amyloid (Lue et al. 1999). 
Stereological and biochemical analyses have shown that the reduction in synaptic 
density within the AD brain correlates with cognitive defects better than the 
traditional hallmarks of β-amyloid plaques and neurofibrillary tangles (Masliah et al. 
2001).  
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Four genes from GWAS and EWAS analyses of AD are linked to synaptic function 
(Smith et al. 2016). Two of these, BIN1 and PICALM, have functions in vesicular 
trafficking. Specifically, studies have shown that the BIN1 gene has roles in a 
number of specific pathways, including clathrin-mediated endocytosis (CME) which 
is an essential step in the intracellular trafficking of proteins and lipids such as 
nutrients, growth factors and neurotransmitters in synapses (Dreyling et al. 1996, 
Wigge et al. 1998, Cousin et al. 2001). Originally identified as a tumour suppressor 
(Sakamuro et al. 1996), the BIN1 gene product is expressed most abundantly in 
brain and muscle (Wechsler-Reya et al. 1997), with several alternatively spliced 
brain specific isoforms. BIN1 is one of the few genes that has been reproducibly 
identified by GWAS that does not fall near or within the APOE locus, in addition it is 
the only gene to be significantly associated with AD in both GWAS and EWAS.  
 
Like BIN1, PICALM is also involved in CME (Dreyling et al. 1996). PICALM directs 
the trafficking of the VAMP2 protein. VAMP2 is a SNARE protein that plays a key 
role in the fusion of vesicles to the presynaptic membrane allowing neurotransmitter 
release into the synapse, a process essential to neuronal function (Harel et al. 2008). 
PICALM has been robustly identified as a risk factor for AD via GWAS (Harold et al. 
2009, Seshadri et al. 2010), however, AD linked SNPs identified in PICALM may still 
be affected by APOE genotype, due to the large amount of attenuation seen when 
adjusted for APOE status (Hu et al. 2011). Jun et al. have also reported this 
interaction observing that genotypes of PICALM conferred risk predominantly in 
APOE ε4–positive participants, providing strong evidence for a synergistic effect (Jun 
et al. 2010). PICALM is also thought to affect APP processing via endocytic 
pathways (Harold et al. 2009).  
 
As a previously known risk factor gene for AD (Lambert et al. 2013), PTK2B was 
shown via network analysis to be linked to the recently identified loci in RHBDF2, 
ANK1 and RPL13 from AD EWAS, providing further evidence for a role in AD 
pathology (De Jager et al. 2014). PTK2B has a number of roles including the 
induction of long term potentiation of nerve cells, a central process of memory 
formation; cell migration and synaptic function (Lambert et al. 2013). 
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1.4.4. Immune cell dysfunction (astrocytes, oligodendrocytes and microglia) 
 
There is a widely accepted link between inflammation, the immune system and AD 
pathology (Haruhiko Akiyama 2000, Tuppo et al. 2005, Salminen et al. 2009, Adriana 
Martorana et al. 2012, Monson et al. 2014) , more specifically the inflammation seen 
in AD has been proposed to exacerbate symptoms (Haruhiko Akiyama 2000). 
Microglia, which are the brain’s resident macrophages, have been shown to increase 
their viability by 22.0~29.4% in response to fibrillar β-amyloid deposits of 0.2 to 
5.0μM, which are commonly seen in AD. Oligomeric β-amyloid at a dose of 5.0μM 
results in cytotoxic microglia (Pan et al. 2011) and ultimately leads to synaptic 
degeneration and neuronal death (Barger et al. 2001). However, relatively few genes 
that have shown robust associations with AD have been directly linked with 
inflammation or immune functions. Most noteworthy a rare variant in TREM2, 
considerably enriched in AD, was recently recognised by a number of AD exome 
sequencing and GWAS projects (Forabosco et al. 2013, Guerreiro et al. 2013, 
Harald Neumann 2013, Jonsson et al. 2013). TREM2 encodes an innate immune 
system receptor on the surface of microglial cells within the brain. With the signalling 
counterpart DAP12 (also called TYROBP) TREM2 forms a molecular complex that 
promotes phagocytosis of bacteria (N'Diaye et al. 2009). Work by Takahashi et al. 
has shown that TREM2 also has a role in the clearance of apoptotic neurones, due 
to its ability to increase migration and phagocytosis of microglia (Takahashi et al. 
2005). Recently one study demonstrated correlation in TREM2 and CD33 gene 
expression in AD (Chan et al. 2015). As CD33 has also been nominated in various 
AD GWAS (Hollingworth et al. 2011, Naj et al. 2011, Kamboh et al. 2012) this 
provides further evidence for an overlap of AD gene pathways in disease. As 
described above, recent protein-protein interaction data also demonstrated that 
several EWAS nominated loci (ANK1, RHBDF2, PICLAM) have a functional link to 
PTK2B (De Jager et al. 2014). PTK2B is an AD risk factor gene that plays a key role 
in the signalling cascade involved in the modulation of microglial and infiltrating 
macrophage cell activation (De Jager et al. 2014).  
 
A further gene related to immune function is RHBDF2, identified by EWAS. 
Differentially methylated CpG sites close to the RHBDF2 gene were identified in two 
independent EWAS (De Jager et al. 2014, Lunnon et al. 2014), which increases 
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RHBDF2 expression in AD brain (De Jager et al. 2014). RHBDF2 transports TNFα 
converting enzyme (TACE, also called ADAM17), which is necessary for the release 
of TNFα from the cell surface (Adrain et al. 2012). RHBDF2 absence in mice affects 
the release of TNFα from the cell surface (Siggs et al. 2012) and therefore impairs 
systemic immune responses to pathogens (McIlwain et al. 2012), although the brain 
phenotype has yet to be researched.  
 
1.4.5. Mitochondrial processes  
 
Mitochondrial dysfunction is one of the most prominent characteristics of AD, in both 
the brain and the periphery (Lunnon et al. 2012, Devall et al. 2014, Devall et al. 
2016), with one of the most robust genes identified from GWAS associated with 
mitochondrial function (TOMM40). This gene is located approximately 2kb 
downstream from APOE and due to the locality of these two genes there is strong 
linkage disequilibrium (LD) for TOMM40 with the APOE locus (Feulner et al. 2010), 
hence many studies have failed to find an association of TOMM40 in AD after 
adjusting for APOE genotype (Yu et al. 2007, Wijsman et al. 2011, Ramanan et al. 
2014). However, one study reports TOMM40 as a possible risk factor for AD 
independent of APOE genotype (Lutz et al. 2010). Specifically this study found a 
poly-T track mutation in TOMM40 that acts independently of APOE genotype, which 
has also seen been reported in another independent study (Cruchaga et al. 2011). In 
addition to increasing risk of developing AD, TOMM40 has also been linked to an 
earlier age of onset for the disease (Roses et al. 2009). Other studies also suggest 
that TOMM40 provides an additional risk for AD, in addition to APOE (Potkin et al. 
2009, Takei et al. 2009). However, until the extent of the LD between TOMM40 and 
APOE is fully characterised, it will be difficult to pinpoint the exact effect the 
TOMM40 mutation has on LOAD pathogenesis.   
 
CLU has various nuclear and mitochondrial isoforms and is thought to regulate the 
rate of cell proliferation. CLU has been consistently replicated across many GWAS 
and holds strong association with AD (Harold et al. 2009, Lambert et al. 2009, Jun et 
al. 2010, Wijsman et al. 2011). The nuclear isoforms result in the promotion of 
apoptosis, whereas mitochondrial isoforms of CLU suppress BAX-dependent release 
of cytochrome c into the cytoplasm and inhibit apoptosis (Zhang et al. 2005). As an 
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increased level of apoptosis in the brain is seen in AD, it could suggest a role of CLU 
mutations in pathogenesis (Behl 2000). SPG7 was identified by EWAS and encodes 
a mitochondrial metalloprotease protein. Mitochondrial proteases degrade misfolded 
and non-assembled polypeptides. They also regulate the activity of specific 
substrates by mediating essential processing steps. These proteases have been 
hypothesised to play a role in neurodegenerative diseases by affecting neuronal 
maintenance and axonal function (Martinelli et al. 2010). 
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1.5.  The ANK1 gene  
 
As previously described, some of the most robust AD-associated differentially 
methylated probes (DMPs) reside within the ANK1 gene (Smith et al. 2016). Lunnon 
et al. identified two CpG loci, residing 90bp apart, within exon 42 of the ANK1 gene 
(longest isoform), which were hypermethylated in multiple cortical brain regions from 
AD donors in their EWAS. Using pyrosequencing, they demonstrated the DMR 
extended across 120bp and included at least six CpG sites (Lunnon et al. 2014). 
Interestingly this pattern of hypermethylation was not seen in the CER, a region 
typically devoid of AD pathology, even in the latest stages of the disease. In addition 
Lunnon et al. looked at the levels of expression of different ANK1 transcripts and 
found expression levels of specific isoforms to be correlated with neuropathology. 
 
The ANK1 gene, located on the short arm of chromosome 8, belongs to the ankyrin 
family which was first discovered in erythrocytes, but since has also been found to 
be expressed in muscles and in the brain. ANK1 is believed to link the integral 
membrane proteins to the underlying spectrin-actin cytoskeleton and play key roles 
in activities such as cell motility, activation, proliferation, contact, and maintenance of 
specialised membrane domains. Multiple isoforms of ankyrin with different affinities 
for various target proteins are expressed in a tissue-specific, developmentally 
regulated manner. Most ankyrins are typically composed of three structural domains: 
an amino-terminal domain containing multiple ankyrin repeats; a central region with a 
highly conserved spectrin-binding domain; and a carboxy-terminal regulatory 
domain, which is the least conserved and subject to variation. The small ANK1 
(sAnk1) protein splice variants make contact with obscurin, a giant protein 
surrounding the contractile apparatus in striated muscle. However, the precise 
function of most of the ANK1 isoforms is not known. Alternative 
polyadenylation accounting for the different sized erythrocytic ANK1 mRNAs has 
also been reported (Gallagher et al. 1997), in addition, muscle-specific isoforms of 
ANK1 resulting from usage of an alternate promoter have also been identified 
(Gallagher et al. 1998). 50% of patients with the blood based disorder Hereditary 
Spherocytosis (HS) have a mutation in the ANK1 gene (Randon et al. 1997, Miraglia 
del Giudice et al. 1998, Hughes et al. 2011). The HS disease results in the 
erythrocytes of the patient losing their biconcave shape and becoming completely 
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spherical. As a result the maximum oxygen carrying ability of the erythrocytes is 
reduced. In addition SNPs in ANK1 have been shown to be associated with Type 2 
Diabetes Mellitus (Imamura et al. 2012, Harder et al. 2013), a disease that is 
considered by many as a risk factor for AD (Luchsinger et al. 2001, Arvanitakis et al. 
2004, Janson et al. 2004, Li et al. 2007, Profenno et al. 2010). Interestingly, in a 
population of Han-Chinese, a SNP within ANK1 was found to be associated with AD 
(Chi et al. 2015). Most recently however, work by Mastroeni et al. (2017) has shown 
a four-fold increase in the expression of ANK1 in laser-capture dissected microglia 
from AD brain compared with control. This highlights the importance of analysing 
epigenomic and transcriptomic changes in specific cell types in complex neurological 
disorders like AD.  
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1.6.  Conclusions  
 
To conclude, it is clear that a complex interplay of different factors, including genetic, 
environmental and epigenetic mechanisms, play a role in the aetiology of AD. The 
use of GWAS studies to identify common disease variants in AD has been at the 
forefront of research to understanding disease aetiology for ten years but a large 
proportion of disease prevalence is yet to be explained. More recently, the falling 
cost of exome and whole genome sequencing has identified rarer variants with a 
larger effect size. In contrast to the large amount of genetic data available for AD, 
epigenetic research in AD is still in its early stages, with just five EWAS of DNA 
methylomic variation in AD having been reported to date (Bakulski et al. 2012, De 
Jager et al. 2014, Lunnon et al. 2014, Sanchez-Mut et al. 2014, Watson et al. 2016). 
However, all of these studies have used bisulfite (BS)-treated DNA, which means 
that the data generated actually represents a sum of two different cytosine 
modifications (5mC and 5hmC). As such, estimates of 5mC in these studies may 
have been confounded by 5hmC levels and so may be an under or over-
representation of actual levels of 5mC in AD at specific loci. Further work is now 
needed to profile 5mC and 5hmC independently in AD and to further characterise 
epigenetic changes in  ANK1 in AD brain, for example by examining the specificity of 
the DMR across different dementias and by investigating different DNA and histone 
modifications across the gene. 
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1.7.  Aims  
 
This project builds on previous epigenetic studies in AD, with the aim to examine 
genome-wide alterations in 5mC and 5hmC independently in AD, and to profile the 
epigenetic landscape of the ANK1 gene in AD in greater detail. The project has the 
following specific aims: 
 
1. To perform the first EWAS to independently measure 5mC and 5hmC in AD brain 
using oxidative-bisulfite treatment in conjunction with the 450K Beadarray.  
2. To investigate the specificity of 5mC changes in the ANK1 gene to different 
neurodegenerative diseases using BS pyrosequencing.  
3. To examine whether changes in histone modifications, namely H3K4me3 and 
H3K27me3, are seen in the ANK1 gene in AD brain using Chromatin 
Immunoprecipitation quantitative PCR (ChIP-qPCR). 
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CHAPTER 2: MATERIALS AND METHODS 
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This chapter describes the generic materials and methods used throughout multiple 
chapters in this thesis. Detailed descriptions of materials and methods specific to 
particular chapters and statistical analysis performed is described in the relevant 
individual chapter. Much of the work presented in this chapter is based on an invited 
book chapter, which is currently under review (Smith 2018), which can be found in 
Appendix 2.  
 
2.1. Human brain tissue cohorts 
 
Brain tissue used in this thesis was collected from multiple Brain Banks within the 
UK. This included the LNDBB (http://www.kcl.ac.uk/iop/depts/cn/research/MRC-
London-Neurodegenerative-Diseases-Brain-Bank/MRC-London-Neurodegenerative-
Diseases-Brain-Bank.aspx), SWDBB, Oxford Brain Bank 
(http://www.medsci.ox.ac.uk/optima/information-for-patients-and-the-public/the-
thomas-willis-oxford-brain-collection), Cambridge Brain Bank, Manchester Brain 
Bank and Newcastle Castle Brain Bank. From each cohort of samples we usually 
requested multiple brain regions, such as the EC, superior temporal gyrus (STG), 
CER, substantia nigra (SN) and striatum (STR). The use of these samples in the 
research presented in this thesis was approved by the University of Exeter Medical 
School Research Ethics Committee (reference number Apr14/C/041∆1). Detailed 
information on each sample cohort is given in the relevant chapters.  
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2.2.  Tissue dissection 
 
Frozen post-mortem brain tissue was received on dry ice from the brain banks and 
then cut into 100mg sections for DNA extraction as follows. All stages of tissue 
dissection were performed in a sterile extraction hood and all materials were clean-
room quality and autoclaved where possible, or purchased sterile/DNase-free. A 
sterile technique was used, and gloves were changed regularly. 
1. The frozen brain tissue was placed in a sterile petri dish on dry ice and cut 
into small sections using a sterile scalpel 
2. An empty frozen 1.5mL microcentrifuge tube was weighed and the weight was 
noted 
3. A section of frozen tissue sample was transferred to the 1.5mL 
microcentrifuge tube with sterile tip or tweezers whilst on dry ice 
4. The microcentrifuge tube was re-weighed and the brain weight was calculated 
(total weight-empty weight) 
5. 100mg of tissue was used for DNA extraction 
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2.3.  DNA extraction 
 
This section documents in detail the nucleic acid extraction method used to isolate 
genomic DNA for studies described in Chapters 3 and 4. All plastic ware used during 
these procedures was sterile and DNase-free.  Before starting experimental 
procedures, all the surfaces and materials were cleaned using ethanol and/or 
Alconox (Sigma-Aldrich, cat no.: 242985) to remove contaminants and DNases 
present.  
 
2.3.1. Overview of genomic DNA isolation using phenol-chloroform 
 
DNA extraction from brain tissue samples using a standard phenol-chloroform 
method has been widely utilised for EWAS using post-mortem brain tissue as it 
provides sufficient yields of high quality DNA for downstream purposes (De Jager et 
al. 2014, Lunnon et al. 2014). The method below is an adaptation of the phenol-
chloroform method developed by Sambrook et al. (2006). Reagents used for the 
phenol-chloroform DNA extraction can be found in Tables 2.1, 2.2 and 2.3. 
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Table 2.1; Reagents required to make lysis buffer. 
 
 
Name Storage pH Volume 
(mL) 
Warnings Supplier  Catalogue 
no.  
1M  
tris-HCL 
Room 
temp 
pH8 10 Corrosive  
Toxic 
VWR 733-1654 
0.5M 
EDTA 
Room 
temp 
pH8 0.2 Irritant Fisher 
Scientific 
11568896 
H2O Room 
temp 
 990 Not 
Hazardous 
  
 
 
Table 2.2; Reagents required to make 1x Te Solution (1L). The solution was 
filtered with a 0.5 micron filter and then autoclaved before use.  
 
 
 
 
Name Storage pH Final 
Concentration 
Warnings Supplier  Catalogue 
no.  
NaCl Room 
temp 
 75mM Irritant Sigma 
Aldrich 
S3014 
Tris-HCl Room 
temp 
pH8 10mM Corrosive  
Toxic  
VWR 733-1654 
EDTA Room 
temp 
pH8 25mM Irritant Fisher 
Scientific 
11568896 
10% 
SDS  
Room 
temp 
 1/20th final 
volume 
Irritant  
Flammable 
Sigma 
Aldrich 
L3771 
H2O Room 
temp 
  Not 
Hazardous  
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Name Storage Concentration Warnings Supplier  Catalogue 
no.  
Proteinase  
K solution 
-20°C 20mg/mL Not 
Hazardous  
Fisher 
Scientific 
10172903 
Ribonuclease A 
(from bovine 
pancreas) 
-20°C 20μg/mL Not 
Hazardous 
Sigma 
Aldrich 
R6513 
Phenol / 
Chloroform / 
Isoamyl Alcohol 
(PCI) 
4-8°C 100% Toxic 
Flammable 
Irritant 
Fisher 
Scientific 
13148563 
Chloroform 
(CHCl3) 
Room 
temp 
100% Irritant 
Toxic 
Flammable  
Sigma 
Aldrich 
C2432 
Ethanol -20°C 100% Flammable Sigma 
Aldrich  
E7023 
NaCl Room 
temp 
75mM Irritant Sigma 
Aldrich 
S3014 
Ethanol Room 
temp 
70% Flammable Sigma 
Aldrich  
E7023 
Elution Buffer 
(H2O / Te)  
Room 
temp 
200-300μL      
per sample 
Not 
Hazardous 
See 
Table 
2.2 
 
 
 
Table 2.3; Other reagents required for phenol-chloroform DNA extraction, 
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2.3.2. Lysis and digestion of cells 
 
1. Fresh lysis buffer was prepared (1mL per 100mg tissue sample) (Table 2.3.1) 
2. Four times weight/volume of lysis buffer was added to the tissue 
3. The tissue was disrupted with a sterile disposable pestle and rotary pestle 
motor   
4. Six times weight/volume of lysis buffer was added to the tissue 
5. DNase-free RNase-A (Table 2.3) was added to a final concentration of 
20μg/mL and samples were incubated for at least 1 hour at 37°C  
6. Proteinase K (Table 2.3) was then added to each sample at a final 
concentration of 400μg/mL   
7. The samples were incubated in a water bath at 50°C overnight  
8. The following morning the level of sample lysis was checked. If the sample 
was not sufficiently lysed a p1000 pipette tip or a syringe was used to re-
suspend the solution and break up any remaining tissue, being careful not to 
lose any of the solution  
9. Proteinase K (Table 2.3) was added to each sample at a final concentration of 
200μg/mL 
10. The samples were left for at least one more hour in the water bath at 50°C 
11. The water bath was then heated to 65°C and left for 20-30 minutes to 
deactivate the Proteinase K 
12. The samples were then cooled to room temperature 
 
2.3.3. Purification of DNA  
 
1. Each sample was transferred to a 2mL phase lock tube and then an equal 
volume of PCI was added to the tube (Table 2.3) 
2. The samples were mixed by inversion 20 times and centrifuged at 16,200 x g 
for 15 minutes  
3. The aqueous layer was transferred into a new 2mL microcentrifuge tube  
4. 1mL of 100% chloroform was added to each sample (Table 2.3) 
5. The samples were mixed by inversion 20 times and centrifuged at 16,200 x g 
for 15 minutes  
6. The aqueous layer was transferred into a new 2mL microcentrifuge tube  
65 
 
7. The chloroform extraction (steps 4 to 6) was repeated 
 
2.3.4. Precipitation of DNA  
 
1. 1 to 1.5mL of ice cold 100% ethanol (Table 2.3) was added to the sample and 
mixed by inversion 
2. If DNA was not visible, 10-20μL 5M NaCl was added (Table 2.3) 
3. The samples were left at -20°C overnight to further precipitate the DNA 
4. The samples were centrifuged at 16,200 x g for 15 minutes  
5. The supernatant was removed by pipetting, being careful not to dislodge the 
DNA pellet 
6. A further 1mL of 70% ethanol (Table 2.3) was added to the DNA pellets 
7. The samples were centrifuged for a further 10 minutes at 16,200 x g  
8. The supernatant was removed by pipetting, being careful not to dislodge the 
DNA pellet. Pellets were left to air-dry for approximately 30 minutes 
9. The samples were re-suspend in 200μL – 300μL H2O                                 
10. The pellet was dissolved overnight at 37°C 
 
2.3.5. Determining the quality and quantity of isolated nucleic acids  
 
1. A visual check was performed to make sure the DNA was well suspended  
2. A 0.8% agarose gel was run for each sample to check for high molecular 
weight DNA, which is not degraded 
3. 2μL of the DNA sample was also loaded on to a Spectrometer (NanoDrop) to 
determine the concentration and further check the quality of the DNA using 
260/280 and 230/280 ratios (above 1.8 and ~2 respectively for pure DNA) 
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2.4. DNA bisulfite treatment (BS) 
 
BS treatment, originally described by Frommer et al. (1992), is a method that 
provides a base-pair level sensitivity measure for DNA modifications (including 
5mC). In this process un-modified cytosine is converted to uracil, but certain 
modifications to cytosine, including 5mC and 5hmC, are unreactive and remain as 
cytosine. The sequence can then be amplified via subsequent PCR, resulting in all 
uracil and thymine residues being amplified as thymine and only modified cytosine 
residues being amplified as cytosine. BS treatment using the Zymo EZ-96 DNA 
Methylation-GoldTM Kit (Cambridge Bioscience, cat no.: D5007) ideally utilises 500ng 
high quality DNA in 20μL to provide sufficient BS-treated material for profiling of 
cytosine modification using beadarrays or pyrosequencing. This method has been 
used to treat DNA samples in all EWAS studies of AD published to date (Bakulski et 
al. 2012, De Jager et al. 2014, Lunnon et al. 2014, Sanchez-Mut et al. 2014, 
Sanchez-Mut et al. 2016, Watson et al. 2016) and was used in Chapter 4 of this 
thesis. The method below is an adaptation of the sodium BS treatment method 
developed by the manufacturer. Steps 14-17 deviate from the original protocol which 
is available from http://www.zymoresearch.com/downloads/dl/file/id/59/d5007i.pdf. 
 
2.4.1. Starting material 
 
1. 500ng (25ng/μL in 20μL) of DNA was added to each well of a 96 well PCR 
plate  
 
2.4.2. Sodium BS conversion  
 
1. 130μL of the CT conversion reagent (Table 2.4) was added to each DNA 
sample in the conversion plate and mixed by pipetting 
2. The plate was sealed with the provided film and transferred to a thermal 
cycler with the following steps performed:   
1. 98°C for 10 minutes 
2. 64°C for 2.5 hours  
3. 4°C storage for up to 20 hours  
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3. 400μL of M-Binding buffer was added to the wells of a Silicon-ATM binding 
plate mounted on a collection plate 
4. The samples were transferred from the conversion plate (Step 2) to the 
corresponding wells of the Silicon-A™ binding plate (Step 3) and mixed by 
pipetting 
5. The plate was centrifuged at 3,500 x g for 5 minutes then the flow-through 
was discarded  
6. 400µL of M-Wash buffer (Table 2.5) was added to each well of the plate 
7. The samples were centrifuged at 3,500 x g for 5 minutes 
8. 200µL of M-Desulphonation buffer was added to each well and the plate was 
left to stand at room temperature (20-30°C) for 20 minutes 
9. The plate was centrifuged at 3,500 x g for 5 minutes then the flow-through 
was discarded  
10. 400µL of M-Wash buffer (Table 2.5) was added to each well of the plate 
11. The plate was centrifuged at 3,500 x g for 5 minutes then the flow-through 
was discarded  
12. 400µL of M-Wash buffer (Table 2.5) was added and centrifuged for 10 
minutes 
13. The Silicon-A™ binding plate was placed onto an elution plate 
14. 15µL of M-Elution buffer was added directly to each well of the Silicon-A™ 
binding plate.  
15. The plate was incubated for 5 minutes at room temperature  
16. The plate was then centrifuged at 4,000 x g for 3 minutes to elute the DNA 
17. Steps 15 to 17 were repeated  
 
The eluted DNA was ready for immediate analysis or was stored at or below -20°C 
for later use. For long term storage, BS treated DNA was stored at or below -70°C.  
 
2.4.3. Quality control (QC) 
 
BS conversion quality was assessed using BS-specific PCR amplification (Section 
2.7.1) followed by gel electrophoresis (Section 2.7.2). A single visible PCR band was 
taken as an indication of suitable BS conversion efficiency.  
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Name Volume (mL) Supplier 
M-Dissolving Buffer 0.5 Zymo 
M-Dilution Buffer  3 Zymo 
CT Conversion Reagent  Bottle provided Zymo 
Ultra-pure H2O 9 User 
 
 
Table 2.4; CT Conversion Reagent required for BS conversion. using the  
Zymo EZ-96 DNA Methylation-GoldTM Kit (cat no.: D5007). The CT conversion 
reagent is supplied as a powder and must be dissolved prior to use and mixed at 
room temperature with frequent vortexing or shaking for 15 minutes 
 
 
 
 
 
Name Volume (mL) Supplier 
M-Wash Buffer  36 Zymo 
100% Ethanol 144 User 
 
 
Table 2.5; Reagents required for the M-Wash Buffer for BS conversion using 
the Zymo EZ-96 DNA Methylation-GoldTM Kit (cat no.: D5007). 
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2.5. DNA methylation and hydroxymethylation profiling in parallel 
 
Oxidative BS (OxBS) treatment is one of the first methods enabling the 
quantitative mapping of 5mC in the absence of confounding by 5hmC in genomic 
DNA at single-nucleotide resolution. Using a selective chemical oxidation of 5hmC to 
5fC, followed by BS conversion, results in the conversion of 5hmC to uracil. As such 
only cytosines that are methylated are protected from the conversion and after 
subsequent PCR amplification, one can assess the level of just 5mC. Simultaneous 
BS treatment of a matched sample of DNA, provides a value for the total DNA 
modifications (5mC + 5hmC) at each site, as both modifications are protected from 
the conversion and are not converted to uracil (Booth et al. 2012). Subsequently 
after PCR amplification, the subtraction of the OxBS signal from the standard BS 
signal gives a 5hmC proxy value for each nucleotide (Figure 2.1.).   
 
OxBS treatment using the CEGX® TrueMethyl® Array kit requires 1μg high 
molecular weight genomic DNA per sample. This is sufficient to allow 500ng to be 
processed through each of the BS and OxBS conversion processes in parallel. The 
protocol described below results in a final volume of 12μL of BS treated DNA and 
12μL of OxBS treated DNA for downstream analyses. The method below was used 
in Chapter 3 of this thesis as per the manufacturer’s protocol, which is available from 
https://www.cambridge-epigenetix.com/resources/user-guides.  
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2.5.1.  Starting Material 
 
1. The digestion control sample was thawed on ice 
2. 1μg DNA sample was added to a 1.5 mL microcentrifuge tube and the final 
volume was adjusted to 49 μL using ultra-pure H2O from the TrueMethyl® kit  
3. 1μL of cutting control was added to each DNA sample and mixed well before 
vortexing 
 
2.5.2. CEGX TrueMethyl® conversion  
 
2.5.2.1. DNA oxidation  
 
1. Before starting the workflow the heat block was set to 37°C and magnetic 
binding solution 1 (Table 2.6) and 80% acetonitrile (Table 2.7) was prepared 
2. The magnetic bead binding solution 1 was vortexed thoroughly before use to 
ensure the solution is homogenous and 100μL was added to each 1.5 mL 
microcentrifuge tube containing 50μL DNA and vortexed to mix 
3. The samples were incubated for 20 minutes at room temperature 
4. The samples were briefly centrifuged to collect the sample at the bottom of 
the tube 
5. The tubes were placed into a magnetic separation rack to pellet beads for 5 
minutes at room temperature 
6. The supernatant was carefully removed and discarded. If beads were 
accidentally pipetted they were dispensed back into the tube and steps 5 and 
6 were repeated 
7. The following wash steps were performed, leaving the 1.5mL tubes in the 
magnetic separation rack:  
a. 1mL 80% acetonitrile (Table 2.7) wash was added to the tubes without 
disturbing the bead pellet 
b. The 1mL 80% acetonitrile wash was removed and discarded, carefully 
avoiding aspiration of the bead pellet 
c. Steps 8a and 8b were repeated another two times so that ultimately 
three 1ml 80% acetonitrile washes were performed in total. As much of 
the final wash was removed by pipetting as possible 
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d. The bead pellets were air dried for 5 minutes at room temperature, with 
the lids of the tubes left open 
8. The following denaturation steps were then completed:  
a. The 1.5mL tubes were left in the magnetic separation rack, and 50μL of 
denaturing solution was added directly onto the bead pellet. The lids of 
the tubes were closed before removing them from the magnetic 
separation rack 
b. The denaturing solution was vortexed thoroughly to fully suspend the 
bead pellet 
c. The sample was incubated for 5 minutes at room temperature  
d. The sample was incubated for 30 minutes at 37°C (performed in the 
pre-heated benchtop heating block) 
9. The tubes were briefly centrifuged to collect the beads at the bottom of the 
tubes 
10. The tubes were placed into a magnetic separation rack and beads were 
pelleted for 5 minutes at room temperature 
11. Avoiding the bead pellet, 50μl eluate was transferred into a new 1.5mL tube 
and centrifuged briefly. The sample was placed on ice before proceeding 
immediately to step 12 
12. The DNA oxidation reaction was performed in 0.2mL PCR tubes as described 
in Table 2.8.  
13. The oxidation reaction mix was incubated at 40°C for 30 minutes in a PCR 
thermocycler with a heated lid  
14. The samples were centrifuged at 14,000 x g for 10 minutes at room 
temperature to pellet any black precipitate 
15. The orange supernatant was transferred into new 0.2mL PCR tubes and this 
was used in subsequent steps of the protocol 
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Name Volume (mL) Supplier 
Magnetic Bead Solution  0.24 CEGX 
Binding Buffer 1  12 CEGX 
 
 
Table 2.6; Magnetic Bead Binding Solution 1 required for the CEGX 
TrueMethyl® Array kit. The Magnetic Bead Binding Solution 1 (green cap) is 
prepared by the addition of Binding Buffer 1 to pre-vortexed Magnetic Bead solution. 
After adding the buffer, the green cap was replaced and vortex thoroughly. The 
Magnetic Bead Binding Solution 1 was stored between 2-8°C. The solution was 
equilibrated to room temperature for a minimum of 30 minutes before use. 
 
 
 
 
Name Volume (mL) Supplier 
100% Acetonitrile  32 User 
ultra-pure H2O 8 CEGX 
 
 
Table 2.7; 80% Acetonitrile required for the CEGX TrueMethyl® Array kit. This 
was prepared fresh for each experiment and mixed by inversion. The amounts listed 
below are sufficient for 12 samples. 
 
 
 
 Volume per reaction (μL) 
Component oxBS BS 
Denatured DNA from step 12 24 24 
Oxidant Solution  1 - 
Ultra-Pure Water - 1 
Total volume  25 25 
 
 
Table 2.8; Reagents required for the Oxidation reaction in the CEGX 
TrueMethyl® Array kit. Oxidant Solution was thawed on ice prior to use. The 
samples were mixed briefly by vortexing, and then briefly centrifuged before placing 
in a PCR thermocycler. 
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2.5.2.2. BS conversion  
 
1. BS reagent solution was prepared by adding 4.2mL BS diluent to one BS 
reagent aliquot (sufficient for 24 reactions). The lid was tightly sealed and the 
solution was incubated at 60°C for 15 minutes (using a water bath). 
Subsequently the samples were vortexed until the BS reagent solution was 
completely dissolved. It was ensured that the same BS reagent solution 
aliquot was used for each OxBS and BS treated sample pair 
2. The oxidised samples from step 15 of the DNA oxidation protocol were 
equilibrated to room temperature 
3. The BS conversion reaction setup was performed in 0.2mL PCR tubes as 
described in Table 2.9.  
4. The 0.2mL PCR tubes containing the BS conversion reaction mix were placed 
into a thermocycler. The BS DNA conversion was performed using the 
thermal profile shown in Table 2.10.  
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Component Volume per reaction (μL) 
DNA solution (step 15) 25 
BS Reagent Solution 170 
BS Additive 5 
 
 
Table 2.9; Reagents required for the BS conversion mix in the CEGX 
TrueMethyl® Array kit. To this sample tube the BS reagent solution was first 
added, followed by the BS additive. The PCR tubes were then vortexed thoroughly 
and briefly centrifuged to collect the samples at the bottom of the tubes. 
 
 
 
 
Step Time (min) Temperature (°C) 
Denaturation 5 95 
Incubation 20 60 
Denaturation 5 95 
Incubation 40 60 
Denaturation 5 95 
Incubation 165 60 
Denaturation 5 95 
Incubation 20 60 
Denaturation 5 95 
Incubation 40 60 
Denaturation 5 95 
Incubation 165 60 
Hold Indefinite 20 
 
 
Table 2.10; The BS conversion thermal profile for the CEGX TrueMethyl® Array 
kit. 
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2.5.2.3. Clean up of BS converted DNA 
 
1. The magnetic binding solution 2 was prepared (Table 2.11.) 
2. The magnetic bead binding solution 2 and desulfonation buffer (Table 2.12.) 
were equilibrated to room temperature for a minimum of 30 minutes before 
use. A fresh stock of 70% ethanol was also prepared for the experiment 
(Table 2.13.)  
3. Once the BS conversion was complete, tubes were centrifuged at 14,000 x g 
for 10 minutes at room temperature. This pelleted any precipitated salts 
accumulated during the BS incubation 
4. Without disturbing the pellet, 195μL of the supernatant was transferred to a 
new 1.5mL microcentrifuge tube 
5. The magnetic bead binding solution 2 (Table 2.11) was vortexed thoroughly to 
ensure the solution was homogenous before aliquoting 
6. 1mL of magnetic bead binding solution 2 (Table 2.11) was added to each of 
the 1.5mL microcentrifuge tubes containing 195μL BS converted sample from 
step 23. The lid was closed, tube inverted and the base flicked to dislodge the 
sample, before being vortexed to mix 
7. The samples were incubated for 20 minutes at room temperature  
8. At the end of the incubation, samples were briefly centrifuged to collect the 
sample at the bottom of the tube 
9. The samples were then placed  into a magnetic separation rack to pellet 
beads for 30 minutes at room temperature  
10. The supernatant was removed and discarded, avoiding the bead pellet. If 
beads were accidentally pipetted, they were dispensed back into the tube and 
steps 9 and 10 were repeated 
11. The following wash steps were completed, leaving the 1.5mL tubes in the 
magnetic separation rack:  
a. 1.4mL 70% ethanol wash (Table 2.13) was added to the tubes without 
disturbing the bead pellet 
b. The 1.4mL 70% ethanol wash was removed and discarded, carefully 
avoiding aspiration of the bead pellet. As much of the wash was 
removed as possible 
12. The following desulfonation steps were then completed:  
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a. The 1.5mL tubes were left in the magnetic separation rack and 1mL 
Desulfonation buffer (Table 2.12) was added directly onto the bead 
pellet. The lids of the tubes were closed before removing from the 
magnetic separation rack. The tubes were vortexed to fully suspend 
the bead pellet in desulfonation buffer and then centrifuged briefly 
b. The tubes were placed back into the magnetic separation rack and 
incubated for 5 minutes at room temperature in the desulfonation buffer 
to pellet the beads 
c. The 1ml desulfonation buffer was removed and discarded, carefully 
avoiding aspiration of the bead pellet. As much of the desulfonation 
buffer was removed by pipetting as possible 
13. The following wash steps were completed, leaving the 1.5mL tubes in the 
magnetic separation rack: 
a. 1mL 70% ethanol wash was added to the tubes without disturbing the 
bead pellet 
b. The 1mL 70% ethanol wash was removed and discarded, carefully 
avoiding aspiration of the bead pellet 
c. Steps 13a and 13b were repeated so that ultimately 1mL 70% ethanol 
washes were performed two times in total. As much of the final wash 
was removed as possible 
d. The bead pellets were air dried for 15 minutes at room temperature, by 
leaving the lids of the tubes open 
14. Following the wash steps the following elution steps were performed:  
a. 12μL of elution buffer (provided) was added directly onto the bead 
pellet, leaving the 1.5mL tubes in the magnetic separation rack. The 
lids of the tubes were closed before removing from the magnetic 
separation rack 
b. The bead pellet was resuspended in the elution buffer by thorough 
vortexting. The sample was incubated for 20 minutes at room 
temperature to elute the TrueMethyl® converted DNA from the beads 
15. At the end of the incubation (step 14b), the 1.5mL microcentrifuge tubes were 
briefly centrifuged to collect the sample at the bottom of the tube. The tubes 
were then  placed into a magnetic separation rack to pellet beads for 5 
minutes at room temperature  
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16. 12μL eluate was transferred into a new 1.5mL tube, avoiding the bead pellet 
 
The DNA was then ready for immediate analysis or could be stored at or below -
20°C for later use. For long term storage, the DNA was stored at -80°C.  
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Name Volume (mL) Supplier 
Magnetic Bead Solution 2.64 CEGX 
Binding Buffer 2 220 CEGX 
 
 
Table 2.11; Preparation of Magnetic Bead Binding Solution 2 for the CEGX® 
TrueMethyl® Array kit. The Magnetic Bead Binding Solution 2 was prepared by the 
addition of pre-vortexed Magnetic Bead solution to Binding Buffer 2. Subsequently 
the solution was vortexed thoroughly. Magnetic Bead Binding Solution 2 was stored 
between 2-8°C. 
 
 
 
 
Name Volume (mL) Supplier 
Desulfonation Buffer Bottle provided CEGX 
100% Ethanol 150 User 
 
 
Table 2.12; Preparation of Desulfonation Buffer for the CEGX TrueMethyl® 
Array kit. The Desulfonation Buffer was diluted with 100% Ethanol before use with 
the lid sealed tightly and mixed thoroughly by inversion. Desulfonation Buffer is 
stored long term between 2-8°C to prevent ethanol evaporation. 
 
 
 
Name Volume (mL) Supplier 
100% Ethanol 70 User 
ultra-pure H2O 30 CEGX 
 
 
Table 2.13; Preparation of 70% Ethanol for the CEGX TrueMethyl® Array kit. 
The amounts below are sufficient for 12 samples. The ethanol was thoroughly mixed 
by inversion. 
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2.5.3. Quality control  
 
To assess OxBS conversion quality it was recommended to integrate a Digestion 
control (provided) with the initial 1μg gDNA sample in Section 2.5.1 step 3 and 
interrogate the control using PCR, followed by gel electrophoresis, as described 
below.  
 
2.5.3.1. Amplification of digestion control  
 
1. A PCR reaction mix was prepared as shown in Table 2.14.  
2. Samples were then amplified according to the thermocycling conditions 
outlined in Table 2.15. 
 
2.5.3.2. TaqαI digestion of the digestion control amplicon 
 
1. The following digestion reaction mix was prepared as outlined in Table 2.16. 
2. TaqαI digestion mixes were incubated for 18 hours at 65°C 
3. Samples were then denatured at 80°C for 20 minutes 
4. Digestion mixes were then run on a 2% agarose gel (Section 2.7.) 
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Component Volume (μL) 
Ultra-Pure Water 39 
10X polymerase buffer 5 
10mM dNTP mix 2 
Digestion Control Fwd PCR Primer 
(100μM) 
0.5 
Digestion Control Rev PCR Primer 
(100μM) 
0.5 
DNA (from 2.5.2 step 35) 1 
Uracil tolerant DNA polymerase (5U) 1 
TOTAL volume 50 
 
 
Table 2.14; Digestion control PCR mix for assessing the conversion quality of 
oxidative bisulfite (OxBS) treated DNA. 
 
 
 
Segment Number of Cycles Temperature (°C) Duration 
(seconds) 
1 1 95 120 
2 40 
95 30 
60 30 
72 15 
3 1 4 ∞ 
 
 
Table 2.15; PCR conditions for the digestion control. 
 
 
 
Component Volume (μL) 
 Digestion 
Control 
Digestion –ve 
Control 
Cutting 
Control 
10X TaqαI 2.2 2.2 2.2 
TaqαI RE (20U/μL) 2 - 2 
100X BSA 4 4 4 
Processed Digestion Control 
amplicon DNA (10ng/μL) 
10 10 - 
Cutting Control DNA (20ng/μL) - - 5 
Ultra-Pure Water 3.8 5.8 8.8 
TOTAL volume 22 22 22 
 
Table 2.16; TaqαI digestion conditions. 
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2.6. Polymerase chain reaction (PCR) 
 
The amplification of DNA is used in every chapter within this thesis. PCR is a method 
used extensively to amplify a segment of DNA to generate numerous copies of the 
same fragment. Various components, including DNA, nucleotides, buffers, primers 
and polymerase are combined together and subjected to cycles of heating and 
cooling in a thermocycler. During the first stage of PCR the mix is heated to a high 
temperature to activate the heat sensitive polymerase taq. This is in turn followed by 
three steps: 
 
1. A denaturation step, where the mix is heated to 95ºC to denature the 
double-stranded DNA 
2.  An annealing step where the mix is cooled to a primer-specific temperature 
(usually between 50ºC and 65ºC) to allow the primers to anneal with high 
specificity to the correct annealing sequence in the DNA 
3. An extension step at 72ºC to allow the taq polymerase to synthesise the 
complementary strand of DNA using the deoxynucleotides (dNTPs) 
 
These three steps are repeated for a specific number of cycles to allow the synthesis 
of an exponential number of DNA amplicons. A final step of 72ºC is added to allow a 
final extension. 
 
The PCR in Chapters 3 and 4 in this thesis was performed using BS-converted 
genomic DNA as the reaction template (see Section 2.4 and 2.5). This presents 
more of a challenge than using standard unconverted genomic DNA for several 
reasons. First, extended incubations using BS-treated DNA can lead to extensive 
damage to the DNA template. Second, BS treatment leads to reduced sequence 
complexity (the DNA largely comprises three bases rather than four), leading to a 
higher redundancy of the target sequence, and third, regions of interest often lie 
within CG-rich sequences, which become long stretches of Thymine following BS 
conversion, which can cause polymerase slippage. These reasons result in a higher 
chance of mispriming and non-specific PCR amplification. These issues were 
addressed in this thesis with careful primer design, using the following criteria which 
are widely reported to be optimal for successful BS-PCR: 
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1. Primers did not contain any CpG sites within their sequence to avoid 
discrimination between methylated or unmethylated DNA 
2. Primers were not placed in a repetitive region 
3. Primers only contained non-CpG cytosines within their sequence to ensure 
exclusive amplification of BS-converted DNA 
4. Primer length was at least 20 bases, to reduce non-specific amplification 
 
The cycling conditions, primer sequences and reagents used in the ANK1 PCR 
reactions in this thesis (Chapters 3 and 4), together with their description and 
quantities in a standard PCR reaction, are described in Table 2.17, Table 2.18 and 
Table 2.19, respectively.  
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Step Temperature (°C) Time 
Number  
of Cycles 
Hotstart 95 15min 1 
Denaturation 95 45sec 
40 Annealing 60 45sec 
Extension 72 3min 
Final Extension 72 10min 1 
 
Table 2.17; ANK1 Polymerase chain reaction (PCR) thermocycling conditions. 
 
 
 
 
 
 
Primer Name Sequence Length 
(bp) 
GC % 
ANK1_F GTGGAGGGAGGTGTTATGTA 20 50 
ANK1_R [Btn]CTTCCCTTCCTTTCCTAAATCATT 24 37.5 
ANK1_CPG1_S TTGGGTTTTTTAGGGT 16 37.5 
ANK1_CPG2_S AGGGGTTTTTTTATAGTTATT 21 23.8 
 
Table 2.18; ANK1 Polymerase chain reaction (PCR) and pyrosequencing 
primer sequences. 
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Reagent Function 
Reagent 
Concentration 
Volume 
(μL) 
Supplier 
Catalogue 
no.  
PCR Buffer 
maintains optimal 
pH  
10X 3 
Solis 
BioDyne 
01-02-
01000 
Magnesium 
Chloride 
(MgCl2) 
Required 
substrate for the 
Taq polymerase  
25mM 1.98 
Solis 
BioDyne 
01-02-
01000 
DNA 
nucleotides 
DNA bases 
needed for the 
synthesis of new 
DNA  
10mM 0.3 
Fisher 
Scientific  
1183-3933 
PCR 
primers 
Short, single-
stranded 
oligonucleotides 
complementary to 
target sequence 
10μM 1.5 IDT  
Taq DNA 
Polymerase 
Heat resistant 
enzyme that 
catalyses the 
PCR reaction 
5U/μL 0.3 
Solis 
BioDyne 
01-02-
01000 
DNA 
Single stranded 
BS or OxBS 
treated DNA 
10ng/μL 2   
Ultra-pure 
Water 
Makes up 
reaction volume 
Final volume of 
30μL 
20.92   
 
Table 2.19; ANK1 Polymerase chain reaction (PCR) reagents and volumes. 
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2.7. Agarose gel electrophoresis  
 
The visualisation of DNA/Chromatin via gel electrophoresis was needed in various 
quality control stages in each data chapter, for example checking the efficiency of BS 
and/or OxBS conversion in Chapters 3 and 4, and checking the level of chromatin 
shearing in Chapter 5. In addition gel electrophoresis was used to check the quality 
of the all DNA extracted as described in Section 2.3.   
 
Agarose gel electrophoresis enables the separation of DNA molecules based on 
their size. It is most commonly used to assess the quality and quantity of DNA and to 
determine the efficiency of molecular biology techniques such as DNA extraction or 
PCR amplification. The gels used in this thesis ranged from 0.8 to 2.0% agarose 
(Sigma Aldrich, cat no.: A9539) in 1% tris-borate EDTA (TBE) buffer (Fisher 
Scientific, cat no.: 10031223). The concentration of agarose influences the amount 
of resistance applied to molecules passing through the matrix, therefore the 
concentration of agarose selected is dependent on the size of the molecule to be 
separated. A small amount of the Syto60 compound (Fisher Scientific, cat no.: 
10194852) is added ubiquitously to the gel before it cools. Once cooled DNA 
samples were added to the gel matrix, an electrical charge was applied across it, 
causing the negatively charged DNA to migrate towards the positive anode, at a 
speed determined by the DNA fragment size. Smaller molecules move through the 
matrix faster, and therefore move further through the gel in the allocated time. The 
separated DNA was then viewed using the fluorescent Syto60, which intercalates 
into the DNA structure allowing it to be visualised after laser exposure. The laser 
light is absorbed by the Syto60 and reemitted; these wavelengths of light are then 
detected by the Odyssy Clx system (LI-COR, USA), which were then observed. In 
this thesis, agarose gel electrophoresis was used for the inspection of DNA 
extraction quality (Chapter 3 and 4) using a 0.8% gel, PCR products (Chapter 3 and 
4) using a 2% gel and visualising sheared Chromatin (Chapter 5) using a 1.5% gel.  
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2.8.  Infinium HumanMethylation450 BeadChip Array 
 
The 450K array combines BS/OxBS converted DNA and whole-genome 
amplification with direct, array-based capture and scoring of the CpG loci (Pidsley et 
al. 2016).  This enables the quantification of 5mC levels at 485,577 CpG sites, 
covering 99% of Reference Sequence database (RefSeq) genes.  Important 
regulatory regions such as CpG islands (96% covered), island shores and shelves, 5′ 
and 3′ UTRs, promoters and gene bodies are also covered (Bibikova et al. 2011). 
Signal intensity is measured with the Illumina iScan or HiScan system to generate 
beta values, a measure of the levels of DNA modification, at each locus. One or two 
probes are used to interrogate a single CpG locus, depending on the probe design 
for a particular CpG site, as the Infinium I design has two probes per site, whilst the 
Infinium II has one probe per site.  The type I probe design is based on the 
assumption that the methylation status of CpG sites within 50bp of the probe are 
correlated with the query CpG (Illumina 2015). However, if underlying probes are not 
associated with 5mC at the target site this could lead to a source of bias. The 
Infinium II probes use a single bead type with the 5mC state determined by a single 
base extension step after hybridisation by two different coloured dyes (green for 
methylated/modified sites and red for unmethylated/unmodified sites). This design 
includes the addition of a degenerate R [A/G] base at underlying CpG sites, and 
therefore is less influenced by nearby co-methylation patterns. Allele-specific single 
base extension of the probes incorporates a biotin nucleotide or a dinitrophenyl 
labelled nucleotide. Signal amplification of the incorporated label further improves 
the overall signal-to-noise ratio of the assay. This method was used in Chapter 3.  
 
A full description of this methodology, used in Chapter 3, can be found on the 
Illumina website http://www.illumina.com/products/by-type/microarray-kits/infinium-
methylation-epic.html.  Briefly, the first stage in the process includes a denaturing 
and neutralisation stage before the BS or OxBS treated DNA is whole-genome 
amplified. The denatured DNA was then isothermally amplified in an overnight step. 
The whole-genome amplification uniformly increases the amount of the DNA sample 
by several thousand folds without significant amplification bias. A controlled 
enzymatic process then fragmented the amplified product. The process uses 
endpoint fragmentation to prevent over fragmentation. After an isopropanol 
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precipitation, centrifugation at 4°C collected the fragmented DNA. The precipitated 
DNA was then suspended in Hybridisation buffer. DNA samples were then 
dispensed onto BeadChip arrays and incubated in an Illumina Hybridisation Oven to 
hybridise the samples onto the BeadChip array surface. 12 samples were applied to 
each BeadChip array, which were kept separate with an IntelliHyb seal. DNA 
samples annealed to locus-specific sites on the BeadChip array. Un-hybridised and 
nonspecifically hybridised DNA was washed away and the BeadChip array then 
underwent extension and staining in capillary flow-through chambers. Single-base 
extension of the oligonucleotides on the BeadChip array, using the captured DNA as 
a template, incorporated detectable labels on the BeadChip array and determined 
the 5mC/5hmC level at the specific CpG sites. Finally, the BeadChip array was 
imaged on the Illumina HiScan or iScan System (Illumina, San Diego, CA, USA), 
using a laser to excite the fluorophore of the single-base extension product on the 
beads. The scanner recorded high resolution images of the light emitted from the 
fluorophores. These in turn were used by the genome studio® software to produce a 
beta value for each locus.  
 
2.8.1. Data normalisation and quality control 
 
The DNA modification level at each CpG site was determined by calculating the ratio 
of the intensity of the fluorescent signal for M (modified) and U (unmodified), which 
gives a β (DNA modification) value for each site ranging from 0 (i.e. all cytosines at 
that site are unmodified) to 1 (i.e. all cytosines at that site are modified). The β value 
is calculated by the following equation:  
 
 
 
 
To avoid negative values after background adjustment, Illumina recommends adding 
a constant offset (+100) to the denominator to regularise β values when both 
methylated and unmethylated probe intensities are low (Du et al. 2010). The Illumina 
450K array has become one of the most popular methodologies to assess genome-
wide DNA modifications in AD in recent years (De Jager et al. 2014, Lunnon et al. 
2014, Watson et al. 2016), and as such was selected for the EWAS presented in 
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Chapter 3 of this thesis. However, although this technology has been proven to be 
robust, it is not without its own limitations: for example, one disadvantage is the 
difference in performance between the two types of probe (Dedeurwaerder et al. 
2011). Specifically, the β-values obtained from Infinium II probes have been shown 
to be less accurate and reproducible than those obtained from Infinium I probes.  As 
a result this has led to the development of several normalisation methods (Wang et 
al. 2015). Our research group has developed the wateRmelon package in R 3.3.2 
(Vienna 2012, Pidsley et al. 2013), which offers a range of normalisation function 
and tools that were used to pre-process and normalise the DNA modification data 
presented in this thesis.  
 
The presence of SNP variation within close proximity of the query CpG site is 
another issue with the probe design on the array. The 5mC data at these sites could 
be confounded by the presence of the polymorphism (Chen et al. 2013, Price et al. 
2013). Therefore the DNA modification levels detected by these probes could simply 
be a representation of the underlying genetic polymorphisms. Additionally, 6-8% of 
the probes in the array have been found to cross-hybridise with other genomic 
locations and therefore do not accurately estimate the 5mC levels at the annotated 
site (Chen et al. 2013, Price et al. 2013). As a result of these issues, probes known 
to either cross-hybridise with another site or contain SNP variation were excluded 
prior to further analysis in this thesis.  
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2.9. Pyrosequencing  
 
Pyrosequencing was used in both Chapters 3 and 4 of this thesis. Pyrosequencing is 
designed to detect changes in specified variable positions in, or base-calling of, DNA 
prepared from biological samples in molecular biology applications.  The principle of 
pyrosequencing is based on work by (Nyren 1987) who noted that DNA 
polymerisation can be monitored by measuring pyrophosphate production, which in 
turn can be detected as light. Pyrosequencing, although originally designed as a less 
complex method of sequencing compared to Sanger sequencing, is now also widely 
used to sequence BS treated DNA and therefore gain highly sensitive measures of 
DNA modification at CpG sites. The fundamental basis of pyrosequencing is that 
pyrophosphate is released when a deoxyribonucleotide triphosphate is added to the 
end of a growing strand of DNA. The pyrophosphate is then converted by a 
sulfurylase enzyme to adenosine triphosphate, a cofactor for the enzyme luciferase. 
Luciferase oxidises the oxidation of luciferin to oxyluciferin and light. As a result of 
deoxyribonucleotide triphosphates being sequentially added to the reaction and 
because the light emitted is continuously monitored, the DNA sequence and 
therefore the level of DNA modification at a specific genomic locations can be 
determined (Harrington et al. 2013) (Figure 2.1). Pyrosequencing was used as a 
validation method in Chapter 3 and the main method of interrogation in Chapter 4. 
Biotinylated PCR primers (Table 2.18) were used to amplify a region of DNA for 
pyrosequencing. In addition, sequencing primers specific to the region of interest 
(approximately 100bp) were designed, these primers also had stringent design 
conditions as follows:  
1. Sequencing primers did not contain any CpG sites within their sequence to 
avoid discrimination between methylated or unmethylated DNA 
2. Sequencing primers were not placed in a repetitive region 
3. Sequencing primers only contained non-CpG cytosines within their sequence 
to ensure exclusive amplification of BS-converted DNA 
4. Sequencing primer length was no longer than 21 bases, to ensure efficient 
annealing  
5. Sequencing primer annealing temperature was designed to be as close to 
40°C as possible to be efficient within the pyrosequencer 
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All primers for PCR and pyrosequencing where designed using the PyroMark Assay 
Design software from Qiagen. CpG assay designs were created using the PyroMark 
Q24 software from Qiagen, using standard conditions. Two BS control regions were 
used per assayed region to confirm BS conversion efficiency. The method below 
details the process of pyrosequencing as per manufacturer’s instructions on a 
targeted genomic region of BS or OxBS treated DNA as used in this thesis. A full 
guide is also available from the manufacturer 
(https://www.qiagen.com/gb/resources/resourcedetail?id=59f0275d-e60f-4517-b786-
b0e0ca13952e&lang=en). For further practical information please see 
https://www.youtube.com/watch?v=LbEz9GBKW-s .  
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2.9.1. Immobilising PCR product 
 
1. Sepharose beads (Streptavidin Sepharose High Performance, GE Healthcare, 
cat no.:11565015) were gently shaken to re-suspend  
2. 2μL of beads (per sample) and Binding Buffer (Qiagen, cat no.: 979306) 
(40μL per sample) were combined in a 1.5mL centrifuge tube  
3. Ultra-pure H2O was added to make a total volume of 60μL per sample  
4. 60μL of the immobilising solution was pipetted into each well of a 24-well PCR 
plate 
5. 20μL of biotinylated PCR product was added to each well of the PCR plate 
6. The plate was then sealed and agitated  for at least 10 minutes (1,400rpm)  
 
2.9.2. Preparing the vacuum workstation  
 
1. The appropriate troughs were filled with each reagent as follows:  
a. 50mL 70% Ethanol (Sigma Aldrich, cat no.: E7023)  
b. 50mL Denaturation Solution (0.2M Sodium Hydroxide (NaOH)) 
(Qiagen, cat no.: 979307) 
c. 70mL 1 X Wash Buffer (Qiagen, cat no.: 979308) 
d. 70mL high-purity water  
e. 70mL high-purity water  
2. The vacuum pump was switched on and filter probes were lowered into trough 
(e) (high-purity water). All water was washed through the probes and the 
trough was re-filled.  
3. The vacuum pump was turned off and returned to the “parking” position 
 
2.9.3. Sequencing primer setup  
 
1.  The sequencing primer was diluted to 0.3μM in Annealing Buffer (Qiagen, cat 
no.: 979309); 25μL of the resulting solution was pipetted into each well of a 
Q24 well plate 
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2.9.4. Combining the Q24 plate 
 
1.  Once the PCR plate has finished its agitation it was moved to the Vacuum 
Workstation 
2.  The vacuum tool was turned on and the filter probes were immersed in the 
wells of the PCR pate 
3.  The vacuum tool with the DNA bound sepharose beads was then moved to 
the ethanol trough (a) and ethanol was aspirated for 5 seconds  
4.  The vacuum tool was then moved to the denaturation solution trough (b) and 
denaturation solution was aspirated for 5 seconds 
5.  The vacuum tool was then moved to the wash buffer trough (c) and wash 
buffer was aspirated for 10 seconds 
6. The vacuum tool was then raised to 90° and the filter probes were left to dry 
for 20 seconds 
7.  The vacuum tool was then turned off and lowered into the waiting Q24 plate 
containing the sequencing primer 
8.  The vacuum tool was then agitated from side to side to dislodge the beads 
into the solution 
9.  The Q24 plate was then transferred to a heat block and incubated at 80°C for 
2 minutes. It was then left to stand at room temperature for 5 minutes  
 
2.9.5. Loading the pyrosequencer 
 
1.  The sequencing cartridge was filled with reagents as described for each 
assay in the pre-run information produced by the Pyromark Q24 software  
2.  The cartridge and plate were loaded into the sequencer; the appropriate run 
was loaded from an external memory drive and was run 
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2.9.6. Pyrosequencing data quality control 
 
Analysis of the pyrogram was performed using the PyroMark Q24 software. BS 
conversion efficiency of less than 90% resulted in the exclusion of the affected 
samples. Using the inbuilt quality checker, traces were included or excluded from 
downstream analysis. 5mC/5hmC values were reported as percentages of 
modifications at each CpG site and these were taken forward for downstream 
analysis.  
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2.10.  Chromatin Immuno-Precipitation (ChIP) 
 
This protocol was utilised in Chapter 5. The ChIP PCR method used in this thesis 
enables the relative quantification of specific histone modifications (H3K4me3 and 
H3K27me3) at specific loci within the ANK1 gene.   
 
2.10.1. ChIP protocol 
 
 ChIP uses immunoprecipitation to investigate the interaction between histone 
proteins and the DNA in a cell. It is used to determine whether specific histone 
proteins/ histone modifications are associated with specific genomic regions or loci 
(Orlando 2000).  In the ChIP method DNA and associated proteins on chromatin in 
living cells or tissues are crosslinked using formaldehyde. The DNA-protein 
complexes (chromatin) are then sheared to between 100-600bp in length by 
sonication. Cross-linked DNA fragments associated with the histone modification(s) 
of interest are then selectively immunoprecipitated from the cell debris using a 
protein modification-specific antibody. The associated DNA fragments are then 
purified and quantified via quantitative PCR (qPCR). The reagents used were 
provided in the True MicroChIP Kit (Diagenode, cat no.: C01010130).  
 
2.10.1.1. Tissue preparation  
  
1. Tissue was cut into sections of between 10-15mg as described in Section 2.2. 
  
2.10.1.2. DNA-protein cross linking  
 
1. 5472.5µL of 1X phosphate buffered saline (PBS) (Sigma Aldrich cat no.: 
P5493) and 27.5µL of protease inhibitor cocktail (PIC) (Diagenode, cat no.: 
C01010130) were combined. 1mL of cold PBS plus PIC was added to each 
sample and tissue was disaggregated using a dounce homogeniser (30-50 
times) to get a homogenous suspension. Samples were transferred into 1.5 
mL LoBind Eppendorf tubes. The dounce homogeniser was washed with 
water, ethanol and then water again between samples  
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2. 27µL of 36.5% formaldehyde (Sigma Aldrich cat no.: F8775) was added to 
each 1mL sample (to make a final concentration of ~1%) and inverted 
immediately two to three times to ensure complete mixing 
3. The samples were incubated for 10 minutes at room temperature with 
agitation at 8 minutes and then samples were put on a rotating wheel at 40 
rpm for the remaining 2 minutes 
4. Crosslinking was stopped by adding 115µL glycine (Diagenode, cat no.: 
C01010130) and incubating for 5 minutes at room temperature 
5. The samples were centrifuged at 300 x g at 4°C for 10 minutes using a low 
deceleration speed 
6. The supernatant was aspirated leaving approximately 30µL of the solution and 
pellet 
7. 5472.5µL Hanks’ balanced salt solution (HBSS) (Fisher Scientific cat. no.: 
11570616) and 27.5µL PIC were added together. Cells were washed with 
1mL of ice cold HBSS plus PIC and inverted four to five times to re-suspend 
cells 
8. The samples were centrifuged at 300 x g for 10 minutes at 4°C. The 
supernatant was discarded and the cell pellet was kept on ice 
 
2.10.1.3. Cell lysis and chromatin shearing 
 
1. Lysis buffer was prepared by adding 522.38µL lysis buffer (Diagenode, cat 
no.: C01010130) and 2.63µL PIC together. 100µL of complete lysis buffer was 
added per sample. The samples were inverted to re-suspend the cells and 
allow bubbles to form. Before being incubated on ice for 10 minutes to ensure 
complete cell lysis 
2. 1641.75µL HBSS and 8.25µL PIC were combined and 300µL of the resultant 
complete HBSS was added to each sample and inverted four to five times. 
3. The samples were then split into 200µL aliquots 
4. Half of the aliquots were left on ice, while the remaining half were sonicated 
for 35 minutes (cycles of 30 seconds on, 30 seconds off, on high power), 
making sure the water temperature was kept between 4-8°C by using a water 
cooler. The samples were placed on ice when finished 
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5. The sonication was repeated with samples that had been left on ice 
6. The two 200µL aliquots for each sample were combined and centrifuged for 
10 minutes at 14,000 x g at 4°C. The supernatant was then transferred to a 
new tube 
 
2.10.1.4. Magnetic immunoprecipitation 
 
1. 100µL sheared chromatin was added to the seventh row of the automated 
IPStar system (Diagenode, Belgium) for each IP 
2. 2089.5µL ChIP buffer (Diagenode, cat no.: C01010130) was combined with 
10.5µL PIC. 100µL of the resultant complete ChIP buffer was added to each 
sample in the seventh row 
3. 1µg of specific antibody was added  to each tube in the seventh row, 
(equivalent to 1µL H3K4me3 (Diagenode, cat no.: C01010130), 1µL IgG 
(Diagenode, cat no.: C01010130) or 0.55µL H3K27me3 (Diagenode, cat no.: 
C15410195)  
4. 10µL complete ChIP buffer was also added to each 10µL input sample, which 
were then stored at 4°C overnight 
5. The IPStar was then set up according to an on-screen setup procedure 
(indirect method). All reagents were provided in the True MicroChIP Kit 
(Diagenode, cat no.: C01010130) 
Reagent volumes: 
Position A.     Elution Buffer 2mL 
Position B.     Bead Wash 11mL 
Position C-F.  Wash buffer 1-4 3250µL 
    Row 3.            Magnetic beads 10µL 
Immunoprecipitation conditions:  
1. IP reaction 15 hours at 4°C 
2. Bead Incubation 2 hours at 4°C 
3. Washes 4 minutes at 4°C 
The IPStar was run over night for approximately 21 hours. 
 
2.10.1.5. Elution, decrosslinking and DNA isolation 
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1. The following morning the samples were recovered from row 12 and placed 
on the DiaMag02 magnetic rack (Diagenode, Belgium), the supernatant was 
kept and the beads discarded 
2. 100µL of elution buffer (TE1) (Diagenode, cat no.: C01010130) was added to 
each sample; 180µL was also added to each 20µL input sample from the day 
before 
3. 8µL of elution buffer (TE2) (Diagenode, cat no.: C01010130) was added to 
each sample 
4. All samples were incubated for 4 hours at 65°C, manually agitating every 30 
minutes 
5. 1000µL of ChIP DNA binding buffer (Diagenode, cat no.: C01010130) was 
added to each sample and mixed by inversion 
6. 625µL of solution was transferred to a spin column in a collection tube 
(Diagenode, cat no.: C01010130) 
7. Samples were centrifuged at 14,000 x g for 1 minute and the flow through was 
discarded 
8. Steps 6 and 7 were repeated with any remaining solution 
9. 200µL DNA wash buffer (Diagenode, cat no.: C01010130) was added to each 
column and centrifuged at 14,000 x g for 1 minute 
10. The wash step was then repeated 
11. The column was transferred to a new 1.5mL microcentrifuge tube. 40µL of 
DNA elution buffer (Diagenode, cat no.: C01010130) was applied directly to 
the column matrix, and incubated at room temperature for 5 minutes. Samples 
were centrifuged at 14,000 x g for 1 minute to elute the DNA 
12. The elution step was repeated so the samples were eluted in a total volume of 
80µL 
13. Samples were frozen at -20°C ready for qPCR analysis 
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2.11. Quantitative PCR (qPCR) 
 
qPCR was used to detect a specific DNA target sequence in ANK1. This enabled the 
calculation of the enrichment of a sample relative to the unmodified input standard. 
Enrichment of specific DNA sequences represented regions in the ANK1 gene that 
the histone modification of interest is associated with. Each sample, including input, 
negative control and standards were run in triplicate for all primers.   
 
2.11.1. qPCR setup 
 
1. 2μL EvaGreen master mix (SolisBiodyne, cat no.: 08-24-00008), 2μL ChIP 
treated DNA, 1μL forward and reverse primer sequences (Table 5.2) and 5μL 
of H2O was combined per sample replicate in 384 well plates (Table 2.20). 
Seven 1 in 4 serial dilutions and a NTC were included in triplicate per plate 
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Reagent Function 
Reagent 
Concentration 
Volume (μL) 
EvaGreen 
polymerase 
Complete master 
mix containing 
magnesium, 
neucleotides and 
taq polymerase 
5X 2 
PCR primers 
Short, single-
stranded 
oligonucleotides 
complementary to 
target sequence 
2/3μM 1 
ChIP DNA ChIP treated DNA unknown 2 
Ultra-pure Water 
Ensures accurate 
and consistent 
reaction volume 
Water to a final 
volume of 10μL 
5 
 
Table 2.20; ANK1 quantitative polymerase chain reaction (qPCR) reagents and 
volumes. 
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2.11.2. QuantStudio setup  
 
1. The following qPCR programme was used: 95°C for 10 minutes, 45 cycles of: 
95°C for 30 seconds, 60°C for 30 seconds, 72°C for 30 seconds, followed by 
a dissociation stage 
 
2.11.3. Data normalisation and quality control 
 
1. Standard curves generated by dilution series were used to calculate primer 
efficiency using the equation: 
efficiency = log dilution(-1/slope) 
2. Where slope is the gradient of the correlation between average CT score per 
replicate and log concentration 
3. ChIP data was normalised by calculating the percentage of input. This was 
done using the equation:  
% input = 100 x primer efficiency((Ct input-3.32) - Ct IP)) 
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CHAPTER 3: DNA METHYLOMIC AND HYDROXYMETHYLOMIC 
SIGNATURES IN ALZHEIMER’S DISEASE BRAIN 
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The work presented in this chapter is based on work submitted for publication and is 
currently under review at Genome Biology (Smith et al. 2018). A copy of the 
submitted manuscript can be found in Appendix 3. 
 
3.1  Introduction  
 
A number of different DNA modifications have been described however; by far the 
most widely studied is 5mC. This is not surprising considering the abundant, stable 
and functionally relevant nature of this modification (Bird 2007).  It is widely accepted 
to be involved in a vital capacity in the regulation of genomic expression across 
human development, ageing and disease. Coupled with the relative ease of profiling 
this modification using high throughput methods, such as microarrays and 
sequencing-based technologies, has resulted in the publication of a number of 
EWAS in various complex diseases.  Further research has now shown that other 
cytosine modifications not only exist but may also have a function in gene regulation 
(Inoue et al. 2011, Ito et al. 2011). These modifications, including 5hmC, 5fC and 
5caC, occur as stages in the de-methylation of cytosine (Figure 1.5).  
 
3.1.1 DNA hydroxymethylation 
 
5hmC was first discovered in bacteriophages in the 1950s (Wyatt et al. 1952). 
Initially it was believed to be a transient modification, representing an intermediate in 
the demethylation of 5mC to un-modified cytosine, however recent data suggests 
that it may have a functional role, with it now having been studied in multiple human 
tissues (Li et al. 2011, Godderis et al. 2015, Lunnon et al. 2016). Evidence suggests 
that 5hmC may be particularly important in the brain. The highest levels of 5hmC in 
any tissue are found in the adult brain (Szwagierczak et al. 2010), whilst a number of 
studies have shown highly dynamic levels of 5hmC during neurodevelopment (Wang 
et al. 2012, Spiers et al. 2017). A liquid chromatography mass spectrometry (LC-MS) 
study that measured 5hmC in mouse brain showed  varying levels across the brain, 
with highest levels in the hypothalamus, cerebral cortex and hippocampus (Munzel 
et al. 2010). In addition, Kriaucionis et al. (2009) showed  5hmC to be enriched in 
Purkinje neurones, whilst Khare et al. (2012) showed the modification to be 
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abundant in synaptic genes. Taken together, it would be interesting to profile 5hmC 
in the context of neurological disease.  
 
Now that it is becoming increasingly accepted that 5hmC is an independent 
epigenetic mark, one important question to address relates to the functional 
consequence of this mark, and its relationship with DNA expression. Recent studies 
have so far suggested that, like 5mC, it is the location of 5hmC in the genome that is 
associated with alterations in gene expression. 5hmC has been shown to be 
enriched in promoters, gene bodies and intergenic areas near genes which in turn 
positively correlate with gene expression at these loci (Pastor et al. 2011, Song et al. 
2011, Wu et al. 2011, Xu et al. 2011). At the chromatin level 5hmC appears to be 
mainly euchromatic, again suggesting an association with gene transcription 
(Szulwach et al. 2011). However, this interaction between 5hmC localisation and 
gene expression is far from conclusive, with some conflicting reports in the literature 
(Xu et al. 2011).  
 
3.1.2 Role of 5hmC  
 
A growing body of literature indicates that 5hmC is not only an intermediate in the 
TET catalysed process of active 5mC demethylation, but an epigenetic signal in its 
own right and contributes to gene regulation (Branco et al. 2012). 5hmC has been 
shown to be maintained across cellular divisions (Hashimoto et al. 2012) and a 
number of proteins have been shown to have an equal affinity to 5hmC and 5mC 
(Frauer et al. 2011), as well as 5hmC specifically (Spruijt et al. 2013). A chaperone 
protein, ubiquitin like with PHD and ring finger domains 1 (UHRF1), has been found 
to bind both 5mC and 5hmC with similar affinities and is theorised to promote 
DNMT1 activity at hydroxymethylated CpGs. In addition, a number of DNA 
glycosylases and DNA repair proteins have been found to bind to 5hmC, 5fC, and 
5caC, however few of these were shown to bind 5mC. Examples of other 5hmC 
readers have also been documented, including transcriptional regulators, chromatin 
modifiers and DNA damage repair proteins (Yildirim et al. 2011, Iurlaro et al. 2013, 
Spruijt et al. 2013); further cementing its role as a functional epigenetic mark.  A 
number of studies suggest that 5hmC has a function in the growth and development 
of neurones, having being found at relatively high levels in the developing foetal 
106 
 
brain (Lister et al. 2013), as well as being highly abundant in adult brain purkinje 
neurones of the CER and enriched in synapse-related genes in both mouse and 
humans (Khare et al. 2012). In addition, a recent study in mouse has shown 5hmC 
(and 5mC) changes with age (Lardenoije et al. 2015).  
 
3.1.3 5hmC in neurological disease  
 
Changes in the global levels of 5mC and 5hmC have been associated with a number 
of neurological diseases. To date four publications have reported changes in the 
global levels of 5mC, 5hmC or both modifications in AD using immunocytochemistry. 
These results are somewhat contradictory, with numerous studies reporting a global 
decrease in 5mC, 5hmC or both modifications (Chouliaras et al. 2013, Condliffe et al. 
2014, Coppieters et al. 2014); while Lashley et al. (2015) report no detectable 
changes in AD. Bradley-Whitman et al. (2013) however showed an increase in both 
5mC and 5hmC in AD hippocampus. To date only one published study has used 
DNA sequencing to analyse 5hmC  in AD (Zhao et al. 2017). This study utilised a 
genome wide capture and high-throughput sequencing approach in DNA samples 
extracted from 30 post-mortem dorsolateral prefrontal cortex tissue samples, 
identifying 517 differentially hydroxymethylated regions (DHRs) significantly 
associated with neuritic plaques and 60 DHRs associated with neurofibrillary tangles. 
However, one caveat of this study is that due to the low resolution of the sequencing 
analysis, this study was unable to differentiate 5hmC from 5mC. This, coupled with 
low sample numbers, suggests that these results require further validation. 
Numerous other neurological diseases have also been linked to changes in 5hmC 
levels including Autism (Wang et al. 2012, Zhubi et al. 2014), Rett Syndrome 
(Szulwach et al. 2011), Fragile X Syndrome (Wang et al. 2012) and HD (Villar-
Menendez et al. 2013, Wang et al. 2013).   
 
3.1.4 Quantification of 5hmC 
 
To date, it has been difficult to specifically analyse 5hmC levels, in the absence of 
5mC levels at base-pair level resolution. Coupling 5hmC antibody 
immunoprecipitation with sequencing (hMeDIP-seq) is one method that can be used 
to quantitatively measure 5hmC however, work by Matarese et al. (2011) suggests 
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that this technique is not yet technically mature and  sufficiently standardised to be 
used for a 5hmC EWAS. Third generation sequencing platforms are another method 
that could be used as it allows the distinction of modified cytosines in the genome by 
measuring the change in polymerase kinetics during the incorporation of 
fluorescently labelled nucleotides (Flusberg et al. 2010).  However, these methods 
are still under development, costly and time-consuming.  
 
Two recent EWAS have utilised the 450K array to demonstrate robust and 
reproducible changes in 5mC at a number of loci in the AD brain (De Jager et al. 
2014, Lunnon et al. 2014), including the ANK1 gene. However, one caveat of this 
approach is the utilisation of BS-treated DNA, which converts unmodified cytosines 
to thymine, whilst methylated cytosines are unchanged. Although the focus of these 
studies has been on DNA methylomic dysfunction, 5hmC is also protected from 
conversion, and as such these published EWAS actually report a sum of 5mC and 
5hmC levels (Huang et al. 2010).  
 
Recent studies have demonstrated that oxidative-BS (OxBS) treatment enables the 
conversion of 5hmC to thymine, and by running matched BS and OxBS treated 
samples in parallel one can generate a quantitative measurement for total DNA 
modifications (BS data), 5mC (OxBS data) and, by proxy, 5hmC (BS data – OxBS 
data) (Booth et al. 2012, Booth et al. 2013). At least two publications have now 
utilised this approach in combination with the 450K array platform to demonstrate 
brain region-specific differences in DNA modifications in post-mortem tissue from 
non-demented individuals (Field et al. 2015, Lunnon et al. 2016).  
 
3.1.5 Summary 
 
Although EWAS in AD have reported alterations in 5mC at specific loci, these 
studies have utilised BS-treated DNA and, as such, actually report a sum of both 
5mC and 5hmC. Immunocytochemistry has shown global levels of 5hmC are altered 
in AD brain, with 5hmC present in neurones, and enriched in genes with synapse-
related functions. However, to date no study has examined the levels of 5hmC in AD 
at single base resolution due to appropriate genetic tools being unavailable or too 
costly for sequencing an entire human genome. As 5hmC has been shown to be 
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enriched in the human brain, particularly in neurones and synaptic genes, the study 
of 5hmC in AD may lead to a better understanding of the molecular mechanisms that 
underlie this disease.  
 
 
3.2  Aims 
 
- To perform an EWAS of 5mC and 5hmC levels in parallel in AD EC and CER. 
- To assess global 5hmC and 5mC levels in AD EC and CER. 
- To identify differentially modified positions (DMoPs), DMPs and differentially 
hydroxymethylated positions (DHPs) associated with AD neuropathology 
(Braak stage). 
- To compare Braak-associated DMoPs identified in the EC and CER data with 
previously published EWAS EC and CER data in an independent study cohort 
(Lunnon et al. 2014) to check for reproducibility. 
- To identify DMRs and differentially hydroxymethylated regions (DHRs), 
consisting of multiple Braak-associated DMPs and DHPs, respectively. 
- To validate the most interesting loci (ANK1) using another technology 
(pyrosequencing (Qiagen)) in an independent cohort. 
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3.3  Materials and Methods  
 
3.3.1 Subjects and samples 
 
For BS and OxBS Illumina 450K profiling (discovery cohort) we used matched brain 
samples collected from the EC and CER from 96 individuals archived in LNDBB. 
These samples were not utilised in previously published AD EWAS publications 
(Lunnon et al. 2014, Smith et al. 2016, Smith et al. 2018). Our first validation cohort 
consisted of previously published (Lunnon et al. 2014) BS EWAS data generated in 
matched EC (n = 104) and CER (n = 108) brain tissue. Our second validation cohort 
(for pyrosequencing) consisted of matched EC samples from 96 individuals archived 
in the Oxford Brain Bank Collection (Esiri 1993). For all cohorts, individuals had 
varying degrees of AD pathology (Braak Stage 0-VI) and all AD patients were over 
the age of 65 at the time of clinical diagnosis. All samples were dissected by trained 
specialists, snap-frozen and stored at -80°C. Further information about all samples is 
provided in Table 3.1. For the discovery cohort and validation cohort 2, genomic 
DNA was isolated from ~100mg of each dissected brain region using a standard 
phenol-chloroform extraction method as described in Section 2.3, and tested for 
degradation and purity prior to analysis as described in Section 2.7.  
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3.3.2 Methylomic and hydroxymethylomic profiling 
 
1μg DNA from each sample (discovery cohort and validation cohort 2) was treated 
with sodium BS and OxBS in parallel using the true-methyl CEGX 96 kit (CEGX, 
Cambridge, UK) according to the manufacturer’s standard protocol, as described in 
Section 2.1.3. Briefly, DNA samples were split, with half being oxidised (OxBS) and 
the remainder (BS) going through a mock oxidisation step, before all being BS 
treated. Gel electrophoresis of the DNA after a digestion control step (Section 2.5.3) 
was used to test for conversion efficiency (Figure 3.1). All samples were then 
processed using the 450K array (Illumina Inc, CA, USA) according to the 
manufacturer’s instructions, with minor amendments and quantified using an Illumina 
HiScan System (Illumina, CA, USA), as described in Section 2.8. Corresponding 
OxBS and BS treated DNA for the same sample were run together on the same 
BeadChip. Samples were assigned a unique code for the purpose of the experiment 
and grouped by tissue. Samples were randomised in their OxBS and BS pairs with 
respect to sex and disease status to avoid batch effects, and processed in batches 
of 12 BeadChips. Illumina Genome Studio software was used to extract the raw 
signal intensities of each probe (without background correction or normalisation). 
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3.3.3 Data quality control 
 
All computations and statistical analyses were performed using R 3.3.2 (R 
Development Core Team 2012) and Bioconductor 3.5 (Gentleman et al. 2004). 
Signal intensities were imported into R using the methylumi package (Davis et al. 
2012) as a methylumi object. Initial QC checks were performed using functions in the 
methylumi package.  
 
3.3.3.1 Multi-dimensional scaling  
 
Multi-dimensional scaling of both X and Y chromosomes were used to assess 
concordance between sex as recorded on post-mortem records and predicted sex 
using the 65 control SNPs (Figure 3.2). The 65 SNPs were also used to confirm that 
matched BS EC, OxBS EC, BS CER and OxBS CER samples were sourced from 
the same individual.  
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Figure 3.2; Multi-dimensional scaling of sex chromosomes. (A) X Chromosome 
scaling, (B) Y Chromosome scaling. This was used to assess concordance between 
recorded and predicted sex in all samples. 
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3.3.3.2 Sample and probe removal with pfilter 
 
The pfilter function was used to remove samples where 5% of sites had a detection 
p-value > 0.05. Specific sites were also removed if the beadcount was less than 
three in 5% of samples or if 1% of the samples had a detection p-value > 0.05 at that 
position. 15 samples and 38,737 sites were removed at this stage of the analysis.  
 
3.3.3.3 Removal of non-specific and polymorphic probes  
 
Probes with common (minor allele frequency (MAF) > 5%) SNPs in the CG or single 
base extension position, or probes that are nonspecific or miss-mapped were 
flagged (N=43,233 probes) and discarded from our results (Chen et al. 2013).  
 
3.3.3.4 Methylation and hydroxymethylation beta densities  
 
Data was pre-processed in the R package wateRmelon using the dasen function as 
previously described (Pidsley et al. 2013). Plotting the mean normalised beta density 
for all BS and OxBS samples revealed a bimodal distribution for both treatments 
(Figure 3.3). The beta value peak for the OxBS treatment was skewed to the left of 
the BS converted samples, corresponding to the higher global total modification 
levels expected for the BS treatment, which included signal from both 5hmC and 
5mC. A CER beta value shift to the right was observed in relation to the EC, this was 
to be expected due to previous reports of high levels of DNA cytosine modifications 
present in the CER (Kriaucionis et al. 2009).  
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Figure 3.3; Comparison of BS and OxBS data in the EC and CER. Following data 
normalisation with the dasen function in the R package WateRmelon we compared the mean 
betas between BS, and OxBS treated EC (A) and CER (B) samples. 
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3.3.4 Data analysis  
 
After these QC steps 367,480 probes were taken forward for analysis. Array data for 
each tissue was normalised separately and the analysis was performed separately 
by tissue.  To calculate 5hmC levels in a sample, the OxBS signal was subtracted 
from the BS signal. It has been previously reported that a small proportion of probes 
in each sample are characterised by a negative BS-oxBS value, likely resulting from 
technical variance inherent in the Illumina array protocol (Lunnon et al. 2016) and 
could therefore represent noise in the system. However, we make the assumption 
that any technical variation present would equally affect both the BS and OxBS 
signal. Therefore probes with a mean negative 5hmC value across all samples may 
still represent biological differences and were included in our analysis.  We have 
annotated tables to denote where the mean 5hmC level was >0 (5hmC Positive 
probe column).    
 
3.3.4.1 Linear regression analysis 
  
The effects of age and sex were regressed out before subsequent analysis. For the 
identification of DMoPs, DMPs and DHPs specifically altered with respect to 
neuropathological measures of AD, we performed a quantitative analysis where 
samples were analysed with respect to Braak stage using a linear regression model. 
Analysis was repeated to include the bioinformatically derived cell epigenotype 
specific (CETS) score as a covariate. This score is calculated using the R package 
“CETS”, which estimates the cell type composition of biological sample based on 
bulk methylation data (Guintivano et al. 2013). Data was analysed separately for 
each brain region using linear regression and probes were ranked by P value, and 
Q-Q plots assessed to check for P value inflation (Figure 3.4).  
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Figure 3.4; Quantile-quantile (Q-Q) plots of expected versus observed P value to 
check for inflation in linear regression analyses. The Q-Q plots for (A) total DNA 
modifications (BS data), (B) 5mC (OxBS data) and (C) 5hmC (BS – OxBS data) in the EC 
shows no P value inflation in our analyses. Similar Q-Q plots were observed for the CER 
(data not shown). 
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3.3.4.2 Identifying enrichment in specific gene features 
 
To investigate whether our neuropathology-associated DMPs were enriched at 
specific gene features, we used a Fisher’s exact test to test for an enrichment of 
either nominally-significant hypermethylated or hypomethylated loci (P < 0.05) 
compared to all neuropathology-associated DMPs (P <0.05) at each gene feature as 
described by Slieker et al (Slieker et al. 2013). Similarly, to investigate whether our 
neuropathology-associated DHPs were enriched at specific gene features, we used 
a Fisher’s exact test to test for an enrichment of either nominally significant 
hyperhydroxymethylated or hypohydroxymethylated loci (P < 0.05) compared to all 
neuropathology-associated DHPs (P <0.05) at each gene feature. As this is 
exploratory work we considered all DMPs and DHPs with P < 0.05 to ensure we 
captured all biological differences. 
 
3.3.4.3 Differentially modified regions  
 
To identify DMRs and DHRs we identified spatially correlated p-values within our 
data using the Python module comb-p (Pedersen et al. 2012) to group ≥ 2 spatially 
correlated CpGs within a 500bp sliding window with a significance threshold of P = 
0.01 from our regression analysis. A P value of < 0.01 was used to maintain 
consistency with previous publication (Lunnon et al. 2014) and to ensure a more 
stringent identification of DMRs and DHRs.  
 
3.3.4.4 Pathway analysis 
 
Pathway analysis of DMPs and DHPs reaching our significance threshold (P < 5 x 
10-5) was performed using the missmethyl 1.10.0 (Phipson et al. 2016) package from 
Bioconductor. This P value threshold was used to limit the number of associated 
genes included, in an attempt to prevent the identification of false positive pathways. 
Pathways were included if they met the following criteria: (1) the number of genes in 
the gene list was greater than one and less than 2000, (2) more than one gene from 
our analysis was present in the pathway and (3) the P value for the association was 
smaller than 0.05.  
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3.3.5 Targeted Replication using Bisulfite Pyrosequencing  
 
BS pyrosequencing, as described in Section 2.9, was used to quantify 5mC across 
eight individual ANK1 CpG sites, including cg05066959 and cg11823178, spanning 
from 41519302 to 41519420 within chromosome 8 (hg19). A single amplicon (246bp) 
was amplified using primers designed using the PyroMark Assay Design software 
2.0 (Qiagen, UK) as previously described (Lunnon et al. 2014), and sequenced using 
two sequencing primers to maximise coverage across eight CpG sites within a 
118bp region. 5mC was quantified in validation cohort 2 using the Pyromark Q24 
system (Qiagen, UK) following the manufacturer's standard instructions and the Pyro 
Q24 CpG 2.0.6 software. We used linear regression to assess the association 
between DNA methylation and low pathology (Braak scores 0-II: n = 48) to high 
pathology (Braak scores V-VI: n = 48) for total DNA modifications, 5mC and 5hmC at 
eight individual CpG sites. Linear regression was used to maintain consistency with 
the data generated on the array and with previous publication (Lunnon et al. 2014). 
The effects of age and sex were included as covariates in our analysis. For this 
sample cohort we had no samples with middle stage AD pathology (Braak III-IV). We 
then averaged across the 118bp amplicon and used two sample t-test to assess the 
difference in the means between groups. Bonferroni threshold of P < 0.017 was used 
to correct for multiple testing.  
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3.4  Results  
 
3.4.1 AD entorhinal cortex is characterised by global hypermethylation and 
hypohydroxymethylation 
 
The majority of studies investigating 5hmC in AD have used immuno-histochemical 
based methods to quantify global levels (Chouliaras et al. 2013, Condliffe et al. 2014, 
Coppieters et al. 2014, Lashley et al. 2015, Celarain et al. 2016). Although the 450K 
array primarily interrogates CG rich regions, which are, in general, unmethylated, we 
were interested to see if there were any global changes across these regions. To 
investigate these global levels of DNA modifications in our data we averaged levels 
across all probes that passed QC (n = 367,480), identifying a global decrease in 
5hmC (P = 0.040) and increase in 5mC (P = 0.039), with overall no net change in 
total modifications (P = 0.838) in the EC with respect to Braak stage. Conversely, no 
significant Braak stage associated alterations were seen for global levels of 5hmC (P 
= 0.659), 5mC (P = 0.916) or total modifications (P = 0.366) in the CER (P > 0.05).  
 
3.4.2 Highly reproducible alterations in cytosine modifications are detectable in 
AD cortex 
 
Initially, we focused on identifying differences in total DNA modification levels (BS 
data: Table 3.2) in the EC that were associated with Braak stage, whilst controlling 
for age and sex above our nominated significance threshold (P < 5 x 10-5). To 
assess the reproducibility of our results, we first compared the effect size of these 
Braak stage-associated DMoPs from the BS data (Table 3.2), with BS data 
previously generated on an independent set of samples from the EC in AD 
(validation cohort 1) (Lunnon et al. 2014). There was a consistent direction of effect 
between the two studies (Figure 3.5A: sign test P =0.043), with the effect sizes highly 
correlated between studies (r = 0.71, P = 4.85 x 10-6). Similarly, there was also a 
significant excess of consistent direction of effect between the two studies when 
examining the effect size of previously published Braak-associated DMoPs (P < 5 x 
10-5) in the EC (Lunnon et al. 2014) with the effect size of the same probes in the 
current study (Figure 3.5B: sign test P = 9.77 x 10-04), with the effect sizes highly 
correlated between studies (r = 0.78, P = 3.50 x 10-4).  
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In contrast, when we compared the effect size of the Braak-associated DMoPs in the 
CER (P < 5 x 10-5) in the current study (Table 3.3) to BS data previously published in 
the CER in AD (Lunnon et al. 2014) we found no consistent direction of effect (Figure 
3.6A: sign test P = 0.267). Similarly, the effect sizes of the previously published CER 
DMoPs (P < 5 x 10-5) (Lunnon et al. 2014) showed no consistent direction of effect 
with the same probes in the current study (Figure 3.6B: sign test P = 0.188). This 
suggests that regions of the brain that are relatively protected from 
neurodegeneration, such as the CER, do not display consistent disease-associated 
epigenetic changes in total DNA modifications in either a global or loci-specific 
manner.  
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Figure 3.5; Braak-associated EC DMoPs identified in this study are consistent with 
those identified in previous analyses of AD brain. (A) There was a consistent direction of 
effect for Braak-associated DMoPs (P < 5 x 10-5) identified in the EC in the discovery cohort 
when compared with the same probes in a previously published dataset of Braak-associated 
DMoPs in the EC (validation cohort 1) (sign test P =0.043), with the effect sizes highly 
correlated between studies (Pearson’s correlation df = 98, r = 0.71, P = 4.85 x 10-6). (B) 
Similarly, there was a consistent direction of effect for previously published Braak-associated 
DMoPs in the EC (P < 5 x 10-5) (validation cohort 1) when compared with the same probes in 
the current study (sign test P = 9.77 x 10-04), with the effect sizes highly correlated between 
studies (Pearson’s correlation df = 98, r = 0.78, P = 3.50 x 10-4). 
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Figure 3.6; Braak-associated DMoPs in the CER are not consistent between studies 
(A) There was no consistent direction of effect when comparing Braak-associated DMoPs (P 
< 5 x 10
-5
) in the CER in the discovery cohort with the effect size of the same probes in a 
previously published dataset of Braak-associated DMoPs in the CER (validation cohort 1) 
(sign test P =0.267). (B) There was also no consistent direction of effect for previously 
published Braak-associated DMoPs in the CER (P < 5 x 10
-5
) (validation cohort 1) when 
compared with the effect size of the same probes in the current study (sign test P = 0.188). 
A)                              
B)                              
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3.4.3 Locus specific changes in DNA methylation and hydroxymethylation occur 
in AD 
 
We were interested to identify specific loci that showed Braak-associated differential 
5mC and 5hmC in the EC (Tables 3.4-3.5; Figure 3.7). We identified three Braak-
associated DMPs that reached experiment-wide significance (P < 2.2 x 10-7), with a 
further 72 loci reaching our nominal significance threshold of P < 5 x 10-5. Although 
no Braak-associated differentially hydroxymethylated positions (DHPs) reached 
experiment wide significance, we did identify 57 loci that reached our nominal 
significance threshold. Of the three experiment-wide significant DMPs, the first and 
third most significant were found on chromosome 3 and resided in CGGBP1 and 
GNL3 respectively, whilst the second most significant DMP was located in WNT5B 
on chromosome 12. In the CER we only identified seven Braak-associated DMPs 
(Table 3.6) and 12 DHPs (Table 3.7) that reached our nominal significance threshold 
(P < 5 x 10-5). 
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3.4.4 Neuropathology-associated DMPs and DHPs in the EC feature in key 
biological pathways 
 
We performed a pathway analysis of the genes annotated to DMPs and DHPs in the 
EC that reached our nominal significance threshold (P < 5 x 10-5). This P value 
threshold was used to limit the number of associated genes included, in an attempt 
to prevent the identification of false positive pathways.  (Table 3.8 and Table 3.9, 
respectively). As this analysis represented exploratory work all significant pathways 
(P < 0.005) are presented. Relevant pathways of interest included axon midline 
choice point recognition” and “axon choice point recognition”, both of which were 
enriched for DMPs and DHPs (GO:0016199: 5mC P = 2.30 x 10-4, 5hmC P = 1.30 x 
10-4; GO:0016198: 5mC P = 4.20 x 10-4, 5hmC P = 2.55 x 10-4 ), “regulation of 
synapse organisation” (GO:0050807: 5hmC P = 9.11 x 10-4), “synapse organisation” 
(GO:0050808: 5hmC P = 0.001) and “synapse assembly” (GO:0007416: 5hmC P = 
0.002), which were all enriched for DHPs.  
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3.4.5 Neuropathology-associated changes in 5mC and 5hmC are seen across 
gene features 
 
Next, we compared the genetic location of the most significant hyper- or hypo- 
(hydroxy)methylated neuropathology-associated loci in the EC (P < 5 x 10-5), to all 
nominally-significant neuropathology-associated DMPs or DHPs (P < 0.05), with 
relation to gene features that have been described by Slieker et al. (2013) (Figures 
3.8-3.9; Tables 3.10-3.11). We demonstrated an enrichment for the most significant 
DMPs and DHPs across all gene features, most strikingly Braak-associated 
hypomethylation and hyperhydroxymethylation appears to be enriched in the CGIs of 
proximal promotors (P < 1 x 10-330).  
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Figure 3.8: The most significant neuropathology-associated DMPs are enriched at 
specific genomic features in the EC. Taking the genomic location of neuropathology-
associated DMPs above our significance threshold (P < 0.05), we used a Fisher's exact test 
to examine whether these hypermethylated or hypomethylated loci are enriched within 
specific genomic features when compared to all Braak-associated DMPs (P < 0.05) with 
results of the enrichments tests shown in Supplementary Table 9. Abbreviations: CpG island 
(CGI), outside CpG island (nonCGI or NC), CpG island shelf (SHE), CpG island shore 
(SHO), distal promoter (DP), downstream (DS), gene body (GB), intergenic (IG), proximal 
promoter (PP), unannotated (UA).  
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Figure 3.9; The most significant neuropathology-associated DHPs are enriched at 
specific genomic features in the EC. Taking the genomic location of neuropathology-
associated DHPs above our significance threshold (P < 0.05), we used a Fisher's exact test 
to examine whether these hyperhydroxymethylated or hypohydroxymethylated loci are 
enriched within specific genomic features when compared to all Braak-associated DHPs (P 
<0.05), with results of the enrichments tests shown in Supplementary Table 10. 
Abbreviations: CpG island (CGI), outside CpG island (nonCGI or NC), CpG island shelf 
(SHE), CpG island shore (SHO), distal promoter (DP), downstream (DS), gene body (GB), 
intergenic (IG), proximal promoter (PP), unannotated (UA).  
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3.4.6 A number of loci display significant negative correlations in 
neuropathology-associated DNA methylation and hydroxymethylation 
changes 
 
Next, we sought to explore whether there was any overlap in disease-associated 
DMoPs, DMPs and DHPs. We compiled a list of loci that showed a disease-
associated alteration in more than one analysis (P < 5 x 10-5) (Figure 3.10; Table 
3.12). We identified 14 sites (annotated to 14 genes) that showed significant 
changes across more than one analysis (total modifications, 5mC alone and 5hmC 
alone) (Figure 3.11). Of the 14 CpGs nominated, 13 showed no nominally significant 
(P > 0.05) difference in total DNA modifications. Although we did observe 
neuropathology-associated differences in both 5mC and 5hmC, with in each instance 
the levels of both modifications being highly negatively correlated with each other 
(Figure 3.11) and a significant interaction between the two modifications (Figure 
3.12). Of particular interest are differences at a site annotated to the APP gene 
(cg12144476).   In the current study we saw a decrease 5mC in APP with Braak 
stage (Figure 3.11N; Effect size (difference (∆) Braak 0 to Braak VI) = -1.39, P = 4.85 
x 10-06), with a concurrent parallel increase in 5hmC (Figure 3.11N; ∆ = 1.44, P = 
1.61 x 10-05) demonstrating a significant interaction between the two modifications 
(Figure 3.12M; P = 1.77 x 10-10) and no net difference in total DNA modifications. 
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Figure 3.11. 
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Figure 3.11; Scatter plot of beta values against Braak stage for the 14 probes that 
feature in Table 3.12. Shown are beta values, corrected for age and sex, for (A) 
cg20066612 (KCNJ9), (B) cg15624314 (H3F3A), (C) cg08240832 (OPN3),  (D) cg13876163 
(TMEM53), (E) cg18070033 (NHEJ1), (F) cg17026303 (ACVR2B), (G) cg16933762 
(ROBO2), (H) cg15147060 (CGGBP1), (I) cg05052335 (RAPGEF6), (J) cg03503087 
(GFRA1),  (K) cg11530914 (FHOD1), (L) cg05341384 (FOXF1), (M) cg07919466 (KCNC3) 
and (N) cg12144476 (APP). Shown are beta values corrected for age and sex (Y axis), 
against Braak stage (X axis). Purple circles represents 5mC levels (OxBS), yellow circles 
represents 5hmC levels (BS-OxBS). Regression lines are shown for 5mC (purple line), 
5hmC (yellow line) and total DNA modifications (grey line). Solid regression lines indicate P 
< 0.05, whilst dashed lines indicate P > 0.05.  
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3.4.7 ANK1 is characterised by differential DNA methylation in the AD EC 
 
Next, we performed an analysis to identify spatially correlated regions consisting of 
>2 neighboring DMPs (DMRs) or DHPs (DHRs) within a 500bp sliding window 
(comb-p (Pedersen et al. 2012)). We did not identify any DHRs, but we did identify 
four DMRs that reached a Sidak-corrected P value < 0.05 (Table 3.13). This included 
an eight probe DMR within the WNT5A gene (Sidak-corrected P = 3.17 x 10-4), a 
three probe DMR within the TRAF3 gene (Sidak-corrected P = 0.022), a two probe 
DMR within the ANK1 gene (Sidak-corrected P = 0.025) and a six probe DMR within 
the ARID5B gene (Sidak-corrected P = 0.029). The two DMPs we identified in ANK1 
in our regional analysis have previously been nominated as DMoPs in AD EC in two 
independent EWAS using BS-treated DNA (De Jager et al. 2014, Lunnon et al. 
2014). In the current study, we again identified a significant increase in total DNA 
modifications in AD at both these two sites in the EC (Figure 3.13A: cg11823178: ∆ = 
6.69, P = 4.68 x 10-4 and Figure 3.13B: cg05066959: ∆ = 10.98, P = 8.37 x 10-6). 
However, this is the first study to demonstrate that these are specifically attributable 
to increased 5mC (cg11823178: ∆ = 9.31, P = 2.61 x 10-5; cg05066959: ∆ = 13.71, P 
= 8.03 x 10-5), with a small, but non-significant decrease in 5hmC at both sites 
(cg11823178: ∆ = -3.20, P = 0.068; cg05066959: ∆ = -2.72, P = 0.349).  
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Table 3.13; Identification of multiple-probe DMRs associated with Braak stage. 
Spatially correlated P values in a 500bp sliding window  were identified using comb-p 
(Pedersen et al. 2012). Shown are those with a Sidak-corrected P value > 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Position Gene Name 
Probes in 
DMR 
Comb-p P 
Value 
Comb-p Sidak 
corrected P 
Value 
chr3:55517806-55518442 WNT5A 8 2.53 x 10
-9
 3.17 x 10
-4
 
chr14:103367306-103367592 TRAF3 3 8.12 x 10
-8
 0.022 
chr8:41519308-41519400 ANK1 2 2.89 x 10
-8
 0.025 
chr10:63809073-63809171 ARID5B 6 3.60 x 10
-8
 0.029 
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Figure 3.13; Alterations in total DNA modifications, DNA methylation and DNA 
hydroxymethylation are associated with AD neuropathology in the EC. Scatter plot of 
beta values, corrected for age and sex, against Braak stage for probes identified in ANK1. 
Purple circles represent 5mC levels (OxBS), yellow circles represent 5hmC levels (BS-
OxBS). Regression lines are shown for 5mC (purple line), 5hmC (yellow line) and total DNA 
modifications (grey line). Solid regression lines indicate P <0.05, whilst dashed lines indicate 
P > 0.05. Shown are (A) cg11823178 (linear regression 5mC: t83 = 4.2, r = 0.440, P = 2.61 x 
10-5; 5hmC: t83 = -2.0,   r = -0.199, P = 0.068; total modifications: t89 = 3.0, r = 0.356, P = 
4.68 x 10-4) and (B) cg05066959 (5mC: t83 = 4.4, r = 0.415, P = 8.03 x 10
-5; 5hmC: t83 = -1.0, 
r = -0.103, P = 0.349; total modifications: t89 = 4.2, r = 0.440, P = 8.37 x 10
-6).  
A)                              
B)                              
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3.4.8 Oxidative-bisulfite pyrosequencing validation of ANK1 
 
To further confirm that ANK1 epigenetic changes associated with neuropathology 
are driven by DNA hypermethylation, and not hyperhydroxymethylation, we used 
OxBS pyrosequencing to quantify DNA modifications across an extended region 
spanning eight CpG sites, including cg11823178 and cg05066959. DNA used for this 
study was from an independent collection of EC tissue (n = 96) obtained from the 
Oxford Brain Bank Collection (validation cohort 2) (Table 3.1) (Esiri 1993). In this 
cohort we did not have access to Braak stage III or IV samples, and as such 
analysed data using a case (Braak V-VI) /control (Braak 0-II) analysis model. Of the 
eight CpG sites assessed, seven were characterised by significant (P < 0.05) AD-
associated hypermethylation (Figure 3.14A). Interestingly, significant AD-associated 
hypohydroxymethylation was also seen at four of the eight CpG sites (Figure 3.14B), 
with total DNA modifications showing a remarkably similar profile to previously 
published studies (Lunnon et al. 2014) (Figure 3.14C). When we averaged total DNA 
modifications, 5mC and 5hmC levels across the eight CpG sites in the 120bp region, 
we saw a significant increase in total modifications (∆ = 0.79, P = 1.12 x 10-4) and 
5mC (∆ = 0.87, P = 1.23 x 10-05) and a trend towards a decrease in 5hmC, (∆ = -
0.40, P = 0.058) in individuals with AD, compared to controls (Figure 3.14D). This 
data suggests that previous studies of ANK1 5mC in AD have underestimated the 
disease-associated changes in 5mC. 
 
 
 
 
 
 
 
 
 
 
 
 
159 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14 
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Figure 3.14; Sites in ANK1 are characterised by significant DNA hypermethylation and 
hypohydroxymethylation in AD. Using BS and OxBS pyrosequencing we determined (A) 
5mC (B) 5hmC and (C) total DNA modification levels in the EC in AD samples (Braak V-VI) 
compared to control samples (Braak 0-II) in validation cohort 2. We assayed a 120bp region 
containing cg05066959 (chr8:41519308) and cg1182378 (chr8:41519399) (shown in red). 
We demonstrated significant (P < 0.05) neuropathology-associated hypermethylation at 
seven of the eight CpG sites (chr8:41519302: t90 = 3.7, P =3.94x10
-4; chr8:41519304: t90 = 
2.6, P =0.01; chr8:41519308: t90 = 2.4, P =0.02; chr8:41519348: t90 = 4.4, P = 1.75x10
-4; 
chr8:41519411: t90 = 5.0, P =2.03x10
-6; chr8:41519417: t90 = 4.8, P = 6.58x10
-6; 
chr8:41519420: t90 = 5.1, P = 1.98x10
-6), hypohydroxymethylation at four of the eight CpG 
sites (chr8:41519302: t90 = -2.5, P =0.01; chr8:41519348: t90 = -2.4, P = 0.03; 
chr8:41519417: t90 = -2.0, P = 0.05; chr8:41519420: t90 = -2.3, P = 0.02), and increased 
total DNA modifications at six of the eight sites (chr8:41519302: t94 = 2.6, P =0.01; 
chr8:41519348: t94 = 3.4, P = 2.32x10
-3; chr8:41519399: t94 = 2.4, P = 0.02; chr8:41519411: 
t94 = 4.9, P = 4.83x10
-6; chr8:41519417: t94 = 4.7, P =1.03x10
-5; chr8:41519420: t94 = 4.2, P 
=7.90x10-5). P values were calculated using linear regression; data is represented as mean 
(±SEM). (D) Combined analysis of averaged sites within the 120bp amplicon region 
highlighted a significant increase in total modifications (t94 = 4.0, P = 1.11 x 10
-4) and 5mC 
(t90 = 4.6, P = 1.23 x 10
-05), meeting our Bonferroni significance threshold P = 0.017 and a 
trend towards a decrease in 5hmC (t90 = -1.9, P = 0.058) in individuals with AD, compared to 
controls. Box and whisker plot shows median, upper and lower quartiles, and maximum and 
minimum values (excluding outliers) P values were calculated using two sample t-test. 
Key: *P < 0.05, **P < 0.01, ***P < 0.005. 
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3.5 Discussion  
 
This study represents, to our knowledge, the first large scale cross-tissue study of 
5mC and 5hmC, at base-pair level resolution in AD, using matched DNA from both 
affected and unaffected brain regions, utilising independent study cohorts and two 
independent technologies (OxBS-Illumina 450K array and OxBS-pyrosequencing). 
Two previous studies of 5hmC in AD have been recently published. The first used a 
selective chemical labelling technique to enrich for 5hmC, and then sequenced the 
captured libraries from a small cohort of 30 individuals with AD, MCI or no dementia 
(Zhao et al. 2017). The study highlighted a number of AD-associated DHPs and 
demonstrated that gene body 5hmC was positively correlated with cis-acting gene 
expression. One limitation of that study was that the analysis was unable to 
discriminate between 5hmC and 5mC because of the low sequencing resolution. The 
second study, by Ellison and colleagues, utilised  reduced representation 
hydroxymethylation profiling (RRHP) to analyse 5hmC levels in AD hippocampus 
(Ellison et al. 2017). Although this study assessed 5hmC at >2 million sites, the study 
was limited to just three AD cases and two age-matched control subjects.   
 
The majority of studies investigating 5hmC in AD have used immuno-histochemical 
based methods to quantify global levels (Chouliaras et al. 2013, Condliffe et al. 2014, 
Coppieters et al. 2014, Lashley et al. 2015, Celarain et al. 2016). One study reported 
a global decrease in 5hmC in the EC and CER in AD, but no change in 5mC 
(Condliffe et al. 2014). However, other studies have reported global reductions in 
both modifications in the hippocampus (Chouliaras et al. 2013) and another study 
highlighted increased levels of 5mC and 5hmC in the middle frontal gyrus and middle 
temporal gyrus (Coppieters et al. 2014). Our results showed a net increase in 5mC 
and decrease in 5hmC in the EC of AD post-mortem brain, confirming previous 
reports within this tissue.  
 
With a sample number of N = 85 at a set significance threshold of P < 5 x 10-5 we 
have 81.3% power to detect a moderate effect of r = 0.5 (Figure 3.15). In addition, in 
our study the overlap between DMoPs identified across our sample cohorts and 
those identified by Lunnon et al. (2014), despite the use of independent study 
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cohorts, suggests that our study was adequately powered to detect robust AD-
associated differences that can be replicated in other studies. This also suggests 
that although different BS conversion methods and donors were used, there are 
consistent and reproducible changes in total DNA modifications in the EC of donors 
with AD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15; Correlation Power Calculation. With a sample number of N = 85, there is a 
81.3% power to detect r = 0.5.(Champely et al. 2018)  
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We identified three Braak-associated DMPs that reached experiment-wide 
significance (CGGBP1 WNT5B GNL3) CCGBP1 is known to influence the 
expression of the FMR1 gene, which is associated with the fragile X mental 
retardation syndrome (Deissler et al. 1997), whereas GNL3 is hypothesised to 
interact with p53, a tumor suppressor protein (Tsai 2015). WNT5B is part of the wnt 
signaling pathway, previously associated with haematopoiesis (Van Den Berg et al. 
1998).  However, disruption of this pathway has been previously implicated in 
neurodegeneration (Caricasole et al. 2004, Toledo et al. 2010). 
 
Our pathway analysis of genes annotated to DMPs and DHPs identified a number of 
significant relevant pathways of interest, including several synapse related pathways 
that were significantly enriched for DHPs. This suggests that synaptic activity is a 
major pathway that displays altered levels of 5hmC in AD. Interestingly, previous 
work by Khare et al. (2012) has shown that 5-hmC is enriched in genes with 
synapse-related functions in both human and mouse brain. We have also 
demonstrated enrichment for the most significant DMPs and DHPs across all gene 
features, most strikingly Braak-associated hypomethylation and 
hyperhydroxymethylation appears to be enriched in the CGIs of proximal promotors. 
This shows that there could be a change from 5mC to 5hmC in these regions in AD, 
despite a global decrease (across regions covered by the array) in 5hmC with 
disease.  
 
We identified 14 sites (annotated to 14 genes) that showed significant changes 
across more than one analysis (total modifications, 5mC alone and 5hmC alone), 13 
of which showed no difference in total modifications. This is consistent with findings 
from previous EWAS using BS DNA, which had also not shown these loci to be 
associated with AD-neuropathology. One of the genes identified was APP, mutations 
in this gene are associated with early-onset, familial AD (Scheuner et al. 1996). 
However, our study is the first time epigenetic variation in this gene has been 
associated with AD via EWAS, although work by West et al. (1995) has previously 
identified hypomethylation of APP in AD brain.  
 
We did not identify any DHRs; however, given that 5hmC is known to be enriched in 
areas of low CG density (Lunnon et al. 2016), this is perhaps not surprising. We did 
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identify four DMRs within four genes (WNT5A, TRAF3, ANK1 and ARID5B). The two 
DMPs we identified in ANK1 in our regional analysis have previously been 
highlighted as DMoPs in AD EC in two independent EWAS using BS-treated DNA 
(De Jager et al. 2014, Lunnon et al. 2014). We replicated the significant increase in 
total DNA modifications in AD at both these two sites in the EC, and demonstrated 
that previous studies of 5mC in ANK1 in AD have underestimated increments in 5mC 
in disease due to confounding by decreased 5hmC.  
 
Several recent studies have reported the links between epigenetic alterations at the 
ANK1 locus and the development of AD (De Jager et al. 2014, Lunnon et al. 2014, 
Mastroeni et al. 2017). The ANK1 protein is a plasma-bound membrane protein that 
contains an ankyrin repeat domain, which modulates interactions between 
cytoskeletal and membrane proteins (Voronin et al. 2008). One of the main functions 
of ANK1 is compartmentalisation and maintenance of the plasma membrane and it is 
possible that the altered expression of this gene could lead to cell membrane 
dysfunction in AD (Lunnon et al. 2014). It has been shown that microglia, the brain’s 
resident macrophages, have >4-fold increase in ANK1 expression in AD compared 
to control brain samples (Mastroeni et al. 2017), suggesting it is possible that ANK1 
5mC levels will have a downstream effect on immune and inflammatory regulation in 
the brain.  
 
Although our study represents the first cross-tissue EWAS to measure 5mC and 
5hmC in parallel in AD it is not without its own limitations.  First, there are some 
caveats to using the 450K array, for example the presence of probes targeting 
regions containing SNPs and cross-hybridising probes, although these were 
addressed in our analysis pipeline (Section 2.8). In addition, although the 450K array 
is said to allow an “epigenome-wide” analysis, it only actually covers approximately 
485,000 CpG positions of the 28 million CpG sites in the human genome (Lovkvist et 
al. 2016), similarly only a small percentage of potential non-CpG methylation sites 
are covered, meaning >98% of potential modification sites are not assessed. 
Second, although we identified DMPs that reached experiment-wide significance, the 
study would have benefitted from a larger discovery sample size, to allow us to 
identify experiment-wide significant DHPs. Third, our study was performed on “bulk” 
tissue; there is considerable cellular heterogeneity within brain regions and between 
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individuals, with the abundance of specific cell types being altered in AD. Although 
we used a bioinformatic algorithm (CETS (Guintivano et al. 2013)) to control for 
differences in different cell proportions, it would have been optimal to epigenetically 
profile different cell populations in our study. Finally, we are unable to determine 
whether the cytosine modification changes we have identified are the cause or 
consequence of disease.  
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3.6  Conclusions 
 
Our analyses from multiple independent cohorts provide further evidence for a role 
for DNA hypermethylation, coupled with hypohydroxymethylation, across a region 
in ANK1 in AD-associated neuropathology. It indicates that previous estimates of 
hypermethylation in ANK1 were underestimates as it is potentially confounded by 
this hypohydroxymethyation. Our study identifies 13 novel loci that show no 
significant difference in overall DNA modifications, but display significant (opposing) 
differences in 5mC and 5hmC in AD. As these genes were not identified in standard 
BS-treated DNA, these findings highlight the utility of our method for identifying novel 
epigenetically dysregulated genes in AD. Although some of the AD-associated loci 
identified in our study do not have a mean 5hmC level across all samples >0, this 
likely reflects experimental noise resulting from the calculation of 5hmC from two 
separate arrays. However, given that the loci we identified are located within genes 
previously implicated in AD, such as APP, it is likely that our data is highlighting 
novel epigenetically altered loci in disease. To conclude, these novel genes warrant 
further research in AD.  
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CHAPTER 4: ANK1 DNA MODIFICATION IN DIFFERENT 
NEURODEGENERATIVE DISEASES 
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The work presented in this chapter is based on a work submitted for publication and 
is currently under review at Neurobiology of Aging (Smith et al. 2018). A copy of the 
submitted manuscript can be found in Appendix 4. 
 
4.1 Introduction 
 
Dementia encompasses a group of chronic neurodegenerative diseases that 
affected an estimated 46.8 million people worldwide in 2013 (Prince et al. 2015), of 
which AD accounts for ~60% of cases. AD has been hypothesised to have an 
epigenetic contribution to disease aetiology (Lunnon et al. 2013). In 2014 two EWAS 
of AD were published, both using the 450K array and highlighting significantly 
increased DNA modifications in the ANK1 gene in AD cortex (De Jager et al. 2014, 
Lunnon et al. 2014), which has been shown across multiple independent study 
cohorts (Smith et al. 2017) and in Chapter 3 of this thesis. In addition, a GWAS of a 
Han Chinese population published in 2015 identified a SNP in ANK1 that conveyed 
an increased susceptibility for developing AD (Chi et al. 2015). ANK1 links integral 
membrane proteins to the underlying spectrin-actin cytoskeleton and plays key roles 
in activities such as cell motility, activation, proliferation, contact, and maintenance of 
specialised membrane domains (Yang et al. 2011); further information regarding 
ANK1 can be found in Section 1.5. There is now increasing interest in understanding 
the role of epigenetic changes in ANK1 in AD development and progression. One 
important question to be addressed relates to the specificity of ANK1 
hypermethylation to AD. Although AD accounts for ~60% of dementia cases, many 
other dementias share common symptoms and/or pathological hallmarks with AD.   
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4.1.1 Different types of dementias and neurodegenerative diseases  
 
Although AD is the most common form of dementia, ~40% is caused by other 
neurodegenerative diseases (Figure 4.1). VaD and DLB explain 17% and 4% of 
dementia cases, respectively (Prince et al. 2014). Other dementias include HD and 
PD with dementia. A number of dementias have overlapping symptoms, making the 
diagnosis of a specific dementia difficult. In addition different dementias can often co-
occur, which is called mixed dementia, for example AD and DLB, or AD and VaD. 
Together AD, VaD, DLB, HD, PD dementia and mixed dementia make up the vast 
majority (~95%) of dementia cases (Figure 4.1) (Prince et al. 2014). 
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4.1.1.1 Vascular Dementia (VaD) 
 
VaD is the second most common cause of dementia after AD (Prince et al. 2014).  
Characterised by the loss of neurological function due to ischemic events, the risk of 
developing VaD is closely linked to vascular health (Román et al. 1993).  It can be 
caused by a wide variety of vascular disorders, including large, or multiple small 
infarcts or cerebral amyloid angiopathy (CAA). VaD is most common in older people, 
showing a similar age demographic to AD. It is thought that blockage or damage to 
small vessels leads to ischaemic events, damaging neurones and secondary 
structures within the brain.  The symptoms of VaD can occur either suddenly, 
following a stroke, or over time, through a series of small ischaemic events. 
Symptoms of VaD include; slowness of thought, difficulty with planning, trouble with 
understanding, problems with concentration and mood or behavioural changes (NHS 
2017). Given the similarity in symptoms and age demographic for VaD and AD, it 
can sometimes lead to misdiagnosis of AD. In fact, it is estimated that ~17% of VaD 
cases are misdiagnosed (Hunter et al. 2015). Risk factors for VaD are those 
normally associated with cardiovascular health, such as hypertension, cigarette 
smoking, myocardial infarction and diabetes mellitus (Gorelick 2004). Like AD, VaD 
has no treatment that can halt the disease, and prescribed medications only combat 
vascular symptoms, for example anti-hypertensives (Rouch et al. 2015).  VaD has no 
familial inherited cause except for one rare disorder (cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukoencephalopathy - CADASIL) (Joutel et 
al. 1996). VaD can often co-occur with other dementias; it is predicted that a third of 
patients diagnosed with VaD will also have AD-type pathology at autopsy (Kalaria et 
al. 1999).  
 
4.1.1.2 Dementia with Lewy Bodies (DLB) 
 
DLB is the third most common cause of dementia (McKeith 2002). The pathology of 
DLB shares similarities to AD, with the presence of immune regulation and microglial 
activation being consistent between diseases (Mackenzie 2000). However, the 
presence of Lewy bodies within the brain makes DLB considerably more comparable 
to PD (McKeith 2002). DLB is characterised by the deposition of cortical and 
subcortical Lewy bodies, which are abnormal protein aggregates within nerve cells 
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(Spillantini et al. 1997). Amyloid pathology is also common in DLB however 
neurofibrillary tangles are rarely seen (Gomperts et al. 2008). The age of onset of 
this disease varies from as young as 50 to over 85 (LBDA 2016). There are three 
core clinical diagnostic features of DLB, including 1) cognitive fluctuation, 2) mild and 
spontaneous parkinsonism that typically presents as bradykinesia and rigidity and 3) 
visual hallucinations (Cummings 2004). Unlike AD, the deterioration in cognitive 
function does not occur in a linear manner; in fact one of the hallmarks of Lewy body 
dementia is the fluctuation of cognitive functioning. The fluctuation gives the 
impression that the patient is moving through disease stages in a stochastic manner; 
however this variation in cognitive functioning is constant within each stage of the 
disease (McKeith 2007). The clinical diagnosis of DLB can be difficult because of the 
variability and the overlap of symptoms between DLB and other related dementias, 
notably AD and PD dementia. In particular the diagnostic classification of either PD 
dementia or DLB is only disparate by the timing of symptoms; patients who develop 
cognitive symptoms and motor features of PD within one year are classed as having 
DLB. However, if a patient develops motor features first and no dementia symptoms 
until after a year, then PD is diagnosed (Meyniel et al. 2007, Dodel et al. 2008).  
 
4.1.1.3 Huntington’s disease (HD) 
 
Unlike other neurodegenerative disorders, HD only has a genetic cause and there 
are no sporadic cases of disease.  It is caused by an autosomal dominant tri-
nucleotide repeat (CAG) mutation in the Huntingtin gene (HTT). CAG codes for the 
amino acid glutamine; people with fewer than 36 repeated glutamines in HTT 
produce the correctly functioning cytoplasmic protein (Walker 2007). However, a 
sequence of 36 or more glutamines results in an altered form of the HTT (Walker 
2007), causing the build-up of cytosolic protein leading to neuronal cell death. 
Generally, the number of CAG repeats is related to how much this process is 
affected, and accounts for about 60% of the variation of the age of the onset of 
symptoms. The remaining variation has been attributed to other factors, for example, 
other genetic risk loci and environmental interactions (Walker 2007). 36-39 glutamine 
repeats gives rise to a reduced-penetrance form of the disease, with a much later 
onset and slower progression of symptoms (Myers 2004). Whilst with very large 
repeat counts, HD has full penetrance and can occur as early as 20 years of age. 
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However, the average age of onset is between 35 and 44 years of age (Myers 2004). 
HD symptoms are characterised by unwanted choreatic movements, behavioural 
and psychiatric disturbances and dementia. The cognitive decline in HD can be 
present long before the first motor symptoms appear, but it can also be very mild 
even in the advanced stages of the disease (Roos 2010). 
 
4.1.1.4 Parkinson’s disease (PD) 
 
Lewy bodies, as in DLB, are the pathological hallmark of PD. They are α-synuclein 
immuno-reactive inclusions made up of a number of neurofilament proteins together 
with proteins responsible for proteolysis (Spillantini et al. 1997). Mutations in the α-
synuclein gene are responsible for some familial forms of PD in which Lewy bodies 
are also seen (Stefanis 2012). Work by Desikan et al. (2015) has shown association 
of AD and PD with rs393152 within the extended MAPT region, suggesting genetic 
pleiotropy at this locus. Neuronal cell loss within the SN is particularly evident in PD 
(George et al. 2009). Post-mortem counts of neuronal numbers in this region have 
revealed a 50-70% loss of neurones in the SN of PD patients compared with the 
same region in unaffected individuals (George et al. 2009). This long-term 
degenerative disorder mainly affects the motor system, occurring many years before 
the onset of dementia (Jankovic 2008). The earliest symptoms include shaking, 
rigidity, slowness of movement, and difficulty with walking (Jankovic 2008), often 
termed “parkinsonism”. However, dementia becomes common in the advanced 
stages of disease occurring in up to 50% of people with PD after six years (Pigott et 
al. 2015). The majority of PD cases are sporadic, but it is believed that both 
environmental and genetic factors are involved in disease aetiology (Warner et al. 
2003). 
 
4.1.2 Summary  
 
There are many different neurodegenerative diseases that are characterised by 
dementia. AD is the most common form of dementia and has been hypothesised to 
have an epigenetic contribution to disease. Hypermethylation at the ANK1 locus has 
been robustly shown in AD cortex in a number of published studies (De Jager et al. 
2014, Lunnon et al. 2014) as well as in Chapter 3 of this thesis. However, to date the 
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extent to which altered ANK1 5mC is also associated with other neurodegenerative 
diseases is not currently known. Given that many different neurodegenerative 
diseases have similar symptoms and pathological hallmarks this study aimed to 
quantify 5mC levels across a 118bp region of ANK1, previously associated with AD, 
in a number of different neurodegenerative diseases.  
 
 
 
4.2  Aims 
 
- To build a resource of high quality DNA samples from multiple brain regions 
(EC, STG, CER, STR and SN) from  post-mortem brain samples of individuals 
with different dementias and non- demented control donors  
- To quantify 5mC across a 118bp region of ANK1 using the BS 
pyrosequencing assay used in Chapter 3. To compare and contrast 5mC 
levels across the 118bp region in multiple neurodegenerative diseases, 
including AD, VaD, DLB, HD and PD.  
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4.3 Materials and Methods 
 
4.3.1 Subjects and Samples  
 
Post-mortem brain tissue was obtained from six different UK brain banks (the 
SWDBB, the LNDBB, the Manchester Brain Bank, the Oxford Brain Bank, the 
Cambridge Brain Bank and the Newcastle Brain Bank). In total, tissue was obtained 
from 60 AD (Braak V-VI), 119 DLB, 27 VaD, 22 HD, 36 PD and 105 elderly non-
demented control subjects (Braak 0-II). A subset of DLB (N = 39) and VaD (N = 5) 
cases also had co-existing AD pathology. For each disease we analysed the EC, 
STG and CER. For HD cases we also analysed the STR as this is primarily affected 
in disease (Reiner et al. 2011), whilst for PD cases we analysed the STR and SN as 
these are regions of pathology in this disease (Fearnley et al. 1991). For control 
samples we analysed all five brain regions. For a small number of donors tissue was 
not available from all brain regions. Genomic DNA was isolated from ~100mg of 
each dissected brain region using a standard phenol-chloroform extraction method, 
and tested for degradation and purity prior to analysis as previously described (Smith 
et al. 2016) (Section 2.3). Demographic information for samples can be found in 
Table 4.1. 
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Brain Region 
EC STG CER STR SN 
AD 
(N = 60) 
N 58 58 58 - - 
Sex (M/F) 27/31 26/32 26/32 - - 
Mean age (±SD) 77.7 (9.2) 77.6 (9.2) 78.4 (8.8) - - 
All DLB 
(N = 119) 
N 91 107 112 - - 
Sex (M/F) 72/19 84/23 88/24 - - 
Mean age (±SD) 78.8 (7.3) 78.3 (7.2) 78.1 (7.2) - - 
DLB only 
(N = 80) 
N 56 69 76 - - 
Sex (M/F) 47/9 56/13 61/15 - - 
Mean age (±SD) 78.1 (7.1) 77.6 (6.9) 77.4 (7.0) - - 
DLB + AD 
(N = 39) 
N 35 38 36 - - 
Sex (M/F) 25/10 28/10 27/9 - - 
Mean age (±SD) 80.0 (7.5) 79.5 (7.6) 79.5 (7.7) - - 
All VaD 
(N = 27) 
N 23 27 26 - - 
Sex (M/F) 9/14 11/16 11/15 - - 
Mean age (±SD) 83.9 (8.4) 83.6 (7.9) 83.5 (8.1) - - 
VaD only 
(N = 22) 
N 19 22 21 - - 
Sex (M/F) 8/11 10/12 10/11 - - 
Mean age (±SD) 83.3 (7.8) 83.0 (7.4) 82.8 (7.5) - - 
VaD + AD 
(N = 5) 
N 4 5 5 - - 
Sex (M/F) 1/3 1/4 1/4 - - 
Mean age (±SD) 86.8 (12.1) 86.2 (10.6) 86.2 (10.6) - - 
HD 
(N = 22) 
N 19 20 20 19 - 
Sex (M/F) 13/6 13/7 14/6 13/6 - 
Mean age (±SD) 71.1 (5.0) 70.4 (7.1) 70.0 (7.2) 68.8 (12.8) - 
PD 
(N = 36) 
N 33 35 33 5 29 
Sex (M/F) 19/14 21/14 21/12 4/1 19/10 
Mean age (±SD) 78.5 (7.4) 78.2 (7.5) 78.3 (7.5) 83.6 (3.2) 78.9 (7.6) 
Control 
(N = 105) 
N 99 74 98 21 31 
Sex (M/F) 53/46 40/34 48/50 9/12 11/20 
Mean age (±SD) 81.4 (9.6) 81.6 (10.6) 80.7 (10.7) 76.5 (11.7) 77.3 (11.2) 
 
Table 4.1; Sample and demographic information for samples used in the study. Shown 
for each disease cohort are the number of total donors used (N), then for each individual 
brain region, the number of samples available (N), sex distribution and mean age (± 
standard deviation (SD)). 
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4.3.2 ANK1 bisulfite pyrosequencing  
 
Throughout this chapter we refer to 5mC, however as we utilised BS treatment, the 
data we report is actually the sum of both 5mC and 5hmC at the ANK1 locus. Due to 
financial and logistical constraints it was not feasible to perform OxBS treatment in 
this study. BS pyrosequencing was used to quantify 5mC across eight individual 
CpG sites in the ANK1 gene, spanning from 41519302 to 41519420 within 
chromosome 8 (hg19). BS conversion was performed using the Bisulfite-Gold kit 
(Zymo research, USA). A single amplicon (246bp) was generated using primers 
designed using the PyroMark Assay Design software 2.0 (Qiagen, UK) as previously 
described (Lunnon et al. 2014). Pyrosequencing was performed using two 
sequencing primers to maximise coverage across eight CpG sites. 5mC was 
quantified using the Pyromark Q24 system (Qiagen, UK) following the 
manufacturer's standard instructions and the Pyro Q24 CpG 2.0.6 software (Section 
2.9).  
 
4.3.3 Data Analysis  
 
All computations and statistical analyses were performed using R 3.3.2 (R 
Development Core Team 2012). A linear regression analysis was performed, 
controlling for the effects of age, sex and batch effects, comparing control samples 
with samples affected by each neurodegenerative disease. Linear regression was 
used to maintain consistency with Chapter 3 and previous publication (Lunnon et al. 
2014). For the VaD and DLB samples we also performed a second analysis to 
investigate whether co-existing AD pathology influenced the results by comparing 
individuals with and without co-existing AD pathology to control samples, again 
accounting for the effects of age, sex and batch. We then used a two sample t-test to 
assess the difference in the mean of examined 5mC differences averaged across the 
amplicon for each disease studied. Bonferroni significance threshold was calculated 
per test to adjust for multiple testing. However, it should be noted that Bonferroni 
correction is highly conservative and too stringent for this analysis due to the highly 
correlated nature of the brain regions analysed. Finally, we used a paired two-tailed 
t-test to compare adjusted 5mC differences in disease between brain regions. 
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4.4 Results 
 
4.4.1 AD-associated ANK1 DNA hypermethylation is seen across all tissues 
analysed 
 
First, we sought to replicate previous findings of ANK1 DNA hypermethylation in AD. 
Across the 118bp region, we observed significantly increased levels in AD cases 
compared to controls in all eight ANK1 CpG sites in the EC (Figure 4.2A) and seven 
ANK1 CpG sites in the STG (Figure 4.2B). Both the EC and STG exhibit a high 
degree of AD pathology, even in the earliest stages of disease, with the EC being the 
starting point of AD pathology in the cortex (Braak et al. 1991). Conversely, the CER 
remains free of AD pathology until the very last stages of the disease, although even 
then this is limited to β-amyloid plaques with an absence of NFTs of 
hyperphosphorylated tau (Braak et al. 1989). Of note, we observed significant ANK1 
DNA hypermethylation at five ANK1 CpG sites in the CER (Figure 4.2C). This is the 
first time ANK1 5mC differences have been reported in the CER. Interestingly, two of 
the loci that did not display AD-associated ANK1 hypermethylation in the CER were 
chr8:41519308 and chr8:41519399, the two sites included on the 450K array used in 
previous EWAS analyses of AD which did not identify ANK1 hypermethylation in AD 
in the CER (Lunnon et al. 2014). Average 5mC across the amplicon region was 
significantly elevated in AD in the EC (P = 1.29 x 10-07), STG (P = 2.39 x 10-03) and 
CER (P = 7.81 x 10-03) (Figure 4.2D). ANK1 5mC differences between cases and 
controls at both individual sites and across the amplicon were lower in the CER 
compared to other tissues tested (Table 4.2), with a significantly greater 5mC 
difference between cases and controls in the EC (amplicon average corrected 5mC 
difference (Δ) = 4.53%) compared to both the STG (amplicon average Δ = 2.84%; P 
= 7.98 x 10-4) and the CER (amplicon average Δ = 1.17%, P = 2.55 x 10-4). 
Interestingly, this pattern of difference matches the spread of AD pathology 
throughout the brain.  
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Figure 4.2 
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Figure 4.2; ANK1 is hypermethylated in the EC, STG and CER in AD brain. Using BS 
pyrosequencing we assayed a 118bp region of the ANK1 gene ranging from 41519302 to 
41519420 on chromosome 8 (genome build hg19) in (A) EC, (B) STG and (C) CER tissue, in 
AD samples (Braak V-VI) compared to control samples (Braak 0-II) using linear regression. 
We demonstrated significant neuropathology-associated hypermethylation at all assayed 
CpG sites in the EC (chr8:41519302: t153 = 6.9, r = 0.53, P =1.76x10
-10; chr8:41519304: t153 = 
6.6, r = 0.51, P =5.76x10-10; chr8:41519308: t148 = 7.2, r = 0.53, P =3.16x10
-11; 
chr8:41519348: t140 = 6.8, r = 0.55, P = 1.75x10
-4; chr8:41519399: t155 = 2.8, r = 0.25, P = 
5.35x10-3; chr8:41519411: t155 = 5.9, r = 0.45, P =2.27x10
-8; chr8:41519417: t155 = 5.5, r = 
0.39, P = 1.50x10-7; chr8:41519420: t155 = 5.9, r = 0.50, P = 2.53x10
-8), significant 
hypermethylation at seven of the eight CpG sites in the STG (chr8:41519302: t129 = 3.9, r = 
0.54, P =1.49x10-4; chr8:41519304: t129 = 2.4, r = 0.41, P =0.017; chr8:41519308: t121 = 3.6, r 
= 0.47, P =4.43x10-4; chr8:41519348: t114 = 3.2, r = 0.50, P = 0.002; chr8:41519411: t129 = 
3.8, r = 0.63, P =2.22x10-4; chr8:41519417: t129 = 3.6, r = 0.44, P = 4.55x10
-4; 
chr8:41519420: t129 = 3.0, r = 0.45, P = 0.003) and five of the eight sites in the 
CER(chr8:41519302: t152 = 3.7, r = 0.34, P =2.98x10
-4; chr8:41519304: t152 = 2.7, r = 0.32, 
P =0.008; chr8:41519411: t153 = 3.4, r = 0.34, P =8.43x10
-4; chr8:41519417: t151 = 2.2, r = 
0.26, P = 0.028; chr8:41519420: t151 = 2.1, r = 0.13, P = 0.038). Data is represented as 
mean (±SEM) (D) When data was summed across the 118bp amplicon region we observed 
a significant increase in 5mC across all brain regions (two sample t-test, EC: t157 = 5.5, P = 
1.29 x 10
-7
, STG: t132 = 3.1, P = 0.002 and CER: t154 = 2.8, P = 0.005). Meeting our 
Bonferroni significance in EC only (P = 1.85x10-3). Box and whisker plot shows median, 
upper and lower quartiles, and maximum and minimum values (excluding outliers) Key: *P < 
0.05, **P < 0.01, ***P < 0.005.  
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Genomic Location 
AD 
EC STG CER 
∆ P ∆ P ∆ P 
chr8:41519302 4.31 1.76E-10 2.83 1.49E-04 2.09 2.98E-04 
chr8:41519304 4.85 5.76E-10 2.01 0.017 1.42 0.008 
chr8:41519308 5.51 3.16E-11 3.22 4.43E-04 -0.23 0.729 
chr8:41519348 4.99 2.79E-10 2.33 0.002 0.17 0.838 
chr8:41519399 2.87 0.005 1.68 0.150 0.66 0.585 
chr8:41519411 4.58 2.27E-08 4.02 2.22E-04 2.83 8.43E-04 
chr8:41519417 4.30 1.50E-07 3.53 4.55E-04 1.54 0.028 
chr8:41519420 4.80 2.53E-08 3.08 0.003 0.86 0.038 
Amplicon Average 3.14 1.29E-07 1.68 0.002 0.98 0.005 
 
Table 4.2; ANK1 CpG sites are hypermethylated in AD across all brain regions tested. 
Shown for each tissue is chromosomal location (genome build hg19) of CpG sites tested, 
with corrected difference (Δ) in 5mC levels and corresponding P value between controls 
(Braak 0-II) and AD cases (Braak V-VI) after adjusting for the covariates of age, sex and 
batch effects using linear regression. A positive Δ reflects hypermethylation in AD. All P 
values < 0.05 (and their corresponding Δ) are shown in bold. 
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4.4.2 ANK1 DNA hypermethylation in the EC is only observed in DLB cases 
with co-existing AD pathology 
 
Interestingly we observed significant hypermethylation of ANK1 in DLB cases 
compared to controls in the EC (Figure 4.3A) at four of the eight ANK1 CpG sites 
(Table 4.3). We saw no difference between DLB and control samples in either the 
STG (Figure 4.4A) or the CER (Figure 4.4B) at any of the eight ANK1 CpG sites. 
Across the ANK1 amplicon we observed significant DLB-associated 
hypermethylation in the EC (P = 0.0244), but not in the STG or CER (P > 0.05) 
(Figure 4.3B). It is widely reported that DLB and AD frequently co-occur (Rosenberg 
et al. 2001); we were therefore interested to investigate whether we still observed 
DLB-associated DNA hypermethylation in the EC when we stratified for a co-existing 
AD pathology. We found no significant difference in ANK1 5mC in individuals with 
“pure” DLB compared to controls in the EC (N = 56, Figure 4.3C), STG (N = 69, 
Figure 4.4C) and CER (N = 76, Figure 4.4D). However, we did observe significant 
hypermethylation in DLB cases with a co-existing AD pathology compared to 
controls at seven of the eight ANK1 CpG sites in the EC (N = 35, Figure 4.3C) and 
two sites in the STG (N = 38, Figure 4.4C), with no difference in the CER (N = 36, 
Figure 4.4D). When we looked across the whole 118bp region, we saw increased 
ANK1 5mC in the EC in individuals with co-existing AD pathology (P = 1.45 x 10-03) 
(Figure 4.3D), suggesting that the ANK1 hypermethylation seen in some individuals 
with DLB is primarily driven by AD pathology.  
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Figure 4.3 
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Figure 4.3; ANK1 hypermethylation is observed in the EC in individuals with DLB and 
co-existing AD pathology. Using BS pyrosequencing we assayed a 118bp region of the 
ANK1 gene ranging from 41519302 to 41519420 on chromosome 8 (genome build hg19) in 
all DLB samples compared to control samples. (A) We demonstrated significant 
neuropathology-associated hypermethylation at four CpG sites in the EC. (linear regression: 
chr8:41519399: t185 = 2.4, r = 0.24, P = 0.020; chr8:41519411: t185 = 2.6, r = 0.28, P =0.010; 
chr8:41519417: t185 = 2.2, r = 0.24, P = 0.032; chr8:41519420: t185 = 3.0, r = 0.31, P = 
0.003). (B) When data was summed across the 118bp amplicon region we observed a 
significant increase in 5mC in the EC (two sample t-test, t188 = 2.3, P = 0.024), which did not 
meet our stringent Bonferroni significance threshold (1.85x10-3). Some individuals with DLB 
also had co-existing AD pathology; (C) when we compared 5mC levels in ANK1 in 
individuals with DLB and co-existing AD pathology, or individuals with “pure” DLB only to 
controls, we found significant hypermethylation at seven sites in the EC in individuals with 
co-existing AD pathology(chr8:41519302: t131 = 2.3, r = 0.63, P =0.022; chr8:41519304: t131 
= 2.1, r = 0.18, P =0.034; chr8:41519348: t122 = 2.1, r = 0.17, P = 0.034; chr8:41519399: t132 
= 2.6, r = 0.21, P = 0.010; chr8:41519411: t132 = 3.3, r = 0.26, P =0.002; chr8:41519417: t132 
= 3.3, r = 0.26, P = 0.001; chr8:41519420: t132 = 3.7, r = 0.30, P = 2.45x10
-4). (D) When we 
averaged methylation across the region we saw significant hypermethylation in the EC in 
individuals with co-existing AD pathology (two sample t-test, t132 = 3.3, P = 0.001), meeting 
our stringent Bonferroni significance threshold (1.85x10-3). Data is represented as mean 
(±SEM) Box and whisker plots show median, upper and lower quartiles, and maximum and 
minimum values (excluding outliers). Key: *P < 0.05, **P < 0.01, ***P < 0.005.  
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Figure 4.4; ANK1 DNA methylation levels in the STG and CER in individuals with DLB 
Using BS pyrosequencing we assayed a 118bp region of the ANK1 gene ranging from 
41519302 to 41519420 on chromosome 8 (genome build hg19) in all DLB samples 
compared to control samples. We did not observe any disease-associated differences in 
either the STG (A) or CER (B). When we compared 5mC levels in ANK1 in individuals with 
DLB and co-existing AD pathology, or individuals with “pure” DLB only to controls, we found 
significant hypermethylation at two sites in the STG (linear regression, chr8:41519304: t109 
= 2.1, r = 0.18, P =0.034; chr8:41519348: t101 = 2.3, r = 0.20, P = 0.025) (C) but no sites in 
the CER (D) in individuals with co-existing AD pathology. Data is represented as mean 
(±SEM) Key: *P < 0.05, **P < 0.01, ***P < 0.005.  
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4.4.3 ANK1 hypermethylation is seen in the EC only in VaD individuals with co-
existing AD pathology 
 
We observed increased 5mC in individuals with VaD at none of the ANK1 CpG sites 
in the EC (Figure 4.5A), only one site in the STG (Figure 4.6A) and no sites in the 
CER (Figure 4.6B) (Table 4.4), with no difference across the amplicon in any of the 
brain regions tested (P > 0.05) (Figure 4.5B). Because VaD also often co-occurs with 
AD we next examined whether stratifying cases by the presence of AD pathology 
altered these findings. Interestingly, we saw disease-associated hypermethylation in 
the EC at five of the eight ANK1 CpG sites only in individuals with co-existing AD 
pathology (Figure 4.5C), whilst we saw disease-associated hypomethylation at one 
site in the STG (Figure 4.6C) in individuals with “pure” VaD, and no disease-
associated changes in the CER (Figure 4.6D).  When we looked across the 118bp 
region we only saw significant ANK1 hypermethylation in individuals with VaD and 
co-existing AD pathology compared to controls in the EC (P = 0.0163) (Figure 4.5D). 
It is worth noting that our cohort only had a small number of VaD cases with co-
existing AD pathology (N=5). 
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Figure 4.5 
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Figure 4.5; ANK1 hypermethylation is observed in the EC in individuals with VaD and 
co-existing AD pathology. Using BS pyrosequencing we assayed a 118bp region of the 
ANK1 gene ranging from 41519302 to 41519420 on chromosome 8 (genome build hg19) in 
all VaD samples compared to control samples. (A) We found no disease-associated 
differential methylation at any individual sites in the EC, or any difference when averaged 
across the amplicon (B). Some individuals with VaD also had co-existing AD pathology; (C) 
when we compared 5mC levels in ANK1 in individuals with VaD and co-existing AD 
pathology, or individuals with “pure” VaD only to controls, we found significant 
hypermethylation at five sites in the EC in individuals with co-existing AD pathology. (linear 
regression: chr8:41519302: t100 = 2.3, r = 0.20, P =0.027; chr8:41519304: t100 = 2.4, r = 0.21, 
P =0.020; chr8:41519308: t98 = 2.6, r = 0.23, P =0.012; chr8:41519399: t101 = 2.0, r = 0.17, P 
= 0.045; chr8:41519417: t101 = 2.7, r = 0.24, P = 0.008) (D) When we averaged methylation 
across the region we observed significant hypermethylation in the EC in individuals with a 
co-diagnosis of AD (two sample t-test: t101 = 2.4, P = 0.016), which did not meet our stringent 
Bonferroni significance threshold (1.85x10-3). Data is represented as mean (±SEM). Box and 
whisker plots show median, upper and lower quartiles, and maximum and minimum values 
(excluding outliers). Key: *P < 0.05, **P < 0.01, ***P < 0.005.  
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Figure 4.6; ANK1 DNA methylation levels in the STG and CER in individuals with VaD. 
Using BS pyrosequencing we assayed a 118bp region of the ANK1 gene ranging from 
41519302 to 41519420 on chromosome 8 (genome build hg19) in all VaD samples 
compared to control samples. We observed neuropathology-associated hypomethylation at 
one site in the STG (A) and no disease-associated changes in the CER (B). When we 
compared 5mC levels in ANK1 in individuals with VaD and co-existing AD pathology, or 
individuals with “pure” VaD only to controls, we found significant hypomethylation at one 
sites in the STG in individuals with “pure” VaD (linear regression: chr8:41519411: t95 = -2.3, r 
= 0.40, P = 0.026) (C), but no disease-associated differences in the CER (D). Data is 
represented as mean (±SEM) Key: *P < 0.05, **P < 0.01, ***P < 0.005.  
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4.4.4 ANK1 DNA hypermethylation in the EC is seen in both HD and PD. 
 
ANK1 DNA hypermethylation was seen at four of the eight CpG sites in the EC in HD 
(Figure 4.7). However, no differential 5mC was seen in the other brain regions tested 
(Table 4.5), including the STG (Figure 4.8A), the CER (Figure 4.8B) and the STR 
(Figure 4.8C), a region that forms part of the basal ganglia, known to be the first 
brain region to be adversely affected by HD pathology (Walker 2007). Averaging 
across the region again highlighted significant hypermethylation in the EC (P = 6.68 
x 10-3), with no significant change in any other tissue (Figure 4.8D).   
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Figure 4.7; ANK1 DNA methylation patterns in HD. Using BS pyrosequencing we 
assayed a 118bp region of the ANK1 gene ranging from 41519302 to 41519420 on 
chromosome 8 (genome build hg19) in HD samples compared to control samples. In HD 
donors in the EC we observed neuropathology-associated hypermethylation at five sites ( 
linear regression: chr8:41519302: t112 = 2.2, r = 0.31, P =0.027; chr8:41519308: t110 = 3.1, r = 
0.39, P =0.003; chr8:41519348: t104 = 2.5, r = 0.31, P = 0.014; chr8:41519399: t113 = 2.5, r = 
0.28, P = 0.014; chr8:41519420: t113 = 4.0, r = 0.40, P = 1.24x10
-4). Data is represented as 
mean (±SEM) Key: *P < 0.05, **P < 0.01, ***P < 0.005.  
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Genomic Location 
HD 
EC STG CER STR 
∆ P ∆ P ∆ P ∆ P 
chr8:41519302 2.09 0.027 1.20 0.160 0.33 0.681 0.76 0.496 
chr8:41519304 1.89 0.062 0.58 0.532 0.31 0.666 1.14 0.377 
chr8:41519308 3.41 0.003 1.61 0.136 0.99 0.261 -0.48 0.718 
chr8:41519348 2.54 0.014 -0.24 0.797 -0.80 0.470 0.16 0.885 
chr8:41519399 3.89 0.014 1.25 0.388 -0.68 0.673 -0.23 0.901 
chr8:41519411 1.70 0.083 0.38 0.814 0.54 0.649 0.60 0.613 
chr8:41519417 1.51 0.168 0.08 0.950 -0.05 0.960 0.82 0.461 
chr8:41519420 4.31 1.24E-04 2.44 0.089 -0.37 0.509 1.63 0.184 
Amplicon Average 2.21 0.007 0.63 0.431 0.07 0.903 0.84 0.356 
 
Table 4.5; ANK1 CpG sites are hypermethylated in the EC in HD. Shown for each tissue 
is chromosomal location (genome build hg19) of CpG sites tested, with corrected difference 
(Δ) in 5mC levels and corresponding P value between controls and HD cases after adjusting 
for the covariates of age, sex and batch effects (linear regression). A positive Δ reflects 
hypermethylation in disease. All P values < 0.05 (and their corresponding Δ) are shown in 
bold. 
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Figure 4.8; ANK1 DNA methylation levels in the STG, CER and STR in individuals with 
HD. Using BS pyrosequencing we assayed a 118bp region of the ANK1 gene ranging from 
41519302 to 41519420 on chromosome 8 (genome build hg19) in HD samples compared to 
control samples. We did not observe any disease-associated changes in the STG (A), CER 
(B) or STR (C). Data is represented as mean (±SEM) Significant hypermethylation was seen 
in the EC when we averaged methylation across the region (two sample t-test: t118 = 2.8, P = 
0.007), which did not meet our stringent Bonferroni significance threshold (1.39x10-3). (D). 
Box and whisker plot shows median, upper and lower quartiles, and maximum and minimum 
values (excluding outliers). Key: *P < 0.05, **P < 0.01, ***P < 0.005.  
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A similar pattern of ANK1 hypermethylation was observed in PD; two of the eight 
CpG sites were characterised by significant hypermethylation in the EC (Figure 
4.9A), with no differences in 5mC in any of the other brain regions tested (Table 4.6). 
This included the STG (Figure 4.10A), the CER (Figure 4.10B), the STR (Figure 
4.10C) and the SN (Figure 4.10D), with the SN representing the brain region that has 
the highest levels of pathology in PD (Fearnley et al. 1991). Across the 118bp 
amplicon we saw no change in 5mC in any of the five brain regions (Figure 4.9B).  
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Genomic Location 
PD 
EC STG CER STR SN 
∆ P ∆ P ∆ P ∆ P ∆ P 
chr8:41519302 0.37 0.592 0.20 0.777 0.23 0.714 1.43 0.351 -0.25 0.745 
chr8:41519304 0.36 0.628 0.49 0.524 -0.33 0.562 0.89 0.647 0.19 0.823 
chr8:41519308 0.34 0.686 0.80 0.334 -0.55 0.518 -2.46 0.203 0.05 0.956 
chr8:41519348 0.83 0.323 0.07 0.932 0.18 0.838 1.17 0.381 -0.24 0.826 
chr8:41519399 0.03 0.981 -0.10 0.924 0.16 0.893 -3.40 0.200 1.37 0.272 
chr8:41519411 1.65 0.032 -1.32 0.234 0.14 0.875 -0.06 0.978 0.57 0.600 
chr8:41519417 0.95 0.261 -0.87 0.371 -0.42 0.551 -0.98 0.521 0.06 0.950 
chr8:41519420 1.81 0.026 -1.07 0.274 0.28 0.434 -0.01 0.997 0.36 0.714 
Amplicon Average 0.84 0.202 -0.28 0.670 -0.02 0.959 -0.19 0.879 0.29 0.690 
 
Table 4.6; ANK1 CpG sites are hypermethylated in the EC in PD. Shown for each tissue 
is chromosomal location (genome build hg19) of CpG sites tested, with corrected difference 
(Δ) in 5mC levels and corresponding P value between controls and PD cases after adjusting 
for the covariates of age, sex and batch effects (linear regression). A positive Δ reflects 
hypermethylation in disease. All P values < 0.05 (and their corresponding Δ) are shown in 
bold. 
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Figure 4.10; ANK1 DNA methylation levels in the STG, CER, STR and SN in individuals 
with PD Using BS pyrosequencing we assayed a 118bp region of the ANK1 gene ranging 
from 41519302 to 41519420 on chromosome 8 (genome build hg19) in PD samples 
compared to control samples. We did not observe any disease-associated changes in the 
STG (A), CER (B), STR (C) or SN (D), P values were calculated by linear regression. Data is 
represented as mean (±SEM) Key: *P < 0.05, **P < 0.01, ***P < 0.005.  
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4.5 Discussion     
 
This is the first study to assess brain ANK1 5mC differences across multiple 
neurodegenerative diseases. We identified significant 5mC differences in the EC in 
multiple diseases, including AD, HD and PD, with significant DNA hypermethylation 
across the amplicon in AD and HD. Interestingly, we also observed significant 
hypermethylation of ANK1 in the EC in both DLB and VaD at several individual CpG 
sites and across the amplicon, but only in donors with co-existing AD pathology. This 
suggests that ANK1 DNA hypermethylation in the EC is specific to some 
neurodegenerative diseases (AD and HD), and not observed in other forms of 
neuropathology (VaD and DLB). We have previously reported that ANK1 is not 
differentially methylated or hydroxymethylated in the CER in AD at two sites 
interrogated by the Illumina 450K array (chr8:41519308 and chr8:41519399) 
(Lunnon et al. 2014) (Chapter 3). In the current study we again demonstrate that 
these two loci are not significantly differentially methylated in AD CER; however, we 
do highlight AD-associated DNA hypermethylation at five adjacent CpG sites and 
averaged across the 118bp amplicon in the CER. We did not see any ANK1 5mC 
changes in the CER in any of the other neurodegenerative diseases, including those 
with co-existing AD pathology. Reflecting our previous findings, we found that 5mC 
differences in AD are greatest in the EC, an area with high levels of neuropathology 
and lowest in the CER, the region with the least neuropathology. Interestingly, 
although we observed disease-associated ANK1 hypermethylation in the EC at six 
individual sites and across the region in HD and at two individual sites in PD, we did 
not see ANK1 5mC changes in these diseases in their regions of primary 
neuropathology, namely the STR and SN, respectively. This suggests that ANK1 
hypermethylation in neurodegenerative disease is not necessarily specific to regions 
of primary neuropathology, but may instead be specific to particular cell types 
affected in the diseases, such as those in the EC, which are not present in the STR 
and SN. One caveat of our study is that we have analysed “bulk” tissue, and we 
cannot determine which cell type(s) are driving the DNA hypermethylation we see in 
ANK1 in disease. ANK1 encodes for numerous isoforms with their own tissue-
specific enhancers. Although the precise function of most ANK1 isoforms is not 
known, different isoforms have been identified in the brain, blood and muscle 
(Gallagher et al. 1997). Mastroeni et al., recently showed a four-fold increase in 
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ANK1 mRNA expression in microglia from AD brain tissue, but not in neurones or 
astrocytes from the same individuals, suggesting an immune based function for 
ANK1 in the human brain (Mastroeni et al. 2017).  
 
Although the focus of our study was on investigating 5mC changes in 
neurodegenerative disease, BS pyrosequencing actually generates a summative 
measurement of both 5mC and 5hmC. 5mC is generally associated with gene 
silencing, particularly when residing in the promoters of constitutively expressed 
housekeeping genes (Jones 2012), whilst 5hmC has been shown to be enriched in 
gene bodies (Lunnon et al. 2016) and to be found at (relatively) high levels in the 
brain (Szulwach et al. 2011, Khare et al. 2012). In Chapter 3 we have shown that 
ANK1 DNA hypermethylation across the 118bp amplicon in AD is actually 
underestimated when using BS data, as it is confounded by significant DNA 
hypohydroxymethylation at some loci in the amplicon (Smith et al. 2018). Another 
potential caveat of our study ; is that we have only analysed 5mC across eight CpG 
sites in an 118bp region of the ANK1 gene and thus future studies should aim to 
further quantify changes in 5mC across the entire 244kb gene.  
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4.6 Conclusions 
 
Our study has demonstrated disease-associated ANK1 hypermethylation in the EC 
at specific CpG sites in AD, HD and PD and across the region in AD and HD. In 
donors with DLB and VaD we only observed increased ANK1 5mC in the EC only in 
individuals with co-existing AD pathology. The CER showed disease-associated 
hypermethylation at specific CpG loci and across the region in AD, but not in any of 
the other neurodegenerative diseases tested. We saw no disease-associated 
differential ANK1 5mC in the STR in HD or PD, or the SN in PD. This suggests that 
ANK1 is characterised by brain region and disease-specific differential 5mC in 
different neurodegenerative diseases.  
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CHAPTER 5: EXPLORING HISTONE MODIFICATIONS AT THE ANK1 
LOCUS 
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The work presented in this chapter has not yet been published. However, we are in 
the process of writing up this data for publication. 
 
5.1 Introduction 
 
Histone proteins were first discovered by Albrecht Kossel in 1884, but were initially 
dismissed as transcriptional regulators as they were thought to be only an inert 
packaging material. It was Kayne et al. (1988) who demonstrated that histones 
innately repress transcription in vivo. This gave rise to the theory that modifiers of 
histone structure could have an effect on gene transcription. Today it is known that 
histone modifications represent the reversible short-term regulation of 
hetero/euchromatin (Cedar et al. 2009). A large number of histone modifications 
have been described, with many predicted functions, for example the di-methylation 
of the ninth lysine on histone 3 (H3K9me2) is a marker of gene repression (Kim 
2014). Two of the most studied histone modifications are the tri-methylation of lysine 
at positions 4 and 27 of histone 3 (H3K4me3 and H3K27me3), which are markers of 
gene expression and repression respectively. These modifications are the focus of 
this chapter. 
 
5.1.1 H3K4me3  
 
H3K4me3 is a chromatin modification that is consistently present at transcription 
start sites (TSS) of actively transcribed genes in eukaryotes. High levels of the 
modification reflect the amount of transcription, which was initially described by 
Santos-Rosa et al. (2002). Together with other reports (Azuara et al. 2006, 
Kouzarides 2007, Mattout et al. 2010), this has led to the hypothesis that H3K4me3 
is a transcription ‘activating’ histone modification. Mono and di-methylated forms of 
this modification are also thought to be markers of actively transcribed regions, 
although there is less research into these modifications. H3K4me3 is also localised 
at the 5’ end of active genes near the TSS and was found to be associated with the 
initiated form of RNA polymerase II (Barski et al. 2007). However, a report has 
shown widespread decreased H3K4me3 at multiple expressed genes with only 
minimal changes in the transcript abundance of these genes (Clouaire et al. 2012). 
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This suggests that H3K4me3 may not be the sole driver of gene transcription, with 
other epigenetic factors affecting transcription. Alternatively this may be in part due 
to the cell-specific nature of epigenetic changes, meaning that such changes may 
only be detectable at single cell resolution. It is also possible that this modification is 
deposited as a result of transcription rather than driving it.  
 
5.1.2 H3K27me3 
 
Unlike H3K4me3, H3K27me3 is associated with inactive gene promotors, causing a 
dramatic and predictable lack of gene expression (Boyer et al. 2006, Lee et al. 2006, 
Barski et al. 2007). It is involved in the maintenance of the inactive X-chromosome 
silencing as well as being involved in genomic imprinting (Kouzarides 2007). H3K27 
can undergo a number of other modifications (Table 1.2). Lysine at position 27 of 
histone 3 can also exist in mono- or di-methylated states, although the role of these 
other modifications are not as well characterised as H3K27me3. In addition, it is 
known that H3K27me3 is propagated during cellular division; it is suggested that 
H3K27me3 recruits a Polycomb Repressive Complex 2 (PRC2) that in-turn leads to 
the methylation of H3 histones on the newly synthesised DNA (Hansen et al. 2008). 
H3K4me3 and H3K27me3 can occur on the same histone tail: these so-called 
“bivalent modifying patterns” or “primed chromatin” mean that viewing modifications 
as “activating” or “silencing” is overly simplistic(Lesch et al. 2014). These bivalent 
patterns in embryonic stem cells (ESC) are predicted to cause highly dynamic levels 
of gene expression (Bernstein et al. 2005).  
 
5.1.3 Histone modifications and their relationship to DNA modifications  
 
5mC is generally associated with gene silencing when it occurs in the promoter 
regions of genes (Curradi et al. 2002). However, at other genomic locations, for 
example gene bodies, 5mC is believed to result in gene activation or alternative 
splicing (Yang et al. 2014). There is evidence of cross-talk between DNA and histone 
modifications (Kondo 2009). For example, during embryo implantation when the 
epigenetic landscape within each cell is being re-programmed, methylation at CpG 
islands is protected from removal, through a mechanism that is dependent on the 
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recognition of H3K4 methylation. In addition 5mC acts as a template for histone 
modification patterns after DNA replication, mediated through methylcytosine-
binding proteins that are capable of recruiting histone deacetylases (Nan et al. 
1998, Chi et al. 2010) and methyltransferases (Jin et al. 2011). This crosstalk can 
be caused by biochemical interactions between the SET domain (an evolutionary 
conserved sequence motif) of histone methyltransferases which are responsible for 
the methylation of histones and the recruitment of DNA methyltransferases (Cedar et 
al. 2009). 
 
5.1.4 Histone modifications in neurological disease  
 
Similarly to DNA modifications, histone modifications have been associated with 
neurological diseases, such as AD. For example in amyotrophic lateral sclerosis 
(ALS) the acetyltransferase CREB binding protein (CBP) is inhibited by the fused 
in sarcoma (FUS) protein. This in turn leads to histone hypo-acetylation. Similar 
mechanisms are seen in PD, HD and Friedreich’s ataxia (Urdinguio et al. 2009). 
Interestingly, AD has also been linked to incorrect modification of histone proteins. 
Cleavage of the APP protein in AD leads to the production of AICD (Figure 1.1) 
which, coupled with Fe65, activates TIP60, another histone acetyltransferase. This 
leads to the increased acetylation of H3K14 and H4K5 (Kim et al. 2004). In addition, 
work in mice has revealed that neuron-specific overexpression of histone 
deacetylase 2 (HDAC2) decreases dendritic spine density, synapse number, 
synaptic plasticity and memory function. Whereas HDAC2 deficiency causes an 
increase in synaptic number and memory facilitation (Guan et al. 2009). Recent work 
has profiled acetylation of the twenty seventh lysine on histone 3 (H3K27ac) across 
the genome in post-mortem tissue, identifying widespread AD-associated variation in 
this histone modification. Differentially acetylated peaks were identified in genomic 
regions associated with both tau and amyloid neuropathology and variants 
associated with late-onset AD (Marzi et al. 2017). This further supports a role for 
alterations in histone modifications in neurological diseases, such as AD. 
 
To date only one study has examined histone modifications in ANK1, by 
interrogating the ENCODE Chromatin Immunoprecipitation Sequencing (ChIP-seq) 
dataset (Bernstein et al. 2005). This study focused on the proposed erythrocytic 
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specific promotor of ANK1 and the level of enhancer associated histone 
modifications in this region (H3K4me1 and H3K27ac) (Yocum et al. 2012). However, 
this approach was limited to K562 cells (human blood cell line), hence the 
applicability of this data to brain tissue is limited.  
 
5.1.5 Chromatin Immunoprecipitation 
 
ChIP has been widely used to map the location of modified histones, transcription 
variants, transcription factors and many other DNA-protein interactions. ChIP is the 
use of an antibody to target and isolate a protein or histone modification of interest 
and then enrich regions of DNA with which it associates. In recent years this 
technique coupled with micro-array (ChIP-chip) and high-throughput sequencing 
technologies (ChIP-seq) has enabled the profiling of histone modifications on a 
genome-wide scale (Collas 2010). Alternatively, the coupling of ChIP with qPCR 
(ChIP-qPCR) allows the characterisation of histone modifications at a specific 
candidate locus. 
 
5.1.6 Summary  
 
Although we have now shown that 5mC and 5hmC changes are seen in the ANK1 
gene AD brain, in Chapters 3 and 4. At present no study has yet examined 
alterations in histone modifications at the ANK1 locus in AD brain. This chapter aims 
to utilise ChIP-qPCR to quantify H3K4me3 and H3K27me3 modification changes in 
the ANK1 gene in post-mortem brain samples from donors with varying degrees of 
AD pathology.  
 
 
 
 
 
 
 
208 
 
5.2 Aims 
 
- To optimise and use ChIP-qPCR to measure H3K4me3 and H3K27me3 in 
ANK1 in human, post-mortem brain samples. 
- To use the optimised ChIP-qPCR assays on matched brain samples to those 
used for DNA (hyroxy)methylomic profiling in Chapter 3.  
- To investigate whether ANK1 H3K4me3 and H3K27me3 levels are altered in 
the EC of individuals with high levels of neuropathology compared to those 
with low levels.  
- To examine whether ANK1 H3K4me3 and H3K27me3 levels are correlated 
with each other and DNA modification levels in post-mortem brain samples.  
- To investigate whether ANK1 H3K4me3 and H3K27me3 levels are correlated 
with 5mC and 5hmC levels at key loci previously shown to be differentially 
methylated in AD EC (cg11823178 and cg05066959)  
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5.3 Materials and Methods  
 
5.3.1 Subjects and samples 
 
This study used EC tissue from post-mortem brain samples collected from 88 
individuals archived in the LNDBB. 63 of these samples were utilised for DNA 
methylomic and hydroxymethylomic profiling in Chapter 3. Donors used for the study 
had varying degrees of AD pathology, ranging from Braak Stage 0 to Braak Stage 
VI, and were all over the age of 65. All samples were dissected by trained 
specialists, snap-frozen and stored at -80°C. Further demographic information about 
all samples is provided in Table 5.1. 
 
 
 
 
 
 
 
 
 
 Low pathology High pathology 
Number of samples 29 59 
Sex (%) M/F (%) (48) 14/15 (52) (59) 35/24 (41) 
Mean Age (±SD) 79.2 (11.2) 82.2 (8.2) 
Braak Stage 0-III IV-VI 
 
Table 5.1; Demographic information for EC brain samples used in this chapter.  The 
distribution of sex, Braak stage and mean age (± standard deviation (SD)) are provided.         
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5.3.2 ChIP for H3K4me3 and H3K27me3 
 
H3K4me3 and H3K27me3 profiling was performed using methodology documented 
in Chapter 2, Section 2.10.1. Briefly, frozen post-mortem brain tissue samples were 
cut into 10-15mg sections as described in Section 2.2. Following this, DNA and 
associated proteins were cross-linked using formaldehyde and cells were then re-
suspended in HBSS (Section 2.10.1.2). Cells were incubated in lysis buffer 
(Diagenode, cat no.: C01010130) and sonicated for 35 minutes to shear the 
chromatin (Section 2.10.1.3).  After fragmentation each chromatin sample was 
analysed via gel electrophoresis (Section 2.7.2) to check the size of the chromatin 
fragments were between 100-600bp (Figure 5.1). Following this, automated 
magnetic immunoprecipitation was used for each chromatin sample, using three 
separate antibodies (100μL of chromatin per antibody): H3K4me3, H3K27me3 and 
an IgG negative control, as described in Section 2.10.1.4. Finally, DNA was de-
crosslinked from the protein and was purified using spin columns (Diagenode, cat 
no.: C01010130) (Section 2.10.1.5) and eluted in 80μL leaving pure DNA for 
downstream qPCR.  
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Figure 5.1; Chromatin fragmentation gel.  An example gel image of fragmented chromatin 
for samples used in the study. Five of the samples used in the study are shown alongside a 
100bp ladder (Solis BioDyne cat no.: 07-11-00050). All samples were fragmented to 
between 100-600bp before qPCR.  
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5.3.3 ChIP-qPCR 
 
qPCR was used to detect specific DNA target sequences in ANK1. 2μL ChIP treated 
DNA was combined with 2μL EvaGreen master mix (SolisBiodyne, cat no.: 08-24-
00008), 2-3 μM forward and reverse primer sequences (Table 5.2) and 5μL of H2O 
per sample replicate in 384 well plates (Section 2.11.1, Table 2.20). Seven 1 in 4 
serial dilutions and a NTC were included in triplicate per plate. The resulting plate 
was run on a QuantStudio (Thermo Fisher, US) qPCR machine with the following 
settings: 95°C for 10 minutes, 45 cycles of: 95°C for 30 seconds, 60°C for 30 
seconds, 72°C for 30 seconds, followed by a dissociation stage.  
 
5.3.4 ANK1 ChIP-qPCR primer design 
 
ChIP-qPCR primers were designed using Primer3Plus software (Untergasser et al. 
2007). Primers were designed (a) to target loci identified in Chapter 3 and 4 as 
differentially methylated in AD (chr8: 41519302 to 41519420), (b) across the 
remainder of the ANK1 gene in known areas of high H3K4me3 and H3K27me3 
abundance and (c) to other regulatory regions of the ANK1 gene (see Figure 5.2). In 
total 14 ChIP-qPCR assays were designed and used (Table 5.2). Following quality 
checks and optimisation, it was decided that seven primer sets were not suitable for 
inclusion in the final study. Exclusion criteria included: failure to produce reproducible 
Ct. Scores (within 0.5), primer efficiency of less than 85% or greater than 115% and 
the detection of secondary products via melt curve analysis and gel electrophoresis.  
In total six ANK1 and one control primer set (MyoD1) (Taberlay et al. 2011) were 
used in the study.  
 
 
 
 
 
 
 
2
1
3
 
 P
ri
m
e
r 
N
a
m
e
 
G
e
n
o
m
e
 C
o
o
rd
in
a
te
s
 
P
o
s
it
io
n
 
q
P
C
R
 P
ri
m
e
rs
 (
5
' 
to
 3
')
 
T
M
 
(°
C
) 
P
ro
d
u
c
t 
le
n
g
th
 (
b
p
) 
E
ff
ic
ie
n
c
y
 
In
c
lu
d
e
d
  
R
e
a
s
o
n
 f
o
r 
e
x
c
lu
s
io
n
 
F
in
a
l 
C
o
n
c
e
n
tr
a
ti
o
n
 
A
N
K
1
 P
ri
m
e
r 
S
e
t 
1
 
c
h
r8
:4
1
5
1
0
9
7
1
-
4
1
5
1
1
0
5
9
 
F
 
C
C
A
A
A
C
T
C
C
T
C
C
C
C
T
A
A
C
G
 
5
9
.5
 
8
9
 
5
4
%
 
- 
lo
w
 e
ff
ic
ie
n
c
y
  
- 
R
 
A
G
C
T
C
C
A
G
A
C
T
C
C
G
C
T
T
T
G
 
6
0
.7
 
A
N
K
1
 P
ri
m
e
r 
S
e
t 
2
 
c
h
r8
:4
1
5
1
6
7
0
3
-
4
1
5
1
6
7
7
7
 
F
 
T
A
A
G
G
A
A
C
A
T
C
C
C
A
G
C
C
T
T
C
 
5
9
.1
 
7
5
 
8
7
%
 


- 
2
 μ
M
 
R
 
T
G
T
T
T
A
G
A
A
T
G
G
C
C
C
C
T
G
A
G
 
6
0
.1
 
A
N
K
1
 P
ri
m
e
r 
S
e
t 
3
 
c
h
r8
:4
1
5
5
9
5
5
6
-
4
1
5
5
9
6
6
4
 
F
 
A
G
A
G
G
C
A
G
A
C
A
T
A
C
C
A
C
G
A
A
A
C
 
6
0
.6
 
1
0
9
 
7
7
%
 
- 
lo
w
 e
ff
ic
ie
n
c
y
  
- 
 
R
 
A
G
G
A
T
G
G
A
A
C
C
A
C
A
C
C
T
C
T
G
 
6
0
 
A
N
K
1
 P
ri
m
e
r 
S
e
t 
4
 
c
h
r8
:4
1
5
7
0
6
4
0
-
4
1
5
7
0
7
2
6
 
F
 
A
G
G
T
G
T
T
G
G
C
T
G
G
A
G
T
C
A
C
 
5
8
.7
 
8
7
 
- 
- 
in
c
o
n
s
is
te
n
t 
C
t.
 s
c
o
re
s
  
 -
 
R
 
T
A
T
G
G
G
A
G
A
T
C
C
G
T
C
A
T
G
T
G
 
5
9
.3
 
A
N
K
1
 P
ri
m
e
r 
S
e
t 
5
 
c
h
r8
:4
1
6
2
5
4
1
6
-
4
1
6
2
5
4
9
1
 
F
 
C
C
G
A
T
T
T
G
C
A
T
G
T
T
T
T
G
A
G
C
 
6
1
.5
 
7
6
 
9
3
%
 


- 
2
 μ
M
 
R
 
C
T
C
A
G
G
C
A
G
A
A
T
C
T
G
G
A
A
T
A
G
G
 
6
0
.2
 
A
N
K
1
 P
ri
m
e
r 
S
e
t 
6
 
c
h
r8
:4
1
6
4
9
9
4
0
-
4
1
6
5
0
0
6
7
 
F
 
T
C
C
T
A
A
C
A
G
C
C
A
A
A
G
C
T
C
A
C
 
5
8
.1
 
1
2
8
 
7
2
%
 
- 
lo
w
 e
ff
ic
ie
n
c
y
  
- 
 
R
 
T
T
C
G
A
C
C
A
A
G
G
T
C
T
T
G
A
A
C
C
 
6
0
.1
 
A
N
K
1
 P
ri
m
e
r 
S
e
t 
7
 
c
h
r8
:4
1
6
8
6
1
8
1
-
4
1
6
8
6
3
2
8
 
F
 
T
G
G
T
T
C
G
C
A
C
T
A
C
A
A
T
G
A
C
C
 
5
9
.6
 
1
4
8
 
9
7
%
 


- 
2
 μ
M
 
R
 
T
C
G
C
G
T
G
G
A
A
A
A
T
C
T
T
C
A
G
 
5
9
.9
 
A
N
K
1
 P
ri
m
e
r 
S
e
t 
8
 
c
h
r8
:4
1
7
5
3
8
7
1
-
4
1
7
5
3
9
8
6
 
F
 
A
C
C
T
T
C
T
T
C
T
T
T
C
G
G
T
C
A
C
G
 
5
9
.3
 
1
1
6
 
8
0
%
 
- 
lo
w
 e
ff
ic
ie
n
c
y
  
 -
 
R
 
G
C
C
A
A
A
C
A
G
C
T
G
A
A
G
A
A
A
A
T
C
 
5
9
 
A
N
K
1
 P
ri
m
e
r 
S
e
t 
9
 
c
h
r8
:4
1
7
5
4
8
7
7
-
4
1
7
5
5
0
1
2
 
F
 
G
A
G
C
T
T
G
A
T
T
T
G
C
C
C
C
T
T
T
C
 
6
1
.1
 
1
3
6
 
1
0
0
%
 


- 
2
 μ
M
 
R
 
C
G
G
G
G
A
C
C
T
A
C
T
T
C
C
T
T
T
T
C
 
5
9
.9
 
A
N
K
1
 P
ri
m
e
r 
S
e
t 
1
0
 
c
h
r8
:4
1
5
1
9
2
1
4
-
4
1
5
1
9
3
5
9
 
F
 
G
A
G
C
T
C
A
T
A
A
A
G
A
G
G
T
G
A
G
T
G
G
 
5
8
.1
 
1
4
6
 
8
7
%
 
- 
L
o
w
e
r 
e
ff
ic
ie
n
c
y
 t
h
a
n
 
p
ri
m
e
r 
1
1
, 
c
o
v
e
ri
n
g
 
s
a
m
e
 g
e
n
o
m
ic
 r
e
g
io
n
 
- 
R
 
A
G
C
T
G
G
A
G
G
T
C
G
A
T
A
T
T
G
A
T
T
A
C
 
5
8
.7
 
A
N
K
1
 P
ri
m
e
r 
S
e
t 
1
1
 
c
h
r8
:4
1
5
1
9
2
1
6
-
4
1
5
1
9
3
5
9
 
F
 
G
C
T
C
A
T
A
A
A
G
A
G
G
T
G
A
G
T
G
G
A
G
 
5
8
.1
 
1
4
4
 
8
9
%
 


- 
2
 μ
M
 
R
 
A
G
C
T
G
G
A
G
G
T
C
G
A
T
A
T
T
G
A
T
T
A
C
 
5
8
.7
 
A
N
K
1
 P
ri
m
e
r 
S
e
t 
1
2
 
c
h
r8
:4
1
5
1
9
3
4
2
-
4
1
5
1
9
4
6
0
 
F
 
C
A
A
T
A
T
C
G
A
C
C
T
C
C
A
G
C
T
C
A
C
 
5
9
.7
 
1
1
9
 
9
5
%
 


- 
3
 μ
M
 
R
 
G
A
T
C
A
T
T
C
G
C
A
A
G
G
T
G
G
T
T
C
 
6
0
.5
 
A
N
K
1
 P
ri
m
e
r 
S
e
t 
1
3
 
c
h
r8
:4
1
5
1
9
3
4
2
-
4
1
5
1
9
4
8
3
 
F
 
C
A
A
T
A
T
C
G
A
C
C
T
C
C
A
G
C
T
C
A
C
 
5
9
.7
 
1
4
2
 
9
8
%
 
- 
s
e
c
o
n
d
a
ry
 p
ro
d
u
c
t 
 
 -
 
R
 
T
T
C
C
T
C
C
T
T
C
C
C
T
T
C
C
T
T
T
C
 
5
9
.6
 
M
y
o
D
1
 P
ri
m
e
r 
S
e
t 
1
 
c
h
r1
1
:1
7
7
4
1
3
2
1
-
1
7
7
4
1
4
2
8
 
F
 
C
G
C
C
A
G
G
A
T
A
T
G
G
A
G
C
T
A
C
T
 
5
9
.3
 
1
0
8
 
9
5
%
 


- 
2
 μ
M
 
R
 
C
G
G
G
T
C
G
T
C
A
T
A
G
A
A
G
T
C
G
T
 
6
0
.1
 
 T
a
b
le
 5
.2
; 
C
h
IP
-q
P
C
R
 p
ri
m
e
r 
d
e
s
ig
n
. 
T
h
ir
te
e
n
 C
h
IP
-q
P
C
R
 p
ri
m
e
r 
s
e
ts
 w
e
re
 d
e
s
ig
n
e
d
 a
c
ro
s
s
 t
h
e
 A
N
K
1
 g
e
n
e
, 
c
o
v
e
ri
n
g
 k
n
o
w
n
 H
3
K
4
m
e
3
 a
n
d
 
K
3
K
2
7
m
e
3
 p
e
a
k
s
. 
C
h
IP
-q
P
C
R
 p
ri
m
e
rs
 t
o
 M
y
o
D
1
 w
e
re
 u
s
e
d
 a
s
 a
 c
o
n
tr
o
l 
s
e
t.
 T
h
e
 M
y
o
D
1
 p
ri
m
e
r 
d
e
s
ig
n
 w
a
s
 o
b
ta
in
e
d
 f
ro
m
 (
T
a
b
e
rl
a
y
 e
t 
a
l.
 
2
0
1
1
).
  
214 
 
 
 
 
 
 
 
 
Figure 5.2; Visualisation of ChIP-qPCR primer sets designed for this study. In total, 
thirteen ChIP-qPCR primer sets were designed across the ANK1 gene, covering known 
H3K4me3 and K3K27me3 peaks. Displayed is the complete ANK1 gene with all 10 
transcript variants (shown in purple), locations of all 13 primer sets (shown in black) 
established H3K4me3 and H3K27me3 profiles  in ESCs (shown in green), as well as the 
location of CpG sites covered by the 450K array including cg05066959 & cg11823178 
(shown in orange). 
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5.3.5 Data analysis  
 
All samples were run in triplicate for each assay and averaged to collect a mean Ct 
score for each modification. A range of 0.5 Ct maximum was allowed between 
triplicate samples; Ct scores that fell outside this range were excluded and then an 
average of the two remaining scores was used. A control assay (MyoD1) with a 
known histone modification profile was also run for all samples (Figure 5.3). In 
addition a negative control IgG ChIP reaction was run for all samples in all assays, 
as per the manufacturer’s recommendations. Standard curves of a 1 in 4 dilution 
series were run on each plate and samples were normalised according to primer 
efficiency as described in Section 2.8.2.  
 
All computations and statistical analyses were performed using R 3.3.2 (Vienna 
2012). A linear regression analysis was performed, accounting for the effects of age 
and sex, comparing samples with a low neuropathological burden (Braak 0-III) with 
samples with a high neuropathological burden (Braak IV-VI) for each primer region. 
We then used a two sample t-test to assess the difference in the mean of examined 
histone modification levels averaged across all primer regions between low (Braak 0-
III) and high (Braak IV-VI) neuropathological burden. Bonferroni threshold of P < 
0.017 was used to correct for multiple testing. A subset (N = 63) of samples used in 
this chapter had matched DNA methylomic and hydroxmethylomic data as collected 
in Chapter 3. A Pearson’s correlation was used to compare histone modification 
levels with 5mC and 5hmC levels in ANK1 as derived from the Illumina 450K array 
data generated in Chapter 3. 
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Figure 5.3; MyoD1 shows high H3K27me3 levels.  MyoD1 was used as a positive 
control for H3K27me3 as previous studies have shown this to be a genomic region 
with high modification peaks. As expected we found high levels of H3K27me3 in this 
region. Data is represented as a percentage relative to input 
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5.4 Results  
 
5.4.1 ANK1 has decreased levels of H3K4me3 in individuals with high 
neuropathology  
 
We assessed levels of H3K4me3 and H3K27me3 across the ANK1 gene in AD EC 
using the six qPCR assays that passed QC. Of the six regions assayed, four showed 
a significant decrease in the level of H3K4me3 between individuals with low and high 
AD neuropathological burden (Primer Set 5 (chr8:41625416-41625491): Figure 5.4B, 
∆ = -1.60, P = 0.004; Primer Set 7 (chr8:41686181-41686328): Figure 5.4C, ∆ = -
2.53, P = 0.023; Primer Set 9 (chr8:41754877-41755012): Figure 5.4D, ∆ = -0.41, P 
= 0.002; Primer Set 12 (chr8:41519342-41519460), Figure 5.4F, P = 0.033), with no 
significant change in the other two regions tested (Figure 5.4A, Figure 5.4E). We 
observed no significant difference in either H3K27me3 or the IgG control between 
individuals with low and high levels of pathology, in any of the six regions examined 
(Figure 5.4; Figure 5.5; Table 5.3). Averaging the histone modification profiles across 
all six regions tested demonstrated significantly decreased H3K4me3 in cases with 
high AD neuropathology compared to those with low neuropathological burden (∆ = -
0.98, P = 0.004), with no change in H3K27me3 or the IgG control (Figure 5.6). 
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B) A) 
Figure 5.4; H3K4me3 levels are decreased in AD EC in specific regions of the ANK1 
gene. We observed decreased H3K4me3 in individuals with high levels of pathology 
compared to those with low levels of pathology at (B) chr8: 41625416-41625491: (primer 
set 5) (t82 = -2.9, r = 0.29, P = 0.004), (C) chr8: 41686181-41686328 (Primer set 7) (t83 = -
2.3, r = 0.23, P = 0.023) (D) chr8: 41754877-41755012 (Primer set 9) (t80 = -3.2, r = 0.32, P 
=0.002) and (F) chr8: 41519342-41519460 (Primer set 12) (t67 = -2.2, r = 0.37, P =0.033) 
(linear regression). We found no significant difference between AD cases and controls for 
H3K27me3 or the IgG control for any of the brain regions tested. Data is represented as a 
percentage relative to input, box and whisker plots show median, upper and lower quartiles, 
and maximum and minimum values (excluding outliers). Key: *P < 0.05, **P < 0.01, ***P < 
0.005. 
D) C) 
E) F) 
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Genomic region Modification ∆ P 
chr8:41516703-41516777 (Primer set 2)  
H3K4me3 -0.09 0.541 
H3K27me3 0.36 0.138 
IgG 0.15 0.228 
chr8:41625416-41625491 (Primer set 5)  
H3K4me3 -1.60 0.004 
H3K27me3 0.02 0.949 
IgG 0.10 0.096 
chr8:41686181-41686328 (Primer set 7)  
H3K4me3 -2.53 0.023 
H3K27me3 0.49 0.178 
IgG 0.33 0.243 
chr8:41754877-41755012 (Primer set 9)   
H3K4me3 -0.91 0.002 
H3K27me3 0.08 0.884 
IgG 0.13 0.383 
chr8:41519216-41519359 (Primer set 11) 
H3K4me3 -0.25 0.160 
H3K27me3 0.22 0.394 
IgG 0.11 0.361 
chr8:41519342-41519460 (Primer set 12)  
H3K4me3 -0.41 0.033 
H3K27me3 0.11 0.770 
IgG 0.01 0.947 
 
Table 5.3; H3K4me3 levels are decreased in specific regions of the ANK1 gene in AD 
EC. Shown for each genomic region assayed is the corrected difference (Δ) in histone 
modification levels relative to input and corresponding linear regression derived P value 
between individuals with low levels of pathology (Braak 0-III) and those with high levels of 
pathology (Braak IV-VI) after adjusting for the covariates of age, sex and batch effects. A 
positive Δ reflects increased levels of the modification with increasing pathology. All P values 
< 0.05 (and their corresponding Δ) are shown in bold. 
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Figure 5.6; H3K4me3 is decreased across the ANK1 gene in individuals with high 
neuropathology burden.  When we averaged histone modification levels across the six 
regions of ANK1 we examined we identified a significant reduction in H3K4me3 levels in 
individuals with a high level of neuropathology burden, compared to those with a low burden 
(two sample t-test: t86 = -3.2, P = 0.002) meeting our Bonferroni threshold of P = 0.017, with 
no change in H3K27me3 or IgG control.  Data is represented as a percentage relative to 
input. Box and whisker plot shows median, upper and lower quartiles, and maximum and 
minimum values (excluding outliers). Key: *P < 0.05, **P < 0.01, ***P < 0.005. 
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5.4.2 H3K4me3 and H3K27me3 levels are correlated in post-mortem brain 
samples.  
 
H3K4me3 and H3K27me3 histone modifications can have opposing effects on gene 
expression. However, both these modifications can simultaneously exist on the same 
histone tail (Bernstein et al. 2005). We were therefore interested to investigate 
whether there was a correlation of the levels of both modifications across the ANK1 
locus.  As such, we found a positive correlation between H3K4me3 and H3K27me3 
levels (r = 0.32, P = 0.002) (Figure 5.7).  
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Figure 5.7; H3K4me3 Levels are significantly correlated with H3K27me3 levels in post-
mortem brain samples.  H3K4me3 and H3K27me3 averaged across the six genomic 
regions interrogated are significantly correlated with each other (Pearson’s correlation: t86 = 
3.1, r = 0.32, P = 0.002).  
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5.4.3 H3K4me3 levels are correlated with DNA modification levels in the ANK1 
gene 
 
For a subset of 63 individuals used in this study we had already collected DNA 
methylomic and hydroxymethylomic data in the same samples (Chapter 3). Previous 
reports have demonstrated 5mC and H3K4me are (negatively) correlated with each 
other (Balasubramanian et al. 2012). To examine further the relationship between 
histone modifications and cytosine modifications, we first assessed the correlation 
between average H3K4me3 levels across all six regions assayed and the average 
5mC or 5hmC level at 450K derived CpG sites across the ANK1 gene (N = 107 
probes). This showed that 5mC at 11% of CpG sites (12 / 107) within the ANK1 gene 
was significantly correlated with H3K4me3 levels averaged across the six regions 
(Figure 5.8, Table 5.4). Similarly, 5hmC at 10% of CpG sites (11 / 107) was 
significantly correlated with H3K4me3 levels averaged across all six regions (Figure 
5.9, Table 5.5). Five CpG sites were common to both analyses (cg08786207, 
cg08521995, cg13152952, cg09405790 and cg17256609), with an opposite direction 
of correlation seen for 5mC and 5hmC at each of these sites.  
 
We then assessed the correlation between H3K4me3 levels in each individual region 
covered by the primers and 5mC or 5hmC levels at CpG sites covered by the 450K 
array in the same region (± 1kb) to see whether localised correlation existed. Three 
of the six regions showed significant correlation between H3K4me3 levels and 5mC 
levels (chr8:41516703-41516777 (± 1kb) (Primer Set 2): Figure 10A,  r = -0.35, P = 
0.005; chr8: 41519216-41519359 (± 1kb) (Primer Set 11): Figure 10B, r = -0.27, P = 
0.039; and chr8:41519342-41519460 (± 1kb) (Primer Set 12): Figure 10C, r = -0.37, 
P = 0.033). No significant correlation was seen between H3K4me3 levels and 5hmC 
levels in the individual regions. 
 
Finally, two specific 5mC sites in ANK1, cg11823178 (chr8:41519399) and 
cg05066959 (chr8:41519308), have been robustly shown to be hypermethylated with 
increasing AD neuropathology (De Jager et al. 2014, Lunnon et al. 2014, Smith et al. 
2017) (Chapter 3 and 4). We were interested to investigate whether H3K4me3 levels 
were correlated with 5mC and 5hmC levels at these two specific sites, given that 
Primer Set 11 (chr8:41519216-41519359) covered cg05066959 and Primer Set 12 
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(chr8:41519342-41519460) covered cg11823178.This showed a significant negative 
correlation of H3K4me3 levels across chr8:41519342-41519460 (Primer Set 12) with 
5mC levels at chr8:41519399 (cg11823178) (r = -0.36, P = 0.003) (Figure 5.11A). 
There was no correlation between H3K4me3 levels across that region and 5hmC 
levels (Figure 5.11B). There was no significant correlation between H3K4me3 levels 
across chr8:41519342-41519460 (Primer Set 11) with 5mC or 5hmC levels at 
chr8:41519308 (cg05066959). 
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Figure 5.8; Average H3K4me3 levels are correlated with 5mC levels at specific CpG 
sites in ANK1. (A) Pearson’s correlation coefficient (r) between average H3K4me3 levels 
across the six regions tested and 5mC levels at specific CpG sites covered by the 450K 
array (N=107), in relation to ANK1 genomic location. (B) Manhattan plot the association 
between average H3K4me3 levels across the six regions tested and 5mC levels at specific 
CpG sites covered by the 450K array. The dashed line represents P = 0.05. (C) Schematic 
of the assessed genomic region, including all known isoforms of ANK1. No correlations met 
our multiple testing correction threshold (Bonferroni significance P < 4.67 x10-4).  
A) 
B) 
C) 
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Table 5.4; H3K4me3 levels are correlated with 5mC levels at specific CpG sites. Shown 
for each 450K probe is genomic location (hg19), Pearson’s correlation coefficient (r) and 
corresponding P value for the correlation between average H3K4me3 levels across the six 
regions tested and 5mC levels at individual CpG sites. Loci where average H3K4me3 levels 
were significantly correlated with both 5mC and 5hmC levels are shown in bold (N=5). Data 
is only shown for the 12 CpG sites that were correlated. No correlations met our multiple 
testing correction threshold (Bonferroni significance P < 4.67 x10-4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Probe Genomic Coordinates  r P 
cg12148515 chr8:41517301 -0.27 0.032 
cg10794439 chr8:41518051 -0.25 0.048 
cg10715527 chr8:41518139 -0.27 0.035 
cg22532314 chr8:41546072 0.30 0.019 
cg09576978 chr8:41554080 0.27 0.029 
cg08786207 chr8:41559303 0.33 0.007 
cg13152952 chr8:41570554 0.29 0.021 
cg08521995 chr8:41628237 0.33 0.008 
cg17256609 chr8:41643375 -0.26 0.041 
cg08923054 chr8:41654455 0.25 0.048 
cg22746182 chr8:41749867 0.31 0.014 
cg09405790 chr8:41753440 0.26 0.038 
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Figure 5.9; Average H3K4me3 levels are correlated with 5hmC levels at specific CpG 
sites in ANK1. (A) Pearson’s correlation coefficient (r) between average H3K4me3 levels 
across the six regions tested and 5hmC levels at specific CpG sites covered by the 450K 
array, with relation to ANK1 genomic location. (B) Manhattan plot showing the association 
between average H3K4me3 levels across the six regions tested and 5hmC levels at specific 
CpG sites covered by the 450K array. The dashed line represents P = 0.05. (C) Schematic 
of the assessed genomic region, including all known isoforms of ANK1. No correlations met 
our multiple testing correction threshold (Bonferroni significance P < 4.67 x10-4).  
 
A) 
B) 
C) 
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Probe Genomic Coordinates  r P 
cg08786207 chr8:41559303 -0.40 0.001 
cg07680965 chr8:41563429 -0.27 0.031 
cg13152952 chr8:41570554 -0.27 0.030 
cg08521995 chr8:41628237 -0.28 0.027 
cg17256609 chr8:41643375 0.26 0.040 
cg19997384 chr8:41685595 0.33 0.007 
cg16129172 chr8:41686467 0.27 0.031 
cg14354820 chr8:41691767 0.27 0.032 
cg22845790 chr8:41694003 0.25 0.050 
cg05977053 chr8:41752508 -0.27 0.031 
cg09405790 chr8:41753440 -0.27 0.034 
 
Table 5.5; H3K4me3 levels are correlated with 5hmC levels at specific CpG sites. 
Shown for each probe is genomic location (hg19), Pearson’s correlation coefficient (r) and 
corresponding P value for the correlation between average H3K4me3 levels across the six 
regions tested and 5hmC levels at individual CpG sites. Loci where average H3K4me3 
levels were significantly correlated with both 5hmC and 5mC levels are shown in bold (N=5). 
Data is only shown for the 11 CpG sites that were correlated. No correlations met our 
multiple testing correction threshold (Bonferroni significance P < 4.67 x10-4).  
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Figure 5.10; H3K4me3 levels in specific regions are correlated with 5mC levels in 
those regions. H3K4me3 levels at three of the six genomic regions interrogated were 
significantly correlated (Pearson’s correlation) with 5mC levels in those regions (± 1kb), 
including (A) chr8:41516703-41516777 (Primer Set 2): t60 = -2.9, r = -0.35, P = 0.005, (B) 
chr8: 41519216-41519359 (Primer Set 11): t56 = -2.1, r = -0.27, P = 0.039, and (C) 
chr8:41519342-41519460 (Primer Set 12): t61 = -3.0, r = -0.37, P = 0.033. 
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5.4.4 H3K27me3 levels are correlated with DNA modification levels in the ANK1 
gene  
 
Next, we were interested to investigate whether a similar relationship with DNA 
modifications was observed for H3K27me3. First, we assessed the correlation 
between H3K27me3 levels averaged across all six regions assayed and the average 
5mC or 5hmC level at 450K derived CpG sites across the ANK1 gene (N = 107 
probes). This showed that 5mC levels at four of the CpG sites (Figure 5.12, Table 
5.6) and 5hmC levels at seven of the CpG sites (Figure 5.13, Table 5.7) within the 
ANK1 gene were significantly correlated with average H3K27me3 levels. Only one 
probe was common to both analyses (cg22845790), with an opposite direction of 
correlation observed for 5mC (r = -0.30, P = 0.018) and 5hmC (r = 0.34, P = 0.007). 
 
When we looked within the individual regions assayed we observed no significant 
correlation between either 5mC or 5hmC levels with H3K27me3 levels in each 
individual region (± 1kb). Similarly, 5mC and 5hmC levels at the two methylation 
sites in ANK1 that are known to be hypermethylated in AD (chr8:41519308 - 
cg05066959 and chr8:41519399 -cg11823178) were not correlated with H3K27me3 
levels across chr8:41519216-41519359 (Primer Set 11) and chr8:41519342-
41519460 (Primer Set 12), respectively.  
 
 
 
 
 
A) 
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Figure 5.12; Average H3K27me3 levels are correlated with 5mC levels at specific CpG 
sites in ANK1. (A) Pearson’s correlation coefficient (r) between average H3K27me3 levels 
across the six regions tested and 5mC levels with relation to ANK1 genomic location. (B) 
Manhattan plot showing the association between average H3K27me3 levels across the six 
regions tested and 5mC levels at specific CpG sites covered by the 450K array. The dashed 
line represents P = 0.05. (C) Schematic of the assessed genomic region, including all known 
isoforms of ANK1. No correlations met our multiple testing correction threshold (Bonferroni 
significance P < 4.67 x10-4).  
 
 
B) 
C) 
A) 
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Probe Genomic Coordinates r P 
cg00176210 chr8:41654967 -0.28 0.025 
cg26326633 chr8:41655078 -0.30 0.017 
cg22845790 chr8:41694003 -0.30 0.018 
cg01616178 chr8:41755140 0.25 0.047 
 
Table 5.6: H3K27me3 levels are correlated with 5mC levels at specific CpG sites. 
Shown for each probe is genomic location (hg19), Pearson’s correlation coefficient (r) and 
corresponding P value for the correlation between average H3K27me3 level across the six 
regions tested and 5mC levels at individual CpG sites. Loci where average H3K27me3 
levels were significantly correlated with both 5mC and 5hmC levels are shown in bold (N=1). 
Data is only shown for the 4 CpG sites that were correlated. 
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Figure 5.13; Average H3K27me3 levels are correlated with 5hmC levels at CpG sites in 
ANK1. (A) Pearson’s correlation coefficient (r) between average H3K27me3 levels across 
the six regions tested and 5hmC levels at specific CpG sites covered by the 450K array, with 
relation to ANK1 genomic location. (B) Manhattan plot showing the association between 
average H3K27me3 levels across the six regions tested and 5hmC levels at specific CpG 
sites covered by the 450K array. The dashed line represents P = 0.05. (C) Schematic of the 
assessed genomic region, including all known isoforms of ANK1. No correlations met our 
multiple testing correction threshold (Bonferroni significance P < 4.67 x10-4).  
 
 
A) 
B) 
C) 
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Probe Genomic Coordinates  r P 
cg22532314 chr8:41546072 -0.25 0.047 
cg08786207 chr8:41559303 -0.25 0.049 
cg08521995 chr8:41628237 -0.27 0.036 
cg26984624 chr8:41656079 -0.34 0.006 
cg22845790 chr8:41694003 0.34 0.007 
cg09405790 chr8:41753440 -0.33 0.008 
cg19844326 chr8:41755409 0.25 0.045 
 
Table 5.7; H3K27me3 levels are correlated with 5hmC levels at specific CpG sites. 
Shown for each probe is genomic location (hg19), Pearson’s correlation coefficient (r) and 
corresponding P value for the correlation between average H3K27me3 levels across the six 
regions tested and 5hmC levels at individual CpG sites. Loci where average H3K27me3 
levels were significantly correlated with both 5hmC and 5mC levels are shown in bold (N=1). 
Data is only shown for the 7 CpG sites that were correlated. No correlations met our multiple 
testing correction threshold (Bonferroni significance P < 4.67 x10-4).  
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5.5 Discussion 
 
This study has optimised the ChIP-qPCR protocol for use in post-mortem human 
brain tissue. We have measured two histone modifications: H3K4me3, a marker of 
gene expression, and H3K27me3, a marker of transcriptional repression, across six 
regions of the ANK1 gene in human, post-mortem brain samples.  
 
We first investigated whether ANK1 H3K4me3 and H3K27me3 levels are altered in 
the EC of individuals with high levels of AD neuropathology, compared to those with 
low levels. This showed significantly less H3K4me3, with no change in H3K27me3 
across the ANK1 gene in individuals with higher levels of neuropathology (Braak 
stage IV and above). This pattern of histone changes would usually be associated 
with decreased gene expression and would suggest that ANK1 gene expression 
would be reduced in individuals with AD neuropathology. However, a number of 
studies indicate that ANK1 gene expression is increased in AD; Mastroeni and 
colleagues recently showed increased levels of ANK1 gene expression in microglia 
in AD brain, although they showed no change in the astrocytes or neurones 
(Mastroeni et al. 2017). Whilst Lunnon et al. (2014) showed that only certain 
transcript variants have increased expression in AD, whilst other variants have no 
disease-associated changes. In our study we have analysed H3K4me3 and 
H3K27me3 in bulk EC tissue and it may be that different patterns of histone 
modifications are observed in the different cellular subtypes. In the future, further 
studies and analyses on cell sorted post-mortem tissue should be performed to 
determine if the changes we have observed are ubiquitous across cell types, or are 
specific to only certain cell types. Protocols for the separation of separate cellular 
subtypes from post-mortem brain tissue are currently being optimised, which would 
allow this type of analysis in the future (Guez-Barber et al. 2012, Krishnaswami et al. 
2016). 
 
We showed H3K4me3 and H3K27me3 levels across the ANK1 gene are positively 
correlated in post-mortem EC brain tissue. H3K4me3 and H3K27me3 are associated 
with active and inactive gene transcription respectively (Harikumar et al. 2015). 
However, both these modifications have been shown to simultaneously exist on the 
same histone tail of genomes of ESCs (Bernstein et al. 2005). Nonetheless, these 
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bivalent marks are not unique to ESCs, and are in fact found in multiple cell types, 
including neuronal cells, at different stages of development (Pan et al. 2007, 
Golebiewska et al. 2009). The positive correlation of H3K4me3 and H3K27me3 in 
our study in post-mortem brain samples suggests a complex interplay of epigenetic 
mechanisms in the regulation of ANK1 gene expression in the brain.  
 
Cytosine modification (5mC and 5hmC) levels at a number of specific loci were 
found to correlate with average histone modification (H3K4me3 and H3K27me3) 
levels across the ANK1 gene. H3K4me3 has been previously suggested to protect 
from 5mC at both CGIs and non-CGIs start sites (Balasubramanian et al. 2012). In 
our study, H3K4me3 levels were correlated with 5mC levels at 12 CpG sites, and 
5hmC levels at 11 CpG sites, with five CpG sites common to both analyses and 
showing opposite directions of correlations for H3K4me3 with 5mC and 5hmC. 
H3K27me3 levels were correlated with 5mC levels at four CpG sites and 5hmC 
levels at seven CpG sites, with one locus common to both analyses and showing an 
opposite direction of correlation for H3K27me3 with 5mC and 5hmC. Interestingly, 
5hmC levels at four CpG sites (cg08786207, cg08521995, cg22845790 and 
cg090450790) were correlated with both H3K4me3 and H3K27me3 levels. Three of 
the probes showed an opposite direction of correlation with H3K4me3 to H3K27me3, 
as would be expected, given that they are markers of gene expression and 
repression, respectively. However, 5hmC levels at one locus (cg22845790) showed 
a positive correlation with both H3K4me3 and H3K27me3 levels. It was previously 
thought that 5hmC was a transient epigenetic mark, and did not play a role in 
transcriptional regulation. 5hmC has been previously identified at high levels in the 
developing (Spiers et al. 2017) and adult brain (Munzel et al. 2010), particularly in 
neurones (Kriaucionis et al. 2009) and, as such, may represent an important 
epigenetic mark to profile in the context of neurodegenerative diseases. One study 
has shown that 5hmC levels in ESCs are more strongly correlated with levels of 
other histone modifications (i.e. H3K4me1, H3K4me2, H3K18ac, H3K27ac, 
H4K5ac), than they are with H3K4me3 or H3K27me3 (Szulwach et al. 2011). This 
suggests that there is likely a complex relationship between 5hmC levels and histone 
modification levels in ANK1.   
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5mC levels at two CpG sites (cg11823178: chr8:41519399 and chr8:41519308: 
cg05066959) have been previously shown to be hypermethylated in AD in numerous 
published studies (De Jager et al. 2014, Lunnon et al. 2014, Smith et al. 2017) and in 
Chapters 3 and 4 of this thesis. Interestingly, we found H3K4me3 levels across 
chr8:41519342-41519460 (Primer Set 12) to be significantly decreased in individuals 
with high neuropathology and to be negatively correlated with 5mC levels at 
chr8:41519399 (cg11823178). It has previously been suggested that H3K4 
modifications are a preventative mechanism for de novo promoter cytosine 
methylation (Weber et al. 2007). A proposed mechanism for this stems from the 
discovery that Dnmt3L, a Dnmt3 associated protein required for efficient de novo 
cytosine methylation, contains a domain that specifically interacts with unmodified 
H3K4, the binding of which is inhibited by methylation of the H3 tail (Ooi et al. 2007). 
Furthermore mutation of this same domain in Dnmt3L leads to reduced 5mC levels 
(Rose et al. 2014). These observations suggest that H3K4 methylation may play a 
role in blocking de novo 5mC at some genomic loci (Ooi et al. 2007, Otani et al. 
2009, Rose et al. 2014). It is therefore a possibility that the decreased H3K4me3 
levels in this region are facilitating the increased 5mC at chr8:41519399 
(cg11823178) in AD. However, as we did not see any association of H3K4me3 levels 
across chr8:41519216-41519359 (Primer Set 11) with 5mC at chr8:41519308 
(cg05066959), it is difficult to draw any firm conclusions as to whether 
hypermethylation at chr8:41519399 in AD is caused by the reduction in H3K4me3 
levels, or vice versa. In the future it will be of interest to quantify the levels of other 
histone modifications in the ANK1 gene. Furthermore, these levels should be 
integrated with levels of 5mC, 5hmC and miRNAs to build up a complete picture of 
the epigenetic landscape of the ANK1 gene in AD. It is not possible to determine the 
order of events leading up to the changes in H3K4me3 in AD that have been 
reported here. It is feasible, given the highly dynamic nature of histone modifications, 
these changes are as a result of, rather than the cause of, AD pathology. In the 
future it will therefore be of interest to study the temporal pattern and order of 
epigenetic changes in AD.  
 
H3K4me3 has been previously shown (with H3K9me1) to be predictive of expression 
levels in low CpG content promoters (LCPs), whilst H3K27ac and H4K20me1 are 
predictive of high CpG content promoters (HCPs) (Karlić et al. 2010). To date two 
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EWAS of histone modifications in AD have been performed in post-mortem brain 
tissue. The first, quantified H3K27ac across the genome in post-mortem EC tissue 
samples, identifying widespread AD-associated variation (Marzi et al. 2017). 
Interestingly, differentially acetylated regions were identified in the vicinity of genes 
previously implicated in AD neuropathology, for example APP, PSEN1, PSEN2 and 
MAPT. The second EWAS quantified H3K9 acetylation (H3K9ac) in post-mortem 
prefrontal cortex, in a large number of samples (N = 669). This showed that tau 
protein burden had a broad effect on the epigenome, affecting over 5,500 H3K9ac 
domains. In our study we have covered areas of known H3K4me3 and H3K27me3 
peaks in the brain using qPCR assays. However, this method still only profiles a 
small amount of a relatively large (244 kb) gene. As such, in the future an H3K4me3 
and H3K27me3 EWAS in AD using ChIP-Seq would be the optimal next step to 
completely characterise the levels of these histone modifications in AD brain. 
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5.6 Conclusions  
 
This study is the first to interrogate H3K4me3 and H3K27me3 modification profiles 
across the ANK1 gene in AD brain tissue. Overall, these results suggest that 
H3K4me3 levels are reduced in multiple regions in AD EC, and are correlated with 
changes in 5mC and 5hmC.  
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CHAPTER 6: DISCUSSION AND FUTURE PERSPECTIVES 
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6.1  Introduction  
 
The primary aim of this thesis was to expand on the existing knowledge about the 
epigenetic landscape in AD, with a particular focus on DNA and histone 
modifications in the vicinity of the ANK1 gene. This discussion will summarise the 
key findings from each chapter of this thesis and the limitations present within each 
study. Subsequently, it will discuss and attempt to address the limitations when 
studying epigenetic mechanisms in AD. I will emphasise how the research presented 
in this thesis has tackled some of these issues and outline future perspectives for the 
field, which would acknowledging issues that I was unable to address in this thesis. 
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6.2  Key findings from this thesis 
 
6.2.1 Chapter 3: DNA methylomic and hydroxymethylomic signatures of AD 
brain  
 
The aim of this project was to utilise genome-wide profiling technology to quantify 
DNA methylomic and DNA hydroxymethylomic variation simultaneously in human 
post-mortem brain samples with varying degrees of AD pathology. This study 
represented the first EWAS to independently measure 5hmC and 5mC in AD brain. 
 
This study generated a large amount of data and, as such, it was possible to address 
multiple research questions. My first analysis focussed on global levels of 5mC and 
5hmC in disease, given that previous attempts to characterise global 5hmC in AD 
have been performed using immunocytochemistry and therefore provided global 
levels of the modification only (Chouliaras et al. 2013, Condliffe et al. 2014, 
Coppieters et al. 2014, Lashley et al. 2015).  To this end my approach was to 
average 5mC and 5hmC levels across all probes that passed QC to compare how 
global levels of these modifications are altered in AD using Braak stage as a 
measure of disease severity. A global decrease in 5hmC and an increase in 5mC in 
the EC with respect to Braak stage was observed, whilst no significant Braak stage 
associated alterations were seen in the CER. Although, Condliffe et al. (2014) found 
similar patterns in the EC, other studies have focused on different brain regions with 
varying results (Chouliaras et al. 2013, Coppieters et al. 2014, Lashley et al. 2015). 
My results suggest that global changes in the levels of cytosine modifications occur 
in a tissue specific manner in AD. However, it must be noted that only ~2% of 
potential modification sites in the human genome are covered by the 450K array and 
thus the global levels I found to be altered in AD in Chapter 3 are not necessarily 
representative of all sites in the human genome.  
 
My next analysis focussed on identifying DMoPs, DMPs and DHPs specifically 
altered with respect to AD pathology (Braak stage). My analyses demonstrated 
highly reproducible alterations in Braak-associated DNA modification changes in the 
EC; I saw that the effect sizes of DMoPs were highly correlated between my study 
and a previous publication. Interestingly, there was no correlation of the effect sizes 
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of DMoPs in the CER between studies, suggesting that the brain regions which are 
relatively protected from neurodegeneration do not display consistent disease-
associated epigenetic changes in total DNA modifications. My next analysis 
identified 14 CpG sites, which showed significant Braak-associated alterations for 
more than one analysis (DMoPs, DMPs or DHPs). Of these, 13 showed no nominally 
significant difference in total DNA modifications, but showed a significant difference 
in both 5mC and 5hmC, this included the APP gene known to cause FAD. In each 
instance the levels of both modifications were highly negatively correlated with each 
other and showed a significant interaction between the two modifications. In the 
future, it will be important to validate these loci in other sample cohorts and to 
determine the effect these changes have on gene expression, as unlike 5mC which 
is commonly associated with gene silencing, 5hmC has been shown in genomic 
regions which in turn positively correlate with gene expression (Pastor et al. 2011, 
Song et al. 2011, Wu et al. 2011, Xu et al. 2011).  Interestingly, my analyses showed 
that neuropathology-associated changes in 5mC and 5hmC were most pronounced 
at CGIs of proximal promotors, which are regions key for the binding of transcription 
factors leading to gene expression (Spitz et al. 2012).  
 
I identified 72 Braak-associated DMPs and 57 DHPs that reached our significance 
threshold, of which 3 DMPs reached experiment-wide significance. A pathway 
analysis of the significant Braak-associated DMPs and DHPs highlighted common 
pathways to both analyses, which were associated with the axon, with DHPs being 
specifically enriched in these biological pathways associated with the synapse. 
Dysregulation of these pathways could be a driving factor in the pathology of AD, as 
the disease is characterised by synaptic loss and neuronal death (Whitehouse et al. 
1982). My final analysis focussed on identifying Braak-associated DMRs and DHRs. 
I did not identify any DHRs, which was not surprising given that 5hmC has been 
reported to be enriched in areas of low CG density (Lunnon et al. 2016). I did identify 
four DMRs. Of particular interest was a DMR within the ANK1 gene, as two previous 
EWAS of AD have reported a DMoR in this region (De Jager et al. 2014, Lunnon et 
al. 2014). Using pyrosequencing I replicated this DMR using pyrosequencing to 
assay eight neighbouring CpG sites, including the two covered by the array. Of the 
eight CpG sites assessed, seven were characterised by significant AD-associated 
hypermethylation, and four were characterised by significant AD-associated 
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hypohydroxymethylation. My study demonstrated that previous estimates of ANK1 
hypermethylation from EWAS using BS-treated DNA were underestimates (De Jager 
et al. 2014, Lunnon et al. 2014), due to confounding hypohydroxymethylation (Smith 
et al. 2016).  
 
The 450K array paved the way for EWAS as it is relatively cost-effective, high 
throughput and numerous analysis pipelines have been developed. However, it is 
not without limitations.  Many of the array’s design faults, including the presence of 
SNP and cross-hybridising probes, were addressed in the analysis pipeline (Section 
2.8). However, as the array only covers approximately 485,000 CpG positions of the 
28 million in the human genome (Lovkvist et al. 2016), over 98% of potential 
modification sites are not assayed, meaning the likely loss of some disease specific 
variation. Another caveat of all epigenetic studies of AD brain to date, including the 
study in Chapter 3, is the issue of cellular diversity in the brain, with this issue further 
confounded in AD, where the abundance of specific cell types changes in the 
disease. A further limitation, in terms of the ability to translate these findings to novel 
pharmacological targets, is that it is not possible to determine whether these cytosine 
modification changes are the cause or consequence of disease.  
 
In summary, I quantified 5hmC and 5mC levels simultaneously in post-mortem AD 
brain in Chapter 3. In doing so we identified 13 novel epigenetically altered loci that 
showed differential 5mC and 5hmC levels in disease and highlighted that the 
previous estimates of differential ANK1 5mC in AD brain were underestimates.  
 
6.2.2 Chapter 4: ANK1 DNA modification in different neurodegenerative 
diseases 
 
This study aimed to determine DNA modification levels in a number of different 
dementias across a region of the ANK1 gene which was previously reported to 
display hypermethylation and hypohydroxymethylation in AD (Chapter 3). Using BS 
pyrosequencing, ANK1 5mC was assessed in brain samples from donors with AD, 
DLB, VaD, HD, PD and non-demented elderly controls, across a number of different 
brain regions that show disease-specific pathology.  
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Initially I replicated the ANK1 Braak-associated DMoR I reported in the EC in 
Chapter 3 in additional AD samples. We showed DNA hypermethylation in both the 
EC and STG, replicating previous EWAS and pyrosequencing studies. Interestingly, 
we also observed significant ANK1 hypermethylation in the CER, a brain region that 
previous EWAS had shown no significant ANK1 modification change ((Lunnon et al 
2014, Chapter 3, (Smith 2018)).  On closer examination it became apparent that the 
sites of AD-associated hypermethylation in the CER were loci that were not covered 
on the 450K array and therefore would have missed detection in the previous EWAS. 
It was also interesting to note that the increase in 5mC difference in disease 
correlated with tissue specific levels of AD pathology, with the greatest 5mC 
difference seen in the EC, followed by the STG and then the CER, a region with very 
little AD pathology.  When we assayed the ANK1 region in other neurodegenerative 
diseases, it became clear that ANK1 hypermethylation was only present in DLB and 
VaD EC in individuals with co-existing AD pathology and was also not seen in any of 
the other tissues tested. However, I did observe disease-associated ANK1 DNA 
hypermethylation in the EC in individuals with HD and PD cases (without any other 
diagnosis), but observed no difference in the regions of primary pathology for these 
diseases, namely the STR and SN, respectively. This suggests that ANK1 DNA 
hypermethylation is possibly present in a certain population of cells in the EC, which 
are altered in AD, HD and PD.  
 
Similarly to the previous study (Chapter 3) one potential caveat of this study is that 
“bulk” tissue has been used, and therefore it is not possible to determine which cell 
type(s) are driving the DNA hypermethylation seen in ANK1 in disease. Furthermore, 
opposing changes in different cell types could be confounding these results. Unlike 
Chapter 3, Chapter 4 utilised standard BS conversion, therefore the levels of 5mC 
reported are actually the sum of 5mC and 5hmC modifications. From previous 
results this would suggest that the levels reported are in fact underestimates of 5mC.   
Another caveat to my study is that we have only analysed 5mC across eight CpG 
sites in a 118bp region of the ANK1 gene, which in its entirety is 244kb. Finally, and 
similarly to Chapter 3, at present it is not possible to determine whether the reported 
ANK1 hypermethylation across the region in AD, HD and PD in the EC represents a 
cause or a consequence of the disease process.  
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In summary, I successfully determined total DNA modification levels across the 
previously identified ANK1 locus in several neurological diseases including AD, HD, 
PD, DLB and VaD. This study showed differential levels of DNA modifications in the 
EC of AD, HD and PD across the ANK1 locus but not in the other neurodegenerative 
diseases tested. 
 
6.2.3 Chapter 5: Exploring histone modifications at the ANK1 locus 
 
The epigenetic studies of ANK1 in AD in this thesis have focussed on levels of DNA 
modifications. To date, no published studies have examined the histone modification 
profile of this gene in relation to AD pathology. Therefore the aim of this chapter was 
to use ChIP-qPCR to quantify H3K4me3 and H3K27me3 modification levels at 
specific regions across the ANK1 gene in AD. 
 
This study revealed that there is a decrease in the level of the H3K4me3 histone 
modification at specific sites across the ANK1 gene, but no significant change in 
H3K27me3. H3K4me3 is a modification usually associated with gene expression 
(Azuara et al. 2006, Kouzarides 2007, Mattout et al. 2010); therefore these results 
would suggest that ANK1 expression would be decreased in the EC in AD brain. In 
my study H3K4me3 and H3K27me3 levels were significantly correlated, which 
concurs with previous studies that have shown H3K4me3 and H3K27me3 can occur 
simultaneously despite their conflicting functions (Bernstein et al. 2006, Harikumar et 
al. 2015). Bernstein and colleagues have shown that both these modifications exist 
on the same histone tail of genomes of ESCs, leading to highly dynamic changes in 
the expression and repression of the candidate gene (Bernstein et al. 2006). 
Similarly, I hypothesise that a similar mechanism could be regulating ANK1 gene 
expression in AD brain. Previous studies have shown that there is cross talk 
between DNA and histone modifications (Kondo 2009). In Chapter 5 I showed that 
both total H3K4me3 and H3K27me3 levels correlated with 5mC and 5hmC levels at 
specific loci across the ANK1 gene, suggesting a complex interplay of epigenetic 
regulation. In addition, I showed that H3K4me3 levels are negatively correlated with 
5mC but not 5hmC, at chr8:41,519,399 (cg11823178), a loci which was previously 
reported to be highly significantly differentially methylated in Chapter 3 and in 
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multiple published studies (De Jager et al. 2014, Lunnon et al. 2014, Smith et al. 
2018).  
 
Akin to previous chapters one caveat of this study is that it utilised “bulk” brain tissue 
from the EC, meaning that I was unable to account for cellular heterogeneity.  
Second, histone modifications are very dynamic changes to the DNA, more so than 
cytosine modifications (Barth et al. 2010), and as I have assessed DNA in post-
mortem tissue, it is not possible to determine the temporal order of events leading up 
to the changes in H3K4me3 that were reported in Chapter 5. Finally, despite my best 
efforts to cover genomic areas of brain specific histone modification peaks within the 
qPCR assays, this method still only profiles a small amount of what is a large and 
complex gene. Other areas of the gene that I was unable to profile in the current 
study will require further investigation in AD.  
 
In summary, in Chapter 5 I profiled H3K4me3 and H3K27me3 profiles in the ANK1 
gene in AD EC, highlighting disease-associated decreases in H3K4me3, which are 
negatively correlated with 5mC levels at chr8:41,519,399 (cg11823178).   
 
6.2.4 ANK1 functional hypothesis 
 
I have shown ANK1 epigenetic differences exist in AD brain (Table 6.1). Functionally 
I hypothesise that ANK1 epigenetic differences in disease are resulting in either a 
change in total ANK1 expression or changing the expression level of a specific ANK1 
isoform. This change in ANK1 abundance in the brain would then impact on the 
physiology of microglial cells. I hypothesise that the binding of the cytoskeleton to the 
plasma membrane of microglia is altered due to ANK1 epigenetic changes in 
disease, in a similar manner to erythrocytes in HS. This, in turn would contribute to 
the “priming” of microglia within the brain, causing them to adopt a more aggressive 
inflammatory phenotype when exposed to a triggering event, leading to neuronal cell 
death and AD (Figure 6.1). This proposed hypothesis fits with the well described 
inflammatory pathway (Section 1.1.1.2).  
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Marker Method ANK1 position EC STG CER 
D
N
A
 M
e
th
y
la
ti
o
n
  
(C
h
a
p
te
r 
3
 &
 4
) 
BS Array chr8:41518051 ↑ - - 
BS & OxBS 
Pyrosequencing 
chr8:41519302 ↑ ↑ ↑ 
chr8:41519304 ↑ ↑ ↑ 
BS Array, BS & OxBS 
Pyrosequencing 
chr8:41519308 ↑ ↑ - 
BS & OxBS 
Pyrosequencing 
chr8:41519348 ↑ ↑ ↑ 
OxBS Array, BS & 
OxBS 
Pyrosequencing 
chr8:41519399 ↑ - - 
BS & OxBS 
Pyrosequencing 
chr8:41519411 ↑ ↑ ↑ 
chr8:41519417 ↑ ↑ ↑ 
chr8:41519420 ↑ ↑ ↑ 
D
N
A
 H
y
d
ro
x
y
m
e
th
y
la
ti
o
n
 
(C
h
a
p
te
r 
3
) 
OxBS 
Pyrosequencing 
chr8:41519302 ↓ - - 
chr8:41519304 - - - 
chr8:41519308 - - - 
chr8:41519348 ↓ - - 
chr8:41519399 - - - 
chr8:41519411 - - - 
chr8:41519417 ↓ - - 
chr8:41519420 ↓ - - 
H
3
K
4
m
e
3
 
(C
h
a
p
te
r 
5
) 
ChIP-qPCR 
chr8:41625416-
41625491 
↓ - - 
chr8:41686181-
41686328 
↓ - - 
chr8:41754877-
41755012 
↓ - - 
chr8:41519342-
41519460 
↓ - - 
 
Table 6.1: Significant neuropathology-associated epigenetically modified findings in 
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6.3  General Discussion and Future Perspectives  
 
As detailed above, there are a number of limitations associated with studying 
epigenetic mechanisms in AD. There are however emerging methodologies that are 
being developed that address some of these issues. This next section will discuss 
the issues that have arisen in the studies presented in this thesis, with a particular 
emphasis on how I have attempted to consider these in the studies I have presented, 
as well as outlining future perspectives for the field that could address issues that I 
was unable to address at the present time. 
 
6.3.1 Cellular Heterogeneity  
 
Epigenetic profiles are in their nature cell specific, with individual cellular populations 
having a distinct epigenetic profile; therefore it is likely that disease related 
epigenetic changes could be affecting just one or two cellular populations, rather 
than every cell type in a tissue. However, every study reported in this thesis has 
utilised bulk tissue. Therefore epigenetic changes that have been reported in this 
thesis are representative of total cellular populations, potentially masking more 
biologically relevant singular population differences in AD. Chapter 3 attempted to 
address this issue using the bioinformatic CETS correction method, which corrects 
for neuron/glia proportions (Guintivano et al. 2013). Adding this value as a co-variate 
in the analytical models slightly altered the level of significance of the findings, but 
did not dramatically change the ranking of the top loci. One issue with this approach 
is that the algorithm was developed using 5mC profiles generated from fluorescence 
activated cell sorted (FACS) neurones and glia from cortical brain tissue, using the 
antibody NeuN. However, it has been reported in the literature that NeuN is not 
expressed by cerebellar Purkinje neurones (Guintivano et al. 2013). As such, this 
method may not be appropriate for determining neuron/glia proportions in cerebellar 
tissue, limiting its application to cross brain studies. Protocols for the separation of 
additional cellular subtypes from post-mortem brain tissue are now under 
development that will allow this analysis in the future (Guez-Barber et al. 2012, 
Krishnaswami et al. 2016, Mastroeni et al. 2017). These methods either use FACS 
with other antibodies to cell-specific antigens, or laser capture microdissection 
(LCM). However, one consideration for the future is that such discriminatory 
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analyses come at a price; for each additional cell type to be analysed by EWAS, this 
will significantly increase the cost of the experiment. Furthermore, FACS 
methodology is dependent on high quality tissue, robust antibodies suitable for 
identifying nuclei of target cells and currently has a low processing throughput, 
meaning this approach is not currently feasible in large cohorts.  
  
6.3.2 Causality  
 
Epigenetic changes in disease provide promise for future treatments due to their 
transient state. However the dynamic and temporal nature of epigenetic 
modifications means that it can be difficult to interpret epigenetic findings; changes in 
cytosine or histone modifications could be, in fact, a result of the disease process, 
rather than a cause. The issue of causality is especially challenging in the context of 
neurological disorders such as AD, where longitudinal EWAS analyses in the tissue 
of primary pathology (brain) are not possible. Therefore, addressing whether loci 
nominated from epigenome studies are causal in the disease process has been 
difficult, with two-step Mendelian randomisation providing the only potentially feasible 
method for establishing causality to date (Relton et al. 2012). However, recent 
developments in CRISPR-cas9 genome editing technology, have allowed 
researchers to specifically target the DNA methylation machinery making it 
applicable to manipulating epigenetic modifications (Sander et al. 2014), and will 
provide a superior method for causality determination in the future.    
 
6.3.3 Cytosine modifications 
 
One limitation of 5mC studies to date is the confounding effect of other cytosine 
modifications, such as 5hmC. 5hmC in particular has been found to be expressed at 
greater levels in the brain and in development (Kriaucionis et al. 2009, Wang et al. 
2012), suggesting that this previously overlooked modification does have functional 
relevance. Due to the chemistry of traditional BS conversion methods, previous 
EWAS could not distinguish between 5mC and 5hmC. In Chapter 3 I addressed this 
issue by oxidising the DNA prior to BS conversion. The profiling of matched BS and 
OxBS treated samples simultaneously on the 450K array enabled the detection of 
both modifications throughout the genome. However, there are still nuances with this 
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methodology, for example the limited number of CpG sites profiled, and technical 
variation inherent in the profile resulting in some samples having a negative 5hmC 
level. The use of hMeDIP-seq would avoid this issue; however, hMeDIP-seq has a 
relatively low resolution and cannot quantitatively determine 5hmC abundance in a 
single-base resolution (Skvortsova et al. 2017). In addition, further studies are 
needed to interrogate whether other cytosine modifications present in the human 
genome (5fC and 5caC) are relevant in the study of AD.  
 
6.3.4 ANK1 coverage 
 
Within this thesis, assays were designed to target key regions of pre-identified peaks 
in 5mC (Chapter 4) and histone modifications (Chapter 5) or assayed key CpG sites 
throughout the entire genome (Chapter 3). However, none of the methodologies 
employed in this thesis examine every cytosine or histone modification site in the 
ANK1 gene.  One potential solution is to use whole genome bisulfite sequencing 
(WGBS) to measure DNA modifications at single base resolution; however this 
would not distinguish between different DNA modifications. Third generation 
sequencing methodologies now exist that can detect different DNA modifications in 
native DNA, reducing the need for complex treatment strategies and allowing 
separate cytosine modification levels to be detected at every CpG site within the 
genome (Rhoads et al. 2015). However, these methodologies are very expensive, 
require large amounts of DNA and are analytically challenging due to large data 
volumes and new data types, meaning this form of epigenetic study is currently out 
of reach (Schadt et al. 2010). Similarly, looking to the future, the combination of ChIP 
and sequencing methodologies would allow the interrogation of H3K4me3 and 
H3K27me3 across the entire genome in AD; this method has been used successfully 
in AD for other histone modifications (Marzi et al. 2018).  
 
6.3.5 ANK1 expression  
 
The ANK1 gene is known to have multiple splice isoforms which are thought to be 
expressed in a tissue specific manner. Several studies have examined the 
expression levels of ANK1 in human brain (De Jager et al. 2014, Lunnon et al. 2014, 
Mastroeni et al. 2017). Lunnon et al. (2014) used qPCR to assess the level of 
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expression of different ANK1 isoforms and their relation to 5mC levels. Although 
5mC has been traditionally described to be associated with gene repression, this is 
only really true in the context of CGIs within the 5’ promoters of many constitutively 
expressed housekeeping control genes (Deaton et al. 2011). Recent evidence 
suggests that gene body methylation can be associated with gene activation or 
alternative gene splicing (Laurent et al. 2010), therefore it is possible that changes in 
5mC at the ANK1 locus could be driving the expression of specific transcript variants 
resulting in an altered protein isoform within the brains of AD patients. However, due 
to the sequence similarity in the transcript variants of ANK1, it is not possible to 
design specific qPCR assays to target individual variants, with assays available 
targeting multiple variant isoforms. Furthermore the level of ANK1 expression in a 
normal brain is very low, no more than 12 transcripts per million (TPM) (Kapushesky 
et al. 2010), therefore huge sequencing depth would be needed to characterise the 
isoform expression profile in the brain. Long-read sequencing technology may hold 
the answer to this issue as it is able to perform long-read isoform sequencing of 
cDNA, which would allow the quantification of isoforms of any gene of interest 
(Rhoads et al. 2015).  
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6.4  Conclusions 
 
These studies have now provided strong evidence for epigenetic dysfunction in AD, 
as well as identifying genes that could be used as new targets for pharmacological 
intervention. I have demonstrated epigenetic alterations in the ANK1 gene in AD 
brain, which is also seen in some other, but not all dementias. However, many 
questions remain to be answered regarding the role the ANK1 gene plays in AD. The 
most important of which are (1) whether AD-associated ANK1 hypermethylation is a 
cause or a consequence of disease pathology, (2) whether the ANK1 epigenetic 
changes are driven by a specific cellular population and (3) whether the epigenetic 
changes in ANK1 in AD can be manipulated to create novel treatment strategies for 
the disease. Looking to the future, the latest advances in sequencing technology and 
cutting-edge genome manipulation tools will ultimately allow these questions to be 
answered.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 257 
 
APPENDIX 1 – ELUCIDATING NOVEL DISFUNCTIONAL PATHWAYS IN 
ALZHEIMER’S DISEASE BY INTERGRATING LOCI IDENTIFIED IN GENETIC 
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Dementia encompasses a group of chronic neurodegenerative
diseases that affected an estimated 44.4 million people worldwide in
2013. Because of an increasingly aging population, it is predicted that
this figure will rise to an estimated 75.6 million by 2030 and 135.5
million by 2050 (Prince et al., 2013). The worldwide cost of dementia
was estimated to be $604 billion in 2010 (Wimo & A.s.D. International,
2010). Alzheimer's disease (AD) is the most common form of
dementia, accounting for ~60%–80% of cases worldwide (Lobo et al.,
2000). AD is characterized by the accumulation of extracellular
amyloid-β (Aβ) plaques, intracellular neurofibrillary tangles of
hyperphosporylated tau, and widespread gliosis in the brain
(Serrano-Pozo et al., 2011). Despite the progress that has been
made in understanding the cellular pathology of AD, available
treatments only temporarily alleviate some symptoms and do not
modify the underlying disease process. By the time an individual
becomes symptomatic, there are already considerable neuronal cell
loss, plaque deposition, and tangle burdenwithin the brain, which can
appear up to 10 years before a clinical diagnosis is made (Jack et al.,
2010). Reflecting the growing public health and socioeconomic
burden of AD, there has been a year-on-year increase in the numberInc. This is an open access article uof publications investigating the etiology of the disease (Fig. 1) as
researchers seek novel disease-modifying treatments.
Although the neuropathology associated with AD has been well
described, little is known about the mechanisms underlying disease
onset and progression. Quantitative genetic analyses demonstrated
high heritability estimates (58%–79%) for AD (Gatz et al., 2006), and
thus, initial approaches to understanding etiology focused on
uncovering a genetic contribution to disease susceptibility. In recent
years, the recruitment of large cohorts and the relatively inexpensive
cost of assessing genetic variation through genome-wide association
studies (GWAS) have allowed the identification of multiple variants
associated with an elevated risk of developing AD. Many of these
genes have also been robustly associated with AD via subsequent
meta-analyses (Harold et al., 2009; Hollingworth et al., 2011; Lambert
et al., 2013a; Naj et al., 2011), and most recently, polygenic risk
scores for AD have been developed (Escott-Price et al., 2015).
Collectively, common single nucleotide polymorphisms (SNPs) are
believed to only account for 33% of attributable risk (Ridge et al.,
2013), and the mechanism behind their action remains largely
unknown. Exome-sequencing projects have also identified other
variants, for example, TREM2 (Guerreiro et al., 2013), which have a
larger effect size, yet these are relatively rare. In recent years,
researchers have used epigenome-wide association studies (EWAS) to
identify epigenetic changes in disease with the aim to elucidate
additional mechanisms of pathology, which may provide a link to
environmental factors.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. The number of publications in the field of AD. Shown is the number of publications within the PubMed database that can be identified using the search term Alzheimer's disease
between 1969 and 2015.
33A.R. Smith et al. / Neuroepigenetics 6 (2016) 32–50Epigenetic processes mediate the reversible regulation of gene
expression, occurring independently of DNA sequence variation and
acting principally through chemical modifications to DNA and
nucleosomal histone proteins. Dynamic changes to the epigenome
orchestrate a diverse range of important neurobiological and
cognitive processes in the brain (Lunnon & Mill, 2013). DNA
methylation is the best characterized and most stable epigenetic
modification which modulates the transcription of mammalian
genomes. This is due to its ability to be interrogated using archived
genomic DNA resources, which are the focus of most human
epidemiological epigenetic research to date (Lunnon & Mill, 2013).
The methylation of a cytosine in a CpG dinucleotide by DNA
methyltransferase enzymes forms 5-methylcytosine, which can
disrupt the cell's transcriptional machinery by blocking the binding
of transcription factors and attracting methyl-binding proteins that
initiate chromatin compaction and bring about gene silencing (Klose
& Bird, 2006). The predominant focus to date is methylation within
CpG islands located within the 5′ promoters of many constitutively
expressed housekeeping control genes. However, recent data suggest
that the relationship between DNA methylation and transcription
may be more complex, with gene body methylation and non-CpG
methylation often being associated with active gene expression (Aran
et al., 2011; Ball et al., 2009; Hellman & Chess, 2007; Lister et al., 2009)
and alternative splicing (Flores et al., 2012; Lyko et al., 2010). The
mechanisms involved in cytosine demethylation have also been
studied; its demethylation by ten-eleven translocation (TET) enzymes
leads to a stepwise change in the cytosine side chain state from
methylated cytosine to hydroxymethylated cytosine (5-hmC), to
formyl cytosine, to carboxyl cytosine, and finally back to unmodified
cytosine by a yet unclassified enzyme/mechanism (Hill et al., 2014).
Each of these intermediates may have their own effect on gene
transcription, splicing, and subsequent protein function, and recent
studies have shown 5-hmC to be at high levels in the brain (Nestor et
al., 2012; Song et al., 2011), with variation across different anatomical
regions (Lunnon et al., 2016). Recent advances in genomic technology
have allowed the first genome-scale studies assessing methylomic
variation (EWAS) in AD. These studies have identified AD-associated
DNA methylomic variation at numerous loci in the cortex, with
consistent findings across multiple independent study cohorts, in
addition to brain-region–specific changes and blood DNAmethylation
signatures (Lunnon et al., 2014; De Jager et al., 2014). In addition, arecent paper by Yu et al. combined genetic and epigenetic findings by
examining DNA methylation patterns across genes that have
previously been nominated by GWAS, identifying several overlapping
loci (Yu et al., 2014).
Although GWAS and EWAS analyses have identified multiple
genes associated with AD, the extent to which common pathways are
shared in the findings across studies has not yet been explored. This
review aims to integrate the most robust findings from GWAS, exome
sequencing studies, and EWAS performed to date in AD to highlight
common molecular pathways, which could ultimately aid in the
identification of novel pharmacological targets for the disease.
2. Methods
Using the publically available online search GWAS catalogue
(https://www.ebi.ac.uk/gwas/search?query=Alzheimer%27s%
20disease#association) and a P value cutoff of P b 5 × 10−8, we
identified 45 unique GWAS in AD totaling 144 SNPs.We then removed
studies based on poor sample size (b1000 total samples) as well as
those studies that included samples that were non-European in origin.
Following the study selection, SNPs in intronic regions were removed
from the analysis. After filtering for associated disease outcome
measures, including the terms Dementia and core Alzheimer's disease
neuropathological changes, Alzheimer's disease late onset, Alzheimer's
disease, Psychosis and Alzheimer's disease, Alzheimer's disease age of
onset, Alzheimer's disease biomarkers, and Neurofibrillary tangles, we
were left with 22 studies with 49 SNPs in 32 unique genes (Table 1A)
(Harold et al., 2009; Hollingworth et al., 2011; Lambert et al., 2013a;
Naj et al., 2011; Coon et al., 2007; Webster et al., 2008; Li et al., 2008;
Kamboh et al., 2012a; Kamboh et al., 2012b; Lambert et al., 2009;
Seshadri et al., 2010; Naj et al., 2010; Perez-Palma et al., 2014; Nelson
et al., 2014; Abraham et al., 2008; Antunez et al., 2011; Hollingworth
et al., 2012; Cruchaga et al., 2013; Hu et al., 2011; Lambert et al.,
2013b; Beecham et al., 2014; Jonsson et al., 2013). Four genes were
identified from exome sequencing studies (Guerreiro et al., 2013;
Guerreiro et al., 2012; Cruchaga et al., 2014; Pottier et al., 2012) by
performing a literature search in PubMed using the phrases
Alzheimer's disease and Exome sequencing alone and in combination
(Table 1B). Genes from EWAS were compiled from the 2014
publications by Lunnon et al. and De Jager et al. including probes
with P b 1 × 10−7 (Lunnon et al., 2014; De Jager et al., 2014). The
Table 1A
Genes nominated from GWAS
Gene SNPs
identified
P value GO annotation Chromosome Position Title of article First author
and year
Reference
ABCA7 rs3764650 5.00E-17 GO:0,005,215 transporter
activity
GO:0,005,524 ATP binding
GO:0,005,548 phospholipid
transporter activity
GO:0,016,887 contributes
to ATPase activity
19 1,046,521 Common Variants at
ABCA7, MS4A6A/
MS4A4E, EPHA1, CD33
and CD2AP Are
Associated With
Alzheimer's Disease
Hollingworth,
2011
(Hollingworth et al.,
2011)
rs4147929 1.00E-15 19 1,063,444 Meta-Analysis of 74,046
Individuals Identifies 11
New Susceptibility Loci
for Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
APOE, APOC1,
TOMM40
rs4420638 1.00E-39 APOE
GO:0,001,540 beta-
amyloid binding IDA
11305869
GO:0,005,319 lipid
transporter activity IDA
17305370
GO:0,005,515 protein
binding IPI 12950167
GO:0,005,543 phospholipid
binding
19 44,919,689 A High-Density Whole-
Genome Association Study
Reveals That APOE Is the
Major Susceptibility Gene
for Sporadic Late-Onset
Alzheimer's Disease
Coon, 2007 (Coon et al., 2007)
1.00E-39
Sorl1 as an Alzheimer's
Disease Predisposition
Gene?
Webster,
2008
(Webster et al., 2008)
2.00E-44 Candidate Single-
Nucleotide Polymorphisms
From a Genomewide
Association Study of
Alzheimer Disease
Li, 2008 (Li et al., 2008)
1.00E-12 Genome-Wide
Association Analysis of
Age-at-Onset in
Alzheimer's Disease
Kamboh,
2012a
(Kambohet al., 2012a)
8.00E-149 Genome-Wide
Association Study of
Alzheimer's Disease
Kamboh,
2012b
(Kambohetal., 2012b)
rs2075650 2.00E-157 APOC1
GO:0,004,859 phospholipase
inhibitor activity
GO:0,005,504 fatty acid
binding
GO:0,031,210
phosphatidylcholine binding
GO:0,055,102 lipase inhibitor
activity
GO:0,060,228
phosphatidylcholine-sterol
O-acyltransferase activator
activity
19 44,892,362 Genome-Wide
Association Study
Identifies Variants at CLU
and PICALM Associated
With Alzheimer's Disease
Harold, 2009 (Harold et al., 2009)
2.00E-16 Genome-Wide Association
Study Identifies Variants at
CLU and CR1 Associated
With Alzheimer's Disease
Lambert,
2009
(Lambert et al., 2009)
1.00E-295 Genome-Wide Analysis
of Genetic Loci Associated
With Alzheimer Disease
Seshadri,
2010
(Seshadri et al., 2010)
5.00E-36 Dementia Revealed: Novel
Chromosome 6 Locus for
Late-Onset Alzheimer
Disease Provides Genetic
Evidence for Folate-Pathway
Abnormalities
Naj, 2010 (Naj et al., 2010)
9.00E-116 Overrepresentation of
Glutamate Signaling in
Alzheimer's Disease:
Network-Based Pathway
Enrichment Using
Meta-Analysis of
Genome-Wide
Association Studies
Perez-Palma,
2014
(Perez-Palma et al.,
2014)
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Table 1A (continued)
Gene SNPs
identified
P value GO annotation Chromosome Position Title of article First author
and year
Reference
4.00E-13 TOMM40
GO:0,008,320 protein
transmembrane
transporter activity
GO:0,015,288 porin
activity
ABCC9 Gene Polymorphism
Is AssociatedWith
Hippocampal Sclerosis of
Aging Pathology
Nelson, 2014 (Nelson et al., 2014)
rs6859 6.00E-14 19 44,878,777 A Genome-Wide
Association Study for
Late-Onset Alzheimer's
Disease Using DNA Pooling
Abraham,
2008
(Abrahametal., 2008)
rs157580 8.00E-89 19 44,892,009 The Membrane-Spanning
4-Domains, Subfamily A
(MS4A) Gene Cluster
Contains a Common
Variant Associated With
Alzheimer's Disease
Antunez,
2011
(Antunez et al., 2011)
rs157582 9.00E-52 19 44,892,962 Genome-Wide
Association Study of
Alzheimer's Disease With
Psychotic Symptoms
Hollingworth,
2012
(Hollingworth et al.,
2012)
rs769449 2.00E-18 19 44,906,745 GWAS of Cerebrospinal
Fluid tau Levels Identifies
Risk Variants for
Alzheimer's Disease
Cruchaga,
2013
(Cruchaga et al., 2013)
BIN1 rs7561528 4.00E-14 GO:0,005,515 protein
binding
GO:0,032,403 protein
complex binding
GO:0,042,802 identical
protein binding
GO:0,046,982 protein
heterodimerization activity
GO:0,048,156 tau protein
binding
2 127,132,061 Common Variants at
MS4A4/MS4A6E, CD2AP,
CD33 and EPHA1 Are
AssociatedWith Late-Onset
Alzheimer's Disease
Naj, 2011 (Naj et al., 2011)
6.00E-11 Genome-Wide
Association Study of
Alzheimer's Disease
Kamboh,
2012b
(Kambohetal., 2012b)
rs744373 3.00E-14 2 127,137,039 Common Variants at
ABCA7, MS4A6A/
MS4A4E, EPHA1, CD33
and CD2AP Are
Associated With
Alzheimer's Disease
Hollingworth,
2011
(Hollingworth et al.,
2011)
1.00E-10 Meta-Analysis for
Genome-Wide
Association Study
Identifies Multiple
Variants at the BIN1 Locus
Associated With
Late-Onset Alzheimer's
Disease
Hu, 2011 (Hu et al., 2011)
2.00E-09 The Membrane-Spanning
4-Domains, Subfamily A
(MS4A) Gene Cluster
Contains a Common
Variant Associated With
Alzheimer's Disease
Antunez,
2011
(Antunez et al., 2011)
rs6733839 7.00E-44 2 127,135,234 Meta-Analysis of 74,046
Individuals Identifies 11
New Susceptibility Loci
for Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
rs12989701 3.00E-10 2 127,130,409 Meta-Analysis for
Genome-Wide Association
Study Identifies Multiple
Variants at the BIN1 Locus
AssociatedWith Late-Onset
Alzheimer's Disease
Hu, 2011 (Hu et al., 2011)
CASS4 rs7274581 3.00E-08 GO:0,000,155
phosphorelay sensor
kinase activity
GO:0,005,515 protein
binding
20 56,443,204 Meta-Analysis of 74,046
Individuals Identifies 11
New Susceptibility Loci
for Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
CD2AP rs10948363 5.00E-11 GO:0,005,200 structural
constituent of cytoskeleton
GO:0,005,515 protein binding
6 47,520,026 Meta-Analysis of 74,046
Individuals Identifies 11
New Susceptibility Loci
Lambert,
2013a
(Lambert et al., 2013a)
(continued on next page)
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Table 1A (continued)
Gene SNPs
identified
P value GO annotation Chromosome Position Title of article First author
and year
Reference
GO:0,017,124 SH3 domain
binding
for Alzheimer's Disease
rs9349407 9.00E-09 6 47,485,642 Common Variants at
MS4A4/MS4A6E, CD2AP,
CD33 and EPHA1 Are
AssociatedWith Late-Onset
Alzheimer's Disease
Naj, 2011 (Naj et al., 2011)
CD33 rs3865444 2.00E-09 GO:0,004,872 receptor
activity
GO:0,005,515 protein binding
GO:0,030,246 carbohydrate
binding
19 51,224,706 Common Variants at
MS4A4/MS4A6E, CD2AP,
CD33 and EPHA1 Are
AssociatedWith Late-Onset
Alzheimer's Disease
Naj, 2011 (Naj et al., 2011)
CELF1 rs10838725 1.00E-08 GO:0,000,166 nucleotide
binding
GO:0,000,900 translation
repressor activity, nucleic
acid binding
GO:0,003,723 RNA binding
IDA 16946708
GO:0,003,729 mRNA binding
11 47,536,319 Meta-Analysis of 74,046
Individuals Identifies 11
New Susceptibility Loci
for Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
CLU rs9331896 3.00E-25 GO:0,005,515 protein binding
GO:0,016,887 NOT ATPase
activity
GO:0,031,625 ubiquitin
protein ligase binding
GO:0,051,087 chaperone
binding
GO:0,051,787 misfolded
protein binding
8 27,610,169 Meta-Analysis of 74,046
Individuals Identifies 11
New Susceptibility Loci
for Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
rs2279590 6.00E-10 8 27,598,736 Genome-Wide Association
Study Identifies Variants at
CLU and CR1 Associated
With Alzheimer's Disease
Lambert,
2009
(Lambert et al., 2009)
rs11136000 9.00E-10 8 27,607,002 Genome-Wide
Association Study
Identifies Variants at CLU
and PICALM Associated
With Alzheimer's Disease
Harold, 2009 (Harold et al., 2009)
rs569214 4.00E-08 8 27,630,273 The Membrane-Spanning
4-Domains, Subfamily A
(MS4A) Gene Cluster
Contains a Common
Variant Associated With
Alzheimer's Disease
Antunez,
2011
(Antunez et al., 2011)
CR1 rs6656401 6.00E-24 GO:0,001,851 complement
component C3b binding
GO:0,001,855 complement
component C4b binding
GO:0,001,861 complement
component C4b receptor
activity
GO:0,004,877 complement
component C3b receptor
activity
1 207,518,704 Meta-Analysis of 74,046
Individuals Identifies 11
New Susceptibility Loci
for Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
rs3818361 4.00E-14 1 207,611,623 Common Variants at
ABCA7, MS4A6A/
MS4A4E, EPHA1, CD33
and CD2AP Are
Associated With
Alzheimer's Disease
Hollingworth,
2011
(Hollingworth et al.,
2011)
rs6656401 3.00E-10 1 207,518,704 Genome-Wide
Association Study
Identifies Variants at CLU
and CR1 Associated With
Alzheimer's Disease
Lambert,
2009
(Lambert et al., 2009)
rs6701713 5.00E-10 1 207,612,944 Common Variants at
MS4A4/MS4A6E, CD2AP,
CD33 and EPHA1 Are
Associated With
Late-Onset Alzheimer's
Disease
Naj, 2011 (Naj et al., 2011)
FERMT2 rs17125944 8.00E-09 GO:0,005,515 protein
binding
GO:0,005,547
phosphatidylinositol-
14 52,933,911 Meta-Analysis of 74,046
Individuals Identifies 11
New Susceptibility Loci for
Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
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P value GO annotation Chromosome Position Title of article First author
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Reference
3,4,5-trisphosphate
binding
FRMD4A rs7081208 1.00E-10 GO:0,030,674 protein
binding, bridging
10 13,949,865 Genome-Wide Haplotype
Association Study Identifies
the FRMD4A Gene as a Risk
Locus for Alzheimer's
Disease
Lambert,
2013b
(Lambert et al., 2013b)
GLIS3 rs514716 3.00E-09 GO:0,000,978 RNA
polymerase II core
promoter proximal
region sequence-
specific DNA binding
sequence-specific DNA
binding transcription
factor activity involved
in positive regulation
of transcription
GO:0,001,078 RNA
polymerase II core
promoter proximal
region sequence-specific
DNA binding transcription
factor activity involved in
negative regulation of
transcription
9 3,929,424 GWAS of Cerebrospinal
Fluid tau Levels Identifies
Risk Variants for
Alzheimer's Disease
Cruchaga,
2013
(Cruchaga et al., 2013)
HLA-DRB5 rs9271192 3.00E-12 GO:0,042,605 peptide
antigen binding
6 32,610,753 Meta-Analysis of 74,046
Individuals Identifies 11
New Susceptibility Loci for
Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
INPP5D rs35349669 3.00E-08 GO:0,004,445 inositol-
polyphosphate 5-
phosphatase activity
GO:0,005,515 protein
binding
GO:0,017,124 SH3 domain
binding
GO:0,034,594
phosphatidylinositol
trisphosphate phosphatase
activity
GO:0,051,425 PTB
domain binding
2 233,159,830 Meta-Analysis of 74,046
Individuals Identifies 11
New Susceptibility Loci for
Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
MEF2C rs190982 3.00E-08 GO:0,000,977 RNA
polymerase II regulatory
region sequence-specific
DNA binding
GO:0,000,978 RNA
polymerase II core promoter
proximal region sequence-
specific DNA binding
GO:0,000,980 RNA
polymerase II distal enhancer
sequence-specific DNA binding
GO:0,000,981 sequence-
specific DNA binding RNA
polymerase II transcription
factor activity
GO:0,000,983 RNA polymerase
II core promoter sequence-
specific DNA binding
transcription factor activity
5 88,927,603 Meta-Analysis of 74,046
Individuals Identifies 11
New Susceptibility Loci for
Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
MS4A4A rs4938933 8.00E-12 GO:0,016,021 integral
component of membrane
11 60,266,956 Common Variants at
MS4A4/MS4A6E, CD2AP,
CD33 and EPHA1 Are
Associated With Late-Onset
Alzheimer's Disease
Naj, 2011 (Naj et al., 2011)
MS4A4E,
MS4A6A
rs610932 2.00E-14 MS4A4E GO:0,016,021
integral component of
membrane
11 60,171,834 Common Variants at
ABCA7, MS4A6A/MS4A4E,
EPHA1, CD33 and CD2AP
Are Associated With
Alzheimer's Disease
Hollingworth,
2011
(Hollingworth et al.,
2011)
rs983392 6.00E-16 MS4A6A GO:0,016,021
integral component of membrane
11 60,156,035 Meta-Analysis of 74,046
Individuals Identifies 11
New Susceptibility Loci for
Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
(continued on next page)
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Reference
MTHFD1L rs11754661 2.00E-10 GO:0,004,329 formate-
tetrahydrofolate ligase activity
GO:0,004,477 NOT
methenyltetrahydrofolate
cyclohydrolase activity
GO:0,004,488 NOT
methylenetetrahydrofolate
dehydrogenase (NADP+) activity
GO:0,005,524 ATP binding
6 150,885,942 Dementia Revealed: Novel
Chromosome 6 Locus for
Late-Onset Alzheimer
Disease Provides Genetic
Evidence for
Folate-Pathway
Abnormalities
Naj, 2010 (Naj et al., 2010)
NME8 rs2718058 5.00E-09 GO:0,004,550 nucleoside
diphosphate kinase activity IBA
GO:0,005,524 ATP
binding
7 37,801,932 Meta-Analysis of 74,046
Individuals Identifies 11
New Susceptibility Loci for
Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
PICALM rs10792832 9.00E-26 GO:0,005,515 protein
binding
GO:0,005,545
1-phosphatidylinositol
binding
GO:0,030,276 clathrin
binding
GO:0,032,050 clathrin
heavy chain binding
11 86,156,833 Meta-Analysis of 74,046
Individuals Identifies 11
New Susceptibility Loci for
Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
rs561655 7.00E-11 11 86,089,237 Common Variants at
MS4A4/MS4A6E, CD2AP,
CD33 and EPHA1 Are
Associated With Late-Onset
Alzheimer's Disease
Naj, 2011 (Naj et al., 2011)
rs3851179 1.00E-09 11 86,157,598 Genome-Wide Association
Study Identifies Variants at
CLU and PICALM Associated
With Alzheimer's Disease
Harold, 2009 (Harold et al., 2009)
rs536841 3.00E-09 11 86,076,782 The Membrane-Spanning
4-Domains, Subfamily A
(MS4A) Gene Cluster
Contains a Common Variant
Associated With
Alzheimer's Disease
Antunez,
2011
(Antunez et al., 2011)
rs17817600 2.00E-08 11 85,966,428 Genome-Wide Association
Study of Alzheimer's
Disease
Kamboh,
2012b
(Kambohet al., 2012b)
PTK2B rs28834970 7.00E-14 GO:0,004,683 calmodulin-
dependent protein kinase
activity
GO:0,004,713 protein
tyrosine kinase activity
GO:0,004,715 non-membrane
spanning protein tyrosine
kinase activity
GO:0,004,871 signal
transducer activity
8 27,337,604 Meta-Analysis of 74,046
Individuals Identifies 11
New Susceptibility Loci for
Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
PVRL2 rs6857 2.00E-62 GO:0,001,618 virus receptor
activity
GO:0,005,515 protein binding
GO:0,015,026 coreceptor activity
GO:0,042,802 identical protein
binding
GO:0,042,803 protein
homodimerization activity
19 44,888,997 Genome-Wide Association
Meta-analysis of
Neuropathologic Features
of Alzheimer's Disease and
Related Dementias
Beecham,
2014
(Beecham et al., 2014)
SLC24A4,
RIN3
rs10498633 6.00E-09 SLC24A4 GO:0,008,273 calcium,
potassium:sodium antiporter
activity
GO:0,015,293 symporter activity
14 92,460,608 Meta-Analysis of 74,046
Individuals Identifies 11
New Susceptibility Loci for
Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
RIN3 GO:0,005,096 GTPase
activator activity
GO:0,005,515 protein binding
GO:0,017,112 Rab guanyl-
nucleotide exchange factor activity
GO:0,017,137 Rab GTPase binding
SORL1 rs11218343 1.00E-14 GO:0,001,540 beta-amyloid binding
GO:0,004,888 transmembrane
signaling receptor activity
GO:0,005,515 protein binding
GO:0,030,169 low-density
lipoprotein particle binding
11 121,564,878 Meta-Analysis of 74,046
Individuals Identifies 11
New Susceptibility Loci for
Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
38 A.R. Smith et al. / Neuroepigenetics 6 (2016) 32–50
Table 1A (continued)
Gene SNPs
identified
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Reference
GO:0,030,306 ADP-ribosylation
factor binding
NCR2 rs6922617 4.00E-08 GO:0,004,888 transmembrane
signaling receptor activity
6 41,368,363 GWAS of Cerebrospinal
Fluid tau Levels Identifies
Risk Variants for
Alzheimer's Disease
Cruchaga,
2013
(Cruchaga et al., 2013)
TREM2 rs75932628 2.00E-12 GO:0,001,530 lipopolysaccharide
binding
GO:0,004,872 receptor activity
GO:0,005,515 protein binding
GO:0,042,834 peptidoglycan
binding
GO:0,070,891 lipoteichoic
acid binding
6 41,161,514 Variant of TREM2
Associated With the Risk of
Alzheimer's Disease
Jonsson, 2013 (Jonsson et al., 2013)
UTS2D rs9877502 5.00E-09 GO:0,001,664 G-protein coupled
receptor binding
GO:0,005,179 hormone activity
3 190,951,729 GWAS of Cerebrospinal
Fluid tau Levels Identifies
Risk Variants for
Alzheimer's Disease
Cruchaga,
2013
(Cruchaga et al., 2013)
ZCWPW1 rs1476679 6.00E-10 GO:0,008,270 zinc ion binding 7 100,406,823 Meta-Analysis of 74,046
Individuals Identifies 11
New Susceptibility Loci for
Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
Shown are the genes identified from GWAS and their respective SNPs, associated P value, GO annotation, chromosome and genomic position, and the relevant study. Only SNPs with
Pb 5 × 10−8 were included.
39A.R. Smith et al. / Neuroepigenetics 6 (2016) 32–502012 publication by Bakulsk et al. was excluded from the analysis
based on sample size (Bakulski et al., 2012). Gene names were
checked against quoted genomic location using the UCSC Genome
Browser; only genes containing a probe of interest were included. The
resulting gene list contained 48 unique genes that met the criteria for
inclusion for our study (Table 2). Gene annotation for all genes of
interest were taken from the Gene Ontology (GO) Consortium
database, where available, and supplemented with information from
the Entrez gene database. Two genes overlapped between GWAS andTable 1B
Genes nominated from exome sequencing studies
Gene SNPs
identified
GO annotation Chromosome
TREM2 rs2234255 GO:0,001,530 lipopolysaccharide binding
GO:0,004,872 receptor activity
GO:0,005,515 protein binding
GO:0,042,834 peptidoglycan binding
GO:0,070,891 lipoteichoic acid binding
6
rs147564421 6
rs2234253 6
rs142232675 6
rs201258663 6
rs75932628 6
#N/A 6
SORL1 #N/A GO:0,001,540 beta-amyloid binding
GO:0,004,888 transmembrane signaling
receptor activity
GO:0,005,515 protein binding
GO:0,030,169 low-density lipoprotein
particle binding
GO:0,030,306 ADP-ribosylation factor binding
11
#N/A 11
#N/A 11
NOTCH3 rs10408676 GO:0,005,509 calcium ion binding
GO:0,005,515 protein binding
GO:0,019,899 enzyme binding
19
PLD3 rs145999145 GO:0,004,630 phospholipase D activity
GO:0,005,515 protein binding
GO:0,070,290 N-
acylphosphatidylethanolamine-specific
phospholipase D activity
19
Shown are the genes identified from exome sequencing studies and their respective SNPs,exome sequencing studies (TREM2, SORL1), and 1 gene overlapped
between GWAS and EWAS (BIN1), bringing the total number of genes
across all analyses to 81.
3. Pathways
The 81 genes identified were compared in terms of their
molecular/cellular function and grouped by pathways in which the
identified genes operate. By taking significant loci across multiplePosition Title of article First author
and year
Reference
41,127,543 TREM2 Variants in
Alzheimer's Disease
Guerreiro, 2013 (Guerreiro et al., 2013)
41,129,100
41,129,105
41,129,133
41,129,195
41,129,252
41,129,279
1.21E + 08 High Frequency of
Potentially Pathogenic
SORL1 Mutations in
Autosomal Dominant
Early-Onset Alzheimer
Disease
Pottier, 2012 (Pottier et al., 2012)
1.21E + 08
1.21E + 08
15,290,007 Exome Sequencing Reveals
an Unexpected Genetic
Cause of Disease: NOTCH3
Mutation in a Turkish Family
With Alzheimer's disease
Guerreiro, 2012 (Guerreiro et al., 2012)
40,877,595 Rare Coding Variants in the
Phospholipase D3 Gene
Confer Risk for Alzheimer's
Disease
Cruchaga, 2014 (Cruchaga et al., 2014)
GO annotation, chromosome and genomic position, and the relevant study.
Table 2
Genes nominated from EWAS
Gene Probes
identified
P value Functional summary, GO
annotation
Chromosome Position Title of article First author
and year
Reference
ABR cg25018458 1.89E-10 GO:0,005,089 Rho
guanyl-nucleotide exchange
factor activity
GO:0,005,096 GTPase activator
activity
17 980,014 Methylomic Profiling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon,
2014
(Lunnon et al., 2014)
ALDH16A1 cg20618448 1.16E-08 GO:0,004,029 aldehyde
dehydrogenase (NAD) activity
19 49,962,324 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
ANK1 cg05066959 7.13E-14 GO:0,005,198 structural molecule
activity
GO:0,005,200 structural
constituent of cytoskeleton
GO:0,005,515 protein binding
GO:0,008,093 cytoskeletal adaptor
activity
GO:0,019,899 enzyme binding
GO:0,030,507 spectrin binding
GO:0,051,117 ATPase binding
8 41,519,308 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
1.24E-09 8 41,519,308 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
[29
cg11823178 7.83E-14 8 41,519,399 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
3.42E-11 8 41,519,399 Methylomic Profiling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon,
2014
(Lunnon et al., 2014)
cg16140558 1.85E-08 8 41,514,039 Methylomic Profiling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon,
2014
(Lunnon et al., 2014)
ASGR2 cg18659586 1.06E-09 GO:0,004,873 asialoglycoprotein
receptor activity
GO:0,005,515 protein binding
GO:0,030,246 carbohydrate
binding
17 7,017,474 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
ATG16L2 cg21806242 3.71E-10 Regulation of autophagy 11 72,532,891 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
BCAR3 cg02342148 1.60E-08 GO:0,005,085 guanyl-nucleotide
exchange factor activity
GO:0,005,515 protein binding
1 94,145,223 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
BIN1 cg22883290 3.73E-08 GO:0,005,515 protein binding
GO:0,032,403 protein complex
binding
GO:0,042,802 identical protein
binding
GO:0,046,982 protein
heterodimerization activity
GO:0,048,156 tau protein binding
2 127,800,646 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
CDA cg26407544 2.10E-10 GO:0,001,882 nucleoside binding
GO:0,004,126 cytidine deaminase
activity
GO:0,005,515 protein binding
GO:0,008,270 zinc ion binding
1 20,945,355 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
CDH23,
C10orf54
cg23968456 1.09E-08 GO:0,005,509 calcium ion binding
GO:0,005,515 protein binding
10 73,521,631 Methylomic Profiling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon,
2014
(Lunnon et al.,
2014)
3.97E-10 10 73,521,631 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
CXXC5 cg07354506 9.26E-08 GO:0,004,871 signal transducer
activity
GO:0,005,515 protein binding
GO:0,008,134 transcription factor
binding GO:0,008,270 zinc ion
binding
5 139,048,148 Methylomic Profiling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon,
2014
(Lunnon et al., 2014)
FOXK1 cg07180538 4.95E-08 GO:0,000,977 RNA polymerase II
regulatory region
7 4,786,899 Alzheimer's Disease: Early
Alterations in Brain DNA
De Jager,
2014
(De Jager et al., 2014)
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sequence-specific DNA binding
GO:0,000,981 sequence-specific
DNA binding RNA polymerase II
transcription factor activity
GO:0,005,515 protein binding
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
cg25594100 2.54E-11 7 4,786,943 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
GMDS cg07714812 3.81E-08 GO:0,005,515 protein binding
GO:0,008,446 GDP-mannose
4,6-dehydratase activity
GO:0,070,401 NADP+ binding
6 1,635,611 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
GUCY2D cg04157161 7.80E-08 GO:0,004,383 guanylate cyclase
activity
GO:0,004,672 protein kinase
activity
GO:0,004,872 receptor activity
GO:0,005,524 ATP binding
17 7,906,847 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
HMHA1 cg02308560 3.06E-08 GO:0,005,096 GTPase activator
activity
GO:0,005,515 protein binding
GO:0,046,872 metal ion binding
19 1,071,176 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
ITM2C cg18346707 3.30E-08 GO:0,001,540 beta-amyloid
binding
GO:0,005,515 protein binding
GO:0,005,524 ATP binding
2 231,732,249 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
ITPRIPL2 cg16733298 5.24E-08 membrane-associated protein,
intracellular calcium signaling
16 19,127,132 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
KCNN4 cg22904711 1.08E-08 GO:0,005,515 protein binding
GO:0,005,516 calmodulin binding
GO:0,015,269 calcium-activated
potassium channel activity
GO:0,016,286 NOT small
conductance calcium-activated
potassium channel activity
19 44,278,628 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
KDM2B cg11724984 4.76E-09 GO:0,003,677 DNA binding
GO:0,005,515 protein binding
GO:0,008,270 zinc ion binding
GO:0,019,843 rRNA binding
GO:0,032,452 histone
demethylase activity
12 121,890,864 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
LNX1 cg12114584 5.81E-13 GO:0,004,842 ubiquitin-protein
transferase activity
GO:0,005,515 protein binding
GO:0,008,270 zinc ion binding
GO:0,016,874 ligase activity
GO:0,030,165 PDZ domain
binding
4 54,518,744 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
LYVE1 cg18343862 4.96E-08 GO:0,004,872 receptor activity
GO:0,004,888 transmembrane
signaling receptor activity
GO:0,005,515 protein binding
GO:0,005,540 hyaluronic acid
binding
11 10,590,003 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
MAFB cg13579486 3.25E-08 GO:0,003,700 sequence-specific
DNA binding transcription factor
activity
GO:0,005,515 protein binding
GO:0,008,134 transcription factor
binding
GO:0,043,565 sequence-specific
DNA binding
20 39,314,091 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al.,
2014)
MCF2L cg07883124 6.31E-12 GO:0,005,089 Rho
guanyl-nucleotide exchange
factor activity
GO:0,005,545
1-phosphatidylinositol binding
13 113,634,042 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
cg09448088 6.43E-10 13 113,635,690 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
MYO10 cg06742628 1.58E-10 GO:0,005,515 protein binding
GO:0,005,516 calmodulin binding
5 16,886,424 Alzheimer's Disease: Early
Alterations in Brain DNA
De Jager,
2014
(De Jager et al., 2014)
(continued on next page)
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GO:0,005,524 ATP binding
GO:0,005,547
phosphatidylinositol-
3,4,5-trisphosphate binding
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
MYO1C cg05417607 2.25E-08 GO:0,003,774 motor activity
GO:0,003,779 actin binding
GO:0,005,102 receptor binding
GO:0,005,515 protein binding
GO:0,005,516 calmodulin binding
17 1,373,605 Methylomic Profiling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon,
2014
(Lunnon et al., 2014)
2.52E-08 17 1,373,605 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
PASK cg25488284 3.50E-08 GO:0,004,674 protein serine/
threonine kinase activity
GO:0,004,871 signal transducer
activity
GO:0,005,515 protein binding
2 242,048,127 Methylomic Profiling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon,
2014
(Lunnon et al., 2014)
PCNT cg00621289 6.48E-08 GO:0,005,515 protein binding
GO:0,005,516 calmodulin binding
21 47,855,916 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
cg04147621 1.39E-08 21 47,856,020 Methylomic Profiling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon,
2014
(Lunnon et al., 2014)
cg23449541 9.39E-08 21 47,855,893 Methylomic Profiling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon,
2014
(Lunnon et al., 2014)
PLAT cg17693222 2.14E-08 GO:0,004,252 serine-type
endopeptidase activity
GO:0,005,515 protein binding
8 42,033,472 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
PLXNC1 cg12877335 2.36E-11 GO:0,004,872 receptor activity
GO:0,005,102 receptor binding
GO:0,005,515 protein binding
12 94,539,319 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
PODXL cg08737189 3.37E-08 GO:0,005,515 protein binding 7 131,223,417 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
cg19140834 1.22E-09 7 131,217,668 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
PSMA1 cg27443779 1.18E-08 GO:0,003,723 RNA binding
GO:0,004,298 threonine-type
endopeptidase activity
GO:0,005,515 protein binding
11 14,664,793 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
PSTPIP1 cg11652496 2.57E-09 GO:0,003,779 actin binding
GO:0,005,515 protein binding
GO:0,019,903 protein
phosphatase binding
15 77,324,526 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
RBM33 cg13639901 1.54E-13 GO:0,000,166 nucleotide binding
GO:0,044,822 poly(A) RNA
binding
7 155,556,590 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
cg14430943 2.71E-10 7 155,556,652 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
RHBDF2 cg05810363 9.42E-10 GO:0,004,252 serine-type
endopeptidase activity
GO:0,019,838 growth factor
binding
17 74,475,270 Methylomic Profiling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon,
2014
(Lunnon et al., 2014)
3.68E-10 17 74,475,270 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
cg12163800 2.66E-08 17 74,475,355 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
cg13076843 3.81E-08 17 74,475,294 Methylomic Profiling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon,
2014
(Lunnon et al., 2014)
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Table 2 (continued)
Gene Probes
identified
P value Functional summary, GO
annotation
Chromosome Position Title of article First author
and year
Reference
1.68E-09 17 74,475,294 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
SH3PXD2A cg19007269 2.96E-09 GO:0,005,515 protein binding
GO:0,035,091
phosphatidylinositol binding
10 105,420,501 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
SIX3 cg22385702 4.47E-10 GO:0,000,980 RNA polymerase II
distal enhancer sequence-specific
DNA binding
GO:0,001,205 RNA polymerase II
distal enhancer sequence-specific
DNA binding transcription factor
activity involved in positive
regulation of transcription
GO:0,001,222 transcription
corepressor binding
GO:0,003,700 sequence-specific
DNA binding transcription factor
activity
2 45,175,881 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
SLC15A4 cg06653632 9.77E-08 GO:0,005,290 L-histidine
transmembrane transporter
activity
GO:0,015,293 symporter activity
12 129,281,444 Methylomic Profiling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon K (Lunnon et al., 2014)
SLC16A3 cg07012687 6.19E-09 GO:0,005,515 protein binding
GO:0,008,028 monocarboxylic
acid transmembrane transporter
activity
GO:0,015,129 lactate
transmembrane transporter
activity
GO:0,015,293 symporter activity
GO:0,015,355 secondary active
monocarboxylate transmembrane
transporter activity
17 80,195,180 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
SPG7 cg03169557 7.95E-09 GO:0,004,222
metalloendopeptidase activity
GO:0,005,515 protein binding
GO:0,005,524 ATP binding
GO:0,008,233 peptidase activity
GO:0,008,270 zinc ion binding
16 89,598,950 Methylomic Profiling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon K (Lunnon et al., 2014)
3.99E-10 16 89,598,950 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
STK32C cg25917732 9.98E-08 GO:0,004,672 protein kinase
activity
GO:0,004,674 protein serine/
threonine kinase activity
GO:0,004,713 protein tyrosine
kinase activity null
GO:0,005,524 ATP binding
GO:0,016,772 transferase activity,
transferring
phosphorus-containing groups
10 134,038,395 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
TFAP2E cg17474422 1.56E-08 GO:0,000,977 RNA polymerase II
regulatory region
sequence-specific DNA binding
GO:0,000,981 sequence-specific
DNA binding RNA polymerase II
transcription factor activity
GO:0,042,803 protein
homodimerization activity
1 36,039,866 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
TMEM18 cg21644387 7.25E-08 GO:0,003,677 DNA binding 2 663,024 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
TPRG1 cg04252044 2.42E-10 GO:0,042,802 identical protein
binding
3 188,664,747 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
cg12307200 3.06E-17 3 188,664,632 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
(continued on next page)
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Gene Probes
identified
P value Functional summary, GO
annotation
Chromosome Position Title of article First author
and year
Reference
TTC22 cg15645660 4.05E-08 Chaperone activity 1 55,247,356 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
VRTN cg21207436 2.24E-09 GO:0,004,803 transposase activity
GO:0,043,565 sequence-specific
DNA binding
14 74,815,316 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
VWF cg27041424 4.47E-10 GO:0,001,948 glycoprotein
binding
GO:0,002,020 protease binding
GO:0,005,178 integrin binding
GO:0,005,515 protein binding
GO:0,005,518 collagen binding
12 6,232,979 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
WDR81 cg19803550 1.04E-08 GO:0,016,772 transferase activity,
transferring
phosphorus-containing groups
17 1,637,391 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
ZZEF1 cg06753513 3.87E-12 GO:0,005,509 calcium ion binding
GO:0,008,270 zinc ion binding
17 3,977,385 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
Shown are the genes identified from EWAS and their respective probes, associated P value, GO annotation, chromosome and genomic position, and the relevant study. Only probes
with Pb 1 × 10−7 were included.
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genetic and/or epigenetic level in AD: plasma membrane and
cytoskeletal processes, lipid homeostasis, synaptic signaling, immune
cell processes, and mitochondrial processes (Fig. 2). The largest
number of genes fell into the functional group plasma membrane and
cytoskeletal processes (n = 14); however, this could be due to the
fact that this is a proportionally larger pathway and is therefore more
likely to contain an associated gene by chance. Of the pathways weFig. 2. Cellular pathways of genes identified from GWAS or EWAS. The 32 most significant G
(red) were identified from De Jager et al. (2014) and Lunnon et al. (2014) (Table 2). The 4 gr
al. (2012), (2013), and Pottier et al. (2012) (Table 1B). We next compared the molecular and
between studies.have identified, many of them have considerable overlap; for
example, lipid processes are intrinsically linked to the plasma
membrane which is composed of phospholipids and a large
percentage of cholesterol. To better understand the overlap between
GWAS and EWAS nominated genes, we looked at the cellular
localization of genes from each type of study (Fig. 3). The 2 largest
localization groups (cellular membrane and nucleus) were consistent
between methodologies. This would, to some degree, be expectedWAS loci identified (Table 1A) are shown in black. The 48 most significant EWAS loci
een loci were identified via exome sequencing from Cruchaga et al. (2014), Guerreiro et
cellular pathways of the proteins encoded by these genes to look for functional overlap
Fig. 3. Cellular locations of genes nominated from (A) GWAS and (B) EWAS.
45A.R. Smith et al. / Neuroepigenetics 6 (2016) 32–50because the majority of total proteins are involved in these locations
and, in addition, current protein research has focused on these areas
of the cell.
To provide a more structured approach to pathway analysis, all 81
genes were entered into the PANTHER pathway analysis using the
enrichment analysis from gene ontology consortium (Mi et al., 2013).
Fourteen biological process and 4 cellular component pathways were
identified after passing Bonferroni correction. Most pathways
reflected an interaction with Aβ or other AD pathology (Fig. 4). As
the data for these genes were most likely collected from ADFig. 4. Pathway enrichment analysis of 81 identifiedgenes. (A) ThePanther GO tool identified14
(B) Cellular component pathways identified by the Panther GO tool identified 4 cellular compo
columns represent expected number of genes in each pathway, whereas red represents the acpublications, the resulting pathways are not unexpected but are
most likely to be limited.
3.1. Plasma membrane/cytoskeleton
This is the pathway which contained the largest number of
associated genes from our analysis (n = 14). The plasma membrane
insulates the intracellular components from the extracellular envi-
ronment, as well as catalyzing the transport of specific compounds,
including nutrients and ions. Phospholipids that make up thesignificantly enrichedbiological processes pathways (P b .05) after Bonferroni correction.
nent pathways that were significantly enriched (P b .05) after Bonferroni correction. Blue
tual number of genes identified. Key: * = Pb0.05, ** = Pb0.01, *** = Pb0.005.
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the receptor function, membrane integrity, and membrane-
dependent processes seen in AD have been reviewed by A. Farooqui
et al. (Farooqui et al., 1995). The cytoskeleton provides contractility
and couples biochemical responses with mechanical stresses in cells.
It is vital in themovement of cellular machinery around the cell and to
the membrane, as well as orchestrating the procedures needed for
cellular movement and reshaping, a function specifically important to
the microglial cells of the brain in the response to inflammation
(Sheng et al., 1997). For an overview of cell mechanics and the
cytoskeleton, see the review by Fletcher and Mullins 2010 (Fletcher &
Mullins, 2010). The inability of neurons to regulate calcium
homeostasis through cell surface ion channels is an aspect of AD
pathogenesis that appears to be intimately involved in the dysfunc-
tion and death of neurons (Mattson, 2004). Familial AD mutations in
APP and PSEN1 support a role for perturbed calcium regulation in AD
(Mattson, 2004). In addition, all of the enzymatic machinery
responsible for the generation of the pathogenic Aβ plaque formation
are plasma membrane based (Lukiw, 2013), suggesting that damage
to the plasma membrane may be a key factor in the Aβ pathology
typical of AD.
BIN1 has been nominated by both GWAS and EWAS, and in
addition to its role in synaptic signaling, it also has a role in plasma
membrane/cytoskeletal processes because it acts as an amphiphysin,
which is known to promote caspase-independent apoptosis as well as
play an important role in neuronal membrane organization (Wigge
et al., 1997). Major learning defects and seizures have been linked to
decreased expression of amphiphysins inmurine brain (Di Paolo et al.,
2002). In addition, altered expression of BIN1 has been shown in aging
mouse models of AD (Yang et al., 2008), providing further evidence
for its role in AD pathology. Despite having no previous link to AD,
ANK1 is now the one of the strongest reported candidate genes in AD
EWAS, with strong links to cell structure. ANK1 was found to be
hypermethylated in AD brain in 2 separate studies, including 1 with 2
independent validation cohorts (Lunnon et al., 2014; De Jager et al.,
2014). The differentially methylated region in this gene spans at least
6 CpG sites and was significantly associated with neuropathology in
cortical regions but not cerebellum or premortem blood (Lunnon
et al., 2014), indicating tissue specificity of the differentially
methylated region to regions of neuropathology. ANK1 is found in
multiple different isoforms, with some transcript variants specific to
the brain (Gallagher et al., 1997) and some evidence for differential
splicing in AD (Lunnon et al., 2014). As with BIN1, one of the main
functions of ANK1 is compartmentalization and maintenance of the
plasmamembrane, and it is possible that the altered expression of this
gene could lead to neuronal membrane dysfunction in AD (Lunnon
et al., 2014).
The PVRL2 gene identified by GWAS encodes a single-pass type I
membrane glycoprotein, which is one of the plasma membrane
components of adherens junctions. Cell to cell connections brought
about by adherens junctions are vital for effective neuronal signaling
(Marambaud et al., 2002). Interestingly, Marambaud et al. used
various immunological-based methods to investigate the PSEN1/
γ-secretase system, where mutations are associated with familial AD,
and showed that it disrupted adherens junctions in AD (Marambaud
et al., 2002). Expression of PVRL2 has been detected in many
organs including the brain, and it was later suggested that it was
associated with human longevity along with the AD GWAS
nominated loci TOMM40 and APOE (Lu et al., 2014). In addition,
Elias-Sonnenschein et al. showed a significant correlation between
the GWAS nominated locus MS4A4A and Aβ but not tau pathology in
AD (Elias-Sonnenschein et al., 2013). Despite this, there is little to no
research on the specific function of MS4A4A, although the gene
product is associated with GO pathways that indicate that it is an
integral component of the plasmamembrane. Two other genes within
the MS4A gene cluster have also been nominated via GWAS: MS4A4Eand MS4A6A (Hollingworth et al., 2011; Lambert et al., 2013a). One
recent study demonstrated that MS4A6A genotype and AD are
associated with differential expression of isoform variants in blood
and some brain regions (Proitsi et al., 2014).
3.2. Lipid homeostasis
Recent epidemiological, molecular, and biochemical evidence has
strengthened the hypothesis that cholesterol is a risk factor for AD, and
although cholesterol homeostasis in the brain is largely unexplored,
new findings strongly support the involvement of cholesterol in both
the generation and deposition of Aβ (Puglielli et al., 2003). Specifically,
the quantity of cholesterol in the neuronal plasmamembrane has been
shown tomakeneuronsmore susceptible to thedamage causedbyAβ in
AD (Arispe & Doh, 2002). Other studies suggest that cholesterol acts
directly on the amyloid cascadebypromotingamyloidogenic processing
of APP (Mattson, 2004). Interestingly, statins, which are a class of
cholesterol-lowering drugs, decrease Aβ levels as well as plaque
deposition in APP transgenic mouse models (Fassbender et al., 2001).
In addition, high cholesterol levels and changes to cholesterol
metabolism can increase the production of Aβ in cell culture and
murine models (Puglielli et al., 2003). Three of the most significant
genes from AD GWAS are associated with lipid metabolism (APOE,
APOC1, CLU). APOE was first identified as a risk factor for AD in 1993
(Strittmatter et al., 1993) using immunostaining and genotyping
analysis of 30 AD cases and 91 controls. Since 2006 and the wide
application of GWAS to AD research (Grupe et al., 2007), the APOE
polymorphism has been successfully replicated in several other studies
(Coon et al., 2007; Abrahamet al., 2008; Kramer et al., 2011; Logue et al.,
2011; Meda et al., 2012; Ramanan et al., 2014), making APOE the most
robust gene linked to late-onset AD (LOAD) risk to date. The proportion
of genetic variance for LOAD risk attributed to APOE genotype is
estimated to be10%–20% (Slooter et al., 1998).APOE is a 299–amino acid
glycoprotein and the major protein component of very low density
lipoproteins, the major apolipoprotein in the brain (Puglielli et al.,
2003), as well as having a functional role in cholesterol and triglyceride
metabolism (Breslow et al., 1982). There are 3 APOE alleles that affect
one's risk of AD (ε2, ε3, and ε4), in addition to age of onset (Roses &
Allen, 1996). Of the 3 alleles, APOE ε2 demonstrates a protective effect,
with an odds ratio of 0.3 for possessing one ε2 allele, whereas APOE ε4 is
associated with a higher LOAD risk, with an odds ratio of 4.4 and 19.3,
respectively for having 1 or 2 alleles (Corder et al., 1994), as well as a
younger median age of dementia onset (Corder et al., 1994; Reiman
et al., 2007). It has been suggested that the mutated APOE hinders
clearanceof solubleAβprotein fromthebrain, leading toAβ aggregation
into fibrils. Furthermore, APOE has been shown to promote neurode-
generation by directing the toxic Aβ oligomers to synapses (Ramanan
et al., 2014). However, a recent positron emission tomographic study to
measure Aβ in 602 individuals found that the ε4 allele is neither
necessary nor sufficient for thedevelopmentof ADpathology (Ramanan
et al., 2014).
SORL1 has been identified in several studies of AD using GWAS and
exome sequencing methods; in addition, Yu et al. found epigenetic
changes in this gene (Yu et al., 2014). It has many functional domains
with different functions, including cargo transport, chaperone-like
activity, signaling, and intracellular sorting (Jacobsen et al., 2001).
When acting as a sorting receptor, the SORL1 gene product protects
APP from being directed to the endosome where it would be cleaved
by β-secretase, producing Aβ (Louwersheimer et al., 2015). Further-
more, SORL1 can bind APOE, making SORL1 an important component
in the pathophysiology of AD (Elias-Sonnenschein et al., 2013).
3.3. Synaptic signaling
Synaptic dysfunction is possibly the best established of all the
proposed pathological mechanisms for AD to date, as it shows clear
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changes (Masliah et al., 2001). Early stages of AD are characterized by
a 25%–35% decrease in numerical density of synapse per cortical
region (Davies et al., 1987). There has also been evidence that the loss
of synapses correlates with the soluble pool of cortical Aβ (Lue et al.,
1999). Stereological and biochemical analyses have shown that the
reduction in synaptic density within AD brain correlates with
cognitive defects better than the traditional hallmarks of Aβ plaques
and neurofibrillary tangles (Masliah et al., 2001).
We have identified 4 genes from GWAS and EWAS analyses of AD
that have been linked to synaptic function. Two of these, BIN1 and
PICALM, have functions in vesicular trafficking. Specifically, studies
have shown that the BIN1 gene has roles in a number of specific
pathways, including clathrin-mediated endocytosis which is an
essential step in the intracellular trafficking of proteins and lipids
such as nutrients, growth factors, and neurotransmitters in synapses
(Cousin & Robinson, 2001; Dreyling et al., 1996; Wigge & McMahon,
1998). Originally identified as a tumor suppressor (Sakamuro et al.,
1996), the BIN1 gene product is expressed most abundantly in brain
and muscle (Wechsler-Reya et al., 1997), with several alternatively
spliced brain-specific isoforms. BIN1 is one of the few genes
reproducibly identified by GWAS that does not fall near or within
the APOE locus; in addition, it is the only gene in our analysis to be
significantly associated with AD in both GWAS and EWAS.
Like BIN1, PICALM is also involved in clathrin-mediated endocy-
tosis (Dreyling et al., 1996). PICALM directs the trafficking of the
VAMP2 protein. VAMP2 is a SNARE protein that plays a key role in the
fusion of vesicles to the presynaptic membrane, allowing neurotrans-
mitter release into the synapse, a process essential to neuronal
function (Harel et al., 2008). PICALM has been robustly identified as a
risk factor for AD via GWAS (Harold et al., 2009; Seshadri et al., 2010);
however, AD-linked SNPs identified in PICALMmay still be affected by
APOE genotype because of the large amount of attenuation seen when
adjusted for APOE status (Hu et al., 2011). Jun et al. have also reported
this interaction observing that genotypes of PICALM conferred risk
predominantly in APOE ε4–positive participants, providing strong
evidence for a synergistic effect (Jun et al., 2010). PICALM is also
thought to affect amyloid precursor protein processing via endocytic
pathways (Harold et al., 2009).
As a previously known risk factor gene forAD(Lambert et al., 2013a),
PTK2B was shown via network analyses to be linked to RHBDF2, ANK1,
and RPL13, which were recently nominated from EWAS, providing
further evidence for a role in AD pathology (De Jager et al., 2014). PTK2B
has a number of roles including the induction of long-term potentiation
of nerve cells, a central process of memory formation; cell migration;
and synaptic function (Lambert et al., 2013a).
3.4. Immune cell dysfunction (astrocytes, oligodendrocytes, and microglia)
There is a widely accepted link between inflammation, the
immune system, and AD pathology (Adriana Martorana et al., 2012;
Akiyama et al., 2000;Monson et al., 2014; Salminen et al., 2009; Tuppo
& Arias, 2005); more specifically, the inflammation seen in AD has
been proposed to exacerbate symptoms (Akiyama et al., 2000).
Microglia, which are the brain's resident macrophages, have been
shown to increase their viability by 22.0%–29.4% in response to
fibrillar Aβ deposits of 0.2 to 5.0 μmol/L, which are commonly seen in
AD. Oligomeric Aβ at a dose of 5.0 μmol/L results in cytotoxic
microglia (Pan et al., 2011) and ultimately leads to synaptic
degeneration and neuronal death (Barger & Basile, 2001). However,
relatively few genes that have shown robust associations with AD
have been directly linked with inflammation or immune functions.
Most noteworthy, a rare variant in TREM2was recently recognized by
a number of AD exome sequencing studies and GWAS (Guerreiro et
al., 2013; Jonsson et al., 2013; Forabosco et al., 2013; Neumann & Daly,
2012). TREM2 encodes an innate immune system receptor on thesurface of microglial cells within the brain. With the signaling
counterpart DAP12 (also called TYROBP), TREM2 forms a molecular
complex that promotes phagocytosis of bacteria (N'Diaye et al., 2009).
Work by Takahashi et al. has shown that TREM2 also has a role in the
clearance of apoptotic neurones due to its ability to increasemigration
and phagocytosis of microglia (Takahashi et al., 2005). Recently, 1
study demonstrated correlation in TREM2 and CD33 gene expression
in AD (Chan et al., 2015). As CD33 has also been nominated in various
AD GWAS (Hollingworth et al., 2011; Naj et al., 2011; Kamboh et al.,
2012b), this provides further evidence for an overlap of AD gene
pathways in disease. As described above, recent protein-protein
interaction data also demonstrated that several EWAS nominated loci
(ANK1, RHBDF2, PICLAM) have a functional link to PTK2B (De Jager
et al., 2014). PTK2B is an AD risk factor gene that plays a key role in the
signaling cascade involved in the modulation of microglial and
infiltrating macrophage cell activation (De Jager et al., 2014).
A further gene related to immune function is RHBDF2, identified by
EWAS. Differentially methylated CpG sites close to the RHBDF2 gene
were identified in 2 independent EWAS (Lunnon et al., 2014; De Jager
et al., 2014), with recent studies showing that this increases RHBDF2
expression in AD brain (De Jager et al., 2014). RHBDF2 transports
TNFα converting enzyme (TACE, also called ADAM17), which is
necessary for the release of TNFα from the cell surface (Adrain et al.,
2012). RHBDF2 absence in mice affects the release of TNFα from the
cell surface (Siggs et al., 2012) and therefore impairs systemic
immune responses to pathogens (McIlwain et al., 2012), although
the brain phenotype has yet to be researched.3.5. Mitochondrial processes
Mitochondrial dysfunction is one of the most prominent charac-
teristics of AD in both the brain and the periphery (Devall et al., 2016;
Devall et al., 2014; Lunnon et al., 2012), with TOMM40, one of themost
robust genes identified from GWAS, associated with mitochondrial
function. This gene is located approximately 2 kilobases downstream
from APOE, and because of the locality of these 2 genes, there is strong
linkage disequilibrium (LD) for TOMM40with the APOE locus (Feulner
et al., 2010); hence, many studies have failed to find an association of
TOMM40 in AD after adjusting for APOE genotype (Ramanan et al.,
2014; Wijsman et al., 2011; Yu et al., 2007). However, 1 study reports
TOMM40 as a possible risk factor of AD independent of APOE (Lutz et
al., 2010). Specifically, this study found a poly-T track mutation in
TOMM40 that acts independently of APOE genotype, which has also
seen been reported in another independent study (Cruchaga et al.,
2011). In addition to increasing risk of developing AD, TOMM40 has
also been linked to an earlier age of onset for the disease (Roses et al.,
2009). Other studies also suggest that TOMM40 provides an additional
risk for AD, in addition to APOE (Potkin et al., 2009; Takei et al., 2009).
However, until the extent of the LD between TOMM40 and APOE is
fully characterized, it will be difficult to pinpoint the exact effect the
TOMM40 mutation has on LOAD pathogenesis.
CLU has various nuclear andmitochondrial isoforms and is thought
to regulate the rate of cell proliferation. CLU has been consistently
replicated across many GWAS and holds a strong association with AD
(Harold et al., 2009; Lambert et al., 2009; Jun et al., 2010; Wijsman et
al., 2011). The nuclear isoforms result in the promotion of apoptosis,
whereas mitochondrial isoforms of CLU suppress BAX-dependent
release of cytochrome c into the cytoplasm and inhibit apoptosis
(Zhang et al., 2005). As an increased level of apoptosis in the brain is
seen in AD, it could suggest a role of CLU mutations in pathogenesis
(Behl, 2000). SPG7 was identified by EWAS and encodes a mitochon-
drial metalloprotease protein. Mitochondrial proteases degrade
misfolded and nonassembled polypeptides. They also regulate the
activity of specific substrates by mediating essential processing steps.
These proteases have been hypothesized to play a role in
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axonal function (Martinelli & Rugarli, 2010).4. Discussion
The use of GWAS to identify common disease variants in AD has
been at the forefront of research to understanding disease etiology for
10 years. More recently, the falling cost of exome and whole genome
sequencing has identified rarer variants with a larger effect size.
However, only 3 EWAS have been reported in AD to date (Lunnon et
al., 2014; De Jager et al., 2014; Bakulski et al., 2012), which have solely
focused on DNA methylation, although further studies are highly
anticipated. Of all the genes identified from GWAS and EWAS in AD,
only 1 locus was found to be overlapping between these 2
methodologies (BIN1).
As with any pathway identification analysis, there are caveats to
our method. Some pathways are significantly larger than others
containing more genes; therefore, using this method, we are more
likely to find associated genes in these pathways over others.
Secondly, cellular pathways that contain a gene which is either
genetically or epigenetically altered may still be able to function
normally, as similar proteins could “step-in” to fulfill the lost
functionality. Thirdly, in our analysis, we did not filter our results
based on loss of function SNPs or reduced expression; therefore,
despite the alterations in AD, the genes we have identified may well
have no change in their functionality. Fourthly, AD is characterized by
neuronal cell loss and gliosis, and thus, the findings from EWAS may
simply represent an alteration in cellular abundance, and although
EWAS can apply cell-specific corrections to methylation data
(Guintivano et al., 2013), this was not included in our analysis. The
ability to look at single-cell epigenetic profiles in disease would allow
researchers to conclusively quantify changes that occur at both
cellular and disease-state levels; however, single-cell isolation in
postmortem tissue, via laser capture microdissection or
florescent-assisted cell sorting, currently represents a considerable
challenge to the field. Finally, epigenetic research in AD is still in its
early stages with only 2 EWAS included in our analysis; this coupled
with the fact that current methylation data are the sum of 2 different
cytosine modifications (5-methylcytosine and 5-hmC) means that we
may have an underrepresentation of significant EWAS genes in AD. A
further caveat of epigenetic studies compared with genetic studies is
that causality is more difficult to establish, and thus, further studies
examining the functional role of nominated EWAS loci are warranted.5. Conclusion
Looking at the most significant genetic and epigenetic findings in
AD to date, we have identified several pathways that require further
exploration and could ultimately aid in our understanding of AD
etiology. Well-characterized clinical cohorts will also allow the
identification of further rare variants of AD, whereas advances in
methodologies are also allowing the identification of other epigenetic
marks, such as histone modifications and other DNA modifications at
single-nucleotide resolution (Lunnon & Mill, 2013). A number of
recent studies have demonstrated altered global levels of 5-hmC in AD
brain (Condliffe et al., 2014; Chouliaras et al., 2013); however,
studies to investigate loci-specific 5-hmC changes in AD are yet to be
published. There is also the potential for further disease mechanisms
to be identified from current studies as research moves to integrate
GWAS and EWAS data in the same data sets to identify cis
methylation quantitative trait loci. Ultimately, integrating genomic
and epigenomic data with other “omic” modalities will allow the
identification of novel dysfunctional pathways in disease (Lunnon &
Mill, 2013).Acknowledgements
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ABSTRACT 
The study of epigenetic mechanisms in many complex disease phenotypes has recently gained 
considerable research interest.  In recent years a number of epigenome-wide association 
studies (EWAS) of DNA methylation have been published in a range of brain disorders, 
including Alzheimer’s disease (AD). These have utilized post-mortem human brain tissue to 
investigate, in detail, epigenetic changes in a disease relevant tissue from the organism of 
interest. However epigenetic studies of brain disorders present specific experimental design 
challenges.  Here, we describe selected experimental designs that have used post-mortem 
brain tissue to investigate and evaluate DNA methylation in AD and other brain disorders. We 
also evaluate a new approach to analyze DNA hydroxymethylation, a recently identified 
epigenetic modification. Ultimately the use of this method in AD will provide the field with a more 
in depth understanding of genomic regulation in disease. Our aim is to provide guidelines and 
advice for researchers contemplating undertaking EWAS in AD and other brain disorders, from 
the isolation of DNA to performing EWAS in post-mortem brain tissue.  
 
 
 
 
 
 
 
 
1. INTRODUCTION 
 
1.1 Moving beyond genetic variation to understand Alzheimer’s disease: The advent of 
epigenome wide association studies 
Genomic studies for various brain diseases, including Alzheimer’s disease (AD) are now 
commonplace in scientific literature1-10. Genome wide association studies (GWAS), in particular, 
having yielded a vast amount of the current knowledge for genetic risk factors for AD. However, 
for many brain disorders GWAS have reached a saturation point with respect to their ability to 
identify novel genetic variants11,12. Furthermore although whole genome and exome sequencing 
studies are beginning to uncover additional polymorphisms associated with disease, these 
newly discovered variants are usually relatively rare within the population13. Therefore, recent 
studies have extended to investigating genomic regulation via epigenetic mechanisms to explain 
the sporadic, yet partially heritable nature of several diseases, including AD. The term 
“epigenetics” refers to the reversible regulation of gene expression mediated principally through 
changes in DNA methylation and chromatin structure, occurring independently of the DNA 
sequence.14 To date, epigenome wide association studies (EWAS) for brain disorders have 
predominantly focused on studying DNA methylation patterns. There are however several 
additional study design challenges compared to traditional GWAS, for example careful 
consideration of methodological approaches, tissue-specificity and causal inference15.  
Although DNA methylation (5-methylcytosine (5-mC)) is the best understood and most studied 
epigenetic modification, additional DNA modifications have been recently described, for 
example 5-hydroxymethylcytosine (5-hmC), 5-formylcytosine (5-fC) and 5-carboxylcytosine (5-
caC). These modifications were originally thought to represent intermediates in the 
demethylation of 5-mC to un-modified cytosine16, however recent data suggests that 5-hmC 
may also be a functional epigenetic mark, showing tissue-specific patterns in the brain17. DNA 
methylation and hydroxymethylation of cytosine results in the re-modeling of the 3-dimensional 
structure of chromatin, either preventing, or enabling the binding of transcription factors or 
splicing machinery that results in changes in the transcriptional properties of genes as well as 
the splice variants that translate into protein products18. This change in the architecture of the 
gene/protein expression landscape has been hypothesized to be the cause of many diseases 
that currently are without a definitive genetic cause, such as AD. However, it is worth noting that 
epigenetic changes occur at a cellular level, with DNA methylation patterns occurring in a more 
disparate manner between tissues of the same individual, than between individuals within the 
same tissue19. In AD, the progression of disease is well characterized, with the spread of 
hyperphosphorylated tau being predictable in its spread throughout the brain, starting in the 
brain stem and the entorhinal cortex, moving through the prefrontal cortex and the limbic 
regions and in late Braak stage, being present throughout the neocortex, with the cerebellum 
remaining relatively free of neuropathology20.  As such, examining post-mortem brain tissue is 
essential for epigenetic studies in AD. However, it is important to choose an appropriate tissue 
that accurately represents the pathology of AD. Looking in areas of the brain that are affected 
early in AD mean that those who have a clinical diagnosis of AD will already have large 
amounts of neuronal loss and so being able to assess epigenetic changes in affected neurons is 
more challenging. Using brain regions affected later in the disease means fewer people will 
have pathology in these regions and so may be an indication of what is changing during the 
spread of pathology. A cross-tissue study design is therefore optimal as it allows the 
investigation of multiple different brain regions representing the spectrum of pathology. As the 
epigenetic field moves forward it will be important to integrate multi-omic approaches 
(genomics, epigenomics, and transcriptomics), to fully elucidate molecular changes occurring 
during disease pathology.  
1.2 Methods to study DNA methylation and DNA hydroxymethylation profiles in 
Alzheimer’s disease 
 
At present epigenomic studies in AD represent a relatively new scientific endeavor, with 
considerably more review articles than empirical research. Of the studies that have looked at 
DNA methylation profiles in AD brain samples, most methods have used a targeted approach to 
determine the DNA methylation profile in specific genes of interest21 or used 
immunohistochemical methodology to investigate the total global levels of 5-mC and or 5-hmC 
in disease22-24. However, in recent years the first EWAS in AD have been published, with six 
studies performed to date25-30, although only two had sufficient sample numbers to identify 
experiment-wide significant results25,26. In this chapter we will focus on describing methods to 
perform EWAS to characterize 5-mC and 5-hmC profiles in post mortem brain tissue. In addition 
to presenting a method to isolate sufficient yields of high molecular weight DNA, we will also 
describe the EWAS approach taken by Lunnon et al and De Jager et al in 201425,26, which 
utilized the Illumina Infinium 450K BeadChip array in conjunction with bisulfite-treated DNA to 
assess DNA modifications (sum of 5-mC and 5-hmC) at ~485,000 CpG sites in the genome. 
Although this method has since been superseded by the Illumina Infinium EPIC BeadChip array, 
which quantifies DNA modifications at ~850,000 CpG sites in the genome, the principles are 
essentially the same. We also describe a new methodology that has recently become 
available17, which involves bisulfite and oxidative bisulfite treatment of DNA in parallel, in 
conjunction with the Illumina Infinium BeadChip array to assess 5-mC and 5-hmC levels 
separately in the genome. Although this method has been used to study 5-mC and 5-hmC 
levels in post-mortem brain samples, it has not, to date, been applied to the study of AD. We will 
describe the practical elements of the appropriate study design, discussing optimal methods for 
DNA extraction, DNA bisulfite and oxidative bisulfite treatment and finally DNA methylation 
profiling on the Illumina Infinium BeadChip arrays. When performing the described experiments 
it is important, at all times, to be hypervigilant to contamination between samples and from 
external sources. 
 
2. MATERIALS AND METHODS 
 
2.1 DNA extraction from post mortem tissue 
There are many methods and protocols available to isolate DNA from human tissue samples. 
DNA extraction from brain tissue samples using a standard phenol-chloroform method has been 
widely utilized for EWAS using post-mortem brain tissue as it provides sufficient yields of high 
quality DNA for downstream purposes. The protocol below is an adaptation of the phenol-
chloroform method developed by Sambrook and Russell (2006)31. Reagents required for the 
Phenol-Chloroform DNA extraction can be found in Tables 1.1, 1.2 and 1.3. 
 
2.1.1 Weigh brain tissue 
Perform steps 1-6 in a sterile extraction hood (see Note 1.1) 
1. Weigh empty frozen 1.5ml microcentrifuge tube and note the weight 
2. Transfer frozen tissue sample to the 1.5ml microcentrifuge tube with sterile tip or 
tweezers whilst on dry ice 
3. Weigh the microcentrifuge tube and calculate the brain weight (total weight-empty 
weight). The optimum protocol utilizes 100mg of tissue (see Note 1.2) 
 
2.1.2 Lyse and digest cells 
4. Prepare sufficient fresh lysis buffer (1ml per 100mg tissue sample) (Table 1.1) 
5. Add 4 times weight/volume of lysis buffer, for example if utilizing 100mg brain tissue add 
400μl lysis buffer 
6. Disrupt the tissue with a disposable pestle and rotary pestle motor.  Subsequently 
discard the pestle 
7. Add 6 times weight/volume of lysis buffer (for example if utilizing 100mg brain tissue add 
600μl lysis buffer) (see Note 1.3)  
8. Add DNase-free RNase-A (Table 1.2) to a final concentration of 20μg/ml and incubate 
for at least 1hr at 37°C (see Note 1.4) 
9. Add Proteinase K (Table 1.2) to each sample at a final concentration of 400μg/ml  
10. Incubate in a water bath at 50°C overnight (see Note 1.5)  
11. The following morning check the level of sample lysis. If the sample is not sufficiently 
lysed use a p1000 pipette tip or a syringe to re-suspend the solution and break up any 
remaining tissue, being careful not to lose any of the solution. In most cases lysis has 
been achieved and this step is not necessary (see Note 1.6) 
12. Add Proteinase K (Table 1.2) to each sample at a final concentration of 200μg/ml 
13. Leave for at least one more hour in the water bath at 50°C 
14. Heat the water bath to 65°C and leave for 20-30 minutes to deactivate the Proteinase K 
15. Cool the sample to room temperature 
2.1.3 Purification of nucleic acids (Perform these steps in a chemical hood: see Note 1.7) 
16. Transfer sample to a 2ml phase lock tube and then add an equal volume of Phenol / 
Chloroform / Isoamyl Alcohol (PCI) to the tube (Table 1.2) (for example, add 1000μl if 
utilizing 100mg brain tissue) (see Note 1.8) 
17. Invert sample 20 times to mix 
18. Centrifuge 16200 x g for 15 minutes 
19. Carefully remove the aqueous layer into a new 2ml microcentrifuge tube (see Note 1.9)  
20. Add 1ml of 100% chloroform (Table 1.2) 
21. Invert sample 20 times to mix 
22. Centrifuge 16200 x g for 15 minutes 
23. Remove the aqueous layer into a new tube 2mL microcentrifuge tube (see Note 1.10) 
24. Repeat chloroform extraction steps 20 to 23 
2.1.4 Precipitation of DNA 
25. Add 1 to 1.5ml of ice cold 100% ethanol (Table 1.2) to the sample (see Note 1.11) 
26. Mix the sample slowly (see Note 1.12)  
27. If DNA can not be visualized, add between 10-20μl 5M NaCl (Table 1.3) 
28. Leave at -20°C for one hour to further precipitate (see Note 1.13) 
29. Centrifuge at 16200 x g for 15 minutes  
30. Remove supernatant by pipetting, being careful not to dislodge the DNA pellet 
31. Add 1ml 70% ethanol (Table 1.2) 
32. Centrifuge at 16200 x g for 5 minutes, or if pellet detaches from the base of the tube for 
at least 10 minutes 
33. Remove the supernatant by pipetting, being careful not to dislodge the DNA pellet. 
Leave the pellet to air-dry for approximately 30 minutes (see Note 1.14) 
34. Re-suspend in 200μl - 300μl H2O or Te (Table 1.3) (see Note 1.15)                                                                                                         
35. Dissolve the pellet overnight at 37°C 
2.1.5 DNA quality check 
36. Perform a visual check to make sure the DNA is well suspended (see Note 1.16) 
37. Run DNA on a 0.8% agarose gel to check for high molecular weight DNA, which is not 
degraded.  
38. Load 2μl of the DNA sample on to a Spectrometer (NanoDrop) to estimate the 
concentration and further check the quality using 260/280 and 230/280 ratios (above 1.8 
and ~2 respectively for pure DNA) 
 
2.2. Bisulfite treatment of DNA  
Bisulfite treatment, originally described by Frommer et al32, is a method that provides a base-
pair level sensitivity measure for DNA modifications (including 5-mC). In this process un-
modified cytosine is converted to uracil, but certain modifications to cytosine including 5-mC and 
5-hmC remains unreactive. The sequence can then be amplified via subsequent PCR, resulting 
in all uracil and thymine residues being amplified as thymine and only modified cytosine 
residues being amplified as cytosine. Bisulfite treatment using the Zymo EZ-96 DNA 
Methylation-GoldTM Kit ideally utilizes 500ng high quality DNA in 20μl to provide sufficient 
bisulfite treated material for cytosine modification array profiling and subsequent validation 
experiments. This method has been used to treat the DNA samples in all EWAS studies of AD 
published to date25-30. The steps for the protocol are described below, and the manufacturer’s 
protocol is available from http://www.zymoresearch.com/downloads/dl/file/id/59/d5007i.pdf. 
Before you start the protocol make a dilution plate of DNA at 25ng/μl in 20μl in the conversion 
plate provided with the kit.  
1. Add 130μl of the CT conversion reagent (Table 2.1) to each DNA sample in the 
conversion plate and mix the samples by pipetting 
2. Seal the plate with the provided film. Transfer the conversion plate to a thermal cycler 
and perform the following steps:  
1. 98°C for 10min 
2. 64°C for 2.5 hours  
3. 4°C storage for up to 20 hours  
3. Add 400μl of M-Binding buffer (provided) to the wells of a Silicon-ATM binding plate 
(provided) mounted on a collection plate (provided) 
4. Transfer the samples from the conversion plate (Step 2) to the wells of the Silicon-A™ 
binding plate (Step 3). Mix by pipetting up and down 
5. Centrifuge at 3500 x g for 5 minutes. Discard the flow-through (see Note 2.2) 
6. Add 400 µl of M-Wash buffer (Table 2.2) to each well of the plate 
7. Centrifuge at 3500 x g for 5 minutes 
8. Add 200 µl of M-Desulphonation buffer (provided) to each well and allow the plate to 
stand at room temperature (20-30°C) for 20 minutes 
9. Centrifuge at 3500 x g for 5 minutes. Discard the flow-through 
10. Add 400 µl of M-Wash buffer to each well of the plate 
11. Centrifuge at 3500 x g for 5 minutes. Discard the flow-through 
12. Add 400 µl of M-Wash buffer (Table 2.2) and centrifuge for 10 minutes 
13. Place the Silicon-A™ binding plate onto an elution plate (provided) 
14. Add 15 µl of M-Elution buffer (provided) directly to each well of the Silicon-A™ binding 
plate. (see Note 2.3) 
15. Incubate for 5 minutes at room temperature  
16. Centrifuge at 4000 x g for 3 minutes to elute the DNA 
17. Repeat steps 15 to 17.  
Eluted DNA is ready for immediate analysis or can be stored at or below -20°C for later use. For 
long term storage, store at or below -70°C. To assess bisulfite conversion quality it is 
recommended to perform a bisulfite-specific PCR amplification (details available on request) 
followed by gel electrophoresis. If a PCR product is visible this is a good indication of bisulfite 
conversion quality. 
 
2.3 Oxidative bisulfite treatment of DNA 
Oxidative bisulfite treatment is the first method enabling the quantitative mapping of 5-mC in the 
absence of confounding by 5-hmC in genomic DNA at single-nucleotide resolution. Using a 
selective chemical oxidation of 5-hmC to 5-fC, followed by bisulfite conversion, results in the 
conversion of 5-hmC to uracil. As such only cytosines with DNA methylation are protected from 
the conversion and after subsequent PCR amplification, one can assess the level of just 5-mC. 
Simultaneous bisulfite treatment of a matched sample of DNA, provides a value for the total 
DNA modifications (5-mC + 5-hmC) at each site, as both modifications are protected from the 
conversion and are not converted to uracil33. Subsequently after PCR amplification, the 
subtraction of the oxidative bisulfite signal from the standard bisulfite signal gives a 5-hmC 
proxy value for each nucleotide.  
Oxidative bisulfite treatment using the CEGX® TrueMethyl® Array kit requires 1μg high 
molecular weight genomic DNA per sample. This is sufficient to allow 500ng to be processed 
through each of the bisulfite and oxidative bisulfite conversion processes. Input masses of high 
molecular weight gDNA in the range of 50ng – 1μg are also compatible (see Note 3.1). The 
protocol described results in a final volume of 12μl of bisulfite treated DNA and 12μl of oxidative 
bisulfite treated DNA for downstream analyses. The manufacturer’s protocol is available from 
https://www.cambridge-epigenetix.com/resources/user-guides 
2.3.1 Starting material 
1. Add 1μg DNA sample to a 1.5ml microcentrifuge tube and adjust the final volume to 50μl 
using ultra-pure H2O from the TrueMethyl® kit (see Note 3.2) 
 
2.3.2 DNA oxidation 
2. Set heat block to 37°C and prepare Magnetic binding solution 1 (Table 3.1) and 80% 
acetonitrile (Table 3.2) (see Note 3.3) 
3. Vortex Magnetic bead binding solution 1 thoroughly to ensure the solution is 
homogenous and add 100μl of Magnetic bead binding solution 1 to each 1.5ml 
microcentrifuge tube containing 50μl DNA and vortex to mix (see Note 3.4) 
4. Incubate the sample for 20 minutes at room temperature 
5. At the end of the incubation, briefly centrifuge the 1.5ml microcentrifuge tubes to collect 
the sample at the bottom of the tube 
6. Place the tubes into a magnetic separation rack and pellet beads for 5 minutes at room 
temperature 
7. Carefully remove and discard the supernatant, avoiding the bead pellet. If beads are 
accidentally pipetted, dispense them back into the tube and repeat step 6 
8. Leaving the 1.5ml tubes in the magnetic separation rack, complete the following wash 
steps: - 
a. Carefully add 1ml 80% Acetonitrile (Table 3.2) wash to the tubes without 
disturbing the bead pellet 
b. Remove and discard the 1ml 80% acetonitrile wash, carefully avoiding aspiration 
of the bead pellet 
c. Repeat Steps 8a and 8b another two times so that ultimately three 1ml 80% 
acetonitrile washes will have been performed in total. Remove, by pipetting, as 
much of the final wash as possible 
d. Air dry the bead pellets for 5 minutes at room temperature, leaving the lids of the 
tubes open 
9. Complete the following denaturation steps: - 
a. Leaving the 1.5ml tubes in the magnetic separation rack, add 50μl of Denaturing 
solution (provided) directly onto the bead pellet. Close the lid of the tube before 
removing from the magnetic separation rack 
b. Vortex thoroughly to fully suspend the bead pellet in the Denaturing solution  
c. Incubate for 5 minutes at room temperature  
d. Incubate for 30 minutes at 37°C (perform this step in the pre-heated benchtop 
heating block (step 2)) 
10. Briefly centrifuge the 1.5ml microcentrifuge tubes to collect the sample at the bottom of 
the tube 
11. Place the tubes into a magnetic separation rack and pellet beads for 5 minutes at room 
temperature 
12. Avoiding the bead pellet, carefully transfer 50μl eluate into a new 1.5ml tube. Centrifuge 
briefly. Place sample on ice and proceed immediately to step 13 
13. Perform the DNA oxidation reaction in 0.2ml PCR tubes as described in Table 3.3.  
14. Incubate the oxidation reaction mix at 40°C for 30 minutes in a PCR thermocycler with a 
heated lid (see Note 3.5) 
15. Centrifuge the sample at 14000 x g for 10 minutes at room temperature to pellet any 
black precipitate. If the supernatant remains orange, there is an excess of oxidant 
remaining and oxidation has completed (see Note 3.6) 
16. Transfer the orange supernatant into a new 0.2ml PCR tubes and use this in subsequent 
steps of the protocol. Take care not to carry any black precipitate over as this could 
inhibit downstream steps. Proceed immediately to the bisulfite conversion steps 
described below 
 
2.3.3  Bisulfite conversion  
 
17. Prepare the Bisulfite reagent solution by adding 4.2ml Bisulfite diluent to one Bisulfite 
reagent aliquot (sufficient for 24 reactions). Seal the lid tightly and incubate the solution 
at 60°C for 15 minutes (using either a water bath or heated orbital incubator). 
Subsequently vortex the sample until the Bisulfite reagent solution is completely 
dissolved (see Note 3.7) 
18. Equilibrate the oxidized samples from step 16 to room temperature. Do not place the 
oxidized samples on ice to cool as this may cause the solution to precipitate 
19. Perform the bisulfite conversion reactions in the same 0.2ml PCR tubes (Table 3.4).   
20. Place the 0.2ml PCR tube containing the Bisulfite conversion reaction mix into a 
thermocycler. Perform the bisulfite DNA conversion using the thermal profile shown in 
Table 3.5. The complete cycle should take approximately 8 hours to complete. This step 
may be performed overnight if necessary (see Note 3.8) 
 
2.3.4 Clean up of bisulfite converted DNA 
21. Prepare Magnetic binding solution 2 (Table 3.6)(see Note 3.9) 
22. Equilibrate Magnetic bead Binding solution 2 and Desulfonation buffer (Table 3.7) to 
room temperature for a minimum of 30 minutes before use. Also prepare a fresh stock of 
70% ethanol for the experiment (Table 3.8)  
23. Once the bisulfite conversion is complete, centrifuge the 0.2ml PCR tubes containing the 
reactions at 14000 x g for 10 minutes at room temperature. This will pellet any 
precipitated salts accumulated during the bisulfite incubation 
24. Without disturbing the pellet, transfer 195μl of the supernatant to a new 1.5ml 
microcentrifuge tube (see Note 3.10) 
25. Vortex Magnetic bead binding solution 2 (Table 3.6) thoroughly to ensure the solution is 
homogenous before aliquoting 
26. Carefully add 1ml of Magnetic bead binding solution 2 (Table 3.6) to each of the 1.5ml 
microcentrifuge tubes containing 195μl bisulfite converted sample from step 24. Close 
the lid of the tube. Invert tube and flick the base of the tube to dislodge the sample, 
vortex immediately to mix. Place the tube at a 45 degree angle to ensure thorough 
mixing  
27. Incubate for 20 minutes at room temperature (see Note 3.11) 
28. At the end of the incubation, briefly centrifuge the 1.5ml microcentrifuge tubes to collect 
the sample at the bottom of the tube 
a. Place the tubes into a magnetic separation rack and pellet beads for 30 minutes 
at room temperature (see Note 3.12) 
b. Carefully remove and discard the supernatant, avoiding the bead pellet. If beads 
are accidentally pipetted, dispense them back into the tube and repeat step 28a 
29. Leaving the 1.5ml tubes in the magnetic separation rack, complete the following wash 
steps:  
a. Add 1.4ml 70% ethanol wash (Table 3.8) to the tubes without disturbing the bead 
pellet 
b. Remove and discard the 1.4ml 70% ethanol wash, carefully avoiding aspiration 
of the bead pellet. Remove by pipetting as much of the wash as possible 
30. Complete the following desulfonation steps:  
a. Leaving the 1.5ml tubes in the magnetic separation rack, add 1ml Desulfonation 
buffer (Table 3.7) directly onto the bead pellet. Close lid of tube before removing 
from the magnetic separation rack. Vortex to fully suspend the bead pellet in 
Desulfonation buffer and centrifuge briefly 
b. Place the tubes back into the magnetic separation rack and incubate for 5 
minutes at room temperature in the Desulfonation buffer. The beads will pellet 
during this incubation step 
c. Remove and discard the 1ml Desulfonation buffer, carefully avoiding aspiration of 
the bead pellet. Remove by pipetting as much of the Desulfonation buffer as 
possible 
31. Leaving the 1.5ml tubes in the magnetic separation rack, complete the following wash 
steps: 
a. Add 1ml 70% ethanol wash to the tubes without disturbing the bead pellet. 
b. Remove by pipetting and discard the 1ml 70% ethanol wash, carefully avoiding 
aspiration of the bead pellet. 
c. Repeat Steps 31a and 31b so that ultimately 1ml 70% ethanol washes will have 
been performed two times in total. Remove by pipetting as much of the final 
wash as possible 
d. Air dry the bead pellets for 15 minutes at room temperature, leaving the lids of 
the tubes open 
32. Complete the following elution steps:  
a. Leaving the 1.5ml tubes in the magnetic separation rack, add 12μl of Elution 
buffer (provided) directly onto the bead pellet. Close lid of tube before removing 
from the magnetic separation rack. 
b. Vortex thoroughly to fully suspend the bead pellet in the Elution buffer. Incubate 
for 20 minutes at room temperature to elute the TrueMethyl® converted DNA 
from the beads. 
33. At the end of the incubation (step 32b), briefly centrifuge the 1.5ml microcentrifuge tubes 
to collect the sample at the bottom of the tube. Place the tubes into a magnetic 
separation rack and pellet beads for 5 minutes at room temperature (see Note 3.13) 
34. Avoiding the bead pellet, carefully transfer 10 - 12μl eluate into a new 1.5ml tube. This is 
the recovered TrueMethyl® converted DNA sample 
The DNA is ready for immediate analysis or can be stored at or below -20°C for later use. For 
long term storage, store at or below -70°C. To assess oxidative bisulfite conversion quality it is 
recommended to integrate a Digestion control (provided) with the initial 1μg gDNA sample in 
step 1 (see Note 3.2) and interrogate the control using PCR, followed by gel electrophoresis 
(see also the TrueMethyl® Array User guide).  
 
3.3 Illumina Infinium Methylation BeadChip Array 
The Infinium HD Methylation Assay combines bisulfite converted DNA and whole-genome 
amplification with direct, array-based capture and scoring of the CpG loci34. Signal intensity is 
measured with the Illumina iScan or HiScan system to generate beta values, a measure of the 
degree of 5-mC/5-hmC at each locus. The beta values can then be interrogated and compared 
across samples for powerful large-scale studies. One or two probes are used to interrogate a 
CpG locus, depending on the probe design for a particular CpG site. (The Infinium I design has 
two probes per site and Infinium II has one probe per site.)  Allele-specific single base extension 
of the probes incorporates a biotin nucleotide or a dinitrophenyl labeled nucleotide. Signal 
amplification of the incorporated label further improves the overall signal-to-noise ratio of the 
assay. 
 
The first stage in the process includes a denaturing and neutralization stage before the bisulfite 
treated DNA is whole-genome amplified (see Note 4.1). The denatured DNA is isothermally 
amplified in an overnight step. The whole-genome amplification uniformly increases the amount 
of the DNA sample by several thousand folds without significant amplification bias. A controlled 
enzymatic process then fragments the amplified product. The process uses endpoint 
fragmentation to prevent over fragmentation. After an isopropanol precipitation, centrifugation at 
4°C collects the fragmented DNA. The precipitated DNA is then suspended in Hybridization 
buffer. DNA samples are then dispensed onto BeadChip arrays and incubated in an Illumina 
Hybridization Oven to hybridize the samples onto the BeadChip array surface. The new EPIC 
array design enables eight samples to be applied to each BeadChip array, which keeps them 
separate with an IntelliHyb seal. DNA samples anneal to locus-specific sites on the BeadChip 
array. Un-hybridized and nonspecifically hybridized DNA are washed away and the BeadChip 
array then undergoes extension and staining in capillary flow-through chambers. Single-base 
extension of the oligonucleotides on the BeadChip array, using the captured DNA as a template, 
incorporates detectable labels on the BeadChip array and determines the 5-mC/5-hmC level of 
the specific CpG sites. Finally the BeadChip array is imaged on the Illumina HiScan or iScan 
System, using a laser to excite the fluorophore of the single-base extension product on the 
beads. The scanner records high resolution images of the light emitted from the fluorophores. 
These in turn are used by the genome studio® software to produce a beta value at each locus. 
A full description of this methodology can be found on the Illumina website 
http://www.illumina.com/products/by-type/microarray-kits/infinium-methylation-epic.html.   
 
The Infinium HD Methylation Assay platform has opened up multiple possibilities for epigenomic 
research that were previously not feasible; analyzing over 850,000 CpG positions (EPIC array) 
in the human genome has enabled researchers to gain a snap-shot of the global modification 
profile across multiple samples. This approach is considerably more affordable than current 
sequencing alternatives, however the cost per sample is still relatively high at approximately 
£250 per sample. Initially designed as a cancer profiling tool, a large percentage of sites on the 
array are tailored to cancer related targets, a factor that needs to be considered when studying 
other phenotypes. In addition the HD Methylation BeadChip array contains multiple probes 
where cross-hybridizing with multiple DNA fragments is common, coupled with a number of 
probes that contain common small nucleotide polymorphisms (SNPs); both of which should be 
excluded from downstream analysis. As a result of this, and the large amount of data generated 
by this technique, specialist statistical pipelines and digital storage facilities for QC and data 
analysis are required.  
 
4. NOTES 
4.1 Notes for DNA extraction from post mortem brain tissue  
Note 1.1 It is important when undertaking DNA extraction to be hyper-vigilant to contamination 
between samples and from external sources. Materials should be clean-room quality and 
autoclaved where possible or purchased sterile/DNase-free. A sterile technique should be used, 
and gloves should be changed regularly. 
Brain tissue may carry pathogenic material (for example from donors with infectious diseases). 
Therefore performing the first stages in a chemical hood provides the operator with an extra 
level of protection. The quality and ease of this extraction procedure is highly dependent on the 
starting material, for example a 100mg sample of cortical tissue will give approximately half the 
amount of DNA to an identically sized sample of cerebellum tissue. However, donor cerebellum 
samples usually yield higher levels of contaminates in the final DNA sample, compared to other 
brain regions. The level of impurities seen in DNA from the cerebellum does not appear to affect 
downstream analysis of the DNA methylome; however if other analytical methods are going to 
be performed, it can be useful to perform a second PCI cleaning stage. 
Note 1.2 When dissecting small amounts of brain tissue it is important to keep all equipment 
that is in contact with the tissue sterile and cold, for example keeping the scalpel, 
microcentrifuge tube and petri dish on dry ice. This prevents the tissue thawing as it is being 
weighed. In addition, condensation does appear on the surface of chilled microcentrifuge tubes, 
which may have an effect on the weight of the tube, to avoid this quickly rub off condensation 
with some clean tissue before weighing the tube for the first time. If you plan to extract DNA 
from large numbers of samples, it is advisable to cut all tissues to the recommended weight first 
and place back at -80°C. You can then return to these prepared tissues when you are ready to 
extract all of the DNA samples.       
Note 1.3 This section results in the fast vortexing /mixing of the tissue and lysis buffer, if the 
volume of lysis buffer is too large, the tissue/buffer is more likely to spill out at this stage. Larger 
tubes are not advised as the rotary pestle recommended is designed to fit the shape of the 
1.5ml microcentrifuge tube. The pestle can be used to grind the frozen tissue against the side of 
the tube before the rotary motor is used, when removing the pestle from the lysis buffer/tissue 
mix, be careful to remove as much tissue as possible from the pestle by scraping on the side of 
the 1.5ml tube. Used pestles should be disposed of in line with individual institution’s 
recommendations for tissue-contaminated equipment.  
Note 1.4 One hour is the minimum recommended time for RNase treatment; however it is better 
to incubate for approximately two hours. Adding the RNase at this stage eliminates the need to 
remove RNA from the semi-purified DNA at a later stage in preparation, pancreatic RNase is not 
highly active in the presence of 0.5% SDS, but when added at high concentrations, it is 
sufficiently active to degrade most of the cellular RNA. If RNA and DNA are needed for 
downstream experiments, we recommend using the All-prep DNA/RNA mini kit available from 
Qiagen.  
Note 1.5 Proteinase K digests protein in the tissue to expose DNA; therefore it is not 
appropriate for the study of histone modifications. The optimum temperature for enzymatic 
activity is 50°C; the optimum time needed for tissue lysis is dependent on brain tissue.  
Note 1.6 A good sign of lysis is a pale/transparent solution, if tissue is still too viscous to pipette 
use some sterile scissors to cut the tip off a p1000 pipette tip, this will make pipetting easier, 
pipette up and down slowly several times to shear the material further. This method can also be 
performed before the 50°C incubation with Proteinase K if the pestle was insufficient at breaking 
up all the brain tissue.  
Note 1.7 Chloroform and PCI are harmful and there is a danger of serious damage to health by 
prolonged exposure through inhalation and swallowing. Wear protective clothing, including 
safety glasses at all times and performing these steps in the chemical hood is strongly advised. 
Note 1.8 Phase lock tubes can be bought (MaXtract High Density, Qiagen). An alternative is to 
make in-house equivalents as follows: 
Carefully add 1ml vacuum grease (Dow Corning® high-vacuum silicone grease (Sigma)) to the 
cap of a 2ml microcentrifuge tube, using a 50ml syringe (avoiding contamination of the syringe 
tip). Shut the lid and centrifuge at 1200 x g for 10 minutes before use.  
Note 1.9 The aqueous layer contains genetic material, whist the separated (waste) layer 
contains degraded protein and other contaminates.  
Note 1.10 A cloudy white precipitate may be visible on the surface of the aqueous layer. This 
layer of protein and/or detritus has not been efficiently removed by the phenol-chloroform 
extraction. Remove as much of the aqueous layer as possible while avoiding this white 
precipitate. The inclusion of small amounts of this precipitate in your final sample will not usually 
have any detrimental downstream effects on DNA quality or DNA methylation analysis.  
Note 1.11 Cold 100% ethanol aids in the precipitation process of DNA. Store the ethanol at -
20°C for approximately 30 minutes prior to use. 
Note 1.12 At this stage a “cotton wool” like substance should become visible in the ethanol mix, 
which is the precipitated DNA.  Using the visible size of the DNA at this point is a good 
indication of the amount of elution buffer (H2O/Te) needed at the final stage (for example xmm 
diameter of pelleted DNA = x100μl elution buffer, to a maximum volume of 300μL).  
Note 1.13 Low temperatures aid in the precipitation process, samples can be left overnight at -
20°C. If processing large numbers of samples it is recommended to pause at this stage. If you 
decide to incubate the extractions at -20°C overnight, it is important to perform this on all 
samples in the cohort to maintain consistency and minimize batch effects.   
Note 1.14 Do not leave the samples air-drying too long, otherwise it will be difficult to re-
suspend the DNA pellet. Once the smell of ethanol has disappeared and there are no visible 
drops of liquid on the inside of the tube it is appropriate to move on to the next stage.  
Note 1.15 Some applications, for example oxidative bisulfite treatment, are very sensitive to the 
presence of alcohols (ethanol, isopropanol, phenol) as well as solutions containing specific 
compounds (Tris, EB buffer, TE buffer, glycerol, surfactants). If the use of the standard bisulfite 
treatment kit from Zymo is planned then Te is recommended as it provides better stability for 
long term DNA storage. For all other applications ultra-pure H2O is recommended. 
Note 1.16 A clear colorless solution shows the DNA is completely dissolved; the solution could 
still be very viscous due to the concentration of DNA. It is recommended to dilute each sample 
to 100ng/μl to allow accurate pipetting at later stages. 
 
4.2 Notes for bisulfite treatment of DNA  
Note 2.1 The CT conversion reagent is best dissolved by continuous shaking over 15 minutes. 
Securing the tube to a vortexer enables the preparation of other reagents, whilst the CT reagent 
is dissolving.    
Note 2.2 Throughout all centrifugation steps the plates should not have a cover film applied as 
this will prevent efficient movement through the filter. The plates do become very full so care is 
needed to avoid spillage of samples into adjacent wells. Remove flow-through at each stage to 
prevent back-contamination of the filters from the wells of the collection plate. 
Note 2.3 The standard manufacturer’s protocol uses one volume of 30μl to elute DNA, here we 
have documented a change which we have found to yield greater amounts of converted DNA, 
without changing the final elution volume. 
 
4.3 Notes for oxidative bisulfite treatment of DNA 
Note 3.1 Processing samples through the TrueMethyl® Array workflow in batches of 12 to 
produce 12 oxidative bisulfite sample reactions and 12 bisulfite sample reactions is 
recommended. If higher throughput is required a 96 well plate format is available from CEGX®  
Note 3.2 For integration of Digestion control at this stage see TrueMethyl® Array User guide 
step 2.1, followed by step 5 for interrogation of Digestion Control. Inclusion of these steps is 
highly recommended for the first run though of this protocol. 
Note 3.3 Aliquoting the prepared Magnetic bead binding solution 1 into 8 x 1.5ml 
microcentrifuge tubes each containing 1.4ml per tube is recommended. One aliquot may then 
be used per batch of 12 samples processed. 
Note 3.4 No more than 50μl of DNA should be added to the bead purification at this step, if the 
DNA concentration is too low a concentration step will need to be performed. 
Note 3.5 The preparation of the bisulfite reagent solution (step 17) may be completed during 
this incubation time.  
Note 3.6 If the solution turns any color other than orange after the 30 minute incubation, it is a 
sign that the oxidation reaction is compromised. This may lead to incomplete conversion of 5-
hmC to uracil and variability in your results. To avoid this, ensure only ultra-pure H2O provided 
with the TrueMethyl® kit is used in steps containing the oxidant and consider re-purification of 
your sample taking all practicable steps to remove contaminants from the starting DNA sample 
solution.  
Note 3.7 If processing more than one batch of 12 samples, ensure to use the same Bisulfite 
reagent solution aliquot for each oxidative bisulfite and bisulfite treated sample pair. 
Note 3.8 If using a thermal cycler that does not allow you to enter the reaction volume (200μl) 
set the instrument to the largest volume setting available. Since the bisulfite reaction is not 
overlaid with mineral oil, only thermal cyclers with heated lids are suitable for this procedure. 
Converted DNA can be left in the thermal cycler overnight at 20°C hold without any loss of 
quality. 
Note 3.9 Aliquoting the prepared Magnetic bead binding solution 2 into 8 x 50ml polypropylene 
centrifuge tubes each containing 27ml per tube is recommended. One aliquot may then be used 
per batch of 12 samples processed. 
Note 3.10 Failure to perform this centrifugation step will cause compounds to be carried forward 
into the PCR reaction that will inhibit amplification. Use 0.2ml tube adapters in the centrifuge to 
perform this step. 
Note 3.11 Magnetic bead solution 2 is a viscous solution and requires slow and careful pipetting 
to ensure 1ml is dispensed fully into the sample. 
Note 3.12 At the end of the 30 minute incubation the supernatant should become clear. If the 
supernatant isn’t clear after 30 minutes, pellet the beads for a longer period of time.  
Note 3.13 Due to the small elution volume, the tubes should be placed into the rack in a slightly 
elevated position as shown in Figure 1. This helps to keep the bead pellet from separating in 
the tube, therefore preventing accidental bead uptake and ensuring efficient recovery of eluate. 
Placing a plastic tube rack upside down beneath the tubes is recommended to keep the 1.5ml 
microcentrifuge tubes in an elevated position.  
 3.4 Notes for Illumina Infinium Methylation BeadChip Array 
Note 4.1 The Infinium methylation array has a comprehensive set of notes attached to its 
protocol for further information.  One alteration to this standard protocol that is recommended is 
to increase the input volume of bisulfite or oxidative bisulfite treated DNA from 4μl to 7μl and 
simultaneously reduce the volume of NaOH whilst maintaining final concentration (1μl, 0.4M 
NaOH). This increase in DNA volume increases the success rate of the array process without 
changing the overall volume of the whole-genome amplification.  
 
5. Conclusion 
Using these approaches there has been considerable success in identifying DNA methylation 
changes related to the pathology of AD and other brain diseases25,26,35. To date, the largest 
EWAS in AD have been performed on bisuflite-treated DNA on the Illumina Infinium 450K 
Bead25,26. Although the two studies utilized different experimental designs, for example Lunnon 
et al performed a cross-tissue EWAS on ~120 individuals, whilst De Jager et al performed a 
single tissue EWAS on ~700 individuals, reassuringly both studies identified a number of 
overlapping loci36. Through recent advances in epigenomic studies, it is now possible to 
separately measure DNA methylation and DNA hydroxymethylation in the same samples by 
undertaking oxidative bisulfite treatment. Moreover, the recent release of the Illumina Infinium 
EPIC BeadChip array, means that nearly twice as many CpG sites can be investigated. The 
completion of the first EWAS of DNA hydroxymethylation and utilizing the Illumina Infinium EPIC 
BeadChip array are highly anticipated and are hoped to produce novel insights into the role of 
epigenetic mechanisms in AD pathology. 
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Table 1.1 Lysis Buffer Reagents  
Name Storage pH Final 
Concentration 
Warnings 
NaCl Room temp  75mM Irritant 
Tris-HCl Room temp pH8 10mM Corrosive  
Toxic  
EDTA Room temp pH8 25mM Irritant 
10% SDS  Room temp  1/20th final 
volume 
Irritant  
Flammable 
H2O Room temp   Not Hazardous  
 
Table 1.2 1x Te Solution (1L) – stable at room temperature  
Name Storage pH Volume (mL) Warnings 
1M tris-HCL Room temp pH8 10 Corrosive  
Toxic 
0.5M EDTA Room temp pH8 0.2 Irritant 
H2O Room temp  990 Not Hazardous 
Filter with 0.5 micron filter and then autoclave before use.  
 
 
 
 
 
 
Table 1.3 Other reagents needed for Phenol-Chloroform DNA extraction 
Name Storage Concentration Warnings 
Proteinase K solution -20°C 20mg/mL Not Hazardous  
Ribonuclease A (from 
bovine pancreas) 
-20°C 20μg/mL Not Hazardous 
Phenol / Chloroform / 
Isoamyl Alcohol (PCI) 
4-8°C 100% Toxic 
Flammable 
Irritant 
Chloroform (CHCl3) Room temp 100% Irritant 
Toxic 
Flammable  
Ethanol -20°C 100% Flammable 
NaCl Room temp 75mM Irritant 
Ethanol Room temp 70% Flammable 
Elution Buffer (H2O / 
Te)  
Room temp 200-300μL per 
sample 
Not Hazardous 
 
 
 
 
 
 
 
 
Table 2.1 CT Conversion Reagent  
Name Volume (mL) Supplier  
M-Dissolving Buffer 0.5 Zymo 
M-Dilution Buffer  3 Zymo 
CT Conversion Reagent  Bottle  Zymo 
Ultra-pure H2O 9 User 
 
Table 2.2 M-Wash Buffer  
Name  Volume (mL) Supplier 
M-Wash Buffer  36 Zymo 
100% Ethanol 144 User 
 
Table 3.1 Magnetic Bead Binding Solution 1  
Name  Volume (mL) Supplier 
Magnetic Bead Solution  0.24 CEGX 
Binding Buffer 1  12 CEGX 
 
Table 3.2 80% Acetonitrile (for 12 samples)  
Name  Volume (mL) Supplier 
100% Acetonitrile  32 User 
ultra-pure H2O 8 CEGX 
 
 
 
 
 
 
 
Table 3.3 Oxidation reaction 
 Volume per reaction (μL) 
Component oxBS BS 
Denatured DNA from step 12 24 24 
Oxidant Solution  1 - 
Ultra-Pure Water - 1 
Total volume  25 25 
 
Table 3.4 Bisulfite Conversion Reaction Mix  
Component  Volume per reaction (μL) 
DNA solution (step 16) 25 
Bisulfite Reagent Solution 170 
Bisulfite Additive  5 
Total volume  200 
 
Table 3.5 Bisulfite conversion thermal profile 
 
 
 
 
 
 
 
 
 
 
 
Table 3.6 Magnetic Bead Binding Solution 2  
Name  Volume (mL) Supplier 
Magnetic Bead Solution  2.64 CEGX 
Binding Buffer 2 220 CEGX 
 
Table 3.7 Desulfonation Buffer  
Name  Volume (mL) Supplier 
Desulfonation Buffer  Bottle  CEGX 
100% Ethanol 150 User 
 
Table 3.8 70% Ethanol (for 12 samples or 24 bisulfite conversions) 
Name  Volume (mL) Supplier 
100% Ethanol 70 User 
ultra-pure H2O 30 CEGX 
 
Figure 1  
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APPENDIX 3 – PARALLEL PROFILLING OF DNA METHYLATION AND 
HYDROXYMETHYLATION HIGHLIGHTS MEUROPATHOLOGY-
ASSOCIATED VARIATION IN ANK1 AND THIRTEEN NOVEL LOCI IN 
ALZHEIMER’S DISEASE ENTORHINAL CORTEX 
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Parallel profiling of DNA methylation and hydroxymethylation highlights 6 
neuropathology-associated epigenetic variation within ANK1 and thirteen novel loci in 7 
Alzheimer's disease entorhinal cortex. 8 
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ABSTRACT 1 
Background  2 
Alzheimer’s disease is a progressive neurodegenerative disorder that is hypothesized to 3 
involve epigenetic dysfunction. Previous epigenome-wide association studies in Alzheimer’s 4 
disease have been unable to distinguish between two DNA modifications: DNA methylation 5 
and hydroxymethylation. DNA hydroxymethylation has been shown to be enriched in the 6 
human brain, although its role in Alzheimer’s disease has not yet been fully explored. Here 7 
we utilize oxidative bisulfite conversion, in conjunction with the Illumina 450K BeadChip, to 8 
identify neuropathology-associated differential DNA methylation and hydroxymethylation in 9 
two distinct anatomical regions of the brain (entorhinal cortex and cerebellum) dissected 10 
from post-mortem brain samples of donors with varying degrees of Alzheimer’s disease 11 
pathology. 12 
Results 13 
We confirm altered DNA methylation levels in ANK1, and highlight 13 novel genes 14 
(TMEM53, KCNJ9, H3F3A, OPN3, NHEJ1, ACVR2B, ROBO2, CGGBP1, RAPGEF6, 15 
GFRA1, FHOD1, FOXF1, KCNC3 and APP) not previously identified in Alzheimer’s disease 16 
epigenome-wide association studies, which show significant interactions in DNA methylation 17 
and hydroxymethylation levels. We replicate significant ANK1 disease-associated 18 
hypermethylation and hypohydroxymethylation patterns in an independent cohort using 19 
oxidative-bisulfite pyrosequencing. 20 
Conclusions 21 
Our study represents the first cross-tissue epigenome-wide association study of both DNA 22 
methylation and hydroxymethylation in Alzheimer’s disease. We demonstrate that previous 23 
estimates of DNA hypermethylation in ANK1 in Alzheimer’s disease were underestimates as 24 
it is confounded by hypohydroxymethyation. Our study also identifies 13 novel genes that 25 
display DNA modification alterations in Alzheimer’s disease, which would not have been 26 
identified using standard bisulfite based approaches. 27 
 3 
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BACKGROUND 1 
 2 
Alzheimer’s disease (AD) currently affects approximately 35 million people worldwide [1]. It 3 
is a progressive neurodegenerative disease that leads to neuronal cell loss and results in 4 
severe cognitive decline. The characteristic hallmarks of AD include neurofibrillary tangles 5 
(NFTs) of hyperphosphorylated tau and amyloid beta (Aβ) plaques [2]. Although Mendelian 6 
inheritance of mutations in the APP, PSEN1 and PSEN2 genes have been demonstrated in 7 
early-onset familial AD cases, these only account for ~5% of disease incidence [3]. The 8 
majority of AD cases are sporadic, occur late in life and have, as yet, no defined etiology, 9 
with common single nucleotide polymorphisms (SNPs) accounting for only a third of disease 10 
risk [4]. Epigenetic processes mediate the reversible regulation of gene expression, 11 
occurring independently of DNA sequence variation and orchestrate a diverse range of 12 
important neurobiological processes in the brain; with DNA methylation (5-methylcytosine - 13 
5mC) being the best characterized and most stable epigenetic modification [5]. Two recent 14 
epigenome-wide association studies (EWAS) have utilized the Illumina 450K methylation 15 
array (450K array) to demonstrate robust and reproducible changes in DNA methylation at a 16 
number of loci in the AD brain [6, 7], including the ANK1 gene. One caveat of this approach 17 
is the utilization of bisulfite-treated (BS) DNA, which converts unmodified cytosines to 18 
thymine (post PCR), whilst methylated cytosines remain unchanged. Although the focus of 19 
these studies has been on changes in DNA methylation in AD, BS-based approaches 20 
cannot distinguish this modification from DNA hydroxymethylation (5-hydroxymethylcytosine 21 
- 5hmC). 5hmC has been previously identified at high levels in the developing [8] and adult 22 
brain [9], particularly in neurons [10] and, as such, may represent an important epigenetic 23 
mark to profile in the context of neurodegenerative diseases. Furthermore, levels of 5hmC 24 
potentially mask the true abundance of 5mC at specific loci in the genome, confounding 25 
existing EWAS analyses of AD.  26 
 27 
 5 
 
Recent studies have demonstrated that oxidative BS (OxBS) treatment enables the 1 
detection of 5hmC as thymine, and therefore by running matched BS- and OxBS-treated 2 
samples in parallel we can generate a quantitative measurement for total DNA modifications 3 
(BS data), DNA methylation (OxBS data) and, by proxy, DNA hydroxymethylation (BS data – 4 
OxBS data) [11]. We have previously utilized this method in conjunction with 450K arrays to 5 
profile 5mC and 5hmC levels in parallel in post-mortem brain tissue from non-demented 6 
individuals to demonstrate region specific differences in DNA modifications [11]. Here we 7 
perform the first cross-tissue EWAS of DNA methylation and DNA hydroxymethylation 8 
independently in multiple tissues from 96 donors, representing the spectrum of AD pathology 9 
defined by Braak staging, a standardized measure of NFT burden determined at autopsy 10 
[12], ranging from no AD pathology (Braak 0) to late stage AD (Braak VI). From each donor, 11 
we analyzed the entorhinal Cortex (EC), a region of the brain affected early in the disease 12 
[2] and the  cerebellum (CER), which is relatively spared from pathology. 13 
 14 
RESULTS AND DISCUSSION 15 
 16 
AD entorhinal cortex is characterized by global hypermethylation and 17 
hypohydroxymethylation 18 
The majority of studies investigating DNA hydroxymethylation in AD have used immuno-19 
histochemical based methods to quantify global levels [13-17]. One study reported a global 20 
decrease in 5hmC in the EC and CER in AD, but no change in 5mC [18]. However, other 21 
studies have reported global reductions in both modifications in the hippocampus [13] and 22 
another study highlighted increased levels of 5mC and 5hmC in the middle frontal gyrus and 23 
middle temporal gyrus [16]. Although the 450K array primarily interrogates CG rich regions, 24 
which are, in general, unmethylated, we were interested to see if there were any global 25 
changes across these regions. To investigate these global levels of DNA modifications in our 26 
data we averaged levels across all probes that passed quality control (QC) (n = 367,480), 27 
 6 
 
identifying a global decrease in 5hmC (P = 0.040) and increase in 5mC (P = 0.039), with 1 
overall no net change in total modifications (P = 0.838) in the EC with respect to Braak 2 
stage. Conversely, no significant Braak stage associated alterations were seen for global 3 
levels of 5hmC (P = 0.659), 5mC (P = 0.916) or total modifications (P = 0.366) in the CER (P 4 
> 0.05).  5 
 6 
Highly reproducible alterations in cytosine modifications are detectable in AD cortex 7 
Initially, we focused on identifying differences in total DNA modification levels (BS data: 8 
Supplementary Table 1) in the EC that were associated with Braak stage, whilst controlling 9 
for age and sex above our nominated significance threshold (P < 5 x 10-5). To assess the 10 
reproducibility of our results, we first compared the effect size of these Braak stage-11 
associated differentially modified positions (DMoPs) from the BS data (Supplementary 12 
Table 1), with BS data previously generated on an independent set of samples from the EC 13 
in AD (validation cohort 1) [7]. There was a significant excess of consistent direction of effect 14 
between the two studies (Figure 1A: sign test P =0.043), with the effect sizes highly 15 
correlated between studies (r = 0.71, P = 4.85 x 10-6). Similarly, there was also a significant 16 
excess of consistent direction of effect between the two studies when examining the effect 17 
size of previously published Braak-associated DMoPs (P < 5 x 10-5) in the EC [7] with the 18 
effect size of the same probes in the current study (Figure 1B: sign test P = 9.77 x 10-04), 19 
with the effect sizes highly correlated between studies (r = 0.78, P = 3.50 x 10-4). This 20 
suggests that although different BS conversion methods and donors were used, there are 21 
consistent and reproducible changes in total DNA modifications in the EC of donors with AD.  22 
 23 
In contrast, when we compared the effect size of the Braak-associated DMoPs in the CER 24 
(P < 5 x 10-5) in the current study (Supplementary Table 2) to BS data previously published 25 
in the CER in AD [7] we found no consistent direction of effect (Supplementary Figure 1A: 26 
sign test P = 0.267). Similarly, the effect sizes of the previously published CER DMoPs (P < 27 
 7 
 
5 x 10-5) [7] showed no consistent direction of effect with the same probes in the current 1 
study (Supplementary Figure 1B: sign test P = 0.188). This suggests that regions of the 2 
brain that are relatively protected from neurodegeneration, such as the CER, do not display 3 
consistent disease-associated epigenetic changes in total DNA modifications in either a 4 
global or loci-specific manner.  5 
  6 
Locus specific changes in DNA methylation and hydroxymethylation occur in AD 7 
We were interested to identify specific loci that showed Braak-associated differential DNA 8 
methylation and hydroxymethylation in the EC (Supplementary Tables 3-4; Figure 2A). We 9 
identified three Braak-associated differentially methylated positions (DMPs) that reached 10 
experiment-wide significance (P < 2.2 x 10-7), with a further 72 loci reaching our nominal 11 
significance threshold of P < 5 x 10-5. Although no Braak-associated differentially 12 
hydroxymethylated positions (DHPs) reached experiment wide significance, we did identify 13 
57 loci that reached our nominal significance threshold. Of the three experiment-wide 14 
significant DMPs, the first and third most significant were found on chromosome 3 and 15 
resided in CGGBP1 and GNL3 respectively, whilst the second most significant DMP was 16 
located in WNT5B on chromosome 12. CCGBP1 is known to influence the expression of the 17 
FMR1 gene, which is associated with the fragile X mental retardation syndrome [19], 18 
whereas GNL3 is hypothesized to interact with p53, a tumor suppressor protein [20]. 19 
WNT5B is part of the wnt gene family and disruption of the wnt signaling pathway has been 20 
previously implicated in neurodegeneration [21, 22]. In the CER we only identified seven 21 
Braak-associated DMPs (Supplementary Table 5) and 12 DHPs (Supplementary Table 6) 22 
that reached our nominal significance threshold (P < 5 x 10-5). 23 
 24 
Neuropathology-associated DMPs and DHPs in the EC feature in key biological 25 
pathways 26 
 8 
 
We performed a pathway analysis of the genes annotated to DMPs and DHPs in the EC that 1 
reached our nominal significance threshold (P < 5 x 10-5) (Supplementary Table 7 and 2 
Supplementary Table 8, respectively). Relevant pathways of interest included axon midline 3 
choice point recognition” and “axon choice point recognition”, both of which were enriched 4 
for DMPs and DHPs (GO:0016199: 5mC P = 2.30 x 10-4, 5hmC P = 1.30 x 10-4; 5 
GO:0016198: 5mC P = 4.20 x 10-4, 5hmC P = 2.55 x 10-4 ), “regulation of synapse 6 
organization” (GO:0050807: 5hmC P = 9.11 x 10-4), “synapse organization” (GO:0050808: 7 
5hmC P = 0.001) and “synapse assembly” (GO:0007416: 5hmC P = 0.002), which were all 8 
enriched for DHPs. This suggests that synaptic activity is a major pathway that displays 9 
altered levels of 5hmC in AD. Interestingly, previous work by Khare et al. has shown that 5-10 
hmC is enriched in genes with synapse-related functions in both human and mouse brain 11 
[23].  12 
 13 
Neuropathology-associated changes in 5mC and 5hmC are seen across gene features 14 
Next, we compared the genic location of the most significant hyper- or hypo- 15 
(hydroxy)methylated neuropathology-associated loci in the EC (P < 5 x 10-5), to all 16 
neuropathology-associated DMPs or DHPs (P < 0.05), with relation to gene features that 17 
have been described by Slieker et al [24] (Supplementary Figures 2-3; Supplementary 18 
Tables 9-10). We demonstrated an enrichment for the most significant DMPs and DHPs 19 
across all gene features, most strikingly Braak-associated hypomethylation and 20 
hyperhydroxymethylation appears to be enriched in the CGIs of proximal promotors (P < 1 x 21 
10-330). This shows that there could be a change from DNA methylation to DNA 22 
hydroxymethylation in these regions in AD, despite a global decrease (across regions 23 
covered by the array) in 5hmC with disease.  24 
 25 
A number of loci show display significant negative correlations in neuropathology-26 
associated DNA methylation and hydroxymethylation changes 27 
 9 
 
Next, we sought to explore whether there was any overlap in disease-associated DMoPs, 1 
DMPs and DHPs. We compiled a list of loci that showed a disease-associated alteration in 2 
more than one analysis (P < 5 x 10-5) (Figure 2B; Table 1). We identified 14 CpG sites 3 
(annotated to 14 genes) that showed significant changes across more than one analysis 4 
(total modifications, 5mC alone and 5hmC alone) (Supplementary Figure 4). Of the 14 5 
CpGs nominated, 13 showed no nominally significant (P > 0.05) difference in total DNA 6 
modifications. This is consistent with findings from previous EWAS using BS DNA, which 7 
had also not shown these loci to be associated with AD-neuropathology. Although we 8 
observed no difference in total DNA modifications in disease for these 13 loci, we did 9 
observe neuropathology-associated differences in both 5mC and 5hmC, with in each 10 
instance the levels of both modifications being highly negatively correlated with each other 11 
(Supplementary Figure 5) and a significant interaction between the two modifications. Of 12 
particular interest are differences at a site annotated to the APP gene (cg12144476), given 13 
that mutations in this gene are associated with early-onset, familial AD. In the current study 14 
we saw a decrease in 5mC in APP with Braak stage (Supplementary Figure 4N; Effect size 15 
(difference (∆) Braak 0 to Braak VI) = -1.39, P = 4.85 x 10-06), with a concurrent parallel 16 
increase in 5hmC (Supplementary Figure 4N; ∆ = 1.44, P = 1.61 x 10-05) demonstrating a 17 
significant interaction between the two modifications (Supplementary Figure 5M; P = 1.77 x 18 
10-10) and no net change in total DNA modifications. 19 
 20 
ANK1 shows differential DNA methylation in the AD EC 21 
Next, we performed an analysis to identify spatially correlated regions consisting of >2 22 
neighboring DMPs (differentially methylated regions - DMRs) or DHPs (differentially 23 
hydroxymethylated regions – DHRs) within a 500bp sliding window (comb-p [25]). We did 24 
not identify any DHRs; however, given that DNA hydroxymethylation is known to be enriched 25 
in areas of low CG density [11], this is perhaps not surprising. We identified four DMRs that 26 
reached a Sidak-corrected P value < 0.05 (Table 2). This included an eight probe DMR 27 
 10 
 
within the WNT5A gene (Sidak-corrected P = 3.17 x 10-4), a three probe DMR within the 1 
TRAF3 gene (Sidak-corrected P = 0.022), a two probe DMR within the ANK1 gene (Sidak-2 
corrected P = 0.025) and a six probe DMR within the ARID5B gene (Sidak-corrected P = 3 
0.029). The two DMPs we identified in ANK1 in our regional analysis have previously been 4 
nominated as DMoPs in AD EC in two independent EWAS using BS-treated DNA [6, 7]. In 5 
the current study, we again identified a significant increase in total DNA modifications in AD 6 
at both these two sites in the EC (Figure 2C: cg11823178: ∆ = 6.69, P = 4.68 x 10-4 and 7 
Figure 2D: cg05066959: ∆ = 10.98, P = 8.37 x 10-6). However, this is the first study to 8 
demonstrate that these are specifically attributable to increased 5mC (cg11823178: ∆ = 9 
9.31, P = 2.61 x 10-5; cg05066959: ∆ = 13.71, P = 8.03 x 10-5), with a small, but non-10 
significant decrease in 5hmC at both sites (cg11823178: ∆ = -3.20, P = 0.068; cg05066959: 11 
∆ = -2.72, P = 0.349). This suggests that previous studies of DNA methylation in ANK1 have 12 
underestimated increments in 5mC in disease due to confounding by 5hmC.  13 
 14 
Oxidative-bisulfite pyrosequencing validation of ANK1 15 
To further confirm that ANK1 epigenetic changes associated with neuropathology involve 16 
DNA hypermethylation, and not hyperhydroxymethylation, we used OxBS pyrosequencing to 17 
quantify DNA modifications across an extended region spanning eight CpG sites, including 18 
cg11823178 and cg05066959. DNA used for this study was from an independent collection 19 
of EC tissue (n = 96) obtained from the Thomas Willis Oxford Brain Collection (validation 20 
cohort 2) (Supplementary Table 11) [26]. In this cohort we did not have access to Braak 21 
stage III or IV samples, and as such analyzed data using a case (Braak V-VI) /control (Braak 22 
)-II) analysis model. Of the eight CpG sites assessed, seven where characterized by 23 
significant (P < 0.05) AD-associated hypermethylation (Figure 3A). Interestingly, significant 24 
AD-associated hypohydroxymethylation was also seen at four of the eight CpG sites (Figure 25 
3B), with total DNA modifications showing a remarkably similar profile to previously 26 
published studies [7] (Figure 3C). When we averaged total DNA modifications, 5mC and 27 
 11 
 
5hmC levels across the eight CpG sites in the 120bp region, we saw a significant increase in 1 
total modifications (∆ = 0.79, P = 1.12 x 10-4) and 5mC (∆ = 0.87, P = 1.23 x 10-05) and a 2 
trend towards a decrease in 5hmC, (∆ = -0.40, P = 0.058) in individuals with AD, compared 3 
to controls (Figure 3D). This data suggests that previous studies of ANK1 DNA methylation 4 
in AD have underestimated the disease-associated changes in 5mC. 5 
 6 
Several recent studies have reported the links between epigenetic alterations at the ANK1 7 
locus and the development of AD [6, 7, 27]. The ANK1 protein is a plasma-bound membrane 8 
protein that contains an ankyrin repeat domain, which modulates interactions between 9 
cytoskeletal and membrane proteins [28]. One of the main functions of ANK1 is 10 
compartmentalization and maintenance of the plasma membrane and it is possible that the 11 
altered expression of this gene could lead to cell membrane dysfunction in AD [7]. It has 12 
been shown that microglia, the brain’s resident macrophages, have >4-fold increase in 13 
ANK1 expression in AD compared to control brain samples [27], suggesting it is possible 14 
that ANK1 DNA methylation levels will have a downstream effect on immune and 15 
inflammatory regulation in the brain.  16 
 17 
CONCLUSIONS 18 
 19 
Our study represents, to our knowledge, the first large scale cross-tissue study of 5mC and 20 
5hmC, at base-pair level resolution in AD, using matched DNA from both affected and 21 
unaffected brain regions, utilizing independent study cohorts and two independent 22 
technologies (OxBS-Illumina 450K array and OxBS-pyrosequencing). Two previous studies 23 
of DNA hydroxymethylation in AD have been recently published. The first used a selective 24 
chemical labelling technique to enrich for 5hmC, and then sequenced the captured libraries 25 
from a small cohort of 30 individuals with either AD, mild cognitive impairment (MCI) or no 26 
dementia [29]. The study highlighted a number of AD-associated DHPs and demonstrated 27 
that gene body DNA hydroxymethylation was positively correlated with cis-acting gene 28 
 12 
 
expression. One limitation of that study was that the analysis was unable to discriminate 1 
between 5hmC and 5mC because of the low sequencing resolution. The second study, by 2 
Ellison and colleagues, utilized  reduced representation hydroxymethylation profiling (RRHP) 3 
to analyse 5hmC levels in AD hippocampus [30]. Although this study assessed DNA 4 
hydroxymethylation at >2million sites, the study was limited to just three AD cases and two 5 
age-matched control subjects.  In our study the overlap between DMoPs identified across 6 
our sample cohorts and those identified by Lunnon et al. [7], despite the use of independent 7 
study cohorts, suggests that our study was adequately powered to detect robust AD-8 
associated differences that can be replicated in other studies. Our analyses from multiple 9 
independent cohorts provide further evidence for a role for DNA hypermethylation, coupled 10 
with hypohydroxymethylation, across a region in ANK1 in AD-associated neuropathology. It 11 
indicates that previous estimates of hypermethylation in ANK1 were underestimates as it is 12 
potentially confounded by this hypohydroxymethyation. Our study also nominates 13 novel 13 
loci that show no change in overall DNA modifications, but display significant (opposing) 14 
differences in 5mC and 5hmC in AD. As these genes were not identified in standard BS-15 
treated DNA, these findings highlight the utility of our method for identifying novel 16 
epigenetically dysregulated genes in AD. Although some of the AD-associated loci identified 17 
in our study do not have a mean 5hmC level across all samples >0, this likely reflects 18 
experimental noise resulting from the calculation of 5hmC from two separate arrays. 19 
However, given that the loci we identified resided within genes previously implicated in AD, 20 
such as APP, it is likely that our data is highlighting novel epigenetically altered loci in 21 
disease. To conclude, these novel genes warrant further research in AD.  22 
 23 
 24 
METHODS 25 
 26 
Subjects and samples 27 
 13 
 
For BS and OxBS Illumina 450K profiling (discovery cohort) we used matched brain samples 1 
collected from the EC and CER from 96 individuals archived in the MRC London 2 
Neurodegenerative Disease Brain Bank (http://www.kcl.ac.uk/iop/depts/cn/research/MRC-3 
London-Neurodegenerative-Diseases-Brain-Bank/MRC-London-Neurodegenerative-4 
Diseases-Brain-Bank.aspx). These samples were not utilized in previously published AD 5 
EWAS publications [7, 31, 32]. Our first validation cohort consisted of previously published 6 
[7] BS EWAS data generated in matched EC (n = 104) and CER (n = 108) brain tissue. Our 7 
second validation cohort (for pyrosequencing) consisted of matched EC and CER samples 8 
from 96 individuals archived in the Thomas Willis Oxford Brain Collection 9 
(http://www.medsci.ox.ac.uk/optima/information-for-patients-and-the-public/the-thomas-10 
willis-oxford-brain-collection) [26]. For all cohorts, individuals had varying degrees of AD 11 
pathology (Braak Stage 0-VI) and all AD patients were over the age of 65 at clinical 12 
diagnosis. All samples were dissected by trained specialists, snap-frozen and stored at -13 
80°C. Further information about all samples is provided in Supplementary Table 11. For the 14 
discovery cohort and validation cohort 2, genomic DNA was isolated from ~100mg of each 15 
dissected brain region using a standard phenol-chloroform extraction method, and tested for 16 
degradation and purity prior to analysis.  17 
 18 
Methylomic and hydroxymethylomic profiling 19 
1μg DNA from each sample (discovery cohort and validation cohort 2) was treated with 20 
sodium BS and OxBS in parallel using the true-methyl CEGX 96 kit (CEGX, Cambridge, UK) 21 
according to the manufacturer’s standard protocol. Briefly, DNA samples were split, with half 22 
being oxidized (OxBS) and the remainder (BS) going through a mock oxidization step, 23 
before all being BS treated. All samples were then processed using the Illumina Infinium 24 
HumanMethylation450K BeadChip (450K array) (Illumina Inc, CA, USA) according to the 25 
manufacturer’s instructions, with minor amendments and quantified using an Illumina HiScan 26 
System (Illumina, CA, USA). Corresponding OxBS and BS treated DNA for the same sample 27 
were run together on the same BeadChip. Samples were assigned a unique code for the 28 
 14 
 
purpose of the experiment and grouped by tissue. Samples were randomized in their OxBS 1 
and BS pairs with respect to sex and disease status to avoid batch effects, and processed in 2 
batches of 12 BeadChips. Illumina Genome Studio software was used to extract the raw 3 
signal intensities of each probe (without background correction or normalization). 4 
 5 
Data Analysis  6 
All computations and statistical analyses were performed using R 3.3.2 [33] and 7 
Bioconductor 3.5 [34]. Signal intensities were imported into R using the methylumi package 8 
[35] as a methylumi object. Initial QC checks were performed using functions in the 9 
methylumi package to assess concordance between reported and genotyped gender. Non-10 
CpG SNP probes on the array were also used to confirm that both brain regions were 11 
sourced from the same individual where expected. Probes with common (minor allele 12 
frequency (MAF) > 5%) SNPs in the CG or single base extension position or probes that are 13 
nonspecific or mismapped were flagged and discarded from our results [36]. Data was pre-14 
processed in the R package wateRmelon using the dasen function as previously described 15 
[37]. The pfilter function was used to remove samples where 5% of sites with a detection P > 16 
0.05. Specific sites were also removed if the beadcount was less than three in 5% of 17 
samples or if 1% of the samples had a detection P > 0.05 at that position. After these QC 18 
steps 367,480 probes were taken forward for analysis. Array data for each tissue was 19 
normalized separately and the analysis was performed separately by tissue.  To calculate 20 
5hmC levels in a sample, the OxBS signal was subtracted from the BS signal. As we have 21 
previously reported a small proportion of probes in each sample were characterized by a 22 
negative BS-oxBS value, likely resulting from technical variance inherent in the Illumina 23 
array protocol [11]. Therefore probes with a mean negative 5hmC value across all samples 24 
were included in our analysis, however we annotated tables to denote that the mean 5hmC 25 
level was >0 (5hmC Positive probe column).  The effects of age and sex were regressed out 26 
before subsequent analysis. For the identification of DMoPs, DMPs and DHPs specifically 27 
 15 
 
altered with respect to neuropathological measures of AD, we performed a quantitative 1 
analysis where samples were analyzed with respect to Braak stage using a linear regression 2 
model. To ensure that the top DMoPs, DMPs and DHPs were not a result of cell proportion 3 
differences, the CETS package in R [38] was used to determine neuron/glia proportions and 4 
tables annotated with an additional column including this value as an additional co-variate (P 5 
CETS corrected). Data was analyzed separately for each brain region using linear 6 
regression and probes were ranked by P value, and Q-Q plots assessed to check for P 7 
value inflation (see Supplementary Figure 6).  8 
 9 
Identifying enrichment in specific gene features 10 
To investigate whether our top neuropathology-associated DMPs were enriched at specific 11 
gene features, we used a Fisher’s exact test to test for an enrichment of either significant 12 
hypermethylated or hypomethylated loci (P < 5 x 10-5) compared to all neuropathology-13 
associated DMPs (P <0.05) at each gene feature as described by Slieker et al [24]. Similarly 14 
to investigate whether our top neuropathology-associated DHPs were enriched at specific 15 
gene features, we again used a Fisher’s exact test to test for an enrichment of either 16 
significant hyperhydroxymethylated or hypohydroxymethylated loci (P < 5 x 10-5) compared 17 
to all neuropathology-associated DHPs (P <0.05) at each Slieker gene feature. 18 
 19 
 20 
Differentially methylated regions  21 
To identify DMRs and DHRs we identified spatially correlated p-values within our data using 22 
the Python module comb-p [25] to group spatially correlated CpGs within a 500bp sliding 23 
window with a significance threshold of P = 0.01.  24 
 25 
Pathway analysis 26 
 16 
 
Pathway analysis of the genes reaching our significance threshold (P < 5 x 10-5) was 1 
performed using the missmethyl 1.10.0 [39] package from Bioconductor. Pathways were 2 
included if they met the following criteria: (1) the number of genes in the gene list was 3 
greater than one and less than 2000, (2) more than one gene from our analysis was present 4 
in the pathway and (3) the P value for the association was smaller than 0.05.  5 
 6 
Targeted Replication using Bisulfite Pyrosequencing  7 
Bisulfite pyrosequencing was used to quantify DNA methylation across eight individual 8 
ANK1 CpG sites, including cg05066959 and cg11823178, spanning from 41519302 to 9 
41519420 within chromosome 8 (hg19). A single amplicon (246bp) was amplified using 10 
primers designed using the PyroMark Assay Design software 2.0 (Qiagen, UK) as previously 11 
described [7], and sequenced using two sequencing primers to maximize coverage across 12 
eight CpG sites within a 120bp region. DNA methylation was quantified in validation cohort 2 13 
using the Pyromark Q24 system (Qiagen, UK) following the manufacturer's standard 14 
instructions and the Pyro Q24 CpG 2.0.6 software. Data was adjusted for the effects of age 15 
and sex. For this sample cohort we had no samples with middle stage AD (Braak III-IV). In 16 
this instance rather than performing a linear regression analysis across Braak stages we 17 
instead compared control samples (Braak scores 0-II: n = 48) to AD samples (Braak scores 18 
V-VI: n = 48) for total DNA modifications, 5mC and 5hmC at eight individual CpG sites, and 19 
across the 120bp amplicon.  20 
 21 
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FIGURE LEGENDS 
Figure 1: Braak-associated EC DMoPs identified in this study are consistent 
with those identified in previous analyses of AD brain. (A) There was a 
consistent direction of effect for Braak-associated DMoPs (P < 5 x 10-5) identified in 
the EC in the discovery cohort when compared with the same probes in a previously 
published dataset of Braak-associated DMoPs in the EC (validation cohort 1) (sign 
test P =0.043), with the effect sizes highly correlated between studies (r = 0.71, P = 
4.85 x 10-6). (B) Similarly, there was a consistent direction of effect for previously 
published Braak-associated DMoPs in the EC (P < 5 x 10-5) (validation cohort 1) 
when compared with the same probes in the current study (sign test P = 9.77 x 10-04), 
with the effect sizes highly correlated between studies (r = 0.78, P = 3.50 x 10-4). 
 
 
 
Figure 2: Alterations in total DNA modifications, DNA methylation and DNA 
hydroxymethylation are associated with AD neuropathology in the EC. (A) A 
Manhattan plot of association between DNA methylation (purple, above X axis) and 
DNA hydroxymethylation (yellow, below X axis) with Braak stage in the EC highlights 
associations at loci across the genome. We identified three DMPs reaching 
experiment wide significance (red line; P < 2.2 x 10-7), and a further 72 DMPs 
reaching our nominal significance threshold (green line; P < 5 x 10-5). Although no 
DHPs reached experiment wide significance, we identifed 57 DHPs at our nominal 
significance threshold. (B) A circos-plot highlighting Braak-associated DMoPs (grey– 
inner circle), DMPs (purple– middle circle) and DHPs (yellow – outer circle). Loci that 
showed a disease-associated epigenetic alteration in more than one analysis (P < 5 
x 10-5) are inscribed around the outside. (C-D) Scatter plot of beta values, corrected 
for age and gender, against Braak stage for probes identified in ANK1. Purple circles 
represent 5mC levels (OxBS), yellow circles represent 5hmC levels (BS-OxBS). 
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Regression lines are shown for 5mC (purple line), 5hmC (yellow line) and total DNA 
modifications (grey line). Solid regression lines indicate P <0.05, whilst dashed lines 
indicate P > 0.05. Shown are (C) cg11823178 (5mC: r = 0.440, P = 2.61 x 10-5; 
5hmC: r = -0.199, P = 0.068; total modifications: r = 0.356, P = 4.68 x 10-4) and (D) 
cg05066959 (5mC: r = 0.415, P = 8.03 x 10-5; 5hmC: r = -0.103, P = 0.349; total 
modifications: r = 0.440, P = 8.37 x 10-6).  
 
 
Figure 3: Sites in ANK1 are characterized by significant DNA hypermethylation 
and hypohydroxymethylation in AD across an extended region. Using BS and 
OxBS pyrosequencing we determined (A) 5mC (B) 5hmC and (C) total DNA 
modification levels in the entoECrhinal cortex in AD samples (Braak V-VI) compared 
to control samples (Braak 0-II) in validation cohort 2. We assayed a 120bp region 
containing cg05066959 (chr8:41519308) and cg1182378 (chr8:41519399). We 
demonstrated significant (P < 0.05) neuropathology-associated hypermethylation at 
seven of the eight CpG sites, hypohydroxymethylation at four of the eight CpG sites, 
and increased total DNA modifications at four of the eight sites. (D) Global analysis of 
all sites within the 120bp amplicon region highlighted a significant increase in total 
modifications  (P = 1.12 x 10-4) and 5mC (P = 1.23 x 10-05) and a trend towards a 
decrease in 5hmC (P = 0.058) in individuals with AD, compared to controls. Data is 
represented as mean (±SEM) Key: *P < 0.05, **P < 0.01, ***P < 0.005.  
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Supplementary Figure 1: Braak-associated DMoPs in the CER are not consistent between 
studies (A) There was no consistent direction of effect when comparing Braak-associated DMoPs 
(P < 5 x 10-5) in the CER in the discovery cohort with the effect size of the same probes in a 
previously published dataset of Braak-associated DMoPs in the CER [7] (validation cohort 1) (sign 
test P =0.267). (B) There was also no consistent direction of effect for previously published Braak-
associated DMoPs in the CER [7] (P < 5 x 10-5) (validation cohort 1) when compared with the effect 
size of the same probes in the current study (sign test P = 0.188). 
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Supplementary Figure 2: The most significant neuropathology-associated DMPs are 
enriched at specific genomic features in the EC. Taking the genomic location of neuropathology-
associated DMPs above our significance threshold (P < 5 x 10-5), we used a Fisher's exact test to 
examine whether these hypermethylated or hypomethylated loci are enriched within specific 
genomic features when compared to all Braak-associated DMPs (P < 0.05) with results of the 
enrichments tests shown in Supplementary Table 9. Abbreviations: CpG island (CGI), outside CpG 
island (nonCGI or NC), CpG island shelf (SHE), CpG island shore (SHO), distal promoter (DP), 
downstream (DS), gene body (GB), intergenic (IG), proximal promoter (PP), unannotated (UA).  
Supplementary Figure 3: The most significant neuropathology-associated DHPs are enriched 
at specific genomic features in the EC. Taking the genomic location of neuropathology-
associated DHPs above our significance threshold (P < 5 x 10-5), we used a Fisher's exact test to 
examine whether these hyperhydroxymethylated or hypohydroxymethylated loci are enriched within 
specific genomic features when compared to all Braak-associated DHPs (P <0.05) , with results of 
the enrichments tests shown in Supplementary Table 10. Abbreviations: CpG island (CGI), outside 
CpG island (nonCGI or NC), CpG island shelf (SHE), CpG island shore (SHO), distal promoter (DP), 
downstream (DS), gene body (GB), intergenic (IG), proximal promoter (PP), unannotated (UA).  
Supplementary Figure 4: Scatter plot of beta values against Braak stage  for the 14 probes 
that feature in Table 1. Shown are beta values, corrected for age and gender, for (A) cg20066612 
(KCNJ9), (B) cg15624314 (H3F3A), (C) cg08240832 (OPN3),  (D) cg13876163 (TMEM53), (E) 
cg18070033 (NHEJ1), (F) cg17026303 (ACVR2B), (G) cg16933762 (ROBO2), (H) cg15147060 
(CGGBP1), (I) cg05052335 (RAPGEF6), (J) cg03503087 (GFRA1),  (K) cg11530914 (FHOD1), (L) 
cg05341384 (FOXF1), (M) cg07919466 (KCNC3) and (N) cg12144476 (APP). Shown are beta 
values corrected for age and gender (Y axis), against Braak stage (X axis). Purple circles represents 
5mC levels (OxBS), yellow circles represents 5hmC levels (BS-OxBS). Regression lines are shown 
for 5mC (purple line), 5hmC (yellow line) and total DNA modifications (grey line). Solid regression 
lines indicate P < 0.05, whilst dashed lines indicate P > 0.05 .  
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Supplementary Figure 4 (cont.) 
Supplementary Figure 5: Correlation plots of 5mC levels and 5hmC levels for probes that 
feature in Table 1 with no net change in total DNA modifications. Shown are beta levels, 
corrected for age and gender for (A) cg15624314 (H3F3A), (B) cg08240832 (OPN3),  (C) 
cg13876163 (TMEM53), (D) cg18070033 (NHEJ1), (E) cg17026303 (ACVR2B), (F) cg16933762 
(ROBO2), (G) cg15147060 (CGGBP1), (H) cg05052335 (RAPGEF6), (I) cg03503087 (GFRA1), (J) 
cg11530914 (FHOD1), (K) cg05341384 (FOXF1), (L) cg07919466 (KCNC3) and (M) cg12144476 
(APP). Plotted is the % 5hmC (Y axis) against % 5mC after correcting for age and gender for all 
samples. 
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Supplementary Figure 5 (cont.) 
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Supplementary Figure 6: Quantile-quantile (Q-Q) plots of expected versus observed P value 
to check for inflation in linear regression analyses. The Q-Q plots for (A) total DNA 
modifications (BS data), (B) DNA methylation (OxBS data) and (C) DNA hydroxmethylation (BS – 
OxBS data) in the EC shows no P value inflation in our analyses. 
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ABSTRACT 1 
 2 
Recent epigenome-wide association studies in Alzheimer’s disease have highlighted 3 
consistent robust neuropathology-associated DNA hypermethylation of the Ankyrin 1 4 
(ANK1) gene in the cortex. The extent to which altered ANK1 DNA methylation is 5 
also associated with other neurodegenerative diseases is not currently known. In the 6 
current study, we used bisulfite pyrosequencing to quantify DNA methylation across 7 
eight CpG sites within a 118bp region of the ANK1 gene across multiple brain 8 
regions in Alzheimer’s disease, Vascular dementia, Dementia with Lewy bodies, 9 
Huntington’s disease and Parkinson’s disease. We demonstrate disease-associated 10 
ANK1 hypermethylation in the entorhinal cortex in Alzheimer’s disease, Huntington’s 11 
disease and Parkinson’s disease, whilst in donors with Vascular dementia and 12 
Dementia with Lewy bodies we observed elevated ANK1 DNA methylation only in 13 
individuals with co-existing Alzheimer’s disease pathology. We did not observe any 14 
disease-associated differential ANK1 DNA methylation in the striatum in Huntington’s 15 
disease, or the substantia nigra in Parkinson’s disease. Our data suggests that ANK1 16 
is characterized by region and disease-specific differential DNA methylation in 17 
multiple neurodegenerative diseases. 18 
 19 
 20 
Keywords:  21 
Alzheimer’s disease (AD); Ankyrin 1 (ANK1); Brain; Dementia with Lewy Bodies 22 
(DLB); DNA methylation (5-methylcytosine – 5mC); Epigenetics; Huntington’s 23 
disease (HD); Parkinson’s disease (PD); Vascular dementia (VaD) 24 
 25 
 26 
 27 
 28 
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1. INTRODUCTION 1 
 2 
Dementia encompasses a group of chronic neurodegenerative diseases that affected 3 
an estimated 46.8 million people worldwide in 2015 (Wimo, et al., 2017), of which 4 
Alzheimer’s disease (AD) accounts for ~60% of cases. The etiology of AD has been 5 
hypothesized to involve epigenetic mechanisms (Lunnon and Mill, 2013). In 2014 two 6 
epigenome-wide association studies (EWAS) of AD identified significant 7 
hypermethylation of CpG sites in the Ankyrin 1 (ANK1) gene associated with 8 
neuropathology in AD cortex (De Jager, et al., 2014,Lunnon, et al., 2014), which has 9 
been replicated in multiple independent study cohorts (Smith, 2017). Subsequently, a 10 
genome wide association study (GWAS) of a Han Chinese population identified a 11 
single-nucleotide polymorphism (SNP) in ANK1 associated with an increased 12 
susceptibility for developing AD (Chi, et al., 2015). ANK1 links integral membrane 13 
proteins to the underlying spectrin-actin cytoskeleton and plays a key role in cell 14 
motility, activation, proliferation, contact, and maintenance of specialized membrane 15 
domains (Yang, et al., 2011). There is now increasing interest in understanding the 16 
role of epigenetic changes in ANK1 in the development and progression of AD. One 17 
important question to be addressed is whether ANK1 hypermethylation is specific to 18 
AD, or observed in other neurodegenerative disorders. Although AD accounts for 19 
~60% of dementia cases, many other dementias share common symptoms and/or 20 
pathological hallmarks with AD.   21 
 22 
This study aimed to quantify DNA methylation levels across a 118bp region of ANK1, 23 
previously associated with AD, in a number of different neurodegenerative diseases. 24 
Using bisulfite pyrosequencing we assessed ANK1 DNA methylation in brain 25 
samples from donors with AD, Dementia with Lewy bodies (DLB), Vascular dementia 26 
(VaD), Huntington’s disease (HD), Parkinson’s disease (PD) and non-demented 27 
4 
 
elderly controls, across a number of different brain regions that are characterized by 1 
disease-specific pathology.  2 
 3 
 4 
2. MATERIALS AND METHODS 5 
 6 
2.1. Subjects and Samples  7 
Post-mortem brain tissue was obtained from six different UK brain banks (the South 8 
West Dementia Brain Bank (SWDBB), the London Neurodegenerative Disease Brain 9 
Bank (LNDBB) the Manchester Brain Bank, the Oxford Brain Bank, the Cambridge 10 
Brain Bank and the Newcastle Brain Bank). In total, tissue was obtained from 60 AD 11 
(Braak V-VI), 119 DLB, 27 VaD, 22 HD, 36 PD and 105 elderly non-demented control 12 
subjects (Braak 0-II). A subset of DLB (N = 39) and VaD (N = 5) cases also had co-13 
existing AD pathology. For each disease we analyzed the entorhinal cortex (EC), 14 
superior temporal gyrus (STG) and cerebellum (CER). For HD cases we also 15 
analyzed the striatum (STR) as this is primarily affected in disease (Reiner, et al., 16 
2011), whilst for PD cases we analyzed the STR and substantia nigra (SN) as these 17 
are regions of pathology in this disease (Fearnley and Lees, 1991). For control 18 
samples we analyzed all five brain regions. For a small number of donors tissue was 19 
not available from all brain regions. Genomic DNA was isolated from ~100mg of each 20 
dissected brain region using a standard phenol-chloroform extraction method, and 21 
tested for degradation and purity prior to analysis as previously described (Smith, et 22 
al., 2016). Demographic information for samples can be found in Supplementary 23 
Table 1. 24 
 25 
2.2. ANK1 bisulfite pyrosequencing  26 
Bisulfite pyrosequencing was used to quantify DNA methylation across eight 27 
individual CpG sites in the ANK1 gene, spanning from 41519302 to 41519420 within 28 
5 
 
chromosome 8 (hg19). Bisulfite conversion was performed using the Bisulfite-Gold kit 1 
(Zymo research, USA). A single amplicon (246bp) was generated using primers 2 
designed using the PyroMark Assay Design software 2.0 (Qiagen, UK) as previously 3 
described (Lunnon, et al., 2014). Pyrosequencing was performed using two 4 
sequencing primers to maximize coverage across eight CpG sites. DNA methylation 5 
was quantified using the Pyromark Q24 system (Qiagen, UK) following the 6 
manufacturer's standard instructions and the Pyro Q24 CpG 2.0.6 software.  7 
 8 
2.3. Data Analysis  9 
All computations and statistical analyses were performed using R 3.3.2 (R 10 
Development Core Team, 2012). A linear regression analysis was performed, 11 
controlling for the effects of age, gender and batch effects, comparing control 12 
samples with samples affected by each neurodegenerative disease. For the VaD and 13 
DLB samples we also performed a second analysis to investigate whether co-existing 14 
AD pathology influenced the results by comparing individuals with and without co-15 
existing AD pathology to control samples, again accounting for the effects of age, 16 
gender and batch. Our analyses examined DNA methylation differences at (a) 17 
individual CpG sites and (b) averaged across the amplicon. We used a paired two-18 
tailed t-test to compare adjusted DNA methylation differences in disease across brain 19 
regions. 20 
 21 
 22 
3. RESULTS 23 
 24 
3.1. AD-associated ANK1 DNA hypermethylation is seen across all tissues 25 
analyzed 26 
First, we sought to replicate previous findings of ANK1 DNA hypermethylation in AD. 27 
Across the 118bp region, we observed significantly increased levels in AD cases 28 
6 
 
compared to controls in all eight ANK1 CpG sites in the EC (Figure 1A) and seven 1 
ANK1 CpG sites in the STG (Figure 1B). Both the EC and STG exhibit a high degree 2 
of AD pathology, even in the earliest stages of disease, with the EC being the starting 3 
point of AD pathology in the cortex (Braak and Braak, 1991). Conversely, the CER 4 
remains free of AD pathology until the very last stages of the disease, although even 5 
then this is limited to amyloid beta (Aβ) plaques with an absence of neurofibrillary 6 
tangles (NFTs) of hyperphosphorylated tau (Braak, et al., 1989). Of note, we 7 
observed significant ANK1 DNA hypermethylation at five ANK1 CpG sites in the CER 8 
(Figure 1C). This is the first time ANK1 DNA methylation changes have been 9 
reported in the CER. Interestingly, two of the loci that did not display AD-associated 10 
ANK1 hypermethylation in the CER were chr8:41519308 and chr8:41519399, the two 11 
sites included on the Illumina 450K array used in previous EWAS analyses of AD 12 
which did not identify ANK1 hypermethylation in AD in the CER (Lunnon, et al., 13 
2014). Average DNA methylation across the amplicon region was significantly 14 
elevated in AD in the EC (P = 1.29 x 10-07), STG (P = 2.39 x 10-03) and CER (P = 15 
7.81 x 10-03) (Figure 1D). ANK1 DNA methylation differences between cases and 16 
controls at both individual sites and across the amplicon were lower in the CER 17 
compared to other tissues tested (Supplementary Table 2), with a significantly 18 
greater DNA methylation difference between cases and controls in the EC (amplicon 19 
average corrected DNA methylation difference (Δ) = 4.53%) compared to both the 20 
STG (amplicon average Δ = 2.84%; P = 7.98 x 10-4) and the CER (amplicon average 21 
Δ = 1.17%, P = 2.55 x 10-4). Interestingly, this pattern of change matches the spread 22 
of AD pathology throughout the brain.  23 
 24 
3.2. ANK1 DNA hypermethylation in the EC is only observed in DLB cases 25 
with co-existing AD pathology 26 
DLB is the third most common cause of dementia with the age of onset ranging from 27 
50 to 83 years (McKeith, 2002). The pathology of DLB shares similarities to AD, with 28 
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the presence of immune regulation and microglial activation being consistent 1 
between diseases (Mackenzie, 2000). However, the presence of Lewy bodies within 2 
the brain makes DLB considerably more comparable to PD (McKeith, 2002). In fact, 3 
PD dementia is thought to be biologically identical to DLB, only differing in the order 4 
in which the motor or cognitive symptoms occur (Dodel, et al., 2008). Interestingly we 5 
observed significant hypermethylation of ANK1 in DLB cases compared to controls in 6 
the EC (Figure 2A) at four of the eight ANK1 CpG sites (Supplementary Table 3). 7 
We saw no difference between DLB and control samples in either the STG 8 
(Supplementary Figure 1A) or the CER (Supplementary Figure 1B) at any of the 9 
eight ANK1 CpG sites. Across the ANK1 amplicon we observed significant DLB-10 
associated hypermethylation in the EC (P = 0.0244), but not in the STG or CER (P > 11 
0.05) (Figure 2B). It is widely reported that DLB and AD frequently co-occur 12 
(Rosenberg, et al., 2001); we were therefore interested to investigate whether we still 13 
observed DLB-associated DNA hypermethylation in the EC when we controlled for 14 
co-existing AD pathology. We found no significant changes in ANK1 DNA 15 
methylation in individuals with “pure” DLB compared to controls in the EC (Figure 16 
2C), STG (Supplementary Figure 1C) and CER (Supplementary Figure 1D). 17 
However, we did observe significant hypermethylation in DLB cases with co-existing 18 
AD pathology compared to controls at seven of the eight ANK1 CpG sites in the EC 19 
(Figure 2C) and two sites in the STG (Supplementary Figure 1C), with no 20 
difference in the CER (Supplementary Figure 1D). When we looked across the 21 
whole 118bp region, we saw increased ANK1 DNA methylation in the EC in 22 
individuals with co-existing AD pathology (P = 1.45 x 10-03) (Figure 2D), suggesting 23 
that the ANK1 hypermethylation seen in some individuals with DLB is primarily driven 24 
by AD pathology.  25 
 26 
3.3.  ANK1 hypermethylation is seen in the EC only in VaD individuals with 27 
co-existing AD pathology 28 
8 
 
Characterized by the loss of neurological function due to ischemic events, the risk of 1 
developing VaD is closely linked to vascular health (Román, et al., 1993). We 2 
observed increased DNA methylation in individuals with VaD at none of the ANK1 3 
CpG sites in the EC (Figure 3A), only one site in the STG (Supplementary Figure 4 
2A) and no sites in the CER (Supplementary Figure 2B) (Supplementary Table 4), 5 
with no difference across the amplicon in any of the brain regions tested (P > 0.05) 6 
(Figure 3B). Because VaD also often co-occurs with AD we next examined whether 7 
stratifying cases by the presence of AD pathology altered these findings. 8 
Interestingly, we saw disease-associated hypermethylation in the EC at five of the 9 
eight ANK1 CpG sites only in individuals with co-existing AD pathology (Figure 3C), 10 
whilst we saw disease-associated hypomethylation at one site in the STG 11 
(Supplementary Figure 2C) in individuals with “pure” VaD, and no disease-12 
associated changes in the CER (Supplementary Figure 2D).  When we looked 13 
across the 118bp region we only saw significant ANK1 hypermethylation in 14 
individuals with VaD and co-existing AD pathology compared to controls in the EC (P 15 
= 0.0163) (Figure 3D). It is worth noting that our cohort only had a small number of 16 
VaD cases with co-existing AD pathology (N=5). 17 
 18 
3.4. ANK1 DNA hypermethylation in the EC is seen in both HD and PD. 19 
HD is characterized by a trinucleotide repeat in the huntingtin gene (HTT). The 20 
abundance of the repeat is proportional to the level of protein misfolding and 21 
downstream cytosolic accumulation, leading to neuronal cell death and the 22 
symptoms of HD (Walker, 2007).  ANK1 DNA hypermethylation was seen at four of 23 
the eight CpG sites in the EC in HD (Figure 4A). However, no differential DNA 24 
methylation was seen in the other brain regions tested (Supplementary Table 5), 25 
including the STG (Supplementary Figure 3A), the CER (Supplementary Figure 26 
3B) and the STR (Supplementary Figure 3C), a region that forms part of the basal 27 
ganglia, known to be the first brain region to be adversely affected by HD pathology 28 
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(Walker, 2007). Averaging across the region again highlighted significant 1 
hypermethylation in the EC (P = 6.68 x 10-3), with no significant change in any other 2 
tissue (Figure 4B).   3 
 4 
A similar pattern of ANK1 hypermethylation was observed in PD; two of the eight 5 
CpG sites were characterized by significant hypermethylation in the EC (Figure 4C), 6 
with no differences in DNA methylation in any of the other brain regions tested 7 
(Supplementary Table 6). This included the STG (Supplementary Figure 4A), the 8 
CER (Supplementary Figure 4B), the STR (Supplementary Figure 4C) and the SN 9 
(Supplementary Figure 4D), with the SN representing the brain region that has the 10 
highest levels of pathology in PD (Fearnley and Lees, 1991). Across the 118bp 11 
amplicon we saw no change in DNA methylation in any of the five brain regions 12 
(Figure 4D).  13 
 14 
 15 
4. DISCUSSION 16 
 17 
This is the first study to assess brain ANK1 DNA methylation changes across 18 
multiple neurodegenerative diseases. We identified significant DNA methylation 19 
changes in the EC in multiple diseases, including AD, HD and PD, with significant 20 
DNA hypermethylation across the amplicon in AD and HD. Interestingly, we also 21 
observed significant hypermethylation of ANK1 in the EC in both DLB and VaD at 22 
several individual CpG sites and across the amplicon, but only in donors with co-23 
existing AD pathology. This suggests that ANK1 DNA hypermethylation in the EC is 24 
specific to some neurodegenerative diseases (AD, HD and to some extent PD), and 25 
not observed in other forms of neuropathology (VaD and DLB). We have previously 26 
reported that ANK1 is not hypermethylated in the CER in AD at two sites interrogated 27 
by the Illumina 450K array (chr8:41519308 and chr8:41519399). In the current study 28 
10 
 
we again demonstrate that these two loci are not significantly differentially methylated 1 
in AD; however, we do highlight AD-associated DNA hypermethylation at five 2 
adjacent CpG sites and averaged across the 118bp amplicon in the CER. We did not 3 
see any ANK1 DNA methylation changes in the CER in any of the other 4 
neurodegenerative diseases, including those with co-existing AD pathology. 5 
Reflecting our previous findings, we found that DNA methylation differences in AD 6 
are greatest in the EC, an area with high levels of neuropathology and lowest in the 7 
CER, the region with the least neuropathology. Interestingly, although we observed 8 
disease-associated ANK1 hypermethylation in the EC at six individual sites and 9 
across the region in HD and at two individual sites in PD, we did not see ANK1 DNA 10 
methylation changes in these diseases in their regions of primary neuropathology, 11 
namely the STR and SN, respectively. This suggests that ANK1 hypermethylation in 12 
neurodegenerative disease is not necessarily specific to regions of primary 13 
neuropathology, but may instead be specific to particular cell types affected in the 14 
diseases, such as those in the EC, which are not present in the STR and SN. ANK1 15 
encodes for numerous isoforms with their own tissue-specific enhancers. Although 16 
the precise function of most ANK1 isoforms is not known, different isoforms have 17 
been identified in the brain, blood and muscle (Gallagher, et al., 1997). Mastroeni et 18 
al., recently showed a four-fold increase in ANK1 mRNA expression in microglia from 19 
AD brain tissue, but not in neurons or astrocytes from the same individuals, 20 
suggesting an immune based function for ANK1 in the human brain (Mastroeni, et al., 21 
2017). One potential caveat of our study is that we have analyzed “bulk” tissue, and 22 
we cannot determine which cell type(s) are driving the DNA hypermethylation seen in 23 
ANK1 in disease.  24 
 25 
Although the focus of our study was on investigating DNA methylation changes in 26 
disease, bisulfite pyrosequencing actually generates a summative measurement of 27 
both DNA methylation and DNA hydroxymethylation. DNA methylation is generally 28 
11 
 
associated with gene silencing, particularly when residing in the promoters of 1 
constitutively expressed housekeeping genes (Jones, 2012), whilst DNA 2 
hydroxymethylation has been shown to be enriched in gene bodies (Lunnon, et al., 3 
2016) and to be found at (relatively) high levels in the brain (Khare, et al., 4 
2012,Szulwach, et al., 2011). We have recently shown that ANK1 DNA 5 
hypermethylation across the 118bp amplicon in AD is actually underestimated when 6 
using bisulfite data, as it is confounded by significant DNA hypohydroxymethylation 7 
at some loci in the amplicon (Smith, et al., Under Review). Another caveat to our 8 
study is that we have only analyzed DNA methylation across eight CpG sites in a 9 
118bp region of the ANK1 gene and thus future studies should aim to further quantify 10 
changes in DNA methylation across the entire 244kb gene.  11 
 12 
5. CONCLUSIONS 13 
 14 
Our study has demonstrated disease-associated ANK1 hypermethylation in the EC at 15 
specific CpG sites in AD, HD and PD and across the region in AD and HD. In donors 16 
with DLB and VaD we only observed increased ANK1 DNA methylation in the EC in 17 
individuals with co-existing AD pathology. The CER showed disease-associated 18 
hypermethylation at specific CpG loci and across the region in AD, but not in any of 19 
the other neurodegenerative diseases tested. We saw no disease-associated 20 
differential ANK1 DNA methylation in the STR in HD or PD, or the SN in PD. This 21 
suggests that ANK1 is characterized by brain region and disease-specific differential 22 
DNA methylation in different neurodegenerative diseases. At present we are unable 23 
to determine whether these changes represent a cause or a consequence of the 24 
disease process. Further functional studies should therefore be performed to 25 
determine the potential disease causality of this modification.  26 
 27 
 28 
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Figure 1: ANK1 is hypermethylated in the EC, STG and CER in AD brain. Using bisulfite 
pyrosequencing we assayed a 118bp region of the ANK1 gene ranging from 41519302 to 
41519420 on chromosome 8 (genome build hg19) in (A) EC, (B) STG and (C) CER tissue. in 
AD samples (Braak V-VI) compared to control samples (Braak 0-II). We demonstrated 
significant neuropathology-associated hypermethylation at all assayed CpG sites in the EC, 
significant hypermethylation at seven of the eight CpG sites in the STG and five of the eight 
sites in the CER. (D) When data was summed across the 118bp amplicon region we 
observed a significant increase in DNA methylation across all brain regions (EC: P =  1.29 x 
10-7, STG: P = 2.39 x 10-3 and CER: P = 7.81 x 10-3).   Data is represented as mean (±SEM) 
Key: *P < 0.05, **P < 0.01, ***P < 0.005.  
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Figure 2: ANK1 hypermethylation is observed in the EC in individuals with DLB and co-
existing AD pathology. Using bisulfite pyrosequencing we assayed a 118bp region of the ANK1 
gene ranging from 41519302 to 41519420 on chromosome 8 (genome build hg19) in all DLB 
samples compared to control samples. (A) We demonstrated significant neuropathology-associated 
hypermethylation at four CpG sites in the EC. (B) When data was summed across the 118bp 
amplicon region we observed a significant increase in DNA methylation in the EC (P =  0.024). Some 
individuals with DLB also had co-existing AD pathology; (C) when we compared DNA methylation 
levels in ANK1 in individuals with DLB and co-existing AD pathology, or individuals with “pure” DLB 
only to controls, we found significant hypermethylation at seven sites in the EC in individuals with co-
existing AD pathology. (D) When we averaged methylation across the region we saw significant 
hypermethylation in the EC in individuals with co-existing AD pathology (P = 0.001). Data is 
represented as mean (±SEM) Key: *P < 0.05, **P < 0.01, ***P < 0.005.  
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Figure 3: ANK1 hypermethylation is observed in the EC in individuals with VaD and co-
existing AD pathology. Using bisulfite pyrosequencing we assayed a 118bp region of the ANK1 
gene ranging from 41519302 to 41519420 on chromosome 8 (genome build hg19) in all VaD 
samples compared to control samples. (A) We found no disease-associated differential methylation 
at any individual sites in the EC, (B) nor any difference when averaged across the amplicon (B). 
Some individuals with VaD also had co-existing AD pathology; (C) when we compared DNA 
methylation levels in ANK1 in individuals with VaD and co-existing AD pathology, or individuals with 
“pure” VaD only to controls, we found significant hypermethylation at five sites in the EC in 
individuals with co-existing AD pathology. (D) When we averaged methylation across the region we 
observed significant hypermethylation in the EC in individuals with a co-diagnosis of AD (P = 0.016). 
Data is represented as mean (±SEM) Key: *P < 0.05, **P < 0.01, ***P < 0.005.  
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Figure 4: ANK1 DNA methylation patterns in HD and PD. Using bisulfite pyrosequencing we 
assayed a 118bp region of the ANK1 gene ranging from 41519302 to 41519420 on chromosome 8 
(genome build hg19) in HD and PD samples compared to control samples. In HD donors in the EC 
we observed neuropathology-associated hypermethylation at five sites (A) and significant 
hypermethylation when we averaged methylation across the region (P = 0.007) (B). In PD donors in 
the EC we found neuropathology-associated hypermethylation at two sites (C), but no significant 
difference when we averaged across the region (D). Data is represented as mean (±SEM) Key: *P < 
0.05, **P < 0.01, ***P < 0.005.  
 
C
o
rr
e
c
te
d
 m
e
th
y
la
ti
o
n
 c
h
a
n
g
e
 
C
o
rr
e
c
te
d
 m
e
th
y
la
ti
o
n
  
d
if
fe
re
n
c
e
 
Genomic Location 
Genomic Location 
A B 
C D 
C
o
rr
e
c
te
d
 m
e
th
y
la
ti
o
n
 c
h
a
n
g
e
 
C
o
rr
e
c
te
d
 m
e
th
y
la
ti
o
n
  
d
if
fe
re
n
c
e
 
S
u
p
p
le
m
e
n
ta
ry
 T
a
b
le
 1
: S
a
m
p
le
 a
n
d
 d
e
m
o
g
ra
p
h
ic
 in
fo
rm
a
tio
n
 fo
r s
a
m
p
le
s
 u
s
e
d
 in
 th
e
 s
tu
d
y
. S
h
o
w
n
 fo
r e
a
c
h
 d
is
e
a
s
e
 c
o
h
o
rt a
re
 th
e
 n
u
m
b
e
r 
o
f to
ta
l d
o
n
o
rs
 u
s
e
d
 (N
), th
e
n
 fo
r e
a
c
h
 in
d
iv
id
u
a
l b
ra
in
 re
g
io
n
, th
e
 n
u
m
b
e
r o
f s
a
m
p
le
s
 a
v
a
ila
b
le
 (N
), g
e
n
d
e
r d
is
trib
u
tio
n
 a
n
d
 m
e
a
n
 a
g
e
 (±
 s
ta
n
d
a
rd
 
d
e
v
ia
tio
n
 
(S
D
)). 
A
b
b
re
v
ia
tio
n
s
: 
A
lzh
e
im
e
r’s
 
d
is
e
a
s
e
 
(A
D
), 
C
e
re
b
e
llu
m
 
(C
E
R
), 
D
e
m
e
n
tia
 
w
ith
 
L
e
w
y
 
b
o
d
ie
s
 
(D
L
B
), 
E
n
to
rh
in
a
l 
c
o
rte
x
 
(E
C
), 
H
u
n
tin
g
to
n
’s
 d
is
e
a
s
e
 (H
D
), P
a
rk
in
s
o
n
’s
 d
is
e
a
s
e
 (P
D
), S
u
b
s
ta
n
tia
 n
ig
ra
 (S
N
), S
u
p
e
rio
r te
m
p
o
ra
l g
y
ru
s
 (S
T
G
), S
tria
tu
m
 (S
T
R
), V
a
s
c
u
la
r d
e
m
e
n
tia
 
(V
a
D
). 
 
  
B
ra
in
 R
e
g
io
n
 
E
C
 
S
T
G
 
C
E
R
 
S
T
R
 
S
N
 
A
D
 
(N
 =
 6
0
) 
N
 
5
8
 
5
8
 
5
8
 
- 
- 
G
e
n
d
e
r (M
/F
) 
2
7
/3
1
 
2
6
/3
2
 
2
6
/3
2
 
- 
- 
M
e
a
n
 a
g
e
 (±
S
D
) 
7
7
.7
 (9
.2
) 
7
7
.6
 (9
.2
) 
7
8
.4
 (8
.8
) 
- 
- 
A
ll D
L
B
 
(N
 =
 1
1
9
) 
N
 
9
1
 
1
0
7
 
1
1
2
 
- 
- 
G
e
n
d
e
r (M
/F
) 
7
2
/1
9
 
8
4
/2
3
 
8
8
/2
4
 
- 
- 
M
e
a
n
 a
g
e
 (±
S
D
) 
7
8
.8
 (7
.3
) 
7
8
.3
 (7
.2
) 
7
8
.1
 (7
.2
) 
- 
- 
D
L
B
 o
n
ly
 
(N
 =
 8
0
) 
N
 
5
6
 
6
9
 
7
6
 
- 
- 
G
e
n
d
e
r (M
/F
) 
4
7
/9
 
5
6
/1
3
 
6
1
/1
5
 
- 
- 
M
e
a
n
 a
g
e
 (±
S
D
) 
7
8
.1
 (7
.1
) 
7
7
.6
 (6
.9
) 
7
7
.4
 (7
.0
) 
- 
- 
D
L
B
 +
 A
D
 
(N
 =
 3
9
) 
N
 
3
5
 
3
8
 
3
6
 
- 
- 
G
e
n
d
e
r (M
/F
) 
2
5
/1
0
 
2
8
/1
0
 
2
7
/9
 
- 
- 
M
e
a
n
 a
g
e
 (±
S
D
) 
8
0
.0
 (7
.5
) 
7
9
.5
 (7
.6
) 
7
9
.5
 (7
.7
) 
- 
- 
A
ll V
a
D
 
(N
 =
 2
7
) 
N
 
2
3
 
2
7
 
2
6
 
- 
- 
G
e
n
d
e
r (M
/F
) 
9
/1
4
 
1
1
/1
6
 
1
1
/1
5
 
- 
- 
M
e
a
n
 a
g
e
 (±
S
D
) 
8
3
.9
 (8
.4
) 
8
3
.6
 (7
.9
) 
8
3
.5
 (8
.1
) 
- 
- 
V
a
D
 o
n
ly
 
(N
 =
 2
2
) 
N
 
1
9
 
2
2
 
2
1
 
- 
- 
G
e
n
d
e
r (M
/F
) 
8
/1
1
 
1
0
/1
2
 
1
0
/1
1
 
- 
- 
M
e
a
n
 a
g
e
 (±
S
D
) 
8
3
.3
 (7
.8
) 
8
3
.0
 (7
.4
) 
8
2
.8
 (7
.5
) 
- 
- 
V
a
D
 +
 A
D
 
(N
 =
 5
) 
N
 
4
 
5
 
5
 
- 
- 
G
e
n
d
e
r (M
/F
) 
1
/3
 
1
/4
 
1
/4
 
- 
- 
M
e
a
n
 a
g
e
 (±
S
D
) 
8
6
.8
 (1
2
.1
) 
8
6
.2
 (1
0
.6
) 
8
6
.2
 (1
0
.6
) 
- 
- 
H
D
 
(N
 =
 2
2
) 
N
 
1
9
 
2
0
 
2
0
 
1
9
 
- 
G
e
n
d
e
r (M
/F
) 
1
3
/6
 
1
3
/7
 
1
4
/6
 
1
3
/6
 
- 
M
e
a
n
 a
g
e
 (±
S
D
) 
7
1
.1
 (5
.0
) 
7
0
.4
 (7
.1
) 
7
0
.0
 (7
.2
) 
6
8
.8
 (1
2
.8
) 
- 
P
D
 
(N
 =
 3
6
) 
N
 
3
3
 
3
5
 
3
3
 
5
 
2
9
 
G
e
n
d
e
r (M
/F
) 
1
9
/1
4
 
2
1
/1
4
 
2
1
/1
2
 
4
/1
 
1
9
/1
0
 
M
e
a
n
 a
g
e
 (±
S
D
) 
7
8
.5
 (7
.4
) 
7
8
.2
 (7
.5
) 
7
8
.3
 (7
.5
) 
8
3
.6
 (3
.2
) 
7
8
.9
 (7
.6
) 
C
o
n
tro
l 
(N
 =
 1
0
5
) 
N
 
9
9
 
7
4
 
9
8
 
2
1
 
3
1
 
G
e
n
d
e
r (M
/F
) 
5
3
/4
6
 
4
0
/3
4
 
4
8
/5
0
 
9
/1
2
 
1
1
/2
0
 
M
e
a
n
 a
g
e
 (±
S
D
) 
8
1
.4
 (9
.6
) 
8
1
.6
 (1
0
.6
) 
8
0
.7
 (1
0
.7
) 
7
6
.5
 (1
1
.7
) 
7
7
.3
 (1
1
.2
) 
 
S
u
p
p
le
m
e
n
ta
ry
 T
a
b
le
 2
: 
A
N
K
1
 C
p
G
 s
it
e
s
 a
re
 h
y
p
e
rm
e
th
y
la
te
d
 i
n
 A
D
 a
c
ro
s
s
 a
ll
 b
ra
in
 r
e
g
io
n
s
 t
e
s
te
d
. 
S
h
o
w
n
 f
o
r 
e
a
c
h
 t
is
s
u
e
 i
s
 c
h
ro
m
o
s
o
m
a
l 
lo
c
a
ti
o
n
 (
g
e
n
o
m
e
 b
u
ild
 h
g
1
9
) 
o
f 
C
p
G
 s
it
e
s
 t
e
s
te
d
, 
w
it
h
 c
o
rr
e
c
te
d
 d
iff
e
re
n
c
e
 (
Δ
) 
in
 D
N
A
 m
e
th
y
la
ti
o
n
 l
e
v
e
ls
 a
n
d
 c
o
rr
e
s
p
o
n
d
in
g
 P
 v
a
lu
e
 b
e
tw
e
e
n
 
c
o
n
tr
o
ls
 
(B
ra
a
k
 
0
-I
I)
 
a
n
d
 
A
D
 
c
a
s
e
s
 
(B
ra
a
k
 
V
-V
I)
 
a
ft
e
r 
a
d
ju
st
in
g
 
fo
r 
th
e
 
c
o
va
ri
a
te
s
 
o
f 
a
g
e
, 
s
e
x 
a
n
d
 
b
a
tc
h
 
e
ff
e
ct
s
. 
A
 
p
o
s
it
iv
e
 
Δ
 
re
fl
e
ct
s 
h
y
p
e
rm
e
th
y
la
ti
o
n
 i
n
 A
D
. 
A
ll 
P
 v
a
lu
e
s
 <
 0
.0
5
 (
a
n
d
 t
h
e
ir
 c
o
rr
e
s
p
o
n
d
in
g
 Δ
) 
a
re
 s
h
o
w
n
 i
n
 b
o
ld
. 
 
G
e
n
o
m
ic
 
L
o
c
a
ti
o
n
 
A
D
 
E
C
 
S
T
G
 
C
E
R
 
∆
 
P
 
∆
 
P
 
∆
 
P
 
c
h
r8
:4
1
5
1
9
3
0
2
 
4
.3
1
 
1
.7
6
E
-1
0
 
2
.8
3
 
1
.4
9
E
-0
4
 
2
.0
9
 
2
.9
8
E
-0
4
 
c
h
r8
:4
1
5
1
9
3
0
4
 
4
.8
5
 
5
.7
6
E
-1
0
 
2
.0
1
 
0
.0
1
7
 
1
.4
2
 
0
.0
0
8
 
c
h
r8
:4
1
5
1
9
3
0
8
 
5
.5
1
 
3
.1
6
E
-1
1
 
3
.2
2
 
4
.4
3
E
-0
4
 
-0
.2
3
 
0
.7
2
9
 
c
h
r8
:4
1
5
1
9
3
4
8
 
4
.9
9
 
2
.7
9
E
-1
0
 
2
.3
3
 
0
.0
0
2
 
0
.1
7
 
0
.8
3
8
 
c
h
r8
:4
1
5
1
9
3
9
9
 
2
.8
7
 
0
.0
0
5
 
1
.6
8
 
0
.1
5
0
 
0
.6
6
 
0
.5
8
5
 
c
h
r8
:4
1
5
1
9
4
1
1
 
4
.5
8
 
2
.2
7
E
-0
8
 
4
.0
2
 
2
.2
2
E
-0
4
 
2
.8
3
 
8
.4
3
E
-0
4
 
c
h
r8
:4
1
5
1
9
4
1
7
 
4
.3
0
 
1
.5
0
E
-0
7
 
3
.5
3
 
4
.5
5
E
-0
4
 
1
.5
4
 
0
.0
2
8
 
c
h
r8
:4
1
5
1
9
4
2
0
 
4
.8
0
 
2
.5
3
E
-0
8
 
3
.0
8
 
0
.0
0
3
 
0
.8
6
 
0
.0
3
8
 
A
m
p
lic
o
n
 A
v
e
ra
g
e
 
3
.1
4
 
1
.2
9
E
-0
7
 
1
.6
8
 
0
.0
0
2
 
0
.9
8
 
0
.0
0
8
 
          
S
u
p
p
le
m
e
n
ta
ry
 T
a
b
le
 3
: A
N
K
1
 C
p
G
 s
ite
s
 a
re
 h
y
p
e
rm
e
th
y
la
te
d
 in
 th
e
 E
C
 in
 p
a
tie
n
ts
 w
ith
 D
L
B
 a
n
d
 c
o
-e
x
is
tin
g
 A
D
 p
a
th
o
lo
g
y
. S
h
o
w
n
 fo
r 
e
a
c
h
 
tis
s
u
e
 
is
 
c
h
ro
m
o
s
o
m
a
l 
lo
c
a
tio
n
 
(g
e
n
o
m
e
 
b
u
ild
 
h
g
1
9
) 
o
f 
C
p
G
 
s
ite
s
 
te
s
te
d
, 
w
ith
 
c
o
rre
cte
d
 
d
iffe
re
n
c
e
 (Δ
) 
in
 
D
N
A
 
m
e
th
y
la
tio
n
 
le
v
e
ls
 
a
n
d
 
c
o
rre
s
p
o
n
d
in
g
 P
 v
a
lu
e
 b
e
tw
e
e
n
 c
o
n
tro
ls
 a
n
d
 D
L
B
 c
a
s
e
s
 a
fte
r a
d
ju
s
tin
g
 fo
r th
e
 c
o
v
a
ria
te
s
 o
f a
g
e
, s
e
x
 a
n
d
 b
a
tc
h
 e
ffe
c
ts
. A
n
a
ly
s
e
s
 a
re
 s
tra
tifie
d
 in
to
 
“A
ll D
L
B
”, “D
L
B
 O
n
ly” a
n
d
 “D
L
B
 +
 A
D
” g
ro
u
p
s
. A
 p
o
s
itive
 Δ
 re
fle
c
ts
 h
yp
e
rm
e
th
y
la
tio
n
 in
 d
is
e
a
s
e
. A
ll P
 va
lu
e
s
 <
 0
.0
5
 (a
n
d
 th
e
ir c
o
rre
s
p
o
n
d
in
g
 Δ
) a
re
 
s
h
o
w
n
 in
 b
o
ld
. 
 
G
e
n
o
m
ic
 L
o
c
a
tio
n
 
A
ll D
L
B
 
D
L
B
 O
n
ly
 
D
L
B
 +
 A
D
 
E
C
 
S
T
G
 
C
E
R
 
E
C
 
S
T
G
 
C
E
R
 
E
C
 
S
T
G
 
C
E
R
 
∆
 
P
 
∆
 
P
 
∆
 
P
 
∆
 
P
 
∆
 
P
 
∆
 
P
 
∆
 
P
 
∆
 
P
 
∆
 
P
 
c
h
r8
:4
1
5
1
9
3
0
2
 
0
.5
8
 
0
.2
8
6
 
0
.3
4
 
0
.5
1
6
 
0
.2
4
 
0
.5
4
2
 
0
.1
0
 
0
.8
6
3
 
0
.0
2
 
0
.9
6
3
 
0
.1
6
 
0
.7
1
2
 
1
.5
3
 
0
.0
2
2
 
0
.8
1
 
0
.1
9
8
 
0
.3
4
 
0
.5
5
2
 
c
h
r8
:4
1
5
1
9
3
0
4
 
0
.9
7
 
0
.0
8
3
 
0
.7
4
 
0
.1
9
6
 
0
.0
4
 
0
.9
0
7
 
0
.4
9
 
0
.4
3
6
 
0
.2
6
 
0
.6
6
9
 
0
.0
5
 
0
.8
9
2
 
1
.5
1
 
0
.0
3
4
 
1
.4
2
 
0
.0
3
4
 
0
.0
1
 
0
.9
8
6
 
c
h
r8
:4
1
5
1
9
3
0
8
 
0
.3
5
 
0
.6
0
0
 
0
.5
4
 
0
.3
6
8
 
0
.4
2
 
0
.4
1
9
 
0
.1
2
 
0
.8
7
2
 
0
.0
8
 
0
.8
9
5
 
0
.5
8
 
0
.2
6
1
 
1
.0
0
 
0
.2
3
0
 
1
.2
0
 
0
.1
1
0
 
0
.0
6
 
0
.9
3
8
 
c
h
r8
:4
1
5
1
9
3
4
8
 
0
.8
4
 
0
.1
7
1
 
0
.8
9
 
0
.1
1
4
 
0
.3
5
 
0
.5
8
0
 
0
.2
7
 
0
.6
9
2
 
0
.3
9
 
0
.4
9
2
 
0
.4
6
 
0
.4
8
4
 
1
.5
5
 
0
.0
3
4
 
1
.5
8
 
0
.0
2
5
 
-0
.0
2
 
0
.9
8
5
 
c
h
r8
:4
1
5
1
9
3
9
9
 
1
.9
9
 
0
.0
2
0
 
0
.6
8
 
0
.3
8
8
 
0
.3
1
 
0
.7
4
3
 
1
.1
9
 
0
.2
0
8
 
0
.7
0
 
0
.3
9
9
 
0
.2
5
 
0
.7
9
1
 
2
.8
1
 
0
.0
1
0
 
0
.4
5
 
0
.6
4
5
 
0
.3
1
 
0
.7
9
1
 
c
h
r8
:4
1
5
1
9
4
1
1
 
1
.4
4
 
0
.0
1
0
 
0
.0
3
 
0
.9
7
0
 
0
.1
2
 
0
.8
2
9
 
0
.7
6
 
0
.2
2
8
 
0
.1
7
 
0
.8
4
5
 
-0
.0
1
 
0
.9
9
3
 
2
.1
9
 
0
.0
0
1
 
0
.3
9
 
0
.7
1
6
 
0
.3
6
 
0
.6
6
4
 
c
h
r8
:4
1
5
1
9
4
1
7
 
1
.2
8
 
0
.0
3
2
 
-0
.2
2
 
0
.7
5
8
 
0
.0
3
 
0
.9
4
6
 
0
.3
7
 
0
.5
8
8
 
0
.5
5
 
0
.4
6
8
 
-0
.0
7
 
0
.8
8
8
 
2
.4
4
 
0
.0
0
1
 
0
.4
4
 
0
.6
3
5
 
0
.2
5
 
0
.6
9
6
 
c
h
r8
:4
1
5
1
9
4
2
0
 
1
.9
5
 
0
.0
0
3
 
-0
.7
5
 
0
.3
0
2
 
-0
.2
9
 
0
.3
8
1
 
1
.0
5
 
0
.1
5
0
 
0
.7
0
 
0
.3
7
5
 
-0
.4
1
 
0
.2
7
2
 
2
.9
2
 
2
.4
5
E
-0
4
 
0
.6
4
 
0
.5
0
2
 
0
.0
5
 
0
.8
8
8
 
A
m
p
lic
o
n
 A
v
e
ra
g
e
 
1
.0
8
 
0
.0
2
4
 
0
.2
3
 
0
.6
4
1
 
0
.1
6
 
0
.6
2
3
 
0
.5
1
 
0
.3
7
0
 
0
.0
6
 
0
.9
2
0
 
0
.1
4
 
0
.7
0
6
 
1
.9
9
 
0
.0
0
1
 
0
.7
5
 
0
.2
2
9
 
0
.2
0
 
0
.6
3
8
 
          
S
u
p
p
le
m
e
n
ta
ry
 T
a
b
le
 4
: 
A
N
K
1
 C
p
G
 s
it
e
s
 a
re
 h
y
p
e
rm
e
th
y
la
te
d
 i
n
 t
h
e
 E
C
 i
n
 i
n
d
iv
id
u
a
ls
 w
it
h
 V
a
D
 a
n
d
 c
o
-e
x
is
ti
n
g
 A
D
 p
a
th
o
lo
g
y
. 
S
h
o
w
n
 f
o
r 
e
a
c
h
 
ti
s
s
u
e
 
is
 
c
h
ro
m
o
s
o
m
a
l 
lo
c
a
ti
o
n
 
(g
e
n
o
m
e
 
b
u
ild
 
h
g
1
9
) 
o
f 
C
p
G
 
s
it
e
s
 
te
s
te
d
, 
w
it
h
 
c
o
rr
e
ct
e
d
 
d
if
fe
re
n
c
e
 (
Δ
) 
in
 
D
N
A
 
m
e
th
y
la
ti
o
n
 
le
v
e
ls
 
a
n
d
 
c
o
rr
e
s
p
o
n
d
in
g
 P
 v
a
lu
e
 b
e
tw
e
e
n
 c
o
n
tr
o
ls
 a
n
d
 V
a
D
 c
a
s
e
s
 a
ft
e
r 
a
d
ju
s
ti
n
g
 f
o
r 
th
e
 c
o
v
a
ri
a
te
s
 o
f 
a
g
e
, 
s
e
x
 a
n
d
 b
a
tc
h
 e
ff
e
c
ts
. 
A
n
a
ly
s
e
s
 a
re
 s
tr
a
ti
fi
e
d
 i
n
to
 
“A
ll 
V
a
D
”,
 “
V
a
D
 O
n
ly
” 
a
n
d
 “
V
a
D
 +
 A
D
” 
g
ro
u
p
s
. 
A
 p
o
s
it
iv
e
 Δ
 r
e
fl
e
c
ts
 h
yp
e
rm
e
th
y
la
ti
o
n
 i
n
 d
is
e
a
s
e
. 
A
ll 
P
 v
a
lu
e
s
 <
 0
.0
5
 (
a
n
d
 t
h
e
ir
 c
o
rr
e
s
p
o
n
d
in
g
 Δ
) 
a
re
 
s
h
o
w
n
 i
n
 b
o
ld
. 
 
G
e
n
o
m
ic
 L
o
c
a
ti
o
n
 
A
ll
 V
a
D
 
V
a
D
 O
n
ly
 
V
a
D
 +
 A
D
 
E
C
 
S
T
G
 
C
E
R
 
E
C
 
S
T
G
 
C
E
R
 
E
C
 
S
T
G
 
C
E
R
 
∆
 
P
 
∆
 
P
 
∆
 
P
 
∆
 
P
 
∆
 
P
 
∆
 
P
 
∆
 
P
 
∆
 
P
 
∆
 
P
 
c
h
r8
:4
1
5
1
9
3
0
2
 
1
.0
6
 
0
.2
1
4
 
0
.1
7
 
0
.8
0
7
 
0
.8
2
 
0
.2
2
1
 
0
.3
9
 
0
.6
6
8
 
-0
.2
4
 
0
.7
4
2
 
0
.7
2
 
0
.3
2
2
 
3
.9
4
 
0
.0
2
6
 
1
.8
7
 
0
.1
8
0
 
1
.1
1
 
0
.4
2
9
 
c
h
r8
:4
1
5
1
9
3
0
4
 
1
.3
8
 
0
.1
2
7
 
0
.1
6
 
0
.8
2
7
 
0
.5
2
 
0
.4
0
4
 
0
.6
6
 
0
.4
9
2
 
-0
.2
7
 
0
.7
2
8
 
0
.4
3
 
0
.5
2
1
 
4
.4
6
 
0
.0
2
0
 
1
.9
4
 
0
.1
9
7
 
0
.8
0
 
0
.5
3
4
 
c
h
r8
:4
1
5
1
9
3
0
8
 
1
.8
8
 
0
.0
6
3
 
0
.4
9
 
0
.5
6
1
 
0
.6
4
 
0
.3
8
9
 
1
.0
4
 
0
.3
2
7
 
-0
.0
3
 
0
.9
7
5
 
0
.8
2
 
0
.3
1
4
 
5
.4
2
 
0
.0
1
2
 
2
.6
1
 
0
.1
4
0
 
0
.1
3
 
0
.9
3
1
 
c
h
r8
:4
1
5
1
9
3
4
8
 
0
.7
8
 
0
.4
1
2
 
-0
.8
3
 
0
.2
5
7
 
0
.5
7
 
0
.5
2
0
 
0
.1
2
 
0
.9
0
4
 
-1
.2
9
 
0
.0
9
2
 
0
.4
4
 
0
.6
4
7
 
3
.6
2
 
0
.0
6
3
 
1
.2
3
 
0
.4
0
6
 
1
.0
3
 
0
.5
7
7
 
c
h
r8
:4
1
5
1
9
3
9
9
 
1
.4
7
 
0
.2
7
8
 
1
.4
9
 
0
.1
7
6
 
1
.9
6
 
0
.1
3
2
 
0
.5
2
 
0
.7
1
6
 
1
.3
6
 
0
.2
3
3
 
1
.5
6
 
0
.2
6
1
 
5
.7
6
 
0
.0
4
8
 
1
.7
9
 
0
.4
3
7
 
3
.4
0
 
0
.2
0
6
 
c
h
r8
:4
1
5
1
9
4
1
1
 
1
.5
3
 
0
.0
6
8
 
-2
.6
6
 
0
.0
2
6
 
0
.4
7
 
0
.6
3
1
 
1
.1
6
 
0
.1
9
2
 
-2
.9
3
 
0
.0
2
0
 
0
.1
8
 
0
.8
6
7
 
3
.0
2
 
0
.1
0
5
 
-0
.9
6
 
0
.7
0
4
 
1
.6
2
 
0
.4
4
1
 
c
h
r8
:4
1
5
1
9
4
1
7
 
1
.7
8
 
0
.0
7
7
 
-0
.8
4
 
0
.4
1
8
 
0
.6
9
 
0
.3
5
1
 
0
.8
9
 
0
.3
9
4
 
-1
.0
7
 
0
.3
2
8
 
0
.4
1
 
0
.6
0
6
 
5
.7
2
 
0
.0
0
8
 
0
.2
9
 
0
.8
9
2
 
1
.7
7
 
0
.2
6
6
 
c
h
r8
:4
1
5
1
9
4
2
0
 
1
.3
4
 
0
.1
6
4
 
-1
.2
9
 
0
.2
1
7
 
-0
.2
3
 
0
.5
8
9
 
1
.4
6
 
0
.1
3
9
 
-1
.6
2
 
0
.1
4
6
 
-0
.4
1
 
0
.3
7
6
 
0
.5
5
 
0
.7
9
4
 
0
.4
0
 
0
.8
5
8
 
0
.5
4
 
0
.5
1
7
 
A
m
p
lic
o
n
 A
v
e
ra
g
e
 
1
.3
8
 
0
.0
7
3
 
-0
.3
9
 
0
.5
4
6
 
0
.7
3
 
0
.1
2
2
 
0
.8
2
 
0
.3
2
5
 
-0
.7
4
 
0
.3
0
1
 
0
.5
9
 
0
.2
6
0
 
4
.0
6
 
0
.0
1
6
 
1
.1
3
 
0
.4
2
9
 
1
.3
2
 
0
.1
9
6
 
          
S
u
p
p
le
m
e
n
ta
ry
 T
a
b
le
 5
: A
N
K
1
 C
p
G
 s
ite
s
 a
re
 h
y
p
e
rm
e
th
y
la
te
d
 in
 th
e
 E
C
 in
 H
D
. S
h
o
w
n
 fo
r e
a
c
h
 tis
s
u
e
 is
 c
h
ro
m
o
s
o
m
a
l lo
c
a
tio
n
 (g
e
n
o
m
e
 b
u
ild
 
h
g
1
9
) o
f C
p
G
 s
ite
s
 te
s
te
d
, w
ith
 c
o
rre
cte
d
 d
iffe
re
n
c
e
 (Δ
) in
 D
N
A
 m
e
th
y
la
tio
n
 le
v
e
ls
 a
n
d
 c
o
rre
s
p
o
n
d
in
g
 P
 v
a
lu
e
 b
e
tw
e
e
n
 c
o
n
tro
ls
 a
n
d
 H
D
 c
a
s
e
s
 a
fte
r 
a
d
ju
s
tin
g
 fo
r 
th
e
 
c
o
va
ria
te
s
 
o
f 
a
g
e
, 
s
e
x 
a
n
d
 
b
a
tc
h
 
e
ffe
cts. 
A
 
p
o
s
itive
 
Δ
 
re
fle
c
ts
 
h
yp
e
rm
e
th
yla
tio
n
 
in
 
d
is
e
a
s
e
. 
A
ll 
P
 
v
a
lu
e
s
 
<
 
0
.0
5
 
(a
n
d
 
th
e
ir 
c
o
rre
s
p
o
n
d
in
g
 Δ
) a
re
 s
h
o
w
n
 in
 b
o
ld
. 
 
G
e
n
o
m
ic
 L
o
c
a
tio
n
 
H
D
 
E
C
 
S
T
G
 
C
E
R
 
S
T
R
 
∆
 
P
 
∆
 
P
 
∆
 
P
 
∆
 
P
 
c
h
r8
:4
1
5
1
9
3
0
2
 
2
.0
9
 
0
.0
2
7
 
1
.2
0
 
0
.1
6
0
 
0
.3
3
 
0
.6
8
1
 
0
.7
6
 
0
.4
9
6
 
c
h
r8
:4
1
5
1
9
3
0
4
 
1
.8
9
 
0
.0
6
2
 
0
.5
8
 
0
.5
3
2
 
0
.3
1
 
0
.6
6
6
 
1
.1
4
 
0
.3
7
7
 
c
h
r8
:4
1
5
1
9
3
0
8
 
3
.4
1
 
0
.0
0
3
 
1
.6
1
 
0
.1
3
6
 
0
.9
9
 
0
.2
6
1
 
-0
.4
8
 
0
.7
1
8
 
c
h
r8
:4
1
5
1
9
3
4
8
 
2
.5
4
 
0
.0
1
4
 
-0
.2
4
 
0
.7
9
7
 
-0
.8
0
 
0
.4
7
0
 
0
.1
6
 
0
.8
8
5
 
c
h
r8
:4
1
5
1
9
3
9
9
 
3
.8
9
 
0
.0
1
4
 
1
.2
5
 
0
.3
8
8
 
-0
.6
8
 
0
.6
7
3
 
-0
.2
3
 
0
.9
0
1
 
c
h
r8
:4
1
5
1
9
4
1
1
 
1
.7
0
 
0
.0
8
3
 
0
.3
8
 
0
.8
1
4
 
0
.5
4
 
0
.6
4
9
 
0
.6
0
 
0
.6
1
3
 
c
h
r8
:4
1
5
1
9
4
1
7
 
1
.5
1
 
0
.1
6
8
 
0
.0
8
 
0
.9
5
0
 
-0
.0
5
 
0
.9
6
0
 
0
.8
2
 
0
.4
6
1
 
c
h
r8
:4
1
5
1
9
4
2
0
 
4
.3
1
 
1
.2
4
E
-0
4
 
2
.4
4
 
0
.0
8
9
 
-0
.3
7
 
0
.5
0
9
 
1
.6
3
 
0
.1
8
4
 
A
m
p
lic
o
n
 A
v
e
ra
g
e
 
2
.2
1
 
0
.0
0
7
 
0
.6
3
 
0
.4
3
1
 
0
.0
7
 
0
.9
0
3
 
0
.8
4
 
0
.3
5
6
 
          
S
u
p
p
le
m
e
n
ta
ry
 T
a
b
le
 6
: 
A
N
K
1
 C
p
G
 s
it
e
s
 a
re
 h
y
p
e
rm
e
th
y
la
te
d
 i
n
 t
h
e
 E
C
 i
n
 P
D
. 
S
h
o
w
n
 f
o
r 
e
a
c
h
 t
is
s
u
e
 i
s
 c
h
ro
m
o
s
o
m
a
l 
lo
c
a
ti
o
n
 (
g
e
n
o
m
e
 b
u
ild
 
h
g
1
9
) 
o
f 
C
p
G
 s
it
e
s
 t
e
s
te
d
, 
w
it
h
 c
o
rr
e
ct
e
d
 d
iff
e
re
n
c
e
 (
Δ
) 
in
 D
N
A
 m
e
th
y
la
ti
o
n
 l
e
v
e
ls
 a
n
d
 c
o
rr
e
s
p
o
n
d
in
g
 P
 v
a
lu
e
 b
e
tw
e
e
n
 c
o
n
tr
o
ls
 a
n
d
 P
D
 c
a
s
e
s
 a
ft
e
r 
a
d
ju
s
ti
n
g
 
fo
r 
th
e
 
c
o
v
a
ri
a
te
s
 
o
f 
a
g
e
, 
s
e
x
 
a
n
d
 
b
a
tc
h
 
e
ff
e
c
ts
. 
A
 
p
o
s
it
iv
e
 
Δ
 
re
fl
e
c
ts
 
h
yp
e
rm
e
th
yl
a
ti
o
n
 
in
 
d
is
e
a
s
e
. 
A
ll 
P
 
v
a
lu
e
s
 
<
 
0
.0
5
 
(a
n
d
 
th
e
ir
 
c
o
rr
e
s
p
o
n
d
in
g
 Δ
) 
a
re
 s
h
o
w
n
 i
n
 b
o
ld
. 
 
G
e
n
o
m
ic
 L
o
c
a
ti
o
n
 
P
D
 
E
C
 
S
T
G
 
C
E
R
 
S
T
R
 
S
N
 
∆
 
P
 
∆
 
P
 
∆
 
P
 
∆
 
P
 
∆
 
P
 
c
h
r8
:4
1
5
1
9
3
0
2
 
0
.3
7
 
0
.5
9
2
 
0
.2
0
 
0
.7
7
7
 
0
.2
3
 
0
.7
1
4
 
1
.4
3
 
0
.3
5
1
 
-0
.2
5
 
0
.7
4
5
 
c
h
r8
:4
1
5
1
9
3
0
4
 
0
.3
6
 
0
.6
2
8
 
0
.4
9
 
0
.5
2
4
 
-0
.3
3
 
0
.5
6
2
 
0
.8
9
 
0
.6
4
7
 
0
.1
9
 
0
.8
2
3
 
c
h
r8
:4
1
5
1
9
3
0
8
 
0
.3
4
 
0
.6
8
6
 
0
.8
0
 
0
.3
3
4
 
-0
.5
5
 
0
.5
1
8
 
-2
.4
6
 
0
.2
0
3
 
0
.0
5
 
0
.9
5
6
 
c
h
r8
:4
1
5
1
9
3
4
8
 
0
.8
3
 
0
.3
2
3
 
0
.0
7
 
0
.9
3
2
 
0
.1
8
 
0
.8
3
8
 
1
.1
7
 
0
.3
8
1
 
-0
.2
4
 
0
.8
2
6
 
c
h
r8
:4
1
5
1
9
3
9
9
 
0
.0
3
 
0
.9
8
1
 
-0
.1
0
 
0
.9
2
4
 
0
.1
6
 
0
.8
9
3
 
-3
.4
0
 
0
.2
0
0
 
1
.3
7
 
0
.2
7
2
 
c
h
r8
:4
1
5
1
9
4
1
1
 
1
.6
5
 
0
.0
3
2
 
-1
.3
2
 
0
.2
3
4
 
0
.1
4
 
0
.8
7
5
 
-0
.0
6
 
0
.9
7
8
 
0
.5
7
 
0
.6
0
0
 
c
h
r8
:4
1
5
1
9
4
1
7
 
0
.9
5
 
0
.2
6
1
 
-0
.8
7
 
0
.3
7
1
 
-0
.4
2
 
0
.5
5
1
 
-0
.9
8
 
0
.5
2
1
 
0
.0
6
 
0
.9
5
0
 
c
h
r8
:4
1
5
1
9
4
2
0
 
1
.8
1
 
0
.0
2
6
 
-1
.0
7
 
0
.2
7
4
 
0
.2
8
 
0
.4
3
4
 
-0
.0
1
 
0
.9
9
7
 
0
.3
6
 
0
.7
1
4
 
A
m
p
lic
o
n
 A
v
e
ra
g
e
 
0
.8
4
 
0
.2
0
2
 
-0
.2
8
 
0
.6
7
0
 
-0
.0
2
 
0
.9
5
9
 
-0
.1
9
 
0
.8
7
9
 
0
.2
9
 
0
.6
9
0
 
 
C
o
rr
e
c
te
d
 m
e
th
y
la
ti
o
n
 c
h
a
n
g
e
 
C
o
rr
e
c
te
d
 m
e
th
y
la
ti
o
n
 c
h
a
n
g
e
 
C
o
rr
e
c
te
d
 m
e
th
y
la
ti
o
n
 c
h
a
n
g
e
 
Genomic Location Genomic Location 
Genomic Location 
A B 
C 
C
o
rr
e
c
te
d
 m
e
th
y
la
ti
o
n
 c
h
a
n
g
e
 
Genomic Location 
D 
Supplementary Figure 1: ANK1 DNA methylation levels in the STG and CER in individuals 
with DLB Using bisulfite pyrosequencing we assayed a 118bp region of the ANK1 gene ranging 
from 41519302 to 41519420 on chromosome 8 (genome build hg19) in all DLB samples compared to 
control samples. We did not observe any disease-associated changes in either the STG (A) or CER 
(B). When we compared DNA methylation levels in ANK1 in individuals with DLB and co-existing AD 
pathology, or individuals with “pure” DLB only to controls, we found significant hypermethylation at 
two sites in the STG (C) but no sites in the CER (D) in individuals with co-existing AD pathology. 
Data is represented as mean (±SEM) Key: *P < 0.05, **P < 0.01, ***P < 0.005.  
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Supplementary Figure 2: ANK1 DNA methylation levels in the STG and CER in individuals 
with VaD. Using bisulfite pyrosequencing we assayed a 118bp region of the ANK1 gene ranging 
from 41519302 to 41519420 on chromosome 8 (genome build hg19)  in all VaD samples compared 
to control samples. We observed neuropathology-associated hypomethylation at one site in the STG 
(A) and no disease-associated changes in the CER (B). When we compared DNA methylation levels 
in ANK1 in individuals with VaD and co-existing AD pathology, or individuals with “pure” VaD only to 
controls, we found significant hypomethylation at one sites in the STG in individuals with “pure” VaD 
(C), but no disease-associated differences in the CER (D). Data is represented as mean (±SEM) 
Key: *P < 0.05, **P < 0.01, ***P < 0.005.  
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Supplementary Figure 3 ANK1 DNA methylation levels in the STG, CER and STR in individuals 
with HD Using bisulfite pyrosequencing we assayed a 118bp region of the ANK1 gene ranging from 
41519302 to 41519420 on chromosome 8 (genome build hg19) in HD samples compared to control 
samples. We did not observe any disease-associated changes in either the STG (A), CER (B) or 
STR (C). Data is represented as mean (±SEM) Key: *P < 0.05, **P < 0.01, ***P < 0.005.  
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Supplementary Figure 4 ANK1 DNA methylation levels in the STG, CER, STR and SN in 
individuals with PD Using bisulfite pyrosequencing we assayed a 118bp region of the ANK1 gene 
ranging from 41519302 to 41519420 on chromosome 8 (genome build hg19) in PD samples 
compared to control samples. We did not observe any disease-associated changes in either the STG 
(A), CER (B), STR (C) or SN (D). Data is represented as mean (±SEM) Key: *P < 0.05, **P < 
0.01, ***P < 0.005.  
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